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The Endometrium is a dynamic tissue which undergoes cyclical growth in
preparation for pregnancy and regression in the absence of pregnancy. In the mid-
secretory phase of the menstrual cycle, also known as the window of implantation,
the endometrium prepares for the implantation of an embryo by undergoing pre-
decidual changes, leukocyte recruitment and increasing the secretory capacity of the
epithelial cells. In pregnancy, the embryo secretes human chorionic gonadotropin
(hCG), which maintains progesterone production and has direct effects on the
endometrium. Prokineticin 1 (PROK1) is elevated during this transient period and
may be a mediator of endometrial receptivity.
Prokineticins (PROK1 and PROK2) are pleiotropic proteins with multiple functions
including gastrointestinal tract contractility, angiogenesis in the normal and
pathological ovary, testis and prostate, noiciceptive sensitisation, transmission of the
circadian rhythm of the suprachiasmatic nucleus and immune cell activation. The
receptors for the prokineticins (PROKR1 and PROKR2) are two closely related G-
protein coupled receptors. Signalling via these receptors is linked to PLC-fl activation,
inositol phosphate mobilisation, ERK 1/2 and Akt phosphorylation and nitric oxide
production.
Investigation of the temporal pattern of expression of PROK1 and PROKR1 in
pregnant and non-pregnant endometrium has shown (a) both factors to be expressed
in the normal cycling endometrium with an elevation in PROK1 expression during the
secretory phase of the cycle and (b) further elevation of both factors in the pregnant
decidua when compared with the non-pregnant endometrium. Expression of PROK1
was down-regulated in endometrial cancer tissue compared with secretory phase
endometrium, suggesting PROK1-PROKR1 is not involved in the pathogenesis of this
disease. PROK1 and PROKR1 localise to the glandular epithelium, stroma and
vasculature of the non-pregnant and pregnant endometrium. Additionally, PROK1
expression was localised in macrophages and uterine natural killer cells within the
stromal compartment.
In order to investigate signalling and the role of PROK1 in endometrial epithelial cells,
an endometrial epithelial cell line (Ishikawa cells) stably expressing PROKR1 was
utilised. PROK1-PROKR1 interaction, using this cell line, induced a signalling
xxii
cascade involving phosphorylation of cSrc, epidermal growth factor receptor (EGFR)
and ERK 1/2. This cascade to ERK 1/2 phosphorylation was dependent on
activation of Gq protein, PLC-P and Ca2+ as well as phosphorylation of cSrc and
EGFR and activation of the small GTPase Ras.
Gene array analysis was subsequently conducted using RNA extracted from
PROKR1 Ishikawa cells treated with vehicle or 40nM PROK1 for 8 hours. Gene array
analysis was conducted using the Affymetrix GeneChip® Human Genome U133 Plus
2.0 and the ABI 1700 v.2 Applied Biosystems Human Genome Survey microarrays.
A total of 277 genes were differentially expressed in response to PROK1 (226 genes
were up-regulated and 51 genes down-regulated). A number of these genes have
suggested roles in implantation. These include: cyclooxygenase-2 (COX-2), leukaemia
inhibitory factor (LIF), Interleukin (IL)-6, IL-11 and Heparin bound-EGF. Two genes,
COX-2 and LIF were selected for further investigation in this thesis. In the human
endometrium and first trimester decidua, expression of COX-2 and LIF co-localise
with PROKR1 to the glandular epithelium and stromal cells. PROK1 induces mRNA
expression of both of these factors in a time dependent manner in the PROKR1
Ishikawa cell line and first trimester human decidua. Moreover, prostaglandin
production and LIF protein secretion was elevated in response to treatment with
PROK1. Using specific inhibitors of cell signalling, the expression of COX-2 and LIF
in response to PROK1 was dependent on activation of the Gq-PLC-[3-cSrc-EGFR-MEK
signalling pathway. Finally, the expression of PROK1 and LIF in the human
endometrium can be mediated by embryonic hCG secretion. Treatment of PROKR1
Ishikawa cells and first trimester decidua with 1IU hCG results in sequential increase
in PROK1 and LIF expression.
Collectively these data strongly suggest that PROK1-PROKR1 signalling is important
(a) in the preparation of the human endometrium for pregnancy by regulating
expression of implantation related genes and (b) may perform further functions in
early pregnancy under the influence of hCG.
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Chapter 1 - Literature Review
1.1. Introduction
The endometrium is a dynamic tissue, which undergoes proliferation followed by
secretory changes in preparation for embryo implantation each menstrual cycle.
Implantation involves interactions between the embryo and the maternal
endometrium. This is a highly complex process, which, even after many decades
of investigation is still incompletely understood. Implantation of the conceptus
within the endometrium inside a finite window of endometrial receptivity is
essential for the normal progression of pregnancy to term. Implantation at extra¬
uterine sites or implantation that occurs outside of the normal window when the
uterus becomes refractory to implantation are common causes of early pregnancy
loss.
Prokineticin 1 (PROK1) is demonstrated to be elevated during the secretory phase
of the menstrual cycle, the putative 'window of implantation' (Battersby, 2004a,
Ngan, 2006). PROK1 and Prokineticin receptor 1 (PROKR1) its cognate receptor
are expressed in multiple cellular compartments within the endometrium. The
focus of this thesis is the examination of the role of PROK1 and PROKR1 in
endometrial function and its possible role in pregnancy.
This introduction will give a brief overview of the structure, histology, function
and endocrinology of the endometrium throughout the menstrual cycle with a
focus on the peri-implantation phase of the menstrual cycle. The peri-implantation
phase of the menstrual cycle will be described in terms of the endocrine milieu,
morphological changes, the alterations in cytokines, growth factors and lipid
mediators, expression of endometrial adhesion molecules, the immune cell
population of the endometrium and the changes which take place in the
endometrium when it comes under the influence of factors secreted from the
blastocyst. This introduction will also cover in detail the known tissue expression
pattern of the prokineticins and their receptors, signalling induced by prokineticins
and potential functions regulated by the prokineticins in physiological and
pathological states.
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1.2. The Endometrium
The uterus is a pear shaped organ situated within the pelvic cavity (Figure 1.1).
Embryonically the uterus is derived from the fused Mullerian ducts (Koff, 1933).
This was first described by Johannes Muller in 1825. The mullerian duct
epithelium differentiates to give rise to the luminal and glandular epithelium of
the endometrium, while the surrounding urogential ridge mesenchyme
differentiates into the endometrial stroma along with the inner and outer
myometrial layers (Cunha et al, 2002). The uterus is divided into three structural
regions, the fundus, the corpus and the isthmus. It also consists of three layers,
the underlying perimetrium which is a thin membrane, the myometrium which is a
layer of smooth muscle underlying the third layer, the endometrium. The
endometrium itself is further divided into specific regions, the stratum basalis and




Figure 1.1. Representation of the female reproductive tract indicating the uterus, the ovary and uterine tube/
oviduct, cervix and vagina. Adapted from www.trainina.seer.cancer .gov








Figure 1.2. Representation of the functionalis and basalis regions of the endometrium, delineated by the
dotted lines, and the underlying myometrium layer. Adapted from Gargett, 2007.
The endometrium is an incredibly dynamic tissue, undergoing regeneration
and proliferation with formation of new blood vessels, secretory
transformation and preparation for pregnancy. This is followed by the
degeneration and breakdown of the functionalis at menstruation. Menstruation
is only found in a limited selection of mammals, including humans, old world
moneys such as chimpanzees, gorillas, orangutans and gibbons, new world
monkeys such as capuchin monkeys and a species of bat (Dempsey, 1939,
Graham, 1981, Ortiz et al, 1995, Ortiz et al, 2005). The reason for the
development of a sophisticated menstrual cycle within these animals is still
unclear. However, a link has been suggested between menstruating mammals
and their type of placentation, which is haemochorial, i.e. invasive placenta
development. Species that exhibit epitheliochorial placentation i.e. non-invasive
placentation, do not menstruate (Enders, 1991, Smith, 2002).
The human menstrual cycle is split into 3 distinct phases, the proliferative or
follicular phase, the secretory or luteal phase and the menstrual phase. The
function of the endometrium is the provision of a tissue which can support the
implantation and development of an embryo. The proliferative and secretory
phases therefore represent preparation of the functionalis layer of the
endometrium for this function, while menstruation represents the redundancy
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of this tissue in the absence of conception after the endometrium becomes
refractory to implantation.
1.3. The menstrual cycle
1.3.1. The proliferative phase
Menstruation is initiated in the absence of pregnancy in response to falling
estrogen and progesterone concentrations as the corpus luteum degenerates
(Figure 1.3). The regeneration of the endometrium is traditionally considered to
be under the influence of estrogen (Figure 1.3). However, initial endometrial
repair is proposed, based on morphometric data, to be complete within 48
hours after the first two days of menses (i.e. initiation on day 3, Ferenczy,
1976). Maximum proliferation, particularly of the luminal and glandular
epithelium occurs on days 3 - 4 of menses, with re-epithelialisation occurring
by migrating and spreading of denuded basalis over underlying fibroblasts.
Reconstruction of the luminal epithelial barrier is complete by day 5 (Ferenczy,
1979). These initial signs of regeneration occur when estrogen levels are still
low. It has therefore been postulated that initial endometrial regeneration takes
place from endometrial stem cells resident within the basalis region.
Tissues which undergo self-renewal must be in possession of a lifelong
population of stem cells, which are capable of mature cell production and
post-injury regeneration (Lemischka, 2001). The endometrium is a proposed
site of stem cells within the deep basalis region (Padykula, 1991, Gargett,
2007, Figure 1.4). This was based on the high level of proliferation of the
glandular epithelial cells in the basalis (Okulicz et al, 1993, Padykula et al,
1984, Padykula et al, 1989), as a burst of proliferation is characteristic of stem
cell to progenitor transition (LeBlond, 1981). Indeed, it was demonstrated in
1944 that, after removal of all visible endometrium, the entire primate
endometrium could regenerate (Hartman, 1944) suggesting the presence of
stem cells. Support for the non-essential role of estrogen in the initial
regeneration of the endometrium is provided by the evidence that on day 3 of
menses, when regeneration starts, the glandular and luminal epithelium
display little estrogen receptor (ER)« immunoreactivity (Okulicz & Scarrel,
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1998). There is also evidence that even in the absence of all estrogen, from
ovaries, diet and fat reserves, the endometrium still regenerates (Kaitu'u-Lino
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Figure 1.3. Representation of the menstrual cycle indicating follicle growth and rupture, ovarian
hormone levels and endometrial development. Shedding of the functionalis layer of the
endometrium - menstruation - occurs with the decline in estrogen and progesterone levels in the
absence of conception. The endometrium is regenerated, from stem cells present within the
basalis region and under the influence of wound healing factors, during the proliferative phase
when predominant ovarian steroid hormone is estrogen. During the secretory phase of the
menstrual cycle, under the influence of progesterone from the corpus luteum, the endometrium
undergoes secretory changes in preparation for pregnancy. During this phase of the cycle an
influx of uNK cells is observed, the endometrial blood vessels become spiral arterioles, the glands
increase their secretory capacity and become tortuous and the tissue is oedematous. In the
absence of pregnancy the endometrium becomes refractory to implantation and the functionalis
layer is again shed. Adapted from www.soc.ucsb.edu
It is suggested that the regenerative process is influenced by normal wound
healing factors other than estrogen (Johannison et al, 1982). Estrogen, however,
may stimulate epithelial cell proliferation through a paracrine mediator,
possibly through effects on stromal cells. Stromal cell expansion appears to be
dependent on the epithelial compartment and estrogen as tissue recombination
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responsiveness (Bigsby, 2002). Expansion is noted on days 5 - 6 of the cycle
coincident with an elevation in estrogen and ERa expression (Kaitu'u-lino et al,
2007, Ferenczy, 1979). This suggests that the initial epithelial proliferation is
derived from estrogen independent proliferation of stem cells, while further
proliferative effects may be derived from estrogen mediated paracrine signals


















Figure 1.4. Proposed site of the endometrial stem cells. Stem cells which direct regeneration of
the functionalis region of the endometrium are proposed to reside within the basalis layer. These
proliferate during the early proliferative phase of the cycle to give rise to the new functionalis
layer. Adapted from Gargett, 2007.
The proliferative phase 'proper' commences on day 5 of the menstrual cycle.
This phase is characterised by the appearance of short narrow glands and cell
proliferation, which continues until approximately 3 days post ovulation or
after the luteinizing hormone (LH) surge (Tabibzadeh et al, 1990, Ferenczy,
1979). Significant endothelial repair and proliferation also takes place during
this phase of the cycle (Ludwig & Spornitz, 1991, Ferenczy, 1979). During this
repair and proliferation, several growth factors associated with wound healing
are induced, including platelet derived growth factor (PDGF), transforming
growth factor (TGF)-a, epidermal growth factor (EGF), vascular endothelial
growth factor (VEGF), and fibroblast growth factor (FGF) (Werner et al, 1992,
Brown et al, 1992, Greenhalgh, 1996). Several of these growth factors possess
chemotactic properties, which attract inflammatory cells to the region and
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perpetuate the repair and proliferation response (Witte & Barbul, 1997).
Indeed, it is now considered that the action of estrogen on epithelial and
stromal cell proliferation is mediated by the induction of growth factor
expression in the stromal compartment. Blood vessel growth in the
proliferative phase of the cycle is thought to be mediated by EGF (Nelson et al,
1991), TGF-a, TGF-|3, tumour necrosis factor (TNF)-a (Leibovich et al, 1987),
FGF-1 and -2 (Moller et al, 2001), VEGF (Li XF et al, 1994) and PDGF
(Moghaddam et al, 1995, Zhang et al, 1997). By the time of ovulation, at the
proliferative - secretory phase transition, when progesterone takes over as the
dominant hormone, the endometrium presents a thickness of 3 - 4 mm and
displays an undulant surface (Noyes et al, 1975).
1.3.2. The secretory phase
During the secretory phase, the endometrium is mainly under the control of
progesterone (Figure 1.3). However, estrogen is still present albeit at lower
levels than during the proliferative phase. The length of the secretory phase
varies from 8-17 days (Lenton et al, 1984), with the initial secretory changes
apparent in the glandular epithelium by cycle day 15-16 (Noyes et al, 1950).
In the early secretory phase, from LH +0 to +7, the level of progesterone rises
rapidly and structural changes in the endometrium are rapid. Progesterone
inhibits uterine epithelial cell proliferation and induces 17|3-hydroxysteroid
dehydrogenase (HSD) 2, which metabolises estrogen to its less active
derivative estrone, thereby inhibiting its mitogenic effect (Tseng & Gurpide,
1975). The glands change from a relatively undifferentiated state through co¬
ordinated changes to achieve maximum synthesis and secretory capacity by
LH +7 (Dockery & Rogers, 1989, Dockery et al, 1988, Li TC et al, 1988, Hey et
al, 1995). These secretory products are thought to be of importance in
supporting the trophoblast in the initial stages of invasion (Burton et al, 2007).
The secretory phase is characterised by a period of conversion from dominance
of the epithelial compartment to dominance of the stromal compartment
(Lessey, 2002). There is an influx of large granular lymphocytes, characterised
as uterine natural killer cells (uNK), with the presence of macrophages and
CD3+ T cells (Spornitz et al, 1992, Yeaman et al, 1997, Givan et al, 1997). These
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are thought to have relevance in the preparation of the endometrium for
pregnancy. The stromal cells differentiate and undergo pre-decidual changes
with elaboration of proteins thought to be critical for implantation success
(Lessey, 2002). By the time the endometrium is committed to undergoing
decidualization, uNK cells are abundant and are proposed to have effector
functions potentially important for the decidualization process (King, 2000a).
Oedema becomes apparent on days 20 - 23 of the menstrual cycle, associated
with the influx of immune cells, the secretory transformation and decidual
changes (Okada et al, 2001, Daly et al, 1982).
The secretory phase of the menstrual cycle encompasses the period known as
the window of implantation. This is a transient phase of approximately 4 days
duration. This period represents a state of readiness of the endometrium for
implantation, which occurs approximately 7 days after the LH surge (LH +7)
or 5.5 days post ovulation (Aplin, 2000). This window is associated with an
increase in expression of a number of potential 'markers' of receptivity that are
regulated by the endometrial hormonal milieu.
1.4. The receptive endometrium and implantation
The concept of the window of implantation was suggested by Psychoyos in 1973
(Psychoyos, 1973). This proposal of a window of time in which implantation
could take place was elaborated in further studies (McLaren, 1973, Finn & Martin,
1974). Use of animal models to investigate an optimal period of time for
endometrial implantation aided the definition of this window (McLaren & Mitchie,
1954, Hodgen et al, 1983, Psychoyos, 1986). The embryo is capable of adhering to
and growing on almost any tissue in the body (Fawcett, 1950, Kirby, 1963), except
the uterus when the endometrium, specifically the luminal epithelium, is
refractory to implantation (Navot et al, 1991). This 'window' of time during which
implantation can occur in the uterus, based on pregnancy rates observed after IVF,
appears to occur from days 7-11 after the LH surge (Bergh & Navot, 1992).
However, despite many years of interest, no single marker of uterine receptivity to
implantation has been definitively identified in the endometrium.
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From a clinical perspective, failure of fertility is a growing problem with
approximately 1 in 6 couples affected (Lessey, 2000). Although implantation
problems as a cause of infertility are sometimes regarded with scepticism, an
emerging trend reveals that inadequate uterine receptivity is responsible for
approximately 2/3 of implantation failures. Inadequate uterine receptivity is
considered as a major cause of infertility in otherwise healthy women (Achache &
Revel, 2006). This may account for the relatively low success rate of IVF at around
25% (de los Santos, 2003).
Endometrial histology dating applying the classical criteria developed by Noyes
(Noyes et al, 1950) is not accurate, with the day of ovulation based on an increase
in basal body temperature. However, this is not true for all women. Application of
newer criteria examining the LH surge, presence of pinopodes, or examination of
integrin expression (Acosta et al, 2000, Lessey, 2000, Shoupe et al, 1989) were
proposed to date the endometrium more accurately. However, it has been
demonstrated that histological endometrial dating does not necessarily correspond
with fertility (Coutifaris et al, 2004). Molecular and biochemical events are
therefore examined in order to gain insight into this period (Sunder & Lenton,
2000). There is much debate over markers which define the endometrial window of
implantation. However, this phase may be described by a number of parameters
including, enhanced cytokine and growth factor production, production of lipid
mediators, expression of adhesion molecules on the luminal epithelium and
elaboration of extracellular matrix molecules, a change in morphology, infiltration
of bone marrow derived cells and stromal differentiation. By animal knockout
studies and gene array analysis of peri-implantation endometrium a number of
modulators of endometrial receptivity have been proposed. In the event of
pregnancy the endometrium changes further as it comes under the influence of
proteins secreted from the blastocyst. The factors involved in receptivity and
implantation will now be discussed in more detail.
1.4.1. Ovarian hormones influence the receptive endometrium
Regulation of endometrial differentiation, in order to become receptive and
support development and implantation of an embryo, is orchestrated by the
sequential actions of estrogen and progesterone (Huet-Hudson et al, 1989).
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The roles of the steroid hormones are complex and still incompletely
understood (Punyadeera et al, 2003). Hormonal activity depends on
expression of their respective receptors and the levels of each steroid hormone,
with the appropriate cyclical pattern of steroid receptor expression being
crucial for achieving receptivity (Lessey et al, 2003, Ma et al, 2003). In the
proliferative phase of the menstrual cycle, the ER isoforms, ERa and ER|3, are
expressed in the glands; stroma and luminal epithelium with ER|3 also
expressed in the endothelial cells (Critchley et al, 2001, Matsuzaki et al, 1999,
Witek et al, 2001). Progesterone receptor (PR)a is dominant over PR|3
expression in the glandular epithelium during the proliferative phase of the
menstrual cycle (Mote et al, 1999, Diedrich et al, 2007). Under the influence of
estrogen, ER and PR are elevated in the epithelium (Liu et al, 2003, Mote et al,
1999, Diedrich et al, 2007).
During the secretory phase of the cycle, regulated by progesterone, expression
of both ER and PRa are down-regulated in the epithelial compartment with
elevation of PR|3 in the stroma (Lessey et al, 1996, Mote et al, 1999). This
down-regulation in PR expression in the epithelium appears to be a conserved
function in mammals and may allow for a switch from ovarian steroid
regulation of the epithelium to paracrine regulation by the progesterone
sensitive stroma (Lessey, 2000, Figure 1.5). Down-regulation of epithelial PR
appears to characterise the opening of the window of implantation, and
persistence of PR expression in women with luteal phase defect is associated
with the loss of other markers of receptivity in the epithelium (Lessey et al,
1996), suggesting the direct effect of progesterone on the epithelium may serve
to inhibit certain markers of receptivity. Progesterone appears to regulate
expression other epithelial markers of receptivity such as pinopod formation.
However the formation of pinopodes (discussed in Section 1.4.2) is suggested
to be dependent on a down-regulation of PR expression (Stavreus Evers et al,
2001).
Progesterone appears to be required for functions associated with receptivity
such as decidualization (Mulac-Jericevic et al, 2000). Synthetic progestagens
elevate expression of inducible nitric oxide synthase (iNOS) and production of
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nitric oxide (NO), which is thought to contribute to myometrial quiescence
during pregnancy (Cameron et al, 1998). The influx of leukocytes in the
secretory phase of the menstrual cycle is suggestive of steroid control, and
progesterone regulates expression of immune related genes suggesting an
effect on the uterine immune environment. However, as the uterine immune
cells do not possess steroid hormone receptors (Poropatrich et al, 1987, Loke &
King, 1995), this effect on leukocyte recruitment is probably indirect (King,
1996 et al, Makrigiannakis et al, 2006).
Studies in humans and non-human primates using anti-progestins further
highlight the proposed role of progesterone in preparing the endometrium for
implantation. Leukaemia inhibitory factor (LIF), which has been demonstrated
as being essential for implantation (Stewart et al, 1992), is down-regulated by
anti-progestins (Cameron et al, 1997, Puri et al, 2000, Gemzell Danielsson et al,
2003, Sengupta et al, 2003, Danielsson et al, 1997). This is highly interesting
when considering that the regulation of LIF by progesterone is still debated
(Kholkute et al, 2000, Arici et al, 1995, Hambartsoumian et al, 1998a, Ace et al,
1995, Keltz et al, 1996). Treatment of endometrial explants with the
progesterone receptor antagonist, mifepristone, also down-regulates signalling
molecules activated by cytokines including LIF (Catalano et al, 2003). This
renders the endometrium non-receptive (Critchley et al, 1999) suggesting
cytokines and down-stream signalling activation are required for endometrial
receptivity and implantation.
Mifepristone also affects other proposed mediators of endometrial receptivity
including cyclooxygenase 2 (COX-2) and Glycodelin (Gemzell Danielsson,
2003 et al, Marions & Danielsson, 1999, Sengupta et al, 2003). Bonnet monkeys
treated with progesterone antagonist, onapristone, also display a down-
regulation in epithelial expression of integrins av|33 and aipi, which are
thought to be important for mediating attachment of the blastocyst to the
epithelium (Puri et al, 2000). A study employing a gene array approach
examined endometrial expression of genes in women who had an intrauterine
contraceptive device fitted and found 147 genes to be dysregulated during the
window of implantation compared with controls. 52 of these genes were
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characterised implantation genes including LIF and glycodelin (PP14,
placental protein 14), which have previously been shown to be down-regulated
by anti-progestins (Horcajadis et al, 2006, Cameron et al, 1997, Gemzell
Danielsson et al, 2003, Sengupta et al, 2003, Danielsson et al, 1997). These
data highlight the importance of progesterone, whether through direct or






Figure 1.5. Representation of the indirect effect of Progesterone on epithelial cells. Progesterone
responsive stromal cells release signals to mediate paracrine effects on the epithelium (P4 -
progesterone, PR - progesterone receptor, HB-EGF - heparin binding EGF). Adapted from
Sharkey & Smith, 2003, Best Prac & Res Clin Obstet Gynecol.
1.4.2. Morphological changes to the endometrium
One of the major morphological changes in the endometrium thought to
characterise the period of endometrial receptivity is the development of
pinopodes on the luminal epithelium. These were originally described in mice
(Nilsson, 1958) and rats (Warren & Enders, 1964, Fainstat & Chapman, 1965).
The term 'pinopod' from the Greek which means 'drinking foot' was applied to
these structures representing their pinocytotic function. In humans several
differences exist, they appear to arise from the entire apical cell surface and
may not be pinocytic, thus the term uterodome was proposed (Guillomot et al,
1986, Murphy, 2000, Adams et al, 2001), however the term pinopode is still
widely used.
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Piiiopodes
Figure 1.6. Endometrial pinopodes. A indicates normal endometrial microvilli extending from the
surface of individual cells. B indicates pinopodes with smooth surfaces protruding above the
endometrial microvilli. Adapted from Quinn etal, 2007.
Pinopodes are bleb-like protrusions on the apical surface of the endometrium
(Usadi et al, 2003). These project above the level of the microvilli into the
uterine lumen (Figure 1.6). Pinopodes are present for around 2 days of the
menstrual cycle in the period between 6-10 days after progesterone exposure
(Nikas et dl, 1995) corresponding to the proposed window of implantation
(Stavreus-Evers et al, 2001, Aghajanova et al, 2003). Pinopodes are therefore
thought to be progesterone dependent; Homeobox A (HOXA)-IO is also
thought to have a role in pinopode development (Lopata et al, 2002, Bagot et
al, 2001). A delay in the expression of pinopodes potentially represents a poor
pregnancy outcome (Edwards, 1995). Development of pinopodes on the apical
surface is thought to be associated with a loss of polarity, which allows the
epithelia of the trophectoderm and endometrium to adhere (Thie et al, 1996,
Denker, 1990). Pinopodes appear to be preferential sites of embryo -
endometrial interaction (Achache & Revel, 2006) and it is suggested that, by
extracting fluid from the uterine lumen, the pinopodes facilitate the movement
of the blastocyst towards the uterine epithelium by 'drawing' the blastocyst in.
However it is unclear if this occurs in humans as they are not thought to be
pinocytic (Adams et al, 2002). Attachment of embryos in culture to human
epithelial monolayers does however appears to occur by interaction with
pinopodes (Bentin-Ley et al, 1999). It is therefore proposed that pinopodes are
a useful morphological marker of uterine receptivity (Nikas & Psychoyos,
1997). However a recent study has suggested that as pinopodes are dependent
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on progesterone they do not define the window of implantation and may be
detected into pregnancy (Quinn et al, 2007). The appearance of pinopodes is
also associated with the expression of other putative markers of receptivity
including LIF and LIF-receptor (Aghajanova et al, 2003, Kabir-Salmani et al,
2005, Fouladi-Nashta et al, 2005), loss of PR and appearance of integrin av|33
(Lessey et al, 1992). Pinopodes also appear to express growth factors and
cytokines associated with receptivity, which are discussed in Section 1.4.3.
1.4.3. Cytokines, growth factors, lipid mediators and protective mechanisms
involved in uterine receptivity and implantation.
The endometrial milieu of hormones, cytokines, growth factors, lipid
mediators and protective factors present during the window of implantation is
an area which has provided a vast amount of information on how the
endometrium prepares itself for the embryo. Clearly in humans, due to ethical
considerations, little information can be derived about the actual implantation
site. Flowever, much information has been provided by histological studies,
examination of uterine lavage and gene array analysis of receptive
endometrium. With the advent of technology that allowed genes to be knocked
out in vivo, the knowledge of genes involved in the mechanism of implantation
has advanced greatly. Although the implantation mechanisms in rodents and
humans are not identical, with estrogen being an absolute requirement for
implantation in rodents, and differences in placentation, parallels may be
drawn with genes expressed in the human endometrium. Although not
completely equivalent, knockout animals allow genes to be studied, in vivo, in
way that could never be achieved in humans.
A number of cytokines, especially cytokines of the interleukin (IL)-6 family, are
proposed to be important in receptivity and implantation. Broadly, cytokines
are proteins and peptides that are used as signalling compounds. The roles of
LIF, IL-6, IL-11 and IL-1 in the endometrium will be discussed.
The proposed role of LIF in endometrial receptivity arose from initial
investigations in the mouse. In the mouse model it was demonstrated that on
day 4 of pregnancy, coincident with the surge of nidatory estrogen, LIF
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expression was induced in the endometrial glands occurring prior to
implantation, which takes place on midnight of day 4. It was also shown in
this study that LIF expression did not depend on the presence of a blastocyst
as the elevation in LIF expression also occurred in pseudopregnant mice (Bhatt
et al, 1991). The role for LIF in implantation was confirmed by use of the LIF
null mouse model. Blastocysts were produced and developed in the LIF null
mouse, however they did not display any signs of implanting and only
developed weak attachments with the luminal epithelium exemplified by the
demonstration that these blastocysts could be flushed from the uterine lumen
(Stewart et al, 1992). In this study maternal control of LIF expression was
confirmed as the defective component.
Extensive work examining the human endometrium has now characterised the
cycle-dependent expression of LIF with expression in the mid-secretory phase
of the menstrual cycle (Charnock-Jones et al, 1994, Kojima et al, 1994, Arici et
al, 1995, Culinan et al, 1996, Licht et al, 1998). LIF is expressed on pinopodes
(Kabir-Salmani et al, 2005), which, as discussed in section 1.4.2, are potentially
the first points of contact between the endometrium and the embryo. The
blastocyst expresses the two LIF receptor heterodimers - LIF-R and gpl30
(Charnock-Jones et al, 1994, Sharkey et al, 1995, Van Eijk et al, 1996). LIF
potentially enters into a reciprocal relationship with the developing embryo as
human chorionic gonadotropin (hCG), one of the first embryonic products,
induces endometrial expression of LIF (Licht et al, 2001, Perrier d'Hauterive et
al, 2004, Sherwin et al, 2007). LIF has also been demonstrated to induce
expression of hCG and syncytial transformation (Sawai et al, 1995a, 1995b). In
human reproduction it has been demonstrated that women who display
unexplained infertility with multiple failures of implantation display lower
levels of LIF in uterine flushings (Laird et al, 1997, Hambartsoumian, 1998b).
It has recently been suggested that levels of LIF may be used as a predictor of
reproductive outcome, with a higher level of LIF in uterine flushings associated
with reproductive success (Mikolajczyk et al, 2007).
LIF is structurally related to IL-6 and is part of the same family of related
cytokines along with Oncostatin M, Ciliary neurotrophic factor (CNTF) and IL-
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11, which signal through heterodimerisation of their own receptor with the
common receptor gpl30. IL-6 is expressed within the endometrial luminal and
glandular epithelium during the mid - secretory phase of the menstrual cycle
(Tabibzadeh et al, 1995, Vandermolen & Gu, 1996). IL-6 receptors are
expressed on the blastocyst (Nishino et al, 1990, van Eijk et al, 1996), however
a soluble form of the IL-6 receptor (sIL-6R) is suggested to be present in the
endometrium of fertile women (Rie et al, 1995). The formation of a complex
between sIL-6R and IL-6 could induce heterodimerisation with gpl30 on the
blastocyst to induce signalling (Matsuzaki et al, 1995). Similar to LIF,
endometrial IL-6 may have a reciprocal relationship with the developing
embryo as hCG can induce endometrial expression of IL-6 (Sherwin et al,
2007), and IL-6 may stimulate production of hCG from the blastocyst
(Matsuzaki et al, 1995). It is also suggested that IL-6 plays a direct role in
implantation as the IL-6 null mouse displays compromised implantation and
development (Robertson et al, 2000). IL-6 is also proposed to play a role in
trophoblast growth and placentation (Nishino et al, 1990). Further evidence for
the role of IL-6 in receptivity and implantation is provided by the observation
that IL-6 expression is lower in women who suffer recurrent miscarriage
(Jasper et al, 2007).
IL-11, as indicated, is another member of this family and has also been
proposed to have a role in implantation. In the human IL-11 and its receptor
IL-11 R have been identified in the epithelial and stromal cells of the pregnant
and non-pregnant endometrium, and in the trophoblast of the primate (Chen
et al 2002, 2002, Cork et al, 2002, Dimitriadis et al, 2002, 2003, Karpovich et al,
2003, van Rango et al, 2004). The expression of the associated common
receptor, gpl30, required for heterodimerisation has been described above. The
IL-11R null mouse has demonstrated a requirement for IL-11 signalling in
decidualization as, even though blastocysts implant into the uterus of the
mother a defective decidualization response is displayed resulting in
dissolution of the pregnancy before term (Robb et al, 1998, Bilinski et al, 1998).
The IL-1 system is also thought to be of importance in implantation. In mouse
models, administration of IL-1 receptor antagonist (IL-lra) prevented
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implantation (Simon et al, 1994). This is postulated to be due, in part, to the
action of IL-1 on stimulation of integrin expression in the endometrium (Simon
et al, 1997). Indeed it has been demonstrated that IL-lra is downregulated in
the human endometrium during the window of implantation compared to the
proliferative phase (Simon et al, 1995). This suggests a mechanism whereby
the antagonism of IL-1 is removed thereby allowing its pre-implantation
actions (Boucher et al, 2001).
A number of growth factors also have proposed roles in endometrial function
at the time of implantation. Growth factors are naturally occurring proteins,
which are capable of stimulating cellular proliferation and differentiation. The
growth factors discussed herein, are colony stimulating factor (CSF)-l and the
EGF family of growth factors. PROK1 is a growth factor with a potential role
in implantation; however, as PROK1 is the focus of this thesis it will be
discussed in more detail in section 1.5.
CSF-1 was demonstrated to stimulate the proliferation and differentiation of
monocytes, and was subsequently found to be expressed by fibroblasts,
monocytes, macrophages and endothelial cells (Zolti et al, 1991). CSF is
abundantly produced by glandular epithelial cells at the proposed time of
uterine receptivity (Kauma et al, 1991) potentially contributing to the influx of
immune cells at this time. The receptor for CSF-1, c-fms is expressed on the
embryo and early placental tissues (Pampfer et al, 1992, Jokhi et al, 1993)
indicating potential for interaction during implantation. Mice null for CSF-1,
are infertile due to an implantation defect (Pollard et al, 1991), reinforcing the
hypothesis that endometrial CSF-1 is necessary for implantation. Similar to the
factors discussed above, the embryo itself may modulate the endometrial
environment in preparation for its own implantation as hCG induces
endometrial expression of CSF-1 (Licht et al, 1998). Other chemokines such as
regulated upon activation normal T-cell expressed and secreted (RANTES),
macrophage inflammatory protein (MlP)-la and -1|3, and monocyte
chemoattractant protein (MCP)-l also act to recruit macrophages and
granulocytes and can initiate their activation (Simon et al, 1998). It is
suggested that a surge in these chemokines during the window of implantation
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may also contribute to the initiation of implantation (Wood et al, 1997)
indicating that the endometrial stroma is richly populated with immune cells,
their contribution is discussed more detail in Section 1.4.5.
Another 'family' of factors implicated in the regulation of implantation is the
EGF family of molecules, these include EGF itself, TGF-a, amphiregulin,
cripto, heparin binding-EGF (HB-EGF) and betacellulin. EGF is present in the
endometrium throughout the menstrual cycle with a shift from stromal
expression in the proliferative phase of the cycle where it may mimic the action
of estrogen (Nelson et al, 1991), to luminal and glandular expression in the
secretory phase of the cycle (Hofmann et al, 1991). EGF is postulated to play a
role in trophoblast invasion as it downregulates cortnexin 40 (a transmembrane
protein) and increases invasion (Wright et al, 2006). Downregulation of
connexin 40 is associated with a switch from a proliferative to an invasive
phenotype of extravillous trophoblasts (EVT, Wright et al, 2006). Potential for
paracrine signalling exists as the blastocyst expresses the EGF receptor
(Smotrich et al, 1996).
Amphiregulin is potentially involved in implantation, however, mouse models
provide much of this data and little is known about its role in the human.
Amphiregulin is elevated in the diestrous phase of the cycle (Lee DS et al,
2005) and is expressed on day 4, the day of implantation in mice, in the
uterine epithelium (Carson et al, 2000) localised specifically around the site of
blastocyst attachment (Das et al, 1995). However, by day 5 of pregnancy
amphiregulin is absent (Wang & Armant, 2002). Expression of amphiregulin is
thought to be under the control of progesterone (Das et al, 1995). However, it
was noted in the LIF null mouse model that the expected pattern of
amphiregulin expression was absent even though progesterone levels were
normal (Song et al, 2000), indicating amphiregulin may be under the control of
local factors rather than steroid hormones. Amphiregulin expression has been
determined in the rhesus monkey and peaks on day 16 - 20 of the menstrual
cycle (Yue et al, 2000); its role in the human however is currently unclear. It has
been suggested to play a role in human implantation (Giudice et al, 1999) and
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has been localised to the endometrial leukocytes and stromal cells (Ejskjaer et
al, 2005).
HB-EGF has been heavily implicated in the initiation and continuation of
pregnancy. HB-EGF is elevated in the mouse luminal epithelium 6 hours prior
to attachment (Das et al, 1994) and could mediate trophoblast attachment as
the spatiotemporal expression suggests an interaction (Das et al, 1994). In the
human HB-EGF localises to the luminal epithelium, specifically to the
pinopodes (Stavreus-Evers et al, 2002) and is expressed specifically during the
window of implantation (Leach et al, 1999, Yoo et al, 1997). Interactions
between the endometrium and the embryo may be possible via HB-EGF
binding to heparin sulphate proteoglycans (HSPG, Raab & Klagsbrun, 1997),
which are present in the surface of the blastocyst after acquisition of
attachment competence (Carson et al, 1993, Smith et al, 1997). Interactions
may also occur between endometrial HB-EGF and the EGF receptor ErbB4 on
the trophoblast (Chobotova et al, 2002a). Indeed, it has been demonstrated
that cells expressing the transmembrane form of HB-EGF can adhere to active
(ie. have acquired attachment competence) but not dormant blastocysts (Raab
et al, 1996). As indicated for amphiregulin, expression of HB-EGF is absent in
the luminal epithelium of the LIF null mouse at the expected time of the
attachment reaction (Song et al, 2000). The blastocysts in LIF null mice display
very weak interactions with the luminal epithelium and they can be easily
flushed and retrieved from the uterine cavity (Stewart et al, 1992). Therefore it
may be presumed that LIF induced elevation of HB-EGF may be necessary for
the formation of adequate adhesion between the blastocyst and the epithelium.
That LIF expression has been found to be lower in women with unexplained
fertility with implantation defects (Laird et al, 1997, Hambartsoumian, 1998b)
may point towards a role for this cytokine - growth factor cascade in human
reproduction. The role of signalling induced by the EGF family growth factors
in implantation is further reinforced by the demonstration that EGF receptor
null mice on various genetic backgrounds display placental abnormalities
(Sharkey, 1998, Threadgill et al, 1995).
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The lipid mediators produced by the action of COX-2, the prostaglandins are
proposed to be essential to female reproduction, in processes from ovulation
to parturition (Plunkett et al, 1975, Friel et al, 2005). The role of COX-2 and the
prostaglandins in the endometrium during receptivity and implantation is
discussed below.
Although definitive expression of COX-2 has not been demonstrated, by gene
array analysis, to be up-regulated during the window of implantation there is
a great deal of evidence pointing towards its role in implantation. As
indicated, COX-2 does not appear to be up-regulated during the window of
implantation, however it is expressed at the luminal epithelium in both
humans (Jones et al, 1997, Marions & Danielsson, 1999, Stavreus-Evers et al,
2005) and rodents (Lim et al, 1997) at the expected time of implantation.
Indeed, in mice this expression of COX-2 can be more specifically pin-pointed
to the luminal epithelium and stroma underlying the blastocyst at time of the
attachment reaction on day 4 of pregnancy (Chakraborty et al, 1996).
Examination of the COX-2 null mouse model has revealed defects and delays
in implantation, decidualization and parturition (Lim et al, 1997, Cheng &
Stewart, 2003). These defects were found to be due to a lack of downstream
prostaglandin production as administration of exogenous prostaglandin
analogues could partially rescue the defects (Lim et al, 1997).
The cytoplasmic phospholipase A2 null mouse model has provided further
evidence of the requirement for prostaglandins in implantation. Cytoplasmic
phospholipase Ala (cPLA2a), an enzyme involved in the release of
arachidonic acid, is essential for prostaglandin synthesis from membrane
phospholipids (Clark et al, 1995). The involvement of COX-2 and downstream
prostaglandins in implantation is reinforced by the observation that mice
which are null for cPLA2a display a delay in implantation, a defect in embryo
spacing defective placentation and smaller litters (Song et al, 2002, Ye X et al,
2005, Shah & Catt, 2005), similar to the phenotype of the COX-2 null mouse
model. The impact for a potential delay in implantation due to a deficiency in
COX-2 derived prostaglandins is illustrated by the observation in humans that
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a delay in implantation, beyond the normal window of implantation results in
an increased risk of early pregnancy loss (Wilcox, 1999).
A role for prostaglandins in the human has been suggested by the observation
that COX-2 is necessary for decidualization of human stromal cells (Frank et
al, 1994). An increase in vascular permeability in the endometrium is
consistently observed in association with implantation, and it has been
demonstrated that COX-2 derived prostaglandins are mediators of this
permeability (Chakraborty et al, 1996). Regulation of COX-2 expression may
or may not be under the control of progesterone. Studies have reported that
COX-2 staining increases after progesterone withdrawal (Hapangama et al,
2002) and, conversely, that anti-progestins decrease COX-2 staining (Marions
& Danielsson, 1999). Regulation of COX-2 expression is also thought to be
under the control of the implanting blastocyst, and hCG has been
demonstrated to play a role in regulating endometrial expression of COX-2
(Han et al, 1996, Han et al, 1999, Zhou et al, 1999). It appears, however, that
there may also be a maternal component involved in COX-2 regulation as
COX-2 expression is deficient in LIF null mice, which are infertile due to a
maternal defect (Stewart et al, 1992, Song et al, 2000, Fouladi - Nashta et al,
2005). As indicated above, LIF defects have been observed in women with
unexplained infertility and aberrant COX-2 expression may contribute to this
defect.
Protective and stress induced molecules are expressed in the endometrium at
the expected time of implantation and are thought to play a role in preventing
toxic damage to the endometrium.
Heat shock proteins (HSP24, HSP27, HSP70), a-crystalline B-chain (another
member of the heat shock protein family), and metallothioneins are present in
the endometrium during the window of implantation and are thought to
confer protection (Tabibzadeh & Broome, 1999, Jaattela et al, 1993, Jaquier -
Sarlin et al, 1994). They can potentially act as molecular chaperones during
implantation for other molecules required at this time (Sunder & Lenton, 2000,
Mehlen et al, 1995a, Sies, 1993). All these factors are elevated during the
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window of implantation (Gruidl et al, 1997, Ciocca et al, 1983, Borthwick et al,
2003, Carson et al, 2002, Kao et al, 2002, Mirkin et al, 2005, Riesewijk et al,
2003, Tabibzadeh et al, 1996, Talbi et al, 2006). HSP expression is also present
in the decidua during the first trimester of pregnancy (Neuer et al, 1999). The
heat shock protein family member a-crystalline B-chain is also elevated in the
baboon endometrium upon treatment with hCG (Sherwin et al, 2007).
1.4.4. Endometrial adhesion molecules expressed in the receptive
endometrium
The luminal epithelium is considered to be a barrier to implantation as the
blastocyst can only adhere and implant during a narrowly defined window of
implantation when the endometrium is receptive (Cowell, 1969). The
endometrium however is not the only component, the blastocyst must also
become appropriately developed, hatch from its surrounding zona pellucida
to reveal the trophectoderm and acquire adhesion competence (Paria et al,
1993). Adhesion may therefore be considered as a dialogue between the
embryo and the maternal endometrium, which cannot be initiated until both
have reached an appropriate stage of development (Figure 1.7). Initially the
blastocyst and the luminal epithelium come into close contact upon blastocyst
hatching, a stage defined as apposition. This is followed by the formation of
firm contacts with the endometrium known as adhesion (Kimber & Spanswick,
2002). The adhesive molecules expressed by the endometrium are key to this
process and will now be discussed further.
One of the initial contacts between the mother and the embryo is thought to
occur via the pinopodes, as discussed in Section 1.4.2. Briefly, pinopodes are
bleb-like protrusions on the apical surface of the endometrium (Usadi et al,
2003) which are thought to draw in the blastocyst by extracting fluid from the
uterine lumen and interact with the blastocys, however this 'drawing in' may
not occur in humans (Adams et al, 2002). The two polarised epithelial surfaces
are usually non-adhesive, however, there is a marked reduction in the apical-
basal polarity of the luminal epithelium at the time of the attachment reaction
(Denker, 1990, Thie et al, 1996). This reduction in polarity facilitates adhesion
of these surfaces.
Figure 1.7. Representation of the stages of apposition and adhesion of the blastocyst. TE -
trophoblast, LE - luminal epithelium. Molecules potentially involved in mediating the adhesion are
shown. In the initial phases of adhesion, loose connections are formed between the endometrium
and blastocyst via endometrial HB-EGF, CD44 and Galectins. Firm adhesions are formed
between endometrial and blastocyst integrins, proposed to occur by a sandwich model with ECM
bridging ligands. Adapted from Aplin & Kimber, 2004, Reprod Biol Endocrinol.
The initial maternal-foetal dialogue is thought to involve interactions including
maternal HB-EGF with embryonic EGF receptor (EGFR) and heparin sulphate
proteoglycan (HSPG), galectins, CD44 and selectins. As discussed above, HB-
EGF is expressed at the luminal epithelium during the window of implantation
and has been specifically localised in the human endometrium to the
pinopodes (Stavreus-Evers et al, 2002), which, as indicated are implicated in
initial attachment. HB-EGF can interact with HSPG, which forms around the
blastocyst after acquisition of adhesion competence (Carson et al, 1993, Smith
et al, 1997) and EGFR present on the blastocyst surface (Raab et al, 1996,
Rapolee et al, 1998, Dardik et al, 1992). Indeed, it is proposed that HSPG
actually facilitates the binding of HB-EGF to the EGFR ErbB4 (Higashiyama et
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al, 1993, Paria et al, 1999) thereby promoting adhesion. LIF may also play a
role in this interaction as LIF is also present on the pinopodes (Kabir-Salmani
et al, 2005), and may control expression of HB-EGF (Song et al, 2000).
Blastocysts form only very loose connections with the luminal epithelium in
LIF null mice (Chen JR et al, 2000). Expression of LIF at the luminal epithelium
may therefore provide another means of adherence. Pinopodes, therefore,
appear to play a dual role in adhesion, initially by potentially 'drawing in1 the
blastocyst and also by promoting adhesive interactions via adhesive
molecules.
CD44 is elevated in the endometrium during the window of implantation
(Behzad et al, 1994, Home et al, 2002) on the luminal epithelium and is also
expressed in the pre-implantation embryo (Campbell et al, 1995) but not the
invading trophoblast. CD44 may mediate adhesive interactions in different
ways by binding to two different molecules; hyaluronic acid, which is present
in tissues undergoing rapid growth like the blastocyst, or osteopontin. It is
suggested that osteopontin, which is expressed in the endometrial glands
during the secretory phase (Apparaoe et al, 2001), can bind CD44 (Weber et al,
1996), and may act as a bridging ligand for av integrins present on the
endometrial and blastocyst epithelium.
Galectins are a group of soluble lectins, which are thought to mediate
trophoblast attachment. Galectin-1 is thought to modulate interactions
between integrins and ECM components during skeletal muscle differentiation
(Gu et al, 1994) and could potentially regulate such interactions during
implantation (Vicovac et al, 1998, Maquoi et al, 1997). Selectins are well
established as mediators of leukocyte transendothelial trafficking (Alon &
Feigelson, 2002), where they allow tethering and rolling of leukocytes before
firm adhesion and transmigration. An analogy can be drawn between this
process and blastocyst adhesion (Genbacev et al, 2003, Dominguez et al,
2005). L-Selectin expression is found over the whole surface of the blastocyst
(Genbacev et al, 2003) while the selectin ligands are present on the luminal
epithelium (Lai et al, 2005). It is proposed that these may aid the blastocyst in
determining the best place to stop and adhere (Achache & Revel, 2006).
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Once the blastocyst has formed initial contacts with the endometrium, firm
attachment must then be established in order for the blastocyst and the
maternal endometrium to become intimately associated and initiate invasion.
This is proposed to occur mainly by integrin ECM binding. Expression of the
molecules involved in these two systems must be synchronised if an
attachment competent blastocyst is to implant into an appropriately receptive
uterus.
The integrins are among the best characterised markers of uterine receptivity
(Lessey, 1998). Integrins are glycoprotein receptors for a variety of components
of the extracellular matrix (ECM) and are composed of a and (3 subunits
which heterodimerize to form functional integrin receptors for ECM ligands.
The integrins behave as modulators of cellular function through attachment
and signal transduction (Giancotti & Ruoslahti, 1999). The integrins have been
proposed as factors which could potentially be used to define the window of
implantation. Indeed, expression of al|31, a4|31, cxv(33 and av|35 have been
suggested to 'bookend' the window with endometrial expression noted from
cycle days 20 - 24 (Tabibzadeh et al, 1992, Lessey et al, 1992, Lessey et al,
1994, Aplin et al, 1996). In fertile women the expression of cx4 has been
demonstrated as being elevated from the time of ovulation and disappears
around cycle day 24, while (33 is elevated from around cycle day 20 (Acosta et
al, 2000, Gonzalez et al, 1999, Lessey et al, 1992, Illera et al, 2003). A failure to
express a normal array of endometrial integrins has been demonstrated in
many infertile patients with normal histology or those suffering from
endometriosis, hydrosalpinges and polycystic ovarian syndrome (Lessey et al,
1995, Lessey, 2002, Meyer et al, 1997, Ota et al, 1997, Tei et al, 2003). The
significance of this however is unknown as it has been reported that no
significant differences are observed in ccv|33 expression and pinopod formation
in infertile women (Creus et al, 2002), and the mouse null mutant for av(33 and
humans deficient in (33 are fertile (Hodivala-Dilke et al, 1999). These mice
however, do show placental defects. This may imply a certain degree of
redundancy in this system and it is now accepted that use of integrins alone is
insufficient to date the endometrium or completely explain infertility (Lessey,
2000). It is recognised, however, that endometrial integrins identify and bind
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ECM components with Arg-Gly-Asp (RGD) sequences, which have been
implicated in trophoblast ECM adhesion and outgrowth (Armant et al, 1986,
Yelian et al, 1995), suggesting a sandwich model of integrin adhesion.
Clearly, if any of these mechanisms are to take place, the elaboration of the
appropriate integrin ligands is required. ECM components including
fibronectin, collagen IV, laminin and osteopontin are elevated during the
window of implantation in the endometrium (Wewer et al, 1986, Rider et al,
1992, Aplin et al, 1988, Wewer et al, 1985, Garcia et al, 2004). These have been
localised to the implantation site in the baboon endometrium (Fazleabas et al,
1997, BOR). Endometrial ECM components have been shown to support
trophoblast growth in vitro (Armant et al, 1986, Carson et al, 1988).
Thus during the peri-implantation phase of the menstrual cycle the
endometrium expresses a range of adhesion molecules, which may be utilised
by the blastocyst in the event of pregnancy, in order to facilitate initial
endometrium - embryo interactions. Therefore, in order for the endometrium
to become receptive to a hatched blastocyst the appropriate complement of
endometrial adhesion molecules must be expressed.
1.4.5. Immune cell colonisation of the secretory phase and early pregnancy
endometrium
The immune cell population within the endometrium is dynamic with
dramatic differences in cell populations between the proliferative and secretory
phases. Further changes are observed during pregnancy. During the
proliferative phase of the menstrual cycle few leukocytes are observed.
However, by the secretory phase of the cycle leukocytes account for 20 - 30%
of the total stromal cell number (Hunt, 2002) with around 55% of these being
uNK cells (Dockery, 2002) and macrophages accounting for around 20%
(Trundley & Moffett, 2004). This proportion increases to represent 40% of the
decidua in the first trimester of pregnancy (Trundley & Moffett, 2004). These
immune cells modulate the endometrial environment in the initiation and
maintenance of pregnancy, however, in the absence of conception they play
roles in the involutional changes through which the endometrium must pass in
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order to undergo menstruation (Critchley et al, 2001). In the event of
pregnancy the leukocyte population undergoes rapid changes, which diminish
the leukocytes of the adaptive immune system and promote the leukocytes of
the innate immune system.
Macrophages are present within the endometrium throughout the menstrual
cycle. Their numbers are observed to increase in the early secretory phase of the
menstrual cycle, potentially in preparation for implantation, with further
increases observed in the late-secretory phase of the menstrual cycle, when they
are potentially involved in the initiation of menstruation (Salamonsen et al,
2002). The range of cytokines secreted by macrophages depends on their
activation status (Gordon et al, 1995). The steroid hormone milieu is proposed
to determine the macrophage secretory phenotype (Hunt & Robertson, 1996).
However it is more likely that this is an indirect control mechanism via local
stromal cell paracrine mediators as sex steroid receptors are not detectable on
any of the immune cells within the endometrium (Poropatrich et al, 1987, Loke
& King, 1995, King et al, 1996). Macrophages are thought to play a major role
in tolerance of the invading trophoblast. They are proposed to phagocytose
trophoblast debris, act as antigen presenting cells or affect implantation by
producing or responding to cytokines (Rai & Regan, 2002) as their numbers are
elevated in the decidua basalis at the implantation site whereas only a few are
found within the decidua parietalis. Their role as antigen presenting cells is
proposed to involve presenting trophoblast antigens to T-cells whose cytokine
production would then act to control the immune response, which may be
mounted against the trophoblast (Trundley & Moffett, 2004). Macrophage
cytokines themselves are central to activation and suppression of lymphocyte
proliferation and function and are regulators of local immunological events.
However, it is the local endometrial milieu that controls their activation and
therefore their function. Macrophages may also act in a synergistic manner to
amplify each other's activation.
Great interest has been directed towards the uNK and their role in the
endometrium by reproductive biologists. The uNK cells present within the
endometrium display a different phenotype to the majority of circulating
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blood natural killer cells with these being CD56-CD16+ (Koopman et al, 2003)
while natural killer cells within the endometrium are CD56+CD16-. This led to
them being assigned the name of uterine natural killer cells (Starkey et al, 1988,
King et al, 1991, Nishikawa et al, 1991, Geiselhart et al, 1995). A small subset
of peripheral blood NK cells exhibits this phenotype (Nagler et al, 1989). The
interest in uNK cells arose when it was observed that they appeared
immediately after ovulation (Salamonsen et al, 2002) and comprised over half
the endometrial leukocyte population at this time. Further increases in cell
populations occur specifically within the first trimester to comprise 70% of the
leukocyte population, which persists only until week 20 of gestation (Bulmer
et al, 2005).
At the time of decidualization, uNK cells are abundant and are suggested to
play a role in the decidualization process (King, 2000a). UNK cells express
LIF, GM-CSF and CSF-1 (Saito et al, 1993 et al, Jokhi, 1994a, 1994b, 1994c).
Another factor thought to be essential for pregnancy, IL-11, is required for
decidual-specific uNK cell maturation (Ain et al, 2004). These data may
suggest a contribution of the uNK cells towards the preparation of the
endometrium for implantation (Salamonsen et al, 2002). Human uNK cells
produce NO, polypeptide growth factors and angiogenic inducers such as
VEGF (Leonard et al, 2006, Li XF et al, 2001, Tayade et al, 2006, Hanna et al,
2006, Hunt et al, 1997). These factors can potentially promote maturation of
maternal arterioles, placental growth and development and guide or direct
maternal angiogenesis in a hypoxic environment (Carmeliet, 2003, 2005, Croy
et al, 1997) towards extravillous trophoblast and anchoring trophoblast, as
uNK cells are highly motile cells with receptors for trophoblast antigens
(Hanna et al, 2003, Hiby et al, 2004). Hypoxia is thought to contribute to the
regulation of VEGF expression in uNK cells and their interaction with the
endothelium (Leonard et al, 2006). VEGF mediates adhesion of uNK cells to
the vascular basement membrane and endothelial cells, possibly via fibronectin
binding (Burrows et al, 1995) only to developing rather than established vessels
suggesting non-innervated segments of vessels require uNK cell support (Chen
WS et al, 2002, Leonard et al, 2006).
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The function of the uNK cells however is still unclear. That they interact with
the trophoblast within the decidua basalis and are found clustered thickly
around maternal arterioles is accepted (Trundley & Moffett, 2004). It is
thought that they may regulate in some way the implantation process and
modulate placental development in order to ensure that neither under- or over-
invasion takes place in order to avoid rejection or parasitism (Loke & King,
1995), as the trophoblast expresses receptors for the cytokines and growth
factors expressed by the uNK cells (Jokhi et al, 1993, 1994a, King, 1995, Hanna
et al, 2006). The uNK cells may therefore be important determinants of
reproductive outcome.
From their name it may be considered that the uNK cells may attack the
partially foreign invading trophoblast, which is only part 'self' as it expresses
both maternal and paternal proteins. The trophoblast is extra-embryonic tissue
which expresses endogenous retroviral products, oncofetal proteins and
imprinted genes. From the maternal immune system perspective the fetal
tissues do not fit into any category of non-self, allogeneic, foreign or infected
(Moffet et al, 2004, Trundley & Moffett, 2004). It is therefore considered that,
depending on the maternal uNK cell receptor repertoire and the trophoblast
antigen profile, a form of allorecognition may occur (King et al, 1998). The
trophoblast express major histocompatibility complex (MHC) genes, HLA
class I, which are known to be uNK cell ligands. Trophoblast expresses HLA-
C, HLA-E and HLA-G. HLA-C is polymorphic and expression of the paternal
allele is suggested to be required for trophoblast recognition (Loke & King,
1995, Hiby et al, 2001, Trundley & Moffett, 2004, King et al, 2000b). HLA-G in
complex with HLA-E has high affinity for activating and inhibitory receptors
on the uNK cells (Vales-Gomez et al, 1999). Killer inhibitory receptors (KIR) on
the uNK cells, which are specific for HLA-C, and CD94 on natural killer cells,
for which HLA-E is a ligand, influence the development of the human placenta
(Hiby et al, 2004, Dietl et al, 2006). HLA-G is thought to protect against uNK
cell lysis by modulating the uNK cell cytokine profile thereby exerting an
immunosuppressive effect (Trundley & Moffet, 2004, Dietl et al, 2006).
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It is suggested that the overall result of interaction with the trophoblast is an
inhibition of the cytotoxic phenotype with a shift to non-killing uNK cells.
Indeed uNK cells have low cytotoxicity to phenotypic NK cell targets
(Manaseki et al, 1989). Some activities of the uNK cells however appear to be
essential to adequate placental development. Depletion of uNK cells due to
deficiencies in influencing cytokines results in malformation of maternal
vessels in insufficient trophoblast invasion leading to placental failure
(Guimond et al, 1997). The function of the uNK cells may therefore be to
neither advance nor retard the development of the placenta and maternal
vessels but to modulate development depending on expression of HLA class I
molecules, uNK cell receptors and cytokines present in the endometrial milieu.
Only uNK cells and macrophages have the opportunity to encounter the
trophoblast and interact with it thus potentially modulating its behaviour and
influence the overall reproductive outcome. As indicated above a number of
chemokines are present in the endometrium, which may initiate the initial
recruitment of these immune cells into the endometrium, to which the
endometrial vascular permeability may contribute. Once present they may
produce cytokines to perpetuate this recruitment into pregnancy where they
perform functions essential to the development of pregnancy (Ashkar et al,
2003).
1.4.6. Gene arrays on receptive endometrium and implantation genes
implicated by knockout studies
By gene knockout studies and gene array analysis examining expression of
genes during the window of implantation (LH+ 2-4 VS LH+ 6-10 overall
range) a number of factors not thus far discussed have been implicated in the
regulation of uterine receptivity and implantation.
1.4.6.1.Gene array studies of mid-secretory phase endometrium
In a comparison of six independent studies examining gene expression
differentially regulated during the window of implantation, compared with
the early secretory phase of the menstrual cycle, it was found that a
consensus of at least 3 arrays demonstrated significant elevation of 19
genes with significant down-regulation of 6 genes. The individual gene
Chapter 1 Literature Review 31
arrays demonstrated differential regulation of a greater number of genes
but due to differences in study design (e.g. Comparison of different days
after the LH surge) and differences in methodology (e.g. Pooled vs. non-
pooled samples, different gene array platforms) only a small number of
genes displayed consensus among the arrays. These data are summarised
in Table 1. These genes will now be discussed in more detail with reference
to their roles in receptivity and implantation.
Annexins are a superfamily of proteins that bind to calcium and
phospholipids and therefore may alter phospholipase activity and regulate
prostaglandin production, specifically PGF2„ production (Myatt et al, 1992,
Schatz et al, 1986). This may be important for myometrial quiescence as
PGF2u induces contractions of the myometrium (Friel et al, 2005), which
may be detrimental to maintenance of pregnancy.
Apolipoprotein D (ApoD) is required for lipid metabolism, which is
controlled throughout endometrial development and regulated specifically
during the window of implantation (Horcajadas et al, 2007) while anti-
progestins alter the endometrial lipoprotein profile (Benagiano et al, 2004,
Teran et al, 1987). ApoD may act as a transporter molecule for
progesterone and arachidonic acid for cellular function and prostaglandin
synthesis (Rassart et al, 2000). Prostaglandins, as discussed in Section
1.4.3 are thought to be important for implantation and decidualization.
Expression of complement protein lr (Clr) may be linked with expression
of another gene on the list, Ser (Cys) Clade G (CI) inhibitor member 1
(SERPING1). SERPING1 is an estrogen responsive gene in mice (Reese et al,
2001), which encodes a plasma protein that has been shown to regulate the
first component of Clr by inhibition of the proteolytic activity of its
subcomponents (Davis et al, 1986) and is therefore involved in the immune
response.
Decay accelerating factor or CD55 (DAF) is reduced in women with luteal
phase defect and antiphospholipid syndrome, a condition associated with
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implantation defects and early miscarriage (Kaul et al, 1995, Backos et al,
1999, Wilson et al, 1999). DAF is suggested to mediate protection against
lysis by complement.
Table 1. Endometrial genes up- or down-regulated by gene array analysis. Six individual gene
arrays were conducted; these data represent the consensus genes significantly changed on at
least 3 arrays. Adapted and amended from Wang & Dey, 2006, Nature Rev Genetics.
Gene Molecule encoded/ putative LH+ (8- LH+ (7-9) LH+ 7 vs. LH+ (6-8) LH+ 8 vs. MSE vs.
function 10) vs. vs. LH+ LH+2 vs. LH+ (3- LH+3 ESE
LH+ (4-6) (2-4) Riesewijk, 5) Mirkin, Talbi,




ANXA4 Annexin4 + + + +
AOPD Apolipoprotein D + + + + +
BNIP2 BCL-2/ cell death protein + + +
CLDN4 Claudin-4 + + + +
C1R Complement protein 1 r + + +
DAF Decay accelerating factor
for complement
+ + + + +
DF Complement factor D + + +
DKK1 Dickkopf-1 + + + + +
GADD45A Growth arrest and DNA
damage inducible protein
+ + + +
GBP3 Guanylate binding protein 2 + + +
ID4 Inhibitor DNA binding 4 + + + +
IL15 Interleukin 15 + + + + +
MAP3K5 Mitogen activated protein
kinase kinase kinase 5
+ + + +
MT1 Metallothionein 1 family
proteins
+ + + + + +
MAOA Monoamine oxidase A + + + + +
PAEP Progestagen associated
endometrial protein
+ + + +
RARRES1 RAR responder + + +
SERPING1 Ser (or Cys) clade G (CI
inhibitor (member 1)
+ + + +
SPP1 Secreted phosphoprotein 1 + + + + + +
TGF|3 TGF|3 superfamily proteins + + + +
Down-
regulated
CCNB Cyclin B proteins + + + +
FRPHE Frizzled related protein
frpHE
+ + + +
GATA2 GATA-binding protein + + +
MSX1 Hox Msh-like protein 1 + + + +
MSX2 Hox Msh-like protein 2 + + + +
OLFM1 Olfactomedin related ER
localised protein 1
+ + + + +
Complement factor D (DF) is a serine protease essential for the activation
of the alternative complement pathway and is expressed by macrophages
whose numbers increase during the window of implantation (Lesavre et al,
1978).
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Dickkopf-1 (DKK-1), a Wnt signalling antagonist, is a progesterone
regulated gene which is thought to limit Wnt action during endometrial
receptivity (Tulac et al, 2006), by binding low density lipoprotein (LDL)
receptor like protein (Mao et al, 2001). Expression of DKK-1 is down-
regulated during the window of implantation in women with
endometriosis, which may have implication for the defective implantation
associated with this condition (Kao et al, 2003).
IL-15 is an important endometrial chemokine, which mediates production
of NK cells from stem or progenitor cells and also recruits CD16- NK cells
into the endometrium from the peripheral blood (Keskin et al, 2007, Kitaya
et al, 2005). In the absence of IL-15 in the null mouse model a lack of uNK
cells recruitment is associated with a deficiency in spiral arteriole
modification and placental development (Ashkar et al, 2003).
Progestagen associated endometrial protein (PAEP), also known as
placental protein 14 or glycodelin, is elevated in the endometrium during
the secretory phase of the menstrual cycle (Julkunen et al, 1986), where it
represents one of the major glandular secretory products. PAEP is thought
to be essential for implantation and is down-regulated in the presence of
progesterone receptor antagonists which act as contraceptives (Uchida et
al, 2007, Cameron et al, 1997).
The conceptus can regulate expression of secreted phosphoprotein 1 (SPP-
1), which is also known as osteopontin, during decidualization (Herington
et al, 2007). In the human endometrium SPP-1 appears to be regulated by
progesterone (Apparao et al, 2001) and as a component of the ECM is
suggested to be important for adhesion of the blastocyst to the luminal
epithelium
Therefore, during the implantation window, gene array analysis has
demonstrated elevation of a number of genes with relevance to
implantation. However, it is intriguing that factors such as LIF, IL-11 or
COX-2, which knockout studies have identified as important for
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implantation, are not regulated in the endometrium at this time according
to gene array analysis.
1.4.6.2. Reproductive phenotypes of knockout mouse models
By gene knockout models a number of factors, in addition to those
discussed above, are suggested to be important in implantation. It is
intriguing therefore that, given the apparent necessity of these genes in
reproduction as indicated by their reproductive phenotypes, none of these
genes appear to be changed in a consensus of gene array analyses
described above. This may indicate that changes in these genes represent
only small changes on gene arrays, which would be filtered out when
selection criteria were applied.
Basigin is expressed in the luminal epithelium and the sub-luminal stroma
specifically around the implanting blastocyst. However Basigin null mice
fail to implant due to a maternal defect (Igakura et al, 1998, Kuno et al,
1998, Xiao et al, 2002a, 2002b).
FkBP52 (Fk506 binding protein 52) is a co-chaperone related to the heat
shock protein family. FkBP52 null mice display compromised uterine
progesterone receptor activity associated with aberrant expression of
progesterone responsive genes such as HOXA-10, indian hedgehog,
amphiregulin and histidine decarboxylase with a complete failure of
implantation (Tranguch et al, 2005, Yang Z et al, 2006). FkBP52 therefore
appears to be a critical determinant of progesterone actions in the uterus in
preparation for implantation. As indicated in section 1.4.3, other heat
shock family proteins have also been implicated in uterine receptivity and
implantation.
As discussed in section 1.4.3, LIF, IL-6 and IL-11 signal through
heterodimerisation of their receptors with gpl30, with mice null for these
factors or their specific receptor being infertile or displaying compromised
implantation due to a maternal defect. The reproductive phenotype for the
gpl30 STAT null model is therefore unsurprising considering the apparent
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requirement for these cytokines in implantation. The gpl30 STAT null
mouse displays no signs of implantation on day 5.5 post coitus (pc), the
null mice however appeared to be fertile and transferred blastocysts
developed in WT females. This suggests that downstream signalling of the
IL-6 family members though heterodimerisation of its receptors is a
necessary event for implantation, with a maternal defect responsible for the
absence of implantation (Ernst et al, 2001). Indeed, the contraceptive
mifepristone down-regulates signalling molecules which are induced by the
IL-6 family via activation of gpl30 (Catalano et al, 2003), it therefore
appears that gpl30 induced signalling is required for implantation.
HOXA-10 and -11 mice also appear to display implantation defects.
HOXA-10 deficient mice appear to be unable to support decidualization
and display a defect in uterine PGE2 receptors, EP3 and EP4, and COX-2
expression (Benson et al, 1996, Hsieh-Li et al, 1995, Lim et al, 1999). The
HOXA-11 null mice also display a complete absence of implantation, while
WT mice can support the implantation and development of HOXA-11
deficient blastocysts (Hsieh-Li et al, 1995). These suggest a maternal defect
is responsible for the implantation defect in both HOXA-10 and -11 mice.
Another homeobox gene, Hmx3, which belongs to a family distinct from
the larger classes of homeobox genes, also displays an implantation defect
with no implantation sites or decidual swellings on day 5.5 pc, however the
implantation of Hmx3 null blastocysts into WT surrogates again suggests
a maternal defect (Wang et al, 1998). These Hmx3 null mice also display
an absence of uterine LIF expression on day 4 of pregnancy whish is
essential for implantation (Stewart et al, 1992).
COX-2 signalling is essential for on-time implantation and decidualization
(Lim et al, 1997, Cheng & Stewart, 2003). In rodents the predominant
prostaglandin derived from COX-2 is prostacyclin (PGI2), however, this is
not the case in humans (Abel & Kelly, 1979). PGI2 synthase and its nuclear
receptor the Peroxisome proliferators activated receptor (PPAR)-S, along
with its obligate heterodimer the retinoid X receptor (RXR), are expressed at
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the rodent implantation site along with COX-2 (Lim et al, 1999). PPAR6
null animals display a placentation defect, which is characterised by the
formation of only loose connections between the placenta and the maternal
decidua (Barak et al, 2002), suggesting COX-2 - PGI2 - PPAR6 signalling
to be involved in this function.
These data indicate potential roles for genes with known functions during
the window of implantation and genes whose functions have still to be
investigated. Consensus of genes expressed during the window of
implantation from the gene array analysis may suggest genes which can be
used as markers of receptivity as this is a hotly debated topic and thus far
no-single marker has been implicated suggesting best practice may be to
use a selection of markers. Data from gene array and gene knockout
studies may also provide targets to examine in the case of infertility
associated with a possible implantation defect, whether this problem
represents unexplained infertility or infertility associated with luteal phase
defect, endometriosis or PCOS. These molecular markers may be used in
concert with the criteria for the morphological dating of the endometrium
and represent a more accurate picture of the receptive state of the
endometrium.
1.4.7. The effect of embryonic signals on the endometrium
It has been suggested that some changes which are necessary for implantation
only occur in the event of pregnancy and are not observed in the luteal phase of
non-pregnant cycles (Fazleabas & Strakova, 2002, Ghosh & Sengupta, 1998).
This has been investigated in the mouse, in vitro, where it was observed that
blastocysts attached to the endometrium from day 5 of pregnancy but did not
attach in pseudopregnant mice where embryonic signals are absent (Shiotani et
al, 1993). It therefore appears that the endometrium may not become fully
receptive in the absence of specific signals from the pre-implantation embryo
(Sharkey & Smith, 2003). HCG as one of the earliest embryonic products
(Bonduelle et al, 1988, Lopata & Hay, 1989, Hay & Lopata, 1988) is a prime
candidate to mediate these changes. Many studies have shown hCG to induce
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morphological and secretory changes in the endometrium in addition to its
action in preventing luteolysis of the corpus luteum (Shikone et al, 1996).
The LH/CG receptor is expressed in the non-pregnant endometrium and is
localised to the glandular and luminal epithelium and stromal compartment
(Bukovsky et al, 2003, Reshef et al, 1990, Licht et al, 2003, Bernadini et al,
1995). In the baboon, hCG treatment induces epithelial plaque formation in the
luminal epithelium and induces decidual changes in stromal fibroblasts
(Fazleabas et al, 1999) and hCG has also been shown to induce morphological
and functional decidualization of human stromal cells (Han et al, 1999).
Treatment with hCG of human endometrial cells in vitro and via a
microdialysis system of human and baboon endometrium in vivo has
demonstrated regulation of a number of growth factors and cytokines elevated
during the window of implantation and implicated in implantation such as
LIF, VEGF, M-CSF/CSF-1, MMP-9, PP14, IL-1, HB-EGF and IL-6 (Sherwin et
al, 2007, Licht et al, 1998, 2001, 2007, Filicori et al, 2005, Perrier d'Hauterive et
al, 2004, Uzumcu et al, 1998). A number of these factors are thought to have a
reciprocal effect on the trophoblast cells in inducing syncytialisation and
promo ting/controlling invasion (Sawai et al, 1995a, 1995b, Ren et al, 1997,
Morrish et al, 1998).
One of the first signs of successful implantation is an elevation of endometrial
permeability, which is thought to be mediated by COX-2 and COX-2 derived
prostaglandins. It has been demonstrated that hCG induces expression of
COX-2 and production of PGE2 in primary human stromal cells (Han et al,
1999, Zhou et al, 1999), suggesting that it is this embryonic signal, which
mediates the endometrial permeability. It has also been shown that hCG can
induce expression of proteins in leukocytes (Kosala et al, 2002) and peripheral
blood mononuclear cells isolated from women in early pregnancy promote in
vitro invasion of blastocysts when treated with hCG (Nakayama et al, 2002).
The endometrial immune cells may release factors which modulate trophoblast
invasion under the influence of hCG. The hormones to which the endometrium
is exposed throughout the menstrual cycle and early pregnancy influence its
development and preparation for pregnancy. Absence or dysregulation of one
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or more of these factors may result in deficient endometrial preparation for
implantation, a failure to implant or under- or over-invasion of the trophoblast
resulting in pathological pregnancy conditions. In order to avoid these
problems the hormonal influence on the endometrium must be tightly
regulated throughout the cycle and early pregnancy.
1.5. The Prokineticins
The prokineticins are two pleiotropic proteins, which have predicted physiological
and pathological functions in many tissues. Prokineticins were first described and
named by Li et al (2001). Two cDNA's were identified which encoded two
secreted proteins. These were shown to induce contraction in the smooth muscle of
the gastrointestinal tract only and were designated PROK1 and prokineticin 2
(PROK2) due to this contractile activity. While this was the first paper to describe
these proteins in the human, their expression in other species had been previously
demonstrated.
PROK1 is the human orthologue of a non-toxic protein present in the venom of the
black mamba snake Dendroaspis polylepis (Joubert & Strydom, 1980). This protein
is known as venom protein A (VPRA) or mamba intestinal toxin 1 (MIT-1,
Schweitz et al, 1990). This had previously been shown to induce contractions
specifically in the ileum and distil colon of the guinea pig while conversely
inducing relaxation in the proximal colon (Schweitz et al, 1999), which has also
been demonstrated for the human prokineticins (Li M et al, 2001, Hoogerwerf,
2006). The contractile effect is mediated via voltage dependent calcium channels
while the relaxation effect is mediated through nitric oxide release (Schweitz et al,
1999, Li M et al, 2001, Hoogerwerf, 2006). Subsequently LeCouter et al (2001)
described a growth factor, which, similar to VEGF, induced a variety of effects in
adrenal cortex endothelial (ACE) cells. These included a mitogenic response,
chemotaxis, fenestration and angiogenesis and cyst formation in the ovary. This
factor was designated endocrine gland vascular endothelial growth factor (EG-
VEGF) due to its functional similarities with VEGF in ACE cells despite the
absence of structural similarities (LeCouter et al, 2001). The amino acid sequences
for EG-VEGF and PROK1 are identical thus differential functions were described
for the same protein. Herein the proteins will be referred to as Prokineticins.
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PROK2 is the human orthologue of a protein isolated from the skin of the yellow
bellied frog Bombina variegata. This protein was designated Bv8 to reflect its origin
(Bombina variegata) and its size of around 8kDa. Prior to its discovery in humans,
expression of Bv8 had been reported in mouse testis, brain, ovary, kidney, uterus
and heart (Wechselberger et al, 1999). Along with its homologue MIT-1, Bv8 has
been reported to induce hyperalgesia in rats (Mollay et al, 1999). Prokineticins
sensitise the transient receptor potential vanilloid 1 thus inducing hyperalgesia
(Negri et al, 2002, Vellani et al, 2006).
PROK1 forms a mature protein of 86 amino acids with a signal peptide of 19
amino acids and PROK2 forms a mature protein of 81 amino acids (Li M et al,
2001, Lecouter et al, 2001). The gene encoding PROK1 is present on chromosome
lp21 (Kaser et al, 2003). PROK2 is the human paralogue of PROK1 and is located
on chromosome 3p21.1 (Kaser, 2003). A splice variant of PROK2 has been
identified in the testis of the human, mouse and bull. This splice variant contains
an insert of 21 amino acids of which 11 are lysines or arginines; this led to the
splice variant being named Bv8-basic (Wechelberger et al, 1999). The human
PROK1 and PROK2 are around 58% identical (LeCouter et al, 2001). These
proteins display significant homology with DKK-1 and Co-lipase (Glinka et al,
1998, Aravind et al, 1998). Interestingly the prokineticins, DKK-1 and Co-lipase
share a common structural motif of 10 conserved cysteines which are predicted to
form a fold within the molecule with disulphide bonding between the cysteines
(van Tilbeurgh et al, 1992, Boisbouvier et al, 1998). A striking feature of the
prokineticins is their N-terminal amino acid sequence - AVITGA, which is
completely conserved. As may be expected by the conservation of this sequence, it
is absolutely essential to the activity of these proteins. Mutations to this sequence
produce prokineticin receptor antagonists or recombinant proteins, which have no
effect at the receptors (Bullock et al, 2004, Negri et al, 2005).
1.5.1. Prokineticin receptors
The prokineticins are the cognate ligands for two closely related G-protein
coupled receptors (GPCR's). In the study of Li et al (2001), which first
described the human prokineticins, the receptors were suggested to be GPCR's
due to the ability of GTPy to displace prokineticin binding. The receptors were
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subsequently further characterised and demonstrated to be GPCR's termed
PROKR1 and PROKR2, these exhibit 85% amino acid identity with the greatest
difference in their N-terminal sequences (Lin DC et al, 2002, Lin R et al, 2002,
Masuda et al, 2002 et al, Soga, 2002). PROK1 preferentially activates PROKR1
while PROK2 preferentially activates PROKR2 (Lin DC et al, 2002). The
prokineticin receptors are reported to couple to Gi (Lin R et al, 2002) Gq (Lin
DC et al, 2002, Masuda et al, 2002, Soga et al, 2002) or Gs (Chen et al, 2005).
1.5.2. Tissue localisation and potential functions of the prokineticins
Expression of prokineticins and their receptors has been reported in a number
of human and animal tissues including the testis (Wechelberger et al, 1999, Li
M et al, 2001, LeCouter et al, 2001, Lin DC et al, 2002, Samson et al, 2004,
Lecouter et al, 2003) prostate (Pasquali et al, 2006), ovary (Ferrara et al, 2003,
Li M et al, 2001, Kisliouk et al, 2003, Fraser et al, 2005), placenta (LeCouter et
al, 2001, Hoffmann et al, 2006, Chung et al, 2004, Li M et al, 2001),
endometrium (Battersby et al, 2004a, Ngan, 2006 et al, Li M et al, 2001), and a
number of non-reproductive tissues including the brain (Lin DC et al, 2002,
Soga et al, 2002, Cheng et al, 2002, Ng et al, 2005, Li M et al, 2001) adrenal
glands (Lecouter et al, 2001, Lin DC et al, 2002) and colon (Lin DC et al, 2002,
Li M et al, 2001 et al, Soga, 2002). The expression of prokineticins in the colon
is suggested to contribute to its contractility (Li M et al, 2001, Hoogerwerf,
2006). Expression of PROK2 in the brain and central nervous system is
suggested to have a number of roles. PROK2 is suggested to have an essential
role in supporting neuronal survival (Melchiorri et al, 2001). PROK2 exhibits a
profile of circadian oscillation in the suprachiasmatic nucleus and is proposed
to be responsible for the circadian locomotor rhythm (Cheng et al, 2002, Li JD
et al, 2006). Studies both in vitro and in vivo have demonstrated the absolute
necessity of PROK2-PROKR2 signalling in olfactory bulb neurogenesis and
migration of gonadotropin releasing hormone (GnRH) neurones (Ng KL et al,
2005, Matsumoto et al, 2006). Mice lacking expression of PROKR2 display
multiple defects including non-development of the olfactory bulb and atrophy
of the male and female reproductive systems (Matsumoto et al, 2006).
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A role for the prokineticins has also been suggested in the immune response
and haematopoiesis. PROK2 is expressed in peripheral blood cells of the innate
immune system including monocytes, dendritic cells and neutrophils, as well
as bone marrow cells (Lecouter et al, 2004) while PROK1 is expressed in
inflamed tissues (Dorsch et al, 2005). Prokineticins are proposed to promote
survival and differentiation of granulocytic and monocytic cells and induce
chemotaxis of macrophages with induction of an inflammatory phenotype
(Martucci, 2005 et al, Dorsch et al, 2005). Expression of PROK2 and
prokineticin receptors in progenitor and mature blood cells suggests a role for
the prokineticins in haematopoiesis (LeCouter et al, 2004). In other tissues a
role for PROK1 in angiogenesis associated with colorectal cancer and age
related macular degeneration has been suggested in mouse models using in
vivo PROK1 production (Goi, 2004 et al, Tanaka et al, 2006).
The prokineticins are expressed in male and female reproductive tissues. Their
expression has been characterised in a number of tissues and pathologies,
however their functions in these tissues have not yet been fully defined.
In the male reproductive tract, prokineticins and their receptors are expressed
in the testis and the prostate. In the prostate the expression of PROK1 has been
demonstrated in the hyperplastic and cancerous tissue (Pasquali et al, 2006)
potentially suggesting a role for PROK1 in the pathogenesis of this disease. In
the testis PROK1 localises mainly to the testosterone producing Leydig cells
with PROK2 expression in the spermatocytes (Wechselberger et al, 1999,
LeCouter et al, 2003, Samson et al, 2004). PROKR1 is expressed at higher
levels than PROKR2 in the testis (Lecouter et al, 2003). Prokineticin signalling
in the testis is proposed to modulate testosterone transport and angiogenesis
in the normal tissue (LeCouter 2003 et al, Samson et al, 2004). Prokineticins
also potentially contribute to angiogenesis in the pathological testis specifically
in tumours of Leydig cells (Samson et al, 2004).
In female reproduction the prokineticins have potential roles in the normal
functioning of the reproductive tract and pregnancy. In the normal ovary,
expression of PROK1 is dynamic whereas PROK2 does not appear to be
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expressed (Ferrara et al, 2003, Zhang et al, 2003). In the primordial and
primary follicles PROK1 expression is demonstrated in the granulosa cells. In
antral follicles, PROK1 expression is low in the theca cells with strong
expression in the residual thecal cells of the mature atretic follicle (Ferrara et al,
2003). PROK1 expression in the extruded corpus luteum demonstrates
elevation as it matures (Ferrara et al, 2003, Fraser et al, 2005). In vitro studies
have suggested a role for PROK1 in angiogenesis in the corpus luteum though
induction of VEGF expression and roles in proliferation and survival of
corpora lutea endothelial cells (Kisliouk et al, 2005a, 2005b). In the polycystic
ovary expression of PROK1 has demonstrated a correlation between ovarian
hyperplasia and angiogenesis (Ferrara et al, 2003). Indeed, it has been
demonstrated that delivery of PROK1 to the ovary results in gross
angiogenesis and formation of ovarian cysts (LeCouter et al, 2001).
In the non-pregnant endometrium PROK1 is elevated during the secretory
phase of the menstrual cycle and is specifically suggested to be elevated
during the mid-secretory phase (Battersby et al, 2004a, Ngan et al, 2006,
Figure 1.8). PROK2 and the prokineticin receptors are also expressed in the
uterus but do not demonstrate temporal variation across the menstrual cycle
(Battersby et al, 2004a). The prokineticins and their receptors localise to the
epithelium, stromal and endothelial compartments of the endometrial
functional layer in addition to the endothelial and smooth muscle cells of the
myometrium (Battersby et al, 2004a). PROK1 expression is suggested to be
down-regulated in endometrial cancer compared with the normal
endometrium (Ngan et al, 2006) and is also suggested to disappear after
menopause (Ngan et al, 2006). Expression of PROK1 is suggested to be
modulated by ovarian steroid hormones; therefore cyclical expression of
PROK1 may characterise endometrial development from menarche to
menopause (Battersby et al, 2004a, Ngan et al, 2006, Figure 1.8). PROK1 may
also have a role during the implantation window; PROK1 is elevated in the
endometrium during the peri-implantation phase of the menstrual cycle when
the endometrium becomes receptive to blastocyst implantation (Battersby et
al, 2004a, Ngan et al, 2006). During this phase PROK1 may mediate
endothelial leakage, one of the earliest signs of implantation (Plaks et al, 2006)
Chapter 1 Literature Review 43
by inducing fenestrae formation and increasing microvascular permeability
facilitating implantation (LeCouter et al, 2001).
PROK1 and PROKR1 are elevated in early placental tissues during the critical
hypoxic period of placentation (weeks 8 - 10), with localisation of PROK1 to
the syncytio- and cytotrophoblast (Hoffmann et al, 2006). PROK1 expression
is inducible by hypoxia (LeCouter et al, 2001, Hoffmann et al, 2006)
potentially suggesting a role for the prokineticins in placentation. It has been
suggested that PROK1 may play a role in normal pregnancy but not in
pathological pregnancy, as expression of PROK1 is not altered in pre¬
eclamptic placentas (Chung et al, 2004). PROK1, PROKR1 and PROKR2 have
been localised and the pattern of expression investigated in the mouse
placenta. PROK1 and PROKR1 are elevated from day 9.5 to day 10.5 pc in the
mouse placenta, while PROKR2 is elevated from days 10.5 to 14.5 pc
(Hoffmann et al, 2007). PROK1 is expressed in the labyrinth layer, with strong
trophoblast staining, and the ectoplacental cone, while the receptors are
expressed in the labyrinth layer, the trophoblast giant cells and the endothelial
cells (Hoffmann et al, 2007). It is suggested that PROK1 may play dual roles
within the mouse placenta via the trophoblast cells, contributing to placental
growth, and via the giant cells, contributing to decidual invasion. As
macrophages increase in number in the endometrium during early pregnancy
and PROK1 induces chemotaxis of macrophages (Martucci et al, 2005)
recruitment of macrophages may be another role for the prokineticins in early
pregnancy.
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Figure 1.8. Representation of the dynamic variation in endometrial PROK1 expression in concert with
Progesterone across the menstrual cycle. Adapted from Maldonado-Perez et al, 2007.
The prokineticins therefore have diverse proposed functions, which appear to
be tissue specific. A great deal of clarification is required to delineate
functions, signalling and gene activation in the various tissues. It appears that
the main roles of PROK2 are in the brain while PROK1 appears to be mainly
localised in the peripheral tissues.
1.5.3. Prokineticin 1 mediated signalling
Thus far, only preliminary signalling experiments have been performed in order
to elucidate prokineticin mediated intracellular signalling. It has been
established that prokineticin receptors are G-protein coupled receptors (Li et al,
2001, Lin R et al, 2002, Lin DC et al, 2002, Masuda et al, 2002, Soga et al,
2002, Chen et al, 2005) however, their G-protein coupling has not thus far been
established. Additionally, the main body of work investigating prokineticin
mediated intracellular signalling has been performed on immortalised cell lines
transfected with prokineticin receptors with little thought given to the potential
differences in signalling inherent in different tissues or different pathological
states. As indicated above, the study of Li et al predicted the prokineticin
receptors to be GPCR's due to the ability of GTPy to displace prokineticin
binding (Li et al, 2001). In 2002 a number of papers were published describing
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the G-protein coupling of the prokineticin receptors, however, differences in
signalling emerged. In the paper of Lin R et al (2002), prokineticin receptors
were reported to be Gi coupled, activate ERK 1/2, Akt and Enos
phosphorylation and was not dependent on VEGF signalling (a schematic
representing Gi coupled receptor mediated signalling is indicated in Figure
1.9). Gi mediated intracellular signalling leads to inhibition of cAMP
production and can result in ERK 1/2 phosphorylation.
PROK1
Figure 1.9. Schematic representing Gi coupled receptor signalling
The work of R Lin et al was performed in primary cells, namely bovine adrenal
cortex endothelial cells. Other reports published on prokineticin mediated
signalling, however, disagreed with the indication that the prokineticin
receptors were Gi coupled. The reports of Lin DC et al (2002), Masuda et al
(2002) and Soga et al (2002), suggested prokineticin receptors to be Gq
coupled. These studies examined established second messengers induced
upon Gq-coupled receptor activation, including calcium and inositol
phosphate mobilisation (a schematic representing Gq coupled receptor
mediated signalling is indicated in Figure 1.10). Additionally, Chen et al (2005)
reported that stimulation of cells expressing prokineticin receptors 1 and 2
with prokineticin 2 induced production of c AMP and activation of the CRE (c
AMP response element) promoter, therefore suggesting the receptors to be Gs
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coupled (schematic representing Gs coupled receptor mediated signalling is
indicated in Figure 1.11) The studies, however, were not performed in primary
cells but immortalised HEK293 (human embryonic kidney), COS-7 (African
green monkey kidney fibroblast) and CHO (Chinese hamster ovary) cells
transfected with the prokineticin receptors. This allowed one ligand-one
receptor studies to be performed as these cells can be maintained in culture
with stable expression of the transfected receptors. Whereas primary cells,
which have a limited culture time, may express different receptors and
different levels of receptors, therefore it is difficult to know which receptors
and how much of each receptor is expressed without PCR and protein analysis
of receptor expression in each batch of cells. However, an inerrent problem with
immortalised transfected cells is that they may not represent the actual
physiological situation. The current reports examining prokineticin mediated
signalling indicate that prokineticin receptors can couple to multiple G-
proteins, and thus the signalling outcome may depend on which receptor -
ligand combination is present. Thus far, no examination of the signalling
mediated via prokineticin receptors has been performed in a specific human
tissue or pathological condition.
^-PROK1
Figure 1.10. Schematic representing Gq coupled receptor signalling
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Figure 1.11. Schematic representing Gs coupled receptor signalling
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1.6. Aims and objectives of this thesis
As mentioned in section 1.4, an inadequacy in uterine receptivity accounts for a
growing proportion of implantation failures and is now considered as a major
cause of infertility in otherwise healthy women (Achache & Revel, 2006). Infertility
is a growing problem with a great socio-economic impact on health-care and
resources. Assisted conception programmes are high cost, both emotionally and
financially for the people involved. Much effort has been directed to identifying
human markers of uterine receptivity. However, no outstanding candidate has
thus far emerged. Uterine receptivity may therefore be defined by a number of
histological, hormonal, morphological and molecular parameters. Elevation of
PROK1 during the secretory phase of the menstrual cycle revealed a protein with
potential as a marker of uterine receptivity. However, to date, little is known
about PROK1 and its role in the endometrium. It was therefore hypothesised that
endometrial PROK1 signalling via PROKR1 may contribute to uterine receptivity
and possibly the implantation process. The specific aims of this research were to: -
1. Further examine the expression and localisation of PROK1 and PROKR1 in the
non-pregnant endometrium and determine the expression and localisation of
these factors in the pregnant and pathological endometrium. This was
conducted on endometrial tissue taken across the menstrual cycle, from 7-12
weeks of gestation and from well, moderately and poorly differentiated
endometrial cancer samples.
2. Characterise an endometrial cell line stably expressing PROKR1 and determine
the signalling pathways activated upon PROK1-PROKR1 interaction.
3. Determine PROK1 target genes activated upon PROK1-PROKR1 interaction.
This was investigated by gene array analysis using the Affymetrix GeneChip®
Human Genome U133 Plus 2.0 and the ABI 1700 v.2 Applied Biosystems
Human Genome Survey microarrays.
4. Further investigate the temporal regulation and mechanism of two PROK1
regulated genes, COX-2 and LIF.
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5. Determine the physiological relevance of the data obtained using the PROKR1
Ishikawa cell line. This was investigated by protein phosphorylation cascade
activation, temporal regulation and mechanism of gene expression induced by
PROK1 in first trimester decidua.
6. Determine potential paracrine mediators of PROK1 expression in early
pregnancy. This was investigated by examination of PROK1 and LIF expression
induced by hCG in PROKR1 Ishikawa cells and first trimester decidua
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Chapter 2 - General materials and methods
2.1. Reagents and suppliers
A list of suppliers is provided in appendix 1
2.2. Tissue collection
2.2.1. Endometrial Tissue
Endometrial tissue collection was performed with ethical approval from
Lothian Research Ethics Committee under ethics number LREC/05/S1103/32.
Written informed consent was obtained from all subjects prior to tissue
collection. Endometrial biopsies at different stages of the menstrual cycle were
obtained from women with regular menstrual cycles (25 - 35 days) who had
not received a hormonal preparation in the 3 months preceding biopsy
collection. Samples were collected either with an endometrial suction curette
(Pipelle, Laboratoire CCD) or as full thickness endometrial biopsies (including
functional layer and basal-myometrial junction) from women undergoing
hysterectomy for benign gynecological conditions. Shortly after collection,
tissue was snap frozen in dry ice or placed in RNAlater (Ambion) and stored
at -70°C (for RNA extraction) or fixed in neutral buffered formalin and wax
embedded (for immunohistochemical analysis). Biopsies were dated according
to stated last menstrual period and confirmed by histological assessment by a
pathologist. Furthermore, circulating estradiol and progesterone concentrations
(assay described in Section 2.9.3) at the time of biopsy were consistent for both
stated last menstrual period and histological assignment of menstrual cycle
stage. Samples were divided according to phase of menstrual cycle as early
proliferative, mid proliferative, late proliferative to ovulatory, early secretory,
mid secretory and late secretory
2.2.2. Decidua tissue
Decidua tissue collection was performed with ethical approval from Lothian
Research Ethics Committee under ethics number LREC/05/S1103/32.
Written informed consent was obtained from all subjects prior to tissue
collection. First trimester decidua (7-12 weeks) was collected from women
undergoing elective first trimester surgical termination of pregnancy (STOP).
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Shortly after collection, tissue was placed in RNAlater (Ambion) and stored at
-70°C (for RNA extraction), fixed in neutral buffered formalin and wax
embedded (for immunohistochemical analysis) or placed in RPMI 1640
(Sigma; containing 2mM (mmol/litre) L-glutamine, 100U penicillin, and
lOOpg/ml streptomycin, PAA laboratories) for tissue culture. Gestation of
pregnancy was confirmed by ultrasound scan prior to procedure.
2.2.3. Endometrial cancer tissue
Endometrial cancer tissue collection was performed with ethical approval from
Lothian Research Ethics Committee under ethics number LREC/1999/6/4.
Written informed consent was obtained from all subjects prior to tissue
collection. Endometrial cancer tissue was obtained from women undergoing
surgery for removal of endometrial cancer. Shortly after collection, tissue was
placed in RNAlater (Ambion) and stored at -70°C (for RNA extraction) or
fixed in neutral buffered formalin and wax embedded (for
immunohistochemical analysis). Cancer biopsies were assessed by a
pathologist and assigned a grade, grade 1 - well differentiated, grade 2 -
moderately differentiated or grade 3 - poorly differentiated.
2.3. Cell culture
2.3.1. PROKR1 receptor transfection and amplification
This cell line was kindly produced by Dr K Morgan. Human cDNA encoding
prokineticin receptor 1 (PROKR1) was prepared using RT-PCR. RNA from
IMR-32 neuroblastoma cells was reverse transcribed using random primers
(Promega) and superscript reverse transcriptase (Invitrogen). Receptor cDNA
was amplified using Easy-A DNA polymerase (Stratagene) and specific
primers:
Forward 5' GGA TCC AAG CTT GAT GGA GAC CAC CAT GGG G 3'
Reverse 5' CTC GAG GAT ATC TTA TTT TAG TCT GAT GCA GTC CAC CT
3'.
The PCR product was excised from a 1% agarose gel following electrophoresis,
purified, ligated into sequencing vector pCR4 (Invitrogen) and cloned into
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E.Coli TOPIO cells. Cloned plasmid DNA was subjected to automated DNA
sequencing to confirm the cDNA sequence prior to subcloning the Hind III-
EcoRV fragment into pcDNA 3.1(+). This expression construct was
transfected into Ishikawa cells using electroporation and G418 resistant clones
were isolated. These cells are subsequently termed PROKR1 Ishikawa cells.
2.3.2. Cell culture conditions
A cell line of immortalised endometrial cells (Ishikawa) was used throughout
the study. The Ishikawa cell line was deposited by A. Taylor at the University
of Leicester from endometrial epithelial cells taken from endometrial
adenocarcinoma. Cells were transfected with PROKR1 cDNA in the sense
direction (as indicated in Section 2.3.1) and cultured in complete DMEM
Glutamax medium (Section 2.11) supplemented with 200pg/ml G418
antibiotic. All cell culture took place in humidified conditions at 37°C with 5%
carbon dioxide. Cells were routinely passaged in T162 flasks at 37°C to
maintain sufficient numbers of cells for experimental treatments. Wild type
(WT) Ishikawa cells were maintained as above without the addition of G418
antibiotic.
2.3.2.1. Passaging of cells
Cells grown in T162 flasks were passaged at 3-4 day intervals, when cell
density within culture vessels reached ~70%. Complete DMEM Glutamax
medium was removed and cells were washed twice with approximately
10ml phosphate buffered saline (PBS), without CaCE or MgCE, to remove
any remaining medium containing serum. The PBS was removed and
replaced with 3ml of 0.05% Trypsin-EDTA and cells incubated for
approximately 5 minutes at 37°C until the cells became detached from the
surface of the culture flask. Trypsin digestion was stopped by addition of
7ml Complete DMEM Glutamax medium containing serum, sufficient to
inactivate trypsin activity. In order to passage the cells, 2ml of the cell
suspension was transferred to a fresh T162 flask and the total volume of
the Complete DMEM Glutamax medium made up to 25ml. Cells to be
seeded out for experimental use were counted using a haemocytometer
and plated into culture vessels at the density indicated in Table 2.
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Table 2. Cell density in culture vessels











2.3.3. Cell and tissue treatments
PROKR1 Ishikawa cells were treated with PROK1 (Promokine, reconstituted in
water) at various concentrations (4pM, 40pM, 400pM, 4nM, 40nM) in order to
determine the optimal dose of PROK1 to be used in subsequent studies (the
physiological concentration of PROK1 is currently unknown). 40nM was
revealed as the dose of PROK1 that elicited the optimal response in PROKR1
Ishikawa cells, and was therefore used in all subsequent studies in PROKR1
Ishikawa cells and first trimester decidua tissue.
In order to determine the maximal time of PROK1 induced ERK 1/2
phosphorylation, PROKR1 Ishikawa cells or first trimester decidua were
treated with 40nM PROK1 for 0, 1, 5, 10, 20, 30, 45 or 60 minutes.
In order to determine the time of maximal gene expression in response to
PROK1, PROKR1 Ishikawa cells or first trimester decidua were treated with
40nM PROK1 for 0, 2, 4, 6, 8, 12 or 24 hours.
In order to study signalling molecules activated by PROK1-PROKR1 in
signalling to ERK 1/2, specific inhibitors of signalling molecules were used.
Similarly, in order to determine the signalling molecules that lead to PROK1
mediated gene expression specific inhibitors of signalling molecules were used.
Indicated in Table 3 is a list of the inhibitors used, the signalling molecules
they specifically inhibit and the concentration at which they were applied to the
PROKR1 Ishikawa cells or first trimester decidua tissue. Actinomycin D, an
inhibitor of transcriptional activation and Cyclohexamide, an inhibitor of
protein synthesis were also used. All inhibitors were used at concentrations at
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or below their IC50 or working concentrations reported for other systems and
were dissolved in DMSO. YM254890 was a kind gift of Dr Jun Takasaki; all
other inhibitors were purchased from Calbiochem.
Table 3. Concentrations of inhibitors




YM254890 Gq protein lpM lpM
Pertussis toxin Gi protein 200ng/ml lpg/ml
U73122 Phospholipase C-fi lOpM lOnM
BAPTA-AM Calcium chelator 50pM 2mM
PP2 cSrc lOpM 50pM
AG1478 EGFR 200nM lOOpM
PD98059 MEK 50pM 50pM
NS-398 COX-2 10pM 11.3mM
Cyclohexamide Protein synthesis 10pg/ml 100pg/ml
Actinomycin D Transcriptional activity 250ng/ml 5pg/ml
In order to understand how the various inhibitors inhibit intermediate
signalling molecules the mechanism of inhibition mediated by these chemicals
must be understood.
YM254890 is a cyclic peptide isolated from the culture broth of
Chromobacterium SP (Taniguchi et al, 2003). It contains uncommon amino
acids p-hydroxyleucine, N,0- dimethylthreonine and N-methyldehydroalanine
(Taniguchi et al, 2003). YM254890 blocks the exchange step of GDP for GTP in
Guq activation. YM254890 inhibits Ca2+ mobilisation in cells specifically
expressing Gq coupled receptors. Constitutively active Gq R183C is completely
inhibited by YM254890. This is a fairly new inhibitor and the half life is
currently unknown.
The mechanism of action of U73122 is thought to involve the electrophillic
maleimide side chains of the molecule, as substitution of this moiety results in
loss of activity (Smith RJ, 1990). It is suggested that the inhibition occurs by
alkylation of sulfhydryl groups or other nuceophiles needed for the activation
or activity of a protein permissive for second messenger function. The steroid
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portion of the molecule is necessary for the inhibitory action in part by
conferring lipophilicity to the molecule (Yule, 1992). U73122 inhibits
intracellular calcium mobilisation at the level of IP3 production (Smith et al,
1990). Additionally, GTPyS stimulation of phosphoinositide turnover is
inhibited by U73122 (Yule et al, 1992), demonstrating that U73122 acts at the
level of PLC. The half life of U73122 in cell culture systems is unclear as it has
recently been demonstrated that the availability of U73122 to interact with
PLC may be hampered through conjunction of the malemide group to non¬
specific biological nucleophiles such as L-glutamine, reducing the biological
half life of the molecule (Wilsher NE, 2007)
BAPTA-AM is the cell permeable form of BAPTA. It is hydrolysed once
loaded into cells by Cytosolic esterases and is trapped intracellularly as the
active chelator BAPTA (Calbiochem). Chelation is the binding or complexation
of a bi- or multi-dentate ligand, in this case calcium. BAPTA-AM sequesters
calcium rendering it unable to initiate downstream signalling events.
Upon expression of Src family members p56lck and p59hnT by vaccinia virus,
PP2 specifically inhibited their activity. PP2 also inhibits the phosphorylation
of endolase, this is specifically mediated by Src family member p56lck (Hanke
et al, 1996)
EGFR forms a ternary complex with ATP and the peptide substrate. AG1478
competes with ATP binding to cause signalling inhibition (Ward et al, 1994).
This occurs due to the non-polar meta- substituents on the aniline ring of the
molecule (Wakeling et al, 1996). It is therefore competetitive with ATP and
non-competitive with substrate.
MEK's are activated by phosphorylation on serine residues by up-stream
kinases. MEK's can then catalyse phosphorylation of both threonine and
tyrosine residues. PD98059 blocks tyrosine and threonine phosphorylation of
MAPKK. PD98059 does not compete for ATP binding and inhibits through an
allosteric mechanism, PD98059 does not bind the active site but interacts at
another site thereby blocking access to activating enzymes. PD98059 actively
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inhibits activation and phosphorylation of MEK (Dudley et al, 1995, Alessi et
al, 1995).
NS-398 acts as a competitive, non-reversible inhibitor specifically for COX-2
over COX-1. NS-398 binding to COX-2 mediates a conformational transition of
the enzyme leading to significantly tighter binding of the inhibitor to the
enzyme without any chemical modification of the enzyme or inhibitor. NS-398
competitively binds to the active site of COX-2 only as COX-1 mediated
prostaglandin production is not inhibited in the presence of NS-398 (Futaki et
al, 1994, Copeland et al, 1994).
Actinomycin D inhibits RNA polymerase by complexing with DNA via
deoxyguanosine residues (Calbiochem)
Cyclohexamide inhibits transferase II (Felicetti et al, 1966), this action is
sulfhydryl dependent (Sutler et al, 1966). Cyclohexamide may retard the
peptide elongation by inactivating the sulfhydryl groups of transferase II. The
GTP hydrolysis reaction required for chain elongation also involved sulfhydryl
dependent enzymes (Baliga et al, 1969).
Human chorionic gonadotropin (hCG, Sigma) was used at a concentration of
1IU (international unit). The physiological concentration appears to vary from
around 1IU to 33000 IU, varying between patients, gestation of pregnancy etc.
Therefore 1IU of hCG was chosen as the minimum dose likely to elicit a
response in both cells and tissue. Previous studies have used doses ranging
from 1-50IU (Perrier d'Hauterive, 2004).
2.3.4. Transient transfection of c-Myc ERK, dominant negative isoforms of
signalling molecules and COX-2 luciferase promoter reporter constructs
2.3.4.1.Production and characterisation of dominant negative isoforms of
signalling molecules
The dominant negative constructs utilised in this study were kindly
provided by Dr Zvi Naor (Department of Biochemistry, Tel Aviv
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University, Tel Aviv, Israel) and have been previously characterized and
described (Harris et al, 2002, Levi et al, 1998). Further information on the
production and characterisation of DN-cSrc, DN-EGFR, DN-Ras and DN-
MEK are indicated below.
DN-cSrc was originally cloned by Nada et al (1991), it is also known as
Csk. Csk is a protein tyrosine kinase, which negatively regulates cSrc by
specifically phosphorylating a negative regulatory site. Initially Csk was
purified from the membrane fraction of neonatal rat brain by sequential
column chromatography. The cDNA that encodes Csk was cloned and the
primary structure deduced (nucleotide sequence and deduced amino acid
sequence provided in Figure 2.1, Nada et al, 1991). Csk lacks a tyrosine
residue at a site corresponding to tyrosine 416 - a site for
autophosphorylation. The members of the Src family share a highly
conserved sequence around this site and are autophosphorylated at a
tyrosine residue equivalent to Tyr416. Csk however shows no
autophosphorylation. The dominant negative effect was demonstrated by
Nada et al (1991) and Dikisc et al (1996).
DN-EGFR was originally cloned by Livneh et al (1986). Full length c DNA
was pieced together from overlapping X phage clones X HER-A21 and
subcloned into PBR322. Final subclone was extended fromn the Sst I site,
15bp before the initiation codon for translation. Both ends were changed to
Xho I sites using synthetic DNA linkers and subcloned into the Pvu II site
of PBR 322 that was changed to an Xho I site in a similar manner. EGFR
receptor c DNA with Xho I ends was placed into and early substitution
SV40 based expression vector. The Sma I site was changed to an Xho I site
and was used for cloning the plasmid. The final plasmid in the correct
orienttarion is denoted as pLSX. Plasmid pLA B71 was constructed by
partial digestion of pLSX with Bal I at nucleotide 2485. Xba I inkers were
added and excess linkers removed by digestion with Xba I followed by
agarose gel electrophoresis. Plasmid pLA NA8 (DN-EGFR) was
constructed from pLA B71 . pLA B71 was digested by Nar I and
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staggered ends filled in with a Klenow fragment of DNA polymerase I. The
blunt ended fragment was ligated with a synthetic 26-bp double stranded
oligonucleotide composed of 18bp which represents sequence 2199 - 2217
of the EGF receptor attached to a 7bp sequence containing the Xba I site,
with the sequence 5' - CCA CAT CGT TCG GAA GCC TCT AGA G - 3'.
The ligated fragment was cleaved by Sma I and excess Xba I was purified
by gel electrophoresis. This 1.2kb fragment was further ligated to a 8kb
Sma-Xba I fragment which was recovered from p LSX. The activity of pLA
NA8 as a dominant negative was demonstrated by Livneh et al (1986) and
Kashles et al (1991). The plasmid map for DN-EGFR is provided in Figure
2.1.
The Asn-17rasHp21 (DN-Ras) gene was isolated by Feig et al (1988) by
randomly mutagenising a cellular rasH bacterial expression vector (p XCR)
and screening for GTP binding mutants with a bacterial colony GTP
binding assay. The entire ras-coding sequence of the metant was
determined by the dideoxy method (Sanger et al, 1977). This construct has
preferential affinity for GDP (Feig et al, 1988). The Asn-17 mutant was
isolated as a rasH mutant with preferential affinity for GDP versus GTP.
The asparagines for serine substitution at position 17 maps to a region of
p21 that is highly conserved among all GTP-binding proteins. The
dominant inhibitory action of this construct is demonstrated by Feig et al
(1988) and Stacey et al (1991). Asn-17rasHp21 displayed approximately a
40 fold decrease in affinity for GTP binding compared with normal
rasFIp21 with GDP binding maintained.
In order to produce DN-MEK, MKKla (MAP kinase kinase/MEK) cDNA
was modified to ensure optial overexpression by generating a Kozak
sequence in the 5' end of the c DNA, The oligonucleotide GGA TCC GCC
GCC ACC ATG GCA CCC AAG AAG AAG CCG was used in a PCR
reaction to replace the first 55 base pairs of MKKla (Seger et al, 1992). The
product was then inserted into Eco RI and Bam HI sites of the pc DNA 3
vector DNA which contains a gene for neomycin resistance, propagated in
XL-1 cells and sequenced to ensure it correst composition. Point mutations
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were made by PCR using the above construct as a template for K97A (DN-
MEK), the sense primer is TCA TGG CCA GAG CGC TAA TTC ATC and
the antisense primer is GGA GTT GGC CAT GGA AGT CGG T. Mutations
were sequenced to ensure their correct composition. Seger et al (1994)
demonstrate that K97A acts as a dominant inhibitory molecule as it is an
inactive form of MEK. The site of MAPK mutations is indicated in Figure
2.1.





Figure 2.1. Dominant negative constructs for A. DN-cSrc, B. DN-EGFR and C. DN-MEK.
2.3.4.2.Transient transfection of c-Myc ERK and dominant negative
isoforms of signalling molecules
In order to investigate the signalling molecules involved in PROK1
mediated signalling to ERK 1/2, PROKR1 Ishikawa cells were co-
transfected with c-Myc tagged ERK and dominant negative isoforms of
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signalling molecules or empty vector (pcDNA3). PROKR1 Ishikawa cells
were seeded into 6 cm dishes at the density indicated in Table 2. 2.5pg of c-
Myc ERK was co-transfected into PROKR1 Ishikawa cells with 7.5pg of
dominant negative (DN) isoforms of signalling molecules in the presence of
Superfect transfection reagent (Qiagen) for 6 hours. The transfection media
was removed and replaced with complete DMEM Glutamax (without
G418) for at least 24 hours. Subsequently the PROKR1 Ishikawa cells were
serum starved overnight for a minimum of 16 hours in serum free DMEM
Glutamax medium prior to stimulation with 40nM PROK1.
2.3.4.3.Transient transfection of COX-2 luciferase promoter reporter
constructs
In order to investigate the COX-2 promoter activation induced by PROK1,
PROKR1 Ishikawa cells were transfected with the full-length COX-2
luciferase promoter reporter construct. PROKR1 Ishikawa cells were
seeded into 12 well plates at the density indicated in Table 2. The COX-2
promoter reporter construct linked to firefly luciferase (1.5pg) was co-
transfected into PROKR1 Ishikawa cells with an internal control, pRL-TK
(0.15pg, containing the renilla luciferase coding sequence, Promega) for 6
hours in the presence of Superfect transfection reagent (Qiagen). The COX-
2 promoter reporter plasmid consisting of a 966-bp fragment of the COX-2
promoter (C2.1; -917 to +49) ligated to a firefly luciferase construct as
described by Bradbury et al (2003), was kindly donated by Dr Robert
Newton (Biomedical research Institute, Department of Biological Sciences,
The University of Warwick, Warwick, UK). The transfection media was
removed and replaced with complete DMEM Glutamax (without G418) for
at least 24 hours. Subsequently the PROKR1 Ishikawa cells were serum
starved overnight for a minimum of 16 hours in serum free DMEM
Glutamax medium. In order to investigate the temporal regulation of
PROK1 mediated COX-2 promoter activation, transfected PROKR1
Ishikawa cells were treated with 40nM PROK1 for 0, 2, 4, 6 and 8 hours. In
order to examine the signaling pathway activation that leads to PROK1
mediated COX-2 promoter activation, PROKR1 Ishikawa cells were treated
with specific inhibitors of Gq, PLC-(3, Ca2+, cSrc, EGFR and MEK at the
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concentration indicated in Table 3 for 1 hour, prior to treatment with 40nM
PROK1 for 6 hours. Luciferase promoter reporter activity was determined
by luciferase assay as described in Section 2.4.
2.3.4.4.Transient transfection of COX-2 luciferase promoter reporter
constructs and dominant negative isoforms of signalling molecules.
In order to further investigate the signalling molecules that lead to PROK1
induced COX-2 promoter reporter activation, PROKR1 Ishikawa cells were
co-transfected with the COX-2 luciferase promoter reporter construct and
renilla, as indicated in Section 2.3.4.2, and 1.5pg of DN isoforms of
signalling molecules or empty vector. The transfection was performed as
indicated in Section 2.3.4.2. The transfection media was removed and
replaced with complete DMEM Glutamax (without G418) for at least 24
hours, subsequently the PROKR1 Ishikawa cells were serum starved
overnight for a minimum of 16 hours in serum free DMEM Glutamax
medium. Transfected cells were subsequently treated with 40nM PROK1
for 6 hours. Luciferase promoter reporter activity was determined by
luciferase assay as described in Section 2.4.
2.4. Luciferase promoter reporter assay
The activity of both firefly and renilla was determined using the dual luciferase
assay kit (Promega) and total luciferase activity was determined by dividing the
relative light units generated by the firefly luciferase by relative light units
generated by the renilla luciferase in the same reaction. Fold increase in luciferase
activity was calculated by dividing the total luciferase activity in cells treated with
PROK1 by the total luciferase activity in cells treated with vehicle or transfected
with empty vector.
2.5. Polymerase chain reaction
2.5.1. RNA extraction and quantification
RNA was extracted from both cells and tissue using TRI-reagent (total RNA
isolation reagent). TRI-reagent was used in conjunction with heavy gel phase
lock tubes. The protocol used was a modified phenol - chloroform extraction.
Samples in TRI-reagent were loaded into phase lock tubes and Bromo-chloro
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propane added to the solution, the tubes were then shaken vigorously for at
least 15 seconds in order to allow adequate mixing of the two solutions.
Samples were then allowed to rest for approximately 10 minutes to allow the
two phases (organic and inorganic) to begin to separate. The samples were
then centrifuged at 4°C for 15 minutes at 14000 RPM to ensure complete
separation of the two phases. Phase lock tubes form a wax layer between the
two phases allowing the top aqueous layer to be simply poured into a fresh
tube without risk of DNA or protein contamination. This aqueous layer is
retained and mixed with isopropanol in order to precipitate the RNA present
in solution. Samples were again centrifuged at 14000 RPM for 15 minutes at
4°C in order to pellet the precipitated RNA present in the solution. RNA pellets
were subsequently washed in 70% RNase free ethanol, before being
resuspended in RNase free water.
Lysis and homogenisation of cells was achieved by addition of TRI-reagent
and mixing by pipetting to ensure a homogenous sample preparation for RNA
isolation. Lysis and homogenisation of tissue samples was achieved by
addition of TRI-reagent followed by homogenisation with a tissue lyser
(Qiagen). Tissue samples were snap frozen in 2ml eppendorf tubes, which
contained a 5mm steel bead. After addition of TRI-reagent the tubes were
loaded onto the homogeniser and subjected to shaking at 25Hz for 6 minutes.
This allowed the tissue to be homogenised by the action of the steel bead. The
homogenised tissue samples were centrifuged at 4°C for 10 minutes at 15000
RPM to clear any cellular debris. After homogenisation samples were loaded
into heavy gel phase lock tubes (Eppendorf) and processed as above. All tubes
used in processing of cells and tissues were RNase free and tips used were
RNase free filter tips. Benches and other equipment were treated with RNase
Zap (Ambion) to eliminate RNase activity.
RNA concentrations were determined using the Genequant spectrophotometer
or the Nanodrop ND-1000 spectrophotometer. The Genequant and Nanodrop
spectrophotometers were used to determine nucleic acid concentration and
purity from a 1:10 diluted 10pl sample (Genequant) or a neat lpl sample
(Nanodrop). Light absorbance of the sample was measured at wavelengths of
Chapter 2 General Materials and Methods 64
260nm and 280nm. The absorbance at 260nm indicates the RNA
concentration, and the 260:280 absorbance ratio indicates the quality of the
sample. A pure sample of RNA should have a 260:280 ratio in the region of
1.9. A 260:280 ratio lower than this indicates contamination of the sample by
protein. The samples were compared against a blank standard consisting of
RNase free water, which was used to set zero for the OD measurements. After
samples had been quantified a final reading of water was taken to ensure
adequate cleaning of equipment had been performed between sample
readings.
2.5.2. Reverse transcriptase polymerase chain reaction
Reverse transcriptase PCR was performed on cDNA prepared from total RNA
isolated from cultured cells in an oligo dT primed reaction. cDNA for each
reaction was synthesised from lpg RNA in a volume of lOpl. Briefly, cDNA
was prepared as follows: -
lpg RNA in 10pi volume
1 pi Random Hexamers (200ng/pl)
lpldNTP (lOpM)
This mix was incubated at 65°C for 5 minutes and then placed on ice.
Subsequently:
4pi 1st strand buffer
2pi DTT
lpl RNase inhibitor
were added and the mix and incubated at 37°C for 2 minutes, followed by
addition of:
lpl Superscript reverse transcriptase enzyme.
The mix was then incubated at: -
37°C for 50 minutes
70°C for 15 minutes
In order to amplify PROKR1 or PROK1 cDNA, PCR was performed using
specific primers. The sequences are given in Table 4.
Chapter 2 General Materials and Methods 65
Table 4. Primer sequences for RT-PCR
PROKR1 forward 5' GGA TCC AGG CTT GAT GGA GAC CAC CAT GGG G 3'
PROKR1 reverse 5' CTC GAG GAT ATC TTT TAG TCT GAT GCA GTC CAC CT 3'
PROK1 forward 5' GTG CCA CCC GGG CAG 3'
PROK1 reverse 5' AGC AAG GAC AGG TGT GGT GC 3'
The PCR reaction proceeded as follows. Primers were diluted 1/10 from a
stock concentration of lOOpM to lOpM prior to use in the PCR reaction. A


















A 1% Tris-Acetate-EDTA (TAE) agarose gel containing ethidium bromide was
then prepared and samples electrophoresed for approximately 1 hour 30
minutes at lOOv before visualisation using a UV transilluminator.
2.5.3. Taqman quantitative PCR
Expression of mRNA within tissue and cultured cells was examined by
Taqman PCR in order to quantify expression and detect low expression
transcripts. In order to perform this quantitative method cDNA was prepared
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in a random hexamer primed reaction using 200ng of RNA per reaction. A
reaction mix was prepared as indicated below for each cDNA synthesis
reaction. All PCR reagents were purchased from Applied Biosystems.
RNA (lOOng/pl) 2pl
1 Ox RT buffer lpl




Multiscript Reverse Transcriptase 0.25pl
RNase free water 1.85|ul




Quantitative PCR was conducted on the cDNA using specific primer-probe
mixtures designed and optimised for the detection of the gene of interest in
human. Primer-probe combinations specific to PROK1, PROKR1, COX-2, LIF,
IL6, IL-8 or IL-11 were designed in-house and were custom synthesised and
purchased from Eurogentec. Sequences of primers and probes are given in
Table 5. The probe was fluorescently labelled with FAM at the 5' end with a
TAMRA quencher dye at the 3' end. In the presence of the gene of interest, the
probe anneals to the sequence of interest between the forward and reverse
primers. The 5' 3' nuclease activity of the Taq DNA polymerase cleaves the
probe and separation of the reporter dye from the quencher results in a
measurable increase in fluorescence. An increase in fluorescence is indicative of
an elevation in the PCR product of interest. Gene expression was normalised
by including primer-probe mix to detect the Vic labelled 18s ribosomal subunit
as a loading control for the amount of cDNA added in each sample. The 18s
primer and probe sequences are given in Table 5. Each Taqman PCR reaction
(in duplicate) consisted of:
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cDNA 2pl





18s (forward, reverse, probe mix) 0.75pl
Reaction mixtures were loaded, in duplicate, each consisting of 20pi onto a 96-
well MicroAmp fast optical reaction plate (Applied Biosystems) for analysis
on an ABI 7900 HT Fast Real-Time PCR machine (Applied Biosystems). Data
were analysed and processed using Sequence detector version 1.6.3 (Applied
Biosystems) according to the manufacturers instructions. Results were
expressed as relative to an internal positive RNA standard (cDNA obtained
from a single sample of endometrial tissue) included in all reactions. The data
was analysed utilising the comparative Ct method for relative quantification.
Briefly, the amount of target is normalised to an endogenous control and
relative to a calibrator using the formula: -
2-aact
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Table 5. Taqman primer and probe sequences













5' GTG CCA CCC GGG CAG 3'
5' AGC AAG GAC AGG TGT GGT GC 3'
5'ACA AGG TCC CCT TGT TCA GGA AAC GCA 3'
5' TCT TAC AAT GGC GGT AAG TCC A 3'
5' CTC TTC GGT GGC AGG CAT 3'
5' TGC AGA CCT GGA CCT CAA GAC AAT TGG 3'
5' CCT TCC TCC TGT GCC TGA TG 3'
5' ACA ATC TCA TTT GAA TCA GGA AGC T 3'
5' TGC CCG ACT CCC TTG GGT GTC A 3'
5' TGG TGG AGC TGTACC GCA TA 3'
5' TGG TCC CGG GTG ATG TTG 3'













5' CTG GCC GTG GCT CTC TT 3'
5' TTA GCA CTC CTT GGC AAA ACT G 3'
5' CCT TCC TGA TTT CTG CAG CTC TGT GTG AA 3'
5' GCC GCC CCA CAC AGA CA 3'
5' CCG TCG AGG ATG TAC GGA AT 3'
5' CCA CTC ACC TCT TCA GAA CGA ATT GAC AAA C 3'
5' CCC AGT TAC CCA AGC ATC CA 3'
5' AGA CAG AGA ACA GGG AAT TAA ATG TGT 3'
5' CCC CAG CTC TCA GAC AAA TCG CCC 3'
5' CGG CTA CCA CAT CCA AGG AA 3'
5' GCT GGA ATT ACC GCG GCT 3'
5' TGC TGG CAC CAG ACT TGC CCT C 3'
2.6. Inositol phosphate assay
Cells were seeded in 12-well plates in complete DMEM Glutamax for 24 hours
prior to incubation with inositol free special DMEM (Sigma) containing lpCi/ml
[3H] myo-inositol (Amersham) for 24 hours. Cells were washed sequentially with
buffer A and buffer A containing lOnM LiCl, before incubation with PROK1 at a
range of concentrations (indicated in Section 2.3) for 60 minutes. The agonist
induced inositol phosphate response is amplified in the presence of Li+ (Berridge et
al, 1982), therefore addition of LiCl enables cleaner results to be obtained.
Reactions were terminated by the removal of PROK1 stimulus and cells were
permeabilised by the addition of ice-cold lOmM formic acid. These samples were
incubated at 4°C for approximately 60 minutes prior to loading of supernatants
into tubes containing AG 1-X8 resin. In order to separate total tritiated inositol
phosphate from formic acid the ion exchange method of Berridge (1983) was
employed. Sample loaded resin was washed sequentially with water and 60mM
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ammonium formate/5mM sodium tetraborate with resin vortexed and allowed to
settle before removal of the supernatant with care taken not to disturb the settled
resin. Subsequently bound tritiated myo-inositol was eluted from the resin by the
addition of 1M ammonium formate/0.1M formic acid. 2.5ml of scintillation fluid
was added to the samples and the tritium content of the eluted fractions
measured by liquid scintillation counting in a Beckman 5000 scintillation counter,
counted with an automatic quench correction for one minute per sample.
2.7. Western immunoblot analysis
2.7.1. Protein extraction and quantification
2.7.1.1.Cells
Following stimulation, cells were washed twice in ice cold PBS without
CaCh and MgCL followed by addition of NP40 lysis buffer. Cells were
incubated in NP40 lysis buffer on ice for approximately 30 minutes in
order for the cells to lyse. Cells were harvested using a rubber policeman
and transferred to a fresh eppendorf tube. Cell lysates were cleared of cell
debris by centrifuging at 4°C for 15 minutes at 15000 RPM. Cleared lysates
were transferred to fresh eppendorf tubes, diluted 1:50 and quantified
using a modified Bradford protein assay kit (BioRad Laboratories). Protein
concentrations were calculated using Assay Zap software and a standard
curve generated by BSA standards of known concentrations.
2.7.1.2.Tissue
Decidua tissue explants were finely chopped using sterile scissors prior to
treatment. Following stimulation, tissue samples were snap frozen in 2ml
eppendorf tubes, which contained a 5mm steel bead. NP40 lysis buffer
was added to the tubes and proteins harvested by homogenisation
following the tissue homogenisation protocol as indicated in Section 2.5.1.
Briefly, samples were loaded onto a tissue lyser (Qiagen) and shaken for 6
minutes at 25Hz. Tissue lysates were cleared of cell debris by
centrifugation, as indicated above in Section 2.7.1.1 and quantified using
protein assay kits (BioRad Laboratories) as indicated above in Section
2.7.1.1.
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2.7.2. Immunoprecipitation
Following stimulation, cells (5x105 for c-myc ERK experiments, 3x106 for cSrc
and EGFR experiments) were washed twice in ice cold PBS without CaCh and
MgCh followed by addition of NP40 lysis buffer. Cells were incubated in
NP40 lysis buffer on ice for approximately 30 minutes in order for the cells to
lyse. Cells were harvested using a rubber policeman and transferred to a fresh
eppendorf tube. Cell lysates were cleared of cell debris by centrifuging at 4°C
for 15 minutes at 15000 RPM. Cleared lysates were transferred to fresh
eppendorf tubes and equal amounts of protein incubated with specific p-Tyr
418 (for investigation of temporal regulation of cSrc and EGFR, Santa Cruz) or
c-myc (for investigation of the effect of dominant negative isoforms of
signaling molecules on PROK1 induced ERK 1/2 phosphorylation, Santa
Cruz) antibody preconjugated to protein A-Sepharose beads. Cell lysates were
incubated with preconjugated antibody overnight at 4°C with gentle rotation.
The beads were spun down at 4°C for 15 minutes at 15000 RPM, the
supernatant removed, fresh NP40 lysis buffer added and the beads
resuspended. This was repeated in order to wash the beads thoroughly. Excess
lysis buffer was removed with a Hamilton syringe after the last wash and
immune complexes solubilized in 20pl Laemmli buffer [125mmol/L Tris-HCl,
4% SDS, 5% 2-Mercaptoethanol, 20% glycerol, 0.05% Bromophenol blue],
2.7.3. Western immunoblot analysis
In order to examine the effect of the dose of PROK1 on ERK 1/2
phosphorylation (dose response), and the time course and phosphorylation
cascade leading to ERK 1/2 phosphorylation in PROKR1 Ishikawa cells, 20pg
of protein was resuspended with Laemmli buffer. In order to examine the time
course of PROK1 mediated ERK 1/2 and phosphorylation cascade leading to
ERK 1/2 phosphorylation in first trimester decidua, 50pg of protein was
resuspended in Laemmli buffer. For COX-2 expression, 40pg of protein was
resuspended in Laemmli buffer. In order to examine the effect of dominant
negative isoforms of signaling molecules on PROK1 induced ERK 1/2
phosphorylation and examine the temporal regulation of cSrc and EGFR by
PROK1 samples were prepared by immunoprecipitation as indicated above.
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Proteins were denatured by boiling for 5 minutes and resolved on a 4 - 20%
SDS-PAGE gradient gel (Invitrogen) run in parallel with SeeBlue protein
loading standards (Invitogen) at 40 milliamps for approximately 2 hours,
amount of protein loaded is indicated above. Proteins separated on the gel
were then immunoblotted to a PVDF membrane (Millipore). The
Polyvinylidene difluoride (PVDF) membrane was sequentially submerged in
methanol, water and then transfer buffer. Blotting paper was also submerged
in transfer buffer. A 'sandwich' was constructed comprising blotting paper,
PVDF membrane, and SDS-PAGE gel followed by a final layer of blotting
paper. In this order the blotting 'sandwich' was placed in a semi-dry blotting
apparatus (Bio-Rad) and proteins transferred by application of 14 volts for 90
minutes. Non-specific binding of antibody was prevented by incubation of the
immunoblot with blocking buffer, chemifluorescence probed immunoblots
were blocked with 4% bovine serum albumin (BSA), fluorescent probed
immunoblots were blocked with a low-fluorescence blocking solution (LiCor).
The immunoblots were incubated with specific primary antibodies for
phosphorylated ERK 1/2, total ERK 1/2, phosphorylated cSrc,
phosphorylated EGFR, COX-2 and p-actin (antibody dilutions indicated in
Table 6) and detected either by alkaline phosphatase-conjugated secondary
antibodies, for chemifluorescent detection, or fluorescent labeled secondary
antibodies, for direct fluorescent detection
Table 6. Antibody dilutions used for Western immunoblots detection
Antibody Species raised in Dilution Purchased from
pERK Rabbit 1:1000 Cell Signalling
tERK Mouse 1:1000 Cell signalling
COX-2 Goat 1:500 Santa Cruz/ Autogen Bioclear
B-Actin Goat 1:800 Santa Cruz/ Autogen Bioclear
p-EGFR Goat 1:500 Santa Cruz/ Autogen Bioclear
cSrc Rabbit 1:500 Santa Cruz/ Autogen Bioclear
2.7.3.1 .Chemifluorescent detection
As indicated above, alkaline phosphatase-conjugated secondary antibodies
were used for ECF - chemifluorescent detection of antibody bound proteins
on the immunoblot. The immunoblots were incubated with primary
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antibody, in 4% BSA blocking buffer, overnight at 4°C with gentle motion.
The immunoblots were then washed a number to times in TNS-tween
before exposure to an alkaline phosphatase conjugated secondary
antibody, directed against the species in which the primary antibody was
raised. The antibody was left to incubate and bind to the immunoblots for
one hour at room temperature with gentle motion. The immunoblots were
again washed with tris neutral saline (TNS)-tween and then exposed to
ECF chemifluorescent substrate (Amersham) for 20 minutes in order to
visualise immunoreactive proteins. Immunoblots were kept in the dark for
this period. Subsequently, excess ECF was removed from the immunoblot
and proteins revealed by phosphorimager analysis using the Typhoon 9400
phosphorimager system. A schematic of the ECF detection process
described is shown in Figure 2.1. In order to control for protein loading, the
blots were stripped, washed in TNS and the process repeated with an
antibody to control for loading e.g. total ERK 1/2. Protein expression was
quantified with Imagequant TL v2003.03, and relative density in the
immunoblots calculated by dividing the value obtained from the
phosphorylated immunoblots by the value obtained from the loading














Figure 2.2. Schematic representing the ECF Western immunoblot detection method.
1. Proteins separated in the SDS-PAGE gel are immunoblotted from the
gel to the PVDF membrane by use of a Transblot semi-dry transfer cell
(BioRad) run at 14V for 90 minutes. The PVDF membrane is
subsequently blocked with 4% BSA blocking buffer for 60 minutes.
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2. The primary antibody is applied to the immunoblot in 4% BSA
blocking buffer. The antibody is left to bind to the protein of interest
overnight at 4°C.
3. The immunoblot is subsequently washed in TNS-tween and the
secondary antibody, with an alkaline phosphatase label, is applied in
4% BSA blocking buffer for one hour.
4. The ECF substrate is subsequently applied to the immunoblot for 20
minutes. The ECF reacts with the alkaline phosphatase enzyme present
on the secondary antibody and gives off a chemifluorescent signal. The
immunoblot is scanned and the chemifluorescent signal detected. The
immunoblots are subsequently stripped of the antibody and probed
with an antibody to detect a loading control.
2.7.3.2.Direct fluorescent detection
Immunoreactive proteins were visualised by a direct fluorescent system. In
contrast to the above chemifluorescent system, both the phosphorylated
protein or main protein of interest and the total/loading control protein
could be detected at the same time. This can be achieved by using primary
antibodies raised in different species. These can then be visualised by using
fluorescently labelled secondary antibodies directed against the different
species, which emit at different wavelengths. This has a number of
advantages; (a) there is no danger of over stripping the blot and thus losing
some of the protein of interest and, (b) provided the immunoblots are kept
in the dark, the fluorescence will not fade enabling the immunoblots to be
re-scanned if required.
The immunoblots were incubated overnight at 4°C with primary antibodies
in low fluorescence blocking buffer with gentle motion, e.g. for detection of
phosphorylated and total ERK 1/2, the immunoblots were incubated with
rabbit anti pERK 1/2 and mouse anti tERK 1/2. The immunoblots were
washed a number of times with PBS-tween before exposure to the
fluorescently labelled secondary antibodies e.g. goat anti rabbit antibody
which emits at 680nm (to detect pERK) and goat anti mouse antibody
which emits at 800nm (to detect tERK). The antibody was left to bind to
the immunoblots for one hour at room temperature in black boxes in order
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to avoid bleaching of the fluorescent label. The immunoblots were then
washed a number of times in PBS-tween before visualisation of the
proteins on the LiCor fluorescent scanner set to detect the different
wavelengths emitted. These different wavelengths were visualised with
different colours (680nm - red, 800nm - green) in order to visually
differentiate between the two. A schematic of the process is described in
Figure 2.2. Proteins were quantified using the LiCor software. Relative
density in immunoblots was calculated by dividing the value obtained
from the phosphorylated blots by the value obtained from the total blots
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Figure 2.3. Schematic representing fluorescent Western immunoblot detection method
1. Proteins separated in the SDS-PAGE gel are immunoblotted from the gel to
the PVDF membrane by use of a Transblot semi-dry transfer cell run at
14V for 90 minutes. The PVDF membrane is subsequently blocked with
low fluorescence blocking buffer for 60 minutes.
2. The proteins of interest are detected with antibodies raised in two different
species, e.g. in order to detect pERK, anti-rabbit pERK is used (protein 1),
in order to detect tERK, anti mouse tERK is used (protein 2). The antibody
is left to bind to the protein of interest overnight at 4°C.
3. The immunoblots are subsequently washed in PBS-tween. The primary
antibodies are detected with fluorescently labelled secondary antibodies
raised against the different species. These antibodies have fluorescent
labels, which emit at either 680nm (red, protein 1) or 800 nm (green,
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protein 2). The immunoblots are incubated with the secondary antibodies
for one hour and the immunoblots scanned with a fluorescent scanner
(LiCor).
2.8. Immunohistochemistry
2.8.1. Tissue fixation, wax embedding and Sectioning
Tissues were fixed in 4% NBF (neutral buffered formaldehyde) for 24 hours
and then transferred to 70% ethanol. Tissues were subsequently processed and
wax embedded using the Leica TP 1050 processor as summarised in Table 7.
Table 7. Tissue processing protocol.
Station Time Temperature Pressure/vacuum
Ethanol 70% 1 1 hr 30 minutes Ambient Ambient
Ethanol 80% 2 1 hr 30 minutes Ambient Ambient
Ethanol 90% 3 1 hr 30 minutes Ambient Ambient
Ethanol 95% 4 1 hr 30 minutes Ambient Ambient
Ethanol 95% 5 1 hr 30 minutes Ambient Ambient
Abs. Ethanol 6 2hrs Ambient Ambient
Abs. Ethanol 7 2 hrs Ambient Ambient
Xylene 8 1 hr Ambient Ambient
Xylene 9 1 hr Ambient Ambient
Xylene 10 1 hr Ambient Ambient
Paraffin wax Left 1 hr 60 degrees P/V
Paraffin wax Middle 1 hr 60 degrees P/V
Paraffin wax right 1 hr 30 minutes 60 degrees P/V
embedded Sections were chilled on ice prior to being cut into 5pm
sections and floated in warm water. Sections were then floated onto glass
slides before being baked overnight.
2.8.2. 3,3'-diaminobenzidine (DAB) immunohistochemistry
In order to examine protein localization of PROK1 or PROKR1 in endometrium
or first trimester decidua, immunohistochemical analysis was performed on
tissue sections prepared as indicated in Section 2.6.1. Tissue sections (5pM)
were dewaxed in xylene, sequentially rehydrated in decreasing concentrations
of ethanol (100%, 95%, 80%, 75%) and finally placed in water when
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rehydration was complete. Antigen retrieval was performed in order to reveal
the epitope sites of the proteins and make them available for the antibodies to
bind. This was achieved by placing the rehydrated tissue sections in a pressure
cooker and boiling them for five minutes in 0.1% citrate buffer (pH 6.0). The
sections were allowed to rest and cool for 20 minutes before placing the slides
in tap water. Endogenous peroxidase activity was quenched with 3% (vol/vol)
H2O2 in methanol at room temperature. Blocking serum (5% serum in Tris-
buffered saline with 0.05% BSA) was applied for one hour in order to block
any non-specific binding. Subsequently PROK1 or PROKR1 antibodies
(dilutions given in Table 8) were applied in the serum block solution and
incubated overnight at 4°C. The tissue sections were then washed sequentially
in TNS-tween and TNS to remove any excess antibody before application of
the secondary antibody, a biotinylated labelled antibody directed against the
species in which the primary antibody was raised. In order to detect the
antibody binding, and therefore protein expression, an avidin-biotin peroxidase
detection system was employed. The sections were washed in TNS and
exposed to the avidin biotin complex (ABC) reagent (Dako) for 30 minutes.
The sections were once again washed in TNS before exposure to the chromagen
3,3"-diaminobenzidine, the colour development was checked under a
microscope and the reaction terminated by placing the slides in water. The
slides were counterstained with haematoxylin, dehydrated in increasing
concentrations of alcohol and mounted.
Table 8. Antibody concentrations used in DAB immunohistochemistry detection
Antibody Species raised in Dilution Purchased from
PROK1 Rabbit 1:1000 Phoenix pharmaceuticals
PROKR1 Rabbit 1:250 Lifespan Biosciences
2.8.3. Double immunofluorescent histochemistry
Co-localizations were performed as described in individual chapters as the
protocol varies depending on the combination of antibodies used. Briefly,
Tissue sections (5qM) were dewaxed in xylene, sequentially rehydrated in
decreasing concentrations of ethanol (100%, 95%, 80%, 75%) and finally placed
in water when rehydration was complete. Antigen retrieval was performed in
order to reveal the epitope sites of the proteins and make them available for
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the antibodies to bind. This was achieved by placing the rehydrated tissue
sections in a pressure cooker and boiling them for five minutes in 0.1% citrate
buffer (pH 6.0). The sections were allowed to rest and cool for 20 minutes
before placing the slides in tap water. Endogenous peroxidase activity was
quenched with 3% (vol/vol) H2O2 in methanol at room temperature. Blocking
serum (5% serum in phosphate buffered saline with 0.05% BSA) was applied
for one hour in order to block any non-specific binding. Subsequently the
antibody was applied in the serum block solution and incubated overnight at
4°C. The tissue sections were then washed sequentially in PBS-tween and PBS
to remove excess antibody. A biotinylated antibody was applied for one hour
followed by a streptavidin detection system. All subsequent steps were
performed in the dark in order to avoid bleaching of the fluorescent detection
labels. Sections were subsequently washed in PBS-tween/PBS followed by re-
blocking in blocking serum and incubation with the second detection antibody
overnight at 4°C. The following day the sections were washed in PBS-
tween/PBS followed by application of a biotinylated or peroxidase antibody
and a streptavidin or tyramide detection system. Sections were washed in PBS
and incubated with nuclear counterstain ToPro (1:2000) in PBS. Sections were
mounted in Permafluor, coverslipped, and fluorescent images were visualised
using a laser scanning confocal microscope (LSM 510, Carl Zeiss, Jena,
Germany). In this work, negative control sections were incubated with IgG
from the appropriate species ie. for sections in which rabbit primary antibodies
were used, rabbit IgG was applied. Sections were subsequently treated as all
other sections with secondary antibodies and detection reagents applied. This
should indicate non-specific binding of the primary antibody. However, it
should also be considered that the secondary antibody may bind non-
specifically. The secondary antibodies are raised against IgG of the species in
which the primary antibody is raised, however, the discrimination between
IgG's of different species (eg. Differences between IgG from rabbit vs goat)
may be doubted. Therefore, after application of the first primary antibody the
secondary antibody directs against the second primary antibody should be
applied. However, the second blocking step applied at the end detection of the
first primary antibody should eliminate this possibility.
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2.9. Gene array
2.9.1. Sample preparation
PROKR1 Ishikawa cells were seeded in complete DMEM Glutamax medium in
5 x 6cm dishes for PROK1 treated and vehicle treated samples and allowed to
settle for 24 hours. The following day cells were incubated in serum free
DMEM Glutamax medium for at least 16 hours. Subsequently, the cells were
stimulated with 40nM PROK1 or vehicle for 8 hours. RNA was extracted using
RNeasy extraction kits (Qiagen). The principle of which is the binding of RNA
strands, from lysed and homogenised samples, to a silica membrane in the
presence of a high salt buffer and ethanol. Contaminants within the samples
are removed through a series of three washes, and a purified RNA sample is
finally eluted from the membrane in RNase free water, achieved through
centrifugation. In order to extract the RNA, cells were lysed in guanidine-
thiocyanate buffer and removed from the plates using rubber policemen (cell
scrapers). The cells were immediately homogenized. The lysis and
homogenisation of the cells was achieved by passing the lysate through a 0.22
bore syringe a number of times in the presence of highly denaturing guanidine-
thiocyanate buffer to prevent degradation by RNases.
RNA samples were initially quantified using the Genequant
spectrophotometer, to give an initial indication of their concentration and
quality. Samples were then diluted to a concentration, which allowed further
quantification and quality assessment on the 2100 Bioanalyser and RNA
nanochip system (Agilent Technologies). The criteria set for sample inclusion in
the gene array was a 260/280> 1.9. This was assessed by the genequant, the
quality, as indicated, was further assessed with the RNA nanochip system,
this gave an RIN (RNA integrity number) which should be around 2, and a
value for 18s/28s, which should also be around 2. Only samples which passed
these quality control tests were included in the pooled samples. The 5 plates
from each treatment were pooled to create one pooled RNA sample. This was
done to reduce sample variability. This experimental process was performed 3
times in total to produce 3 PROK1 treated and 3 vehicle treated RNA samples.
These were hybridized on 6 AB1700 and 6 Affymetrix arrays as follows.
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Hybridisation of the RNA samples to the gene arrays was performed
commercially by Geneservice.
2.9.1.1. ABI
RT-IVT was carried out in accordance with the Applied Biosystems
Chemiluminescent RT-IVT nanoamp (one-cycle) labeling protocol. The
samples were fragmented and subsequently prepared for hybridization to
Applied Biosystems Human Genome Survey Microarray, version 2, for 16
hours. Following hybridization, the arrays were stained, washed using the
Applied Biosystems Chemiluninescence detection kit and scanned using
the Applied Biosystems 1700 Chemiluminescent Microarray Analyser.
2.9.1.2. Affymetrix.
cDNA synthesis and Biotin labeling of cRNA were carried out using the
Ambion Message Amp II cRNA kit. The samples were subsequently
fragmented, prepared for hybridisation using the Affymetrix hybridisation
control kit and hybridised to GeneChip® Human Genome U133 plus 2.0
arrays for 16 hours. Following hybridization the GeneChip arrays were
stained, washed on the fluidics station and scanned.
2.9.2. Data analysis
This analysis was performed by Geneservice. Data acquired using the ABI
technology were filtered according to the manufacturer recommendations
(AB1700 Data Analysis, Applied Biosystems, 2005). All probes with the Flags
measurement of more than 100 and S/N ratios less than 3 in more than 2 out
of 6 samples were discarded. This resulted in a set of high-quality probes for
further processing. Data acquired using Affymetrix technology were generated
using the GCOS version 1.3 software package. After the pre-processing steps,
the data for both platforms were normalized using vsn, variance stabilizing
normalization by W. Huber (Huber, 2002). Normalized data were analyzed for
differential expression with the LIMMA package by G.K. Smyth (Smyth,
2004). Probe-wise linear models were fitted and then computed moderated t-
statistics and log-odds of differential expression by empirical Bayes shrinkage
of the standard errors towards a common value. The p-values for the contrast
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between treated and untreated samples were adjusted for multiple testing
with Benjamini and Hochberg method (Benjamini & Hochberg, 1995).
Cross mapping between AB1700 probes and Affymetrix probesets was
courtesy provided by Applied Biosystems. All unmapped poorly annotated
genes were removed from the analysis. All mapped genes yielding fold
changes greater than 1.5 on both platforms were selected for further
consideration. Upon application of adjusted p-values all genes exhibiting
p<0.05 compared to vehicle treated controls on either platforms were
considered further.
2.9.2.1.GO annotations
This analysis was kindly performed by Dr R Catalano. Gene ontologies
(GO) describe how gene products behave in a cellular context i.e. describe
gene products in terms of their associated biological processes, cellular
components and molecular functions. GO's were assigned to PROK1
regulated genes for biological processes using tools provided by the gene
ontology database (www.geneontology.org).
2.9.2.2.EST tissue library
This analysis was kindly performed by Dr R Catalano. Analysis of the
expressed sequence tag tissue library database for PROK1 regulated genes
were analysed using WebGestalt (Web based gene set analysis toolkit) in
order to examine the tissue expression of PROK1 regulated genes.
2.10. Enzyme linked immunosorbent assays (ELISA)
2.10.1. cAMP ELISA
cAMP turnover was measured in PROKR1 Ishikawa cells. Cells were seeded in
3cm dishes 24 hours prior to serum starvation. Cells were synchronised by
serum withdrawal for at least 16 hours before stimulation. Thereafter, culture
medium was removed and replaced with serum free medium containing 3-
isobutyl-1-methyl xanthine (IBMX; Sigma) to a final concentration of ImM for
90 minutes at 37°C. Cells were then stimulated with PROK1 for 5, 10, 15 and
20 minutes, or with forskolin for 10 minutes. Following stimulation the
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medium was removed and the cells lysed in 0.1 M HC1. cAMP turnover was
quantified using a cAMP competitive ELISA kit (Biomol) according to the
manufacturers instruction and normalised to protein concentrations of the
homogenate. The assay was performed in 96 well goat anti-rabbit IgG coated
microtiter plate. The cAMP standard curve was constructed by diluting the
standard four times in a ratio of 1:4 in HC1 (0.1M) to achieve concentrations of
200pM/ml, 50pM/ml, 12.5pM/ml, 3.13pM/ml and 0.78pM/ml which were
used to construct a standard curve. The standards and samples (lOOpl) were
loaded onto the plate. The alkaline phosphatase - cAMP conjugate and
polyclonal rabbit-cAMP antibody were then added to the wells (50pl per
solution). The plate was then incubated at room temperature for 2 hours on a
plate shaker at approximately 500rpm. The wells were then aspirated and
washed with the ELISA wash buffer (TBS-tween containing sodium azide). In
order to develop the assay, the conjugate and p-Npp (p-Nitrophenyl
Phosphate, Disodium Salt) substrate were added to the wells (5pl and 200pl
respectively) and the plate incubated at room temperature for 1 hour. The
reaction was terminated with 50pl stop solution. The absorbance was
measured at 405nm using a plate reader. Average cAMP concentrations of
samples were determined from the standard curve constructed by
extrapolation using the Assay Zap software (Biosoft). Protein concentrations
of the lysed cells were quantified using a protein assay kit (BioRad) as
described in Section 2.5.1.1 and cAMP values normalised for protein
concentration.
2.10.2. Prostaglandin ELISA
Secreted PGE2 and PGF2a from PROKR1 Ishikawa cells were measured by in
house ELISA's. Cells were seeded out in 3cm dishes 24 hours prior to serum
starvation. Cells were synchronised with serum withdrawal for at least 16
hours before stimulation. Thereafter cells were pre-incubated with the specific
COX-2 inhibitor NS-398 (10pM) prior to stimulation with vehicle, PROK1 or
PROK1 & NS-398 for 2, 4, 6, 8, 12 and 24 hours. Arachidonic acid was added
at a final concentration of 3pg/ml to the media 4 hours prior to the end of the
time point (i.e. For a 6 hour time point arachidonic acid was added at 2
hours). For assay of PGF2(1 the media was frozen immediately while for assay
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of PGE2 an equal volume of methyloximating (MOX) solution
(Methyloxyamine buffer, pH 5.6) was added to stabilise the PGE2 prior to
freezing. PGE2 and PGF2„ secretion into the culture media was assessed using
an ELISA. For this, 96-well plates (amine binding plates, Costar) were coated
with donkey anti-rabbit antibody and then rabbit IgG (lmg/ml diluted in PBS
with 1% carbonate buffer, pH 9.6) at 200pl/well for 16 hours at 4°C. The
solution was aspirated and blocking solution (50mM glycine, lOmg/ml BSA)
was added to the wells (25pl/well) for 2 hours at room temperature.
Following washing, donkey anti-rabbit serum (Scottish Antibody Production
Unit) was added to each well before washing and air-drying. The plates were
stored at 4°C with dessicant. The link was prepared by ether extraction and
purified by reverse phase chromatography using 20mg of synthetic PGE2 or
PGF2u/ 320pL of dry dimethylformamide, 3pi butylchlororomate and 0.05nM
biocytin. The link and antisera were diluted 1:1.5 x 106 in PO4 0.5 M p H 8 and
1:50000 in ELISA buffer (150mM NaCl, lOOmM Tris-HCl, 0.05% Tween 20,
50mM phenol red ImM 2-methylisothiaolone, ImM bromonitrodioxane, 2mM
EDTA, 2mg/ml BSA to a final pH of 7.2) respectively. The prostaglandin
ELISA is a competitive assay with prostaglandin within samples displacing
binding of the biotin labelled prostaglandin link, therefore at the termination of
the colourimetric assay the more intense the colour reaction the less
prostaglandin present in the sample ie. little prostaglandin present in the
sample cannot displace the binding of the biotin labelled prostaglandin
therefore resulting in a more intense colour reaction. For the PGF2a assay, the
ELISA buffer contained no Tween 20. The standard (5120 pg/ml) was then
serially diluted 9 times in buffer. For the PGE2 assay the standards were
diluted in ELISA buffer containing 25% MOX and Tween 20, the PGF2„
standards were diluted in ELISA buffer alone. The standards (lOpg/ml up to
5120pg/ml) were used to construct the standard curve. Samples and synthetic
standards (lOOpl) were added to the plate in duplicate followed by 50pl of the
diluted link and 50pl diluted antisera to all wells except the non specific
binding (NSB) and the maximum binding Bo control wells. Link (50pl) and
ELISA buffer (lOOpl) alone were added to the NSB wells while link (50pl);
ELISA buffer (lOOpl) and antisera (50pl) were added to the B0 wells. The
plates were incubated overnight at 4°C. The following day, the contents of the
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wells were aspirated and the plates were washed 4 times, once for 30 seconds
on an orbital shaker. Following the wash, lOOpl/well of streptavidin-
peroxidase (0.2U/ml) was added to each well on the plate. The plates were
incubated for 20 minutes at 23°C on an orbital shaker. Plates were then
washed and 200pl/well of the substrate (0.3g/litre urea-hydrogen peroxide,
O.lg/L tetramethylbenzene in lOOmM sodium acetate, pH 6) was added for
10 minutes. The reaction was stopped with lOOpl/well sulphuric acid (1M).
The absorbance was measured at 450nm using a plate reader. Average PGE2
and PGF2a concentrations of the media samples were determined from the
standard curve constructed by extrapolation using the Assay Zap software
(Biosoft).
2.10.3. Estradiol and Progesterone
Estradiol was measured by commercial ELISA from Bio-Stat Diagnostics
according to manufacturers instructions. Progesterone was measured
according to the protocol of TIM Fraser (1980). These were performed by Mr
Ian Swanston.
2.10.4. LIF ELISA
Secreted LIF, from both PROKR1 Ishikawa cells and first trimester decidua
was measured using an ELISA kit (R&D systems). Cells were seeded out in
3cm dishes 24 hours prior to serum starvation. Cells were synchronised with
serum withdrawal for at least 16 hours before stimulation. Thereafter cells
were stimulated with PROK1 or vehicle for 2, 4, 6, 8, 12 and 24 hours. Tissue
was finely minced with sterile scissors and serum starved for at least 16 hours
before stimulation with PROK1 or vehicle for 2, 4, 6, 8, 12 and 24 hours.
Culture medium was removed and frozen at -80°C until being assayed for LIF
protein using the ELISA kit as indicated above. Serial dilutions of LIF
standards (3.9pg/ml up to lOOOpg/ml) were made up in calibrator diluent.
Standards and samples were applied to a 96 well plate coated with an
antibody specific for the LIF protein. The plate was incubated for 2 hours at
room temperature before washing with wash buffer supplied with the ELISA
kit. A chromagen was added and the plate incubated for a further hour.
Subsequently the stop solution was added in order to terminate the reaction.
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The coloured product was measured on a spectrophotometer at 570nm with
correction at 540nm. Samples were quantified by the construction of a
standard curve using the values obtained from the standards produced by
serial dilution and comparison of the samples obtained from the samples to
the standard curve.
2.11. Statistics
Statistical analysis of the data in this study was carried out by ANOVA with
Fishers PLSD (predicted least squares difference) applied, using Statview 5.0
(Abacus Concepts). The data is presented as mean ± SEM of at least 3
experiments.
2.12. Commonly used solutions
2.12.1. Tissue culture
Complete medium Dulbecco's Modified Eagles Medium (DMEM)
Glutamax, supplemented with:
10% (v/v) heat inactivated foetal bovine serum
100U/ml Penicillin and lOOpg/ml Streptomycin
200pg/ml G418 (PROKR1 Ishikawa cells only)
Starving Medium Dulbecco's Modified Eagles Medium (DMEM)
Glutamax, supplemented with:
100U/ml Penicillin and lOOqg/ ml Streptomycin
Transfection medium Dulbecco's Modified Eagles Medium (DMEM)
Glutamax
Freezing medium 90% (v/v) heat inactivated foetal bovine serum
10% DMSO
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2.12.2. Inositol phosphate assay
140 mM NaCl 8.2 g
4 mM KC1 300 mg
20 mM HEPES 4.8 g
0.1% BSA (f.a. free) 1 g
8.3 mM D-Glucose 1.5 g
1 mM MgCL 100 mg
1 mM CaCL 100 mg)
2.12.3. Western Immunoblotting
Lysis buffer 150mM NaCl (4.4g)
lOmM EDTA/EGTA (1.86g)
50mM Tris pH 7.4 (25ml)





5X Laemmli protein gel 1M Tris pH 6.8 (6ml)
loading buffer 50% Glycerol (10ml)
10% SDS (2g)
12.5% (3-Mercaptoethanol (2.5ml)
Trace Bromophenol blue (O.lg)
7.5% H20 (1.5ml)
lOx Running Buffer Tris 30.3g
Glycine 188g
10% SDS 100ml
Make up to 1L with H2O
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20x NuPAGE MOPS 50mM MOPS (104.6g)
50mM TRIS base (60.6g)
0.1% SDS (lOg)
ImM EDTA (3g)
Make up to 500ml with H2O
20x NuPAGE MES 50mM MES (97.6g)
50mM TRIS base (60.6g)
0.1% SDS (lOg)
ImM EDTA (3g)
Make up to 500ml with H2O
Transfer buffer Glycine 14.4g
Tris 3g
20% Methanol
Make up tolL with H2O
Stripping buffer 200mM Glycine (15g)
SDS (lOg)
Dissolve in 600ml H2O
Adjust pH to 2.5 with HC1
Make up to 1L with H2O
5x TNS - tween NaCl 146.lg
1M TRIS HC1 (100ml)
5ml Tween
Make up to 1L with H2O
2.12.4. Immunohistochemistry
NBF fixative 40% formaldehyde (100ml)
Distilled water (900ml)
Sodium dihydrogen phosphate monohydrate (4g)
Disodium hydrogen phosphate anhydrous (6.5g)
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Citrate buffer (0.1M) Citric acid monohydrate (42.02g)
Distilled water (900ml)
pH to 5.5 with concentrated NaOH










Peroxide (30ml of 30%
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Chapter 3 - Expression and localisation of PROK1 and PROKR1 in normal and
pathological endometrium
3.1. Introduction
Prokineticins, PROK1 and PROK2, are pleiotropic proteins whose action appears
to be tissue specific. They were initially described, and named, by Li at al (2001),
for their effects in inducing contractions in the gastrointestinal tract. Subsequently,
the action of PROK1 was described by LeCouter et al (2001) as inducing
proliferation, migration and fenestrations in endothelial cells derived from
endocrine glands PROK1 therefore appeared to be an angiogenic factor for
endocrine gland endothelium. Examination of the expression of PROK1 in a range
of human tissues revealed expression in steroidogenic tissues which undergo
angiogenesis including ovary, placenta and testis (LeCouter et al, 2001). Delivery
of PROK1 into the ovary resulted in enlargement of the ovaries with visible blood
vessels and haemorrhagic areas (LeCouter et al, 2001). Indeed, examination of
expression and localisation of PROK1 in the ovary, corpus luteum, polycystic
ovaries, testis and testicular cancers suggest a role for PROK1 in angiogenesis
(LeCouter et al, 2001, Ferrara et al, 2003, Samson et al, 2001, Kisliouk et al,
2005a). This is supported by studies investigating the role of PROK1 in a model of
neovascularisation for age related macular degeneration and delivery of PROK1 in
colorectal cancer (Tanaka et al, 2005, Goi et al, 2004). These studies demonstrated
that cells overexpressing PROK1 induced neovascularisation and formation of
fenestrae within these animal models.
Expression in endocrine tissues and involvement with angiogenesis led to
speculation that PROK1 may be involved in endometrial angiogenesis. The
endometrium is a tissue under direct influence of the steroid hormones and is one
of the few tissues in the adult human which exhibit dynamic angiogenesis as part
of a normal physiological process. The endometrium exhibits rapid growth,
development of blood vessels, formation of glands and secretory transformation
generally within a 28 - 35 day period before it is shed at menstruation and the
cycle initiated again (Smith, 2001). Regeneration of the endometrium starts in the
basal layer during menstruation (Rogers, 2002) and requires neovascularisation in
the proliferative phase of the menstrual cycle in order to support endometrial
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growth. If PROK1 were involved in endometrial neoangiogenesis, a pattern of
expression in the proliferative phase of the menstrual cycle with localisation to the
endothelial and smooth muscle cells would be expected. Examination of
endometrial PROK1 expression, however, demonstrated an elevation in expression
during the secretory phase of the menstrual cycle (Battersby et al, 2004a, Ngan et
al, 2006).
Angiogenesis is also a feature of cancers; tumours are unable to grow to a size
greater than around 1mm2 without development of a blood supply (Folkman,
1971, Gimbrove et al, 1972). PROK1 mRNA expression however is suggested to be
down-regulated in endometrial cancer compared to normal endometrium from the
mid-secretory phase of the menstrual cycle from age-matched control subjects
(Ngan et al, 2006). This suggests that PROK1 may not play a role in
neovascularistion of the endometrium; however, it may play a role in blood vessel
maturation during the secretory phase of the cycle. Its potential role in early
pregnancy endometrium, however, has not been examined.
This study was designed to investigate the expression and localisation of PROK1
and PROKR1 in early pregnancy endometrium (first trimester decidua) and
endometrial cancer compared with normal endometrium. PROK1 or PROKR1
expressing cells were further identified by co-localisation with cluster designation
markers.
3.2. Materials and Methods
3.2.1. Tissue Collection
3.2.1.1. Endometrial Tissue
Endometrial tissue collection was performed with ethical approval from
Lothian Research Ethics Committee under ethics number
LREC/05/S1103/32 as indicated in Section 2.2. Samples were designated
according to phase of menstrual cycle as early proliferative, mid
proliferative, late proliferative to ovulatory, early secretory, mid secretory
and late secretory as assessed by a pathologist according to the Noyes
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criterion. Circulating estradiol and Progesterone concentrations were
consistent for both stated last menstrual period and histological
assessment of menstrual cycle stage.
3.2.1.2. Decidua Tissue
Decidua tissue collection was performed with ethical approval from
Lothian Research Ethics Committee under ethics number
LREC/05/S1103/32 as indicated in Section 2.2. Gestation of pregnancy
was confirmed by ultrasound scan prior to elective first trimester surgical
termination of pregnancy
3.2.1.3. Endometrial Cancer Tissue
Endometrial cancer tissue collection was performed with ethical approval
from Lothian Research Ethics Committee under ethics number
LREC/1999/6/4 as indicated in Section 2.2. Endometrial cancer tissue
was obtained from women undergoing surgery for removal of endometrial
cancer. Cancer biopsies were assessed by a pathologist and designated as
grade 1: well differentiated, grade 2: moderately differentiated or grade 3:
poorly differentiated.
Written informed consent was obtained from all subjects prior to tissue
collection. Shortly after collection, tissue was placed in RNAlater and
stored at -70°C (for RNA extraction), fixed in neutral buffered formalin
and wax embedded (for immunohistochemical analysis).
3.2.2. Polymerase chain reaction
3.2.2.1. RNA extraction
RNA was extracted using TRI-reagent and the phenol-chloroform method
of RNA extraction as described in section 2.5. Briefly, TRI-reagent was
added to tissue in 2.0ml Eppendorf tubes containing a 5mm stainless steel
bead. Tissue was then homogenized using a tissue lyser (Qiagen)
subjecting the samples to shaking at 25Hz for 6 minutes. Homogenised
tissue samples were then cleared of cellular debris by centrifugation at
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15000 RPM for 10 minutes at 4°C. Lysed tissue samples were then loaded
into heavy gel phase lock tubes with the addition of bromo-chloro propane.
Tubes were shaken vigorously to ensure adequate mixing of the two
solutions. Samples were then processed as described in section 2.5.
3.2.2.2. RT-PCR
uNK cell RNA was quantified and prepared at a concentration of
volume of lOpl in order to make cDNA as described in section 2.5.
to amplify PROK1 cDNA, PCR was performed using specific
primers: -
Forward - 5' GTG CCA CCC GGG CAG 3'
Reverse -5' AGC AAG GAC AGG TGT GGT GC 3'
A 1% Tris-Acetate-EDTA (TAE) agarose gel containing ethidium bromide
was then prepared and samples run for approximately 1 hour 30 minutes
before visualisation using a UV transilluminator.
3.2.2.3.Taqman quantitative PCR analysis
Expression of RNA within tissue was examined by Taqman quantitative
PCR analysis as described in section 2.5. Briefly, cDNA was prepared in a
random hexamer primed reaction using 200ng RNA per reaction.
Quantitative PCR analysis was performed on the cDNA using specific
primer probe combinations to detect PROK1 or PROKR1 (sequences given
in Table 5). These were designed in house and were custom synthesised.
The probe was given a FAM fluorescent label with a TAMRA quencher.
Gene expression was normalized by including Vic labelled primer-probe
mix to detect the 18s ribosomal subunit (sequences given in Table 5), as a
loading control for the amount of cDNA added in each sample.
Reaction mixes were loaded in duplicate onto a 96-well MicroAmp fast
optical reaction plate for analysis on an ABI7900 HT Fast Real-Time PCR
machine. Data were analysed and processed using sequence detector
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to an internal positive RNA standard included in all reactions. The data
were analysed using the comparative Ct method for relative quantification.
3.2.3. Immunohistochemistry
3.2.3.1.DAB immunohistochemistry
Tissue sections (5pM) were dewaxed in xylene and sequentially rehydrated
in decreasing concentrations of ethanol (100%, 95%, 80%, 75%) and finally
placed in water when rehydration was complete. Antigen retrieval was
performed in order to reveal the epitope sites of the proteins and make
them available for the antibodies to bind. This was achieved by placing the
rehydrated tissue sections in a pressure cooker followed by boiling for five
minutes in 0.1% citrate buffer (pH 6.0). The sections were allowed to rest
and cool for 20 minutes before adding excess cold water. Endogenous
peroxidase activity was quenched with 3% (vol/vol) H2O2 in methanol at
room temperature. Blocking serum (5% normal swine serum in Tris-
buffered saline with 0.05% BSA) was applied for one hour in order to block
any non-specific binding. Subsequently PROK1 (1:1000) or PROKR1
(1:250) antibody was applied in the serum block solution and incubated
overnight at 4°C. The tissue sections were then washed sequentially in tris
neutral saline (TNS)-tween and TNS to remove any excess antibody before
application of goat anti-rabbit biotinylated antibody. The sections were
washed in TNS and exposed to the ABC reagent (Dako) for 30 minutes.
The sections were again washed in TNS before exposure to the chromagen
3,3"-diaminobenzidine, the colour development was checked under a
microscope and the reaction terminated by placing the slides in water. The
slides were counterstained with haematoxylin and dehydrated in increasing
concentrations of ethanol (75%, 80%, 95%, 100%). Sections were then
mounted in pertex. Negative controls were incubated with isotype matched
IgG in place of primary antibody.
3.2.3.2. Immunofluorescent histochemistry and confocal microscopy
Tissue sections (5qM) were dewaxed in xylene, rehydrated and subjected to
antigen retrieval followed by endogenous peroxidase quench with 3%
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(vol/vol) H2O2 in methanol at room temperature as described in Section
3.2.3.1. Sections were then blocked in 5% normal goat serum block (5%
normal goat serum in phosphate-buffered saline with 0.05% BSA) followed
by incubation overnight at 4°C with CD56 (1:250), CD68 (1:30) or CD31
(1:30). Sections were washed in PBS-tween followed by PBS, incubated for
one hour with goat anti-mouse biotinylated antibody (1:500) followed by
incubation with Streptavidin 488 (green) or 546 (red) in PBS (1:200).
Sections were subsequently re-blocked with 5% goat serum block followed
by incubation with PROK1 (1:1500) or PROKR1 (1:500) overnight at 4°C.
Sections were washed in PBS-tween followed by PBS, incubated for one
hour with goat anti-rabbit peroxidase antibody (1:200) followed by
incubation with TSA plus Fluorescein (green) or Cyanine (red) at 1:50 in
substrate for 10 minutes. Sections were then incubated with the nuclear
counterstain ToPro (1:2000) for 2 minutes, mounted in Permafluor and
coverslipped. Fluorescent images were visualised using a laser-scanning
confocal microscope (LSM 510, Carl Zeiss, Jena, Germany) with a 40 x 1.4
aperture oil immersion lens. Negative controls were incubated with isotype
matched IgG in place of primary antibody.
3.2.4. Statistics
Statistical analysis of the data in this study was carried out by ANOVA with
Fishers PLSD (predicted least squares difference) applied, using Statview 5.0
(Abacus Concepts). The data is presented as mean ± SEM of at least 3
experiments.
3.3. Results
3.3.1. Expression and localisation of PROK1 in normal cycling endometrium
and early pregnancy decidua.
3.3.1.1.Expression of PROK1 throughout the menstrual cycle
Endometrial samples taken across the menstrual cycle were analysed for
expression of PROK1 mRNA by quantitative RT-PCR analysis. PROK1
mRNA expression in secretory phase endometrial samples was
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significantly elevated when compared with proliferative phase endometrial
samples (p<0.05, Figure 3.1) with an apparent peak in expression during
the mid-secretory phase of the menstrual cycle.
3.3.1.2.Expression of PROK1 in first trimester decidua
First trimester decidua samples taken from weeks 7 - 12 of pregnancy
were analysed for expression of PROK1. All samples examined expressed
PROK1 mRNA however the expression of PROK1 was variable (Figure 3.2
A). Sample numbers from each phase of gestation were insufficient to
make comparisons between gestational ages and as the date allocated by
the scan may vary by 3 days either side it is difficult to be completely
certain that the gestational date assigned is correct. However, when PROK1
mRNA expression data from all first trimester decidua were pooled and
compared with PROK1 mRNA expression in the normal cycling
endometrium (from proliferative or secretory phase) it was revealed that
PROK1 expression was significantly elevated in the pregnant compared
with the non-pregnant endometrium (p<0.001, Figure 3.2 B).
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Figure 3.1. Expression of PROK1 across the menstrual cycle. Samples of endometrial tissue
taken from the early proliferative (EP, n=7) mid proliferative (MP, n=9) late proliferative (n=7),
early secretory (ES, n=11), mid secretory (MS, n=12) and late secretory (LS, n=5) were
examined for the expression of PROK1 by Taqman quantitative PCR analysis. PROK1
expression was normalized for loading against expression of 18s and relative to a single
endometrial control. Data are presented as mean ± SEM. (a is significantly different from b
p<0.05). Stage of the menstrual cycle was assessed in tissues by a pathologist according to
the Noyes criterion.
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Figure 3.2. Expression of PROK1 in first trimester decidua and comparison with PROK1
expression across the menstrual cycle. A, samples of first trimester decidua tissue taken
between weeks 7 - 12 of gestation were examined for expression of PROK1 by Taqman
quantitative PCR analysis. PROK1 expression was normalized for loading against
expression of 18s and relative to an internal endometrial control. B, samples of
endometrial tissue taken from the early proliferative (EP, n=7) mid proliferative (MP, n=9)
late proliferative (LP, n=7), early secretory (ES, n=11), mid secretory (MS, n=12), late
secretory (LS, n=5) and first trimester decidua (n=9) were examined for the expression
of PROK1 by Taqman quantitative PCR analysis. PROK1 expression was normalized for
loading against expression of 18s and relative to a single endometrial control. Data are
presented as mean ± SEM. (a is significantly different from b p<0.05, c is different from a
and b p<0.001). Stage of the menstrual cycle was assessed in tissues by a pathologist
according to the Noyes criterion.
3.3.1.3. Locaisation of PROK1 in normal endometrium and first trimester
decidua
Immunohistochemical localisation of PROK1 in the endometrium has been
described previously (Battersby et al, 2004a); therefore only one sample of
secretory phase endometrium is shown. In agreement with previous reports
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staining for PROK1 protein is observed in the glandular epithelium and
stromal cells (Figure 3.3, A and B). However, only very weak staining of
endothelial cells was observed (Figure 3.3, B indicated by arrowhead). In
the first trimester decidua tissue, staining and localisation of PROK1
protein was similar in all samples examined (n=7), therefore only one
sample is presented as an illustration. In first trimester decidua the PROK1
localisation is similar to the non-pregnant endometrium with staining
detected in the glandular epithelium and decidualised stromal cells.
However, extensive staining of the endothelial cells of the microvasculature
is also present in the pregnant endometrium (Figure 3.3 C and D).
Examination of one first trimester decidua sample contaminated with
trophoblast revealed localisation of PROK1 protein to the cytotrophoblast
and syncytiotrophoblast cells of the first trimester (Figure 3.3 E and F). The
negative controls were incubated with isotype matched IgG in place of













Figure 3.3. Localisation of PROK1 in mid-secretory endometrium (A and B) and first trimester
decidua (C, D, E and F). PROK1 (A and B) localises to the glandular epithelial cells (G, indicated
by arrow) stromal cells (S) and weakly to the endothelial cells (E) of the endometrium (A is x10
magnification, B is x20 magnification, scale bar indicates SO^M in each image). PROK1
expression in first trimester decidua (C and D) localises to the glandular epithelial cells (G)
stromal cells (S) and endothelial cells (E) (C is x10 magnification, B is x20 magnification). One
first trimester decidua sample contaminated with trophoblast revealed PROK1 expression within
the trophoblast layers (E and F) localising to the syncytiotrophoblast (STB) and cytotrophoblast
(CTB) layers of the invading trophoblast (E is x10 magnification, F is x20 magnification).
Endometrium (G) and first trimester decidua (H) negative controls were incubated with IgG in
place of the primary antibody, with no immunoreactivity detected.
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3.3.2. Expression and localisation of PROKR1 in normal cycling
endometrium and early pregnancy decidua
3.3.2.1. Expression of PROKR1 throughout the menstrual cycle
Endometrial samples taken across the menstrual cycle were analysed for
expression of PROKR1 by quantitative RT-PCR. PROKR1 mRNA
expression did not alter significantly across the menstrual cycle (Figure
3.4).
2.5 -i
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Figure 3.4. Expression of PROKR1 across the menstrual cycle. Samples of endometrial
tissue taken from the early proliferative (EP, n=7) mid proliferative (MP, n=9) late
proliferative (n=7), early secretory (ES, n=11), mid secretory (MS, n=12) and late secretory
(LS, n=5) were examined for the expression of PROKR1 by Taqman quantitative PCR
analysis. PROKR1 expression was normalized for loading against expression of 18s and
relative to a single endometrial control. Data are presented as mean ± SEM. Stage of the
menstrual cycle was assessed in tissues by a pathologist according to the Noyes criterion.
3.3.2.2.Expression of PROKR1 in first trimester decidua
First trimester decidua samples were analysed for expression of PROKR1.
All samples examined expressed PROKR1 mRNA (Figure 3.5 A). Pooling
of these data and comparison to PROKR1 mRNA expression in the normal
cycling endometrium (from proliferative or secretory phase) revealed that
PROKR1 expression was significantly elevated in the pregnant compared
with the non-pregnant endometrium (Figure 3.5 B, p<0.001)
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Figure 3.5. Expression of PROKR1 in first trimester decidua and comparison with PROK1
expression across the menstrual cycle. A, samples of first trimester decidua tissue taken
between weeks 7 - 12 of gestation were examined for expression of PROKR1 by Taqman
quantitative PCR analysis. PROKR1 expression was normalized for loading against
expression of 18s and relative to an internal endometrial control. B, samples of endometrial
tissue taken from the early proliferative (EP, n=7) mid proliferative (MP, n=9) late proliferative
(n=7), early secretory (ES, n=11), mid secretory (MS, n=12), late secretory (LS, n=5) and first
trimester decidua (n=9) were examined for the expression of PROKR1 by Taqman
quantitative PCR analysis. PROKR1 expression was normalized for loading against
expression of 18s and relative to a single endometrial control. Data are presented as mean ±
SEM. (a is significantly different from b p<0.001). Stage of the menstrual cycle was assessed
in tissues by a pathologist according to the Noyes criterion.
Chapter 3 Expression and localisation of PROK1 and PROKR1 100
3.3.2.3.Localisation of PROKR1 in normal endometrium and first trimester
decidua
PROKR1 expression in the human endometrium has previously been
localised by in situ hybridisation. In this study expression of endometrial
PROKR1 protein was investigated by immunohistochemistry in
endometrium samples collected across the menstrual cycle. Examination of
PROKR1 mRNA revealed no variation across the menstrual cycle while
immunohistochemical analysis appeared to demonstrate greater staining in
samples of secretory phase endometrium compared to proliferative
endometrium, however a large degree of inter-sample variation was
evident. PROKR1 localises to the glandular epithelial cells of proliferative
endometrium with no immunoreactivity detected in stromal or endothelial
cells (Figure 3.6 A and B). In early secretory endometrium PROKR1 again
localises to the glandular epithelial cells, however, immunoreactivity
becomes apparent in some stromal cells with limited immunoreactivity
also noted in the endothelial cells (Figure 3.6 C and D). In mid-secretory
endometrium PROKR1 localises to the glandular epithelial cells and
endothelial cells of the microvasculature along with extensive stromal cell
staining (Figure 3.6 E and F). In first trimester decidua (n=7) PROKR1
localisation is similar to that revealed in mid-secretory endometrium, with
localisation to the glandular epithelium, decidualised stromal cells and
endothelial cells (Figure 3.7 A and B). Examination of the first trimester
decidua sample contaminated with trophoblast also reveals expression of
PROKR1 in the cytotrophoblast and syncytiotrophoblast cells of the first
trimester (Figure 3.7 C and D). Negative controls were incubated with the
primary antibody pre-absorbed with neutralising peptide or with isotype
matched IgG in place of the primary antibody. These exhibited no
immunoreactivity (Figure 3.6 inset F, Figure 3.7 E and F).
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Figure 3.6. Localisation of PROKR1 in human endometrium in mid-proliferative (A and
B), early secretory (C and D) and mid secretory (E and F) phases of the menstrual cycle.
PROKR1 (A and B) was localised to the glandular epithelial cells of the endometrium (G)
in the mid-proliferative phase of the menstrual cycle (A is x10 magnification, B is x20
magnification, scale bars indicate 50(iM in each image). PROKR1 (C and D) was
localised to the glandular epithelial cells (G) with appearance in endothelial cells (E) and
some stromal cells (S) in the early secretory phase of the cycle (C is x10 magnification,
D is x20 magnification). PROKR1 was localised to the glandular epithelium (G) with
extensive stromal cell (S) and endothelial cell (E) localisation in the mid-secretory phase
of the menstrual cycle (E is x10 magnification, F is x20 magnification). Inset F is
negative control in which sections were treated with PROKR1 antibody pre-absorbed
with neutralising peptide (Lifespan Biosciences, at a x10 excess concentration to
antibody); no immunoreactivity was detected. Stage of the menstrual cycle was
assessed in tissues by a pathologist according to the Noyes criterion.
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Figure 3.7. Localisation of PROKR1 in first trimester decidua. PROKR1 (A and B)
localises to the glandular epithelial cells (G), stromal cells (S) and endothelial cells (E) of
first trimester decidua tissue (A is x10 magnification, B is x20 magnification). One first
trimester decidua sample contaminated with trophoblast revealed PROKR1 expression
within the trophoblast layers (C and D) localising to the syncytiotrophoblast (STB) and
cytotrophoblast (CTB) layers of the invading trophoblast (C is x10 magnification, D is x20
magnification, scale bars indicate 50^iM in each image). First trimester decidua (E) and
trophoblast (F) negative controls were incubated with IgG in place of the primary
antibody, with no immunoreactivity detected.
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3.3.3. Identification of PROK1/PROKR1 expressing endometrial cells
3.3.3.1. Expression of PROK1 and PROKR1 in immune cells within the
endometrium
During the peri-implantation phase of the menstrual cycle and during
early pregnancy, when PROK1 expression is elevated, immune cells
infiltrate the endometrium in great numbers. As PROK1 and PROKR1
expression is elevated in first trimester decidua with localization detected
in the stroma where the immune cells reside it was decided to investigate
whether populations of stromal cells that express PROK1 and PROKR1
were immune cells. Immunofluorescent co-localisation conducted on
decidua using the uterine natural killer (uNK) cell marker CD56 (red
channel) revealed clusters of PROK1 expressing stromal cells (green
channel) to be uNK cells (yellow channel, Figure 3.8 A). Further
confirmation of PROK1 expression by uNK cells was obtained by RT-PCR
analysis conducted on RNA extracted from uNK cells isolated from 3
individual decidua samples (kindly provided by Dr N Kane, Figure 3.8
B). PROKR1 however did not localise to uNK cells and PCR analysis
confirmed that PROKR1 is not expressed in uNK cells (data not shown).
Further investigation of the stromal cell population revealed PROK1 (red
channel) and PROKR1 (red channel) expression to be localised to the
CD68 (green channel) expressing macrophages (yellow channel) present
within the decidual stroma by immunofluorescent co-localisation (Figure
3.9 and 3.10 respectively). Tissue sections were incubated with isotype
matched IgG in place of the primary antibody and displayed no
immunoreactivity.
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Figure 3.8. Expression of PROK1 by uNK cells. A, PROK1 (green) and uNK cell marker (CD56,
red) were co-localised (yellow, merge) to stromal cells surrounding blood vessels in decidua. Inset,
negative control was incubated with isotype matched IgG in place of first and second antibody and
demonstrated no immunoreactivity. B, RT-PCR analysis conducted on uNK cells isolated from 3
different decidua using specific primers for PROK1. Positive control is endometrium; negative
control is endometrium with no Tag polymerase enzyme in the RT-PCR reaction.
Figure 3.9. Localisation of PROK1 to macrophages within decidua. PROK1 (red) and macrophage
marker (CD68, green) were co-localised (yellow, merge) to isolated cells within the decidual stroma.
The lower picture presents a magnified view of 3 macrophages within the isolated white box. Inset,
negative control was incubated with isotype matched IgG in place of first and second antibodies
with no immunoreactivity detected.
Figure 3.10. Localisation of PROKR1 to macrophages within decidua. PROKR1 (red) and
macrophage marker (CD68, green) were co-localised (yellow, merge) to isolated cells within
the decidual stroma. The lower picture presents a magnified view of 2 macrophages within
the isolated white box. Inset, negative control was incubated with isotype matched IgG in
place of first and second antibodies with no immunoreactivity detected.
3.3.3.2. Expression of PROKR1 in endometrial endothelial cells
DAB immunohistochemistry staining localised PROKR1 to the endothelial
cells of the endometrium. In order to confirm the expression of PROKR1 in
endothelial cells, PROKR1 (green channel) and the endothelial cell marker
CD31 (red channel) were co-localised by immunofluorescent
histochemistry (yellow channel, Figure 3.11). This confirmed the endothelial
cell expression of PROKR1.
Figure 3.11. Localisation of PROKR1 to endothelial cells of the endometrium. PROKR1
(green) and endothelial cell marker (CD31, red) co-localise (yellow, merge) to the
endothelial cells of the endometrium. Inset, isotype matched IgG in place of first and
second antibodies negative control.
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3.3.4. Expression and localisation of PROK1 in endometrial cancer
3.3.4.1.Expression of PROK1 in well, moderately and poorly differentiated
endometrial cancer
Examination of PROK1 mRNA expression by quantitative PCR in
endometrial cancer samples, representing well, moderately and poorly
differentiated carcinoma revealed no difference in expression between
these different stages (Figure 3.12 A). The levels of PROK1 expression in
endometrial cancer are higher than those for PROK1 in the proliferative
phase of the menstrual cycle but lower than the levels of PROK1





Figure 3.12. Expression of PROK1 in endometrial cancer and normal cycling
endometrium. A. Samples of endometrial cancer tissue from well differentiated (n=4),
moderately differentiated (n=8) and poorly differentiated (n=7) endometrial carcinomas
were examined for the expression of PROK1 by Taqman quantitative PCR analysis. B.
Samples of endometrium from the proliferative and secretory phases of the endometrium
in addition to samples of endometrial carcinoma were examined for PROK1 expression
by Taqman quantitative PCR analysis. PROK1 expression was normalized for loading
against expression of 18s and relative to a single endometrial control. PROK1
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expression is significantly elevated in secretory phase endometrium compared with
proliferative endometrium and endometrial cancer. Data are presented as mean ± SEM
(a is significantly different from b p<0.05).
3.3.4.2.Localisation of PROK1 in well, moderately and poorly
differentiated endometrial cancer
Immunohistochemical analysis of endometrial cancer revealed some
PROK1 protein expression in glandular epithelial cells present in well-
differentiated carcinoma (Figure 3.13 A and B), however PROK1 protein
expression is almost completely absent in moderately (Figure 3.13 C and
D) and poorly (Figure 3.13 E) differentiated carcinoma samples. Negative
controls were incubated with isotype matched IgG in place of primary
antibody and displayed no immunoreactivity (Figure 3.13 F, G and H
representing negative controls for well, moderately and poorly
differentiated carcinoma respectively).
3.3.5. Expression and localisation of PROKR1 in endometrial cancer
3.3.5.1.Expression of PROKR1 in well, moderately and poorly
differentiated endometrial cancer
Examination of PROKR1 mRNA expression by quantitative PCR analysis
in endometrial cancer samples, representing well, moderately and poorly
differentiated carcinoma revealed no difference in expression between these
different stages (Figure 3.14 A). The levels of PROKR1 in endometrial
cancer are similar to those for PROKR1 throughout the menstrual cycle
(Figure 3.14 B).
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Figure 3.13. Localisation of PROK1 in endometrial cancer from well (A and B),
moderately (C and D) and poorly (E) differentiated endometrial cancer samples. PROK1
appears to localise weakly to gland-like structures in well (A x10 magnification, and B
x20 magnification) and moderately (C x10 magnification and D x20 magnification, scale
bars indicate 50uM in each image) differentiated endometrial cancer samples). No
PROK1 immunoreactivity was present in poorly differentiated (E x10 magnification)
cancer samples. Negative controls from well (F), moderately (G) and poorly (H)
differentiated cancer samples were incubated with IgG in place of primary antibody with
no immunoreactivity detected.












Figure 3.14. Expression of PROKR1 in endometrial cancer and normal cycling
endometrium. Samples of endometrial cancer tissue from well differentiated (n=4),
moderately differentiated (n=8) and poorly differentiated (n=7) endometrial carcinomas
were examined for the expression of PROKR1 by Taqman quantitative PCR analysis. B.
Samples of endometrium from the proliferative and secretory phases of the endometrium in
addition to samples of endometrial carcinoma were examined for PROKR1 expression by
Taqman quantitative PCR analysis. PROKR1 expression was normalized for loading
against expression of 18s and relative to a single endometrial control. Data are presented
as mean ± SEM.
3.3.5.2.Localisation of PROKR1 in well, moderately and poorly
differentiated endometrial cancer
Immunohistochemical analysis of endometrial cancer revealed PROKR1
protein expression to be almost absent in well differentiated carcinoma
samples (Figure 3.15 A and B), however some immunoreactivity was
revealed in moderately differentiated samples, possibly in gland-like
structures (Figure 3.15 C and D). PROKR1 protein expression is almost
completely absent in poorly differentiated carcinomas (Figure 3.15 E and
F). Negative controls were incubated with isotype matched IgG in place
of primary antibody and displayed no immunoreactivity (Figure 3.15 G
and H).
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Figure 3.15. Localisation of PROKR1 in endometrial cancer from well (A x10
magnification, B x20 magnification, scale bars indicate 50uM in each image), moderately
(C and D) and poorly (E and F) differentiated endometrial cancer samples. PROKR1
appears to localise weakly to gland-like structures in moderately (C x10 magnification
and D x20 magnification) differentiated endometrial cancer samples. Well and poorly
differentiated cancer samples display little immunoreactivity. Negative controls from
moderately (G) and poorly (H) differentiated cancer samples were incubated with IgG in
place of primary antibody with no immunoreactivity detected.
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3.4. Discussion
This study characterises the expression and localisation of PROK1 and PROKR1 in
the pregnant and non-pregnant endometrium and also endometrial carcinoma. A
population of PROK1 and/or PROKR1 expressing stromal cells have been further
identified as bone marrow derived immune cells. It was decided to focus on
PROK1 as its expression in the endometrium, as assessed by Northern blot and
Taqman quantitative PCR, is suggested to be elevated compared with PROK2 and
expression of PROK2 does not change across the menstrual cycle (LeCouter et al,
2001, Li M et al, 2001, LeCouter et al, 2003, Battersby et al, 2004a).
PROK1 expression is elevated during the secretory phase of the menstrual cycle
(Battersby et al, 2004a), and is suggested to be specifically elevated in the mid-
secretory phase of the cycle, also known as the window of implantation (Ngan et
al, 2006). This study confirms the elevated expression of PROK1 in the secretory
phase of the menstrual cycle compared with the proliferative phase of the
menstrual cycle. However, although PROK1 expression appeared to be further
elevated in the mid-secretory phase of the menstrual cycle this was not significant
when compared with the early- or late-secretory phases. In agreement with
previous data, PROKR1 expression does not appear to exhibit differences between
the stages of the menstrual cycle (Battersby et al, 2004a). This study also confirms
immunolocalisation of PROK1 to the glandular epithelial and stromal
compartments of the non-pregnant endometrium with some endothelial cell
expression (Battersby et al, 2004a). Localisation of PROKR1 in the human
endometrium has previously been investigated by in situ hybridisation. In this
study, immunolocalisation of PROKR1 expression throughout the menstrual cycle
demonstrated expression in the glandular epithelium, the stromal compartment
and enciothelial cells of the vasculature in the non-pregnant endometrium, similar
to that reported previously for in situ hybridisation (Battersby et al, 2004a).
Expression of PROK1 and PROKR1 in the pregnant endometrium was also
examined by real-time PCR and immunohistochemistry. Expression of both
PROK1 and PROKR1 was detected in all samples examined. However, expression
was variable and due to insufficient numbers from each of the weeks of gestation
(7-12 weeks) it was difficult to conclude whether these changes were gestational
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age dependent or due to inter-sample variation. Another factor, which must be
taken into consideration when attempting to categorise these samples in terms of
gestational age, is that the gestational age, as determined by ultrasound, is not
accurate and is usually assigned a gestational week plus a number of days (e.g. 7
weeks + 5 days). However, it is difficult to accurately judge early gestations and
the surgical termination of pregnancy usually doesn't take place until a week or
more after the ultrasound. A sample may therefore be assigned a certain
gestational week when in fact it should belong to another (e.g. assigned to week 7
when in fact it should belong to week 8). Although expression of PROK1 and
PROKR1 was variable in the pregnant endometrium, when taken collectively,
expression of both factors was significantly elevated when compared with non¬
pregnant endometrium.
Localisation of PROK1 and PROKR1 was also investigated in the pregnant
endometrium with expression localised to the glandular epithelium and
endothelial cells. This is similar to the non-pregnant endometrium, with extensive
expression demonstrated in the decidualised stromal compartment. Further
identification of cell populations was performed using cluster designation (CD)
markers to identify cells of bone marrow origin and endothelial cells. Macrophages
were identified within the pregnant endometrium and were demonstrated to
express both PROK1 and PROKR1. However, investigation of uNK cells by PCR
and immunohistochemical analysis revealed them to express PROK1, but not
PROKR1. A single decidua sample was found to be contaminated with
trophoblast tissue, which exhibited immunostaining for both PROK1 and
PROKR1. In agreement with the report of Hoffman et al (2006), PROK1 localised
to the syncytiotrophoblast and cytotrophoblast layers of the invading trophoblast.
The study reported herein also shows that PROKR1 localises to these trophoblast
cell layers.
In this study, investigation of PROK1 and PROKR1 expression in endometrial
cancer revealed no differences between well, moderately or poorly differentiated
cancer samples for either PROK1 or PROKR1. A previous study has reported that
PROK1 expression is lower in endometrial carcinoma compared with normal
endometrium taken during the mid-secretory phase of the menstrual cycle (Ngan
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et al, 2006). In this study expression of PROK1 and PROKR1 in endometrial
cancer was compared with endometrial samples taken across the proliferative and
secretory phases of the cycle rather than solely the mid-secretory phase.
Expression of PROK1 in endometrial carcinoma samples appeared to be higher
than the level of expression observed in the proliferative phase of the menstrual
cycle but was significantly lower than that of the secretory phase. However,
PROKR1 expression in endometrial cancer appeared to be similar to the level of
expression observed in the proliferative phase of the menstrual cycle.
Immunohistochemical analysis of PROK1 and PROKR1 in endometrial cancer
revealed little immunostaining for either protein in well, moderately or poorly
differentiated samples.
It has been suggested that elevation of PROK1 expression in the secretory phase of
the menstrual cycle may be due to regulation by steroid hormones, as PROK1 has
a progesterone response element in its promoter region (Battersby et al, 2004a).
PROK1 expression is also suggested to be subject to regulation by estrogen (Ngan
et al, 2006). The physiological relevance for this is unclear as during the
proliferative phase when estrogen is elevated PROK1 expression is low. PROK1
expression is elevated post ovulation and its expression appears to parallel
progesterone secretion. Indeed it has been demonstrated that progesterone induces
expression of PROK1 in endometrial explants (Battersby et al, 2004a). During the
secretory phase of the cycle PROK1 localises to the epithelial and stromal
compartments. However, during the secretory phase of the cycle stromal cell
expression of the progesterone receptor is elevated while epithelial cell expression
is down-regulated (Mote et al, 1999, Lessey et al, 1996). It is therefore possible
that progesterone regulation of PROK1 in the endometrium may be mediated via
direct and indirect mechanisms. Progesterone may directly induce expression of
PROK1 in the stromal cells where progesterone receptor expression is present.
Whereas in epithelial cells, where the receptors are absent, progesterone may
mediate PROK1 expression though indirect mechanisms via local paracrine
mediators from the stromal cells.
Elevation of PROK1 in the mid-secretory phase of the menstrual cycle, the stage of
endometrial receptivity, may suggest a role for PROK1 in preparation of the
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endometrium for implantation. PROK1 induces production of nitric oxide (Lin R
et al, 2002) and induces formation of fenestrae in endothelial cells (LeCouter et al,
2001). These actions may contribute to the edema and hyperpermeability observed
in the endometrium at the time of implantation (Lessey, 2002). Hyperaemia and
endothelial leakage are considered to be some of the first signs of implantation
(Plaks ef al, 2006).
During the secretory phase of the menstrual cycle and early pregnancy the
endometrium experiences a large influx of immune cells, mainly uNK cells and
macrophages (Loke & King, 1995). The uNK represent over half of the endometrial
leukocyte population in the secretory phase of the cycle with their numbers rising
further in early pregnancy where they account for around 70% of the leukocytes
present (King et al, 1998). During the secretory phase and early pregnancy they are
found, as demonstrated in Figure 3.8, clustered around the spiral arterioles and
glandular epithelium. In pregnancy they are also found thickly clustered around
the invading trophoblast (Trundley & Moffett, 2004). uNK cells are thought to
play a role in the remodelling of the endometrial vessels upon implantation
(Guimond et al, 1997). Factors released from the uNK cells, including VEGF
(Leonard et al, 2006, Li XF et al, 2001, Tayade et al, 2006, Hanna et al, 2006) are
thought to potentially act as trophic signals to 'guide' the trophoblast towards the
maternal arterioles and guide maternal blood vessel growth towards the invading
trophoblast (Carmeliet, 2005). PROK1 has been demonstrated as a chemotactic
factor for endothelial cells (Lecouter et al, 2001) and may therefore also act as a
trophic signal. Upon PROK1-PROKR1 interaction nitric oxide may be generated
(Lin R et al, 2002). uNK cells expressing PROK1 could potentially interact with
PROKR1 on endothelial cells or the trophoblast and produce nitric oxide or other
factors, which may influence vascular remodelling or trophoblast invasion and
placentation. A deficiency in uNK cells is associated with inadequate vascular
remodelling and trophoblast invasion (Ashkar et al, 2003). PROK1 expression in
uNK may therefore contribute to this remodelling and placentation.
A role for PROK1 and PROKR1 has been suggested in the immune response and
in the survival and differentiation of granulocytic and monocytic cells (Dorsch et
al, 2005, LeCouter et al, 2004). Expression of PROK1 and PROKR1 in
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macrophages may imply a role for these proteins in their activation. It is
suggested that macrophages may act in a synergistic manner to control each
other's activation and the prokineticin system may play a role in this regulation as
prokineticins appear to control macrophage activation (Martucci et al, 2005).
Chemokines produced by the immune cells within the endometrium are thought to
promote further recruitment of immune cells into the endometrium (Salamonsen
et al, 2002, Thelen et al, 2001). It is possible that PROK1 or products derived from
PROK1-PROKR1 interaction may promote this recruitment during the secretory
phase of the cycle and may account, in part, for the dramatic increase in immune
cell numbers in the secretory phase and into early pregnancy.
In this study, expression of PROK1 and PROKR1 was investigated in endometrial
cancer since it was suggested that PROK1 may play a role in normal and
pathological angiogenesis (LeCouter et al, 2001, LeCouter et al, 2003). However,
expression of PROK1 and PROKR1 was not dramatically altered compared with
normal endometrium. Indeed, in the case of PROK1 expression the level in
endometrial cancer was significantly down-regulated compared with the secretory
phase of the menstrual cycle. Hence these factors seem unlikely to play a role in
endometrial angiogenesis.
PROK1 is elevated in the non-pregnant endometrium at a time when it is
undergoing preparation for pregnancy. PROK1 and its receptor PROKR1 are
further elevated in the event of pregnancy where localisation to discrete immune
cells is evident. Their signalling, action, target gene regulation and mediators of
their expression however are currently unknown or incompletely understood in the
endometrium. The PROK1-PROKR1 system clearly warrants further investigation
and the remainder of this thesis is dedicated to answering some of these questions
to decipher potential roles for PROK1 and PROKR1 in endometrial physiology.
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Chapter 4 - Establishment of Ishikawa endometrial cell line stably expressing
PROKR1 and characterisation of PROK1 induced signalling in PROKR1
Ishikawa cells
4.1. Introduction
Prokineticin 1 (PROK1) and prokineticin receptor 1 (PROKR1) are expressed in the
endometrium and first trimester decidua as described in chapter 3. Signalling
induced by PROK1-PROKR1 has been investigated in primary adrenal cortex
endothelial (ACE) cells and cell lines transfected with PROKR1. However, to date
there has been no characterisation of the signalling downstream of PROK1-
PROKR1 in the endometrium.
In the paper which first described the existence of human prokineticins, it was
suggested that their receptors were G-protein coupled receptors (GPCR's) due to
displacement of their specific binding by GTPyS (Li M et al, 2001). The signalling
activated by PROK1 binding to an uncharacterised receptor was subsequently
investigated in ACE cells. R Lin et al (2002), demonstrated elevation of ERK 1/2
phosphorylation in response to treatment with PROK1 in ACE cells. However, the
receptors had not been characterised as GPCR's, receptor tyrosine kinases (RTK'S)
or others. VEGF and PROK1 induce similar effects on ACE cells, acting as chemo-
attractants and inducing formation of fenestrae (LeCouter et al, 2001). It was
therefore presumed that PROK1 and VEGF might activate the same receptor in
ACE cells. In order to investigate whether this was the case, PROK1 was pre-
incubated with a soluble VEGF receptor prior to addition to ACE cells. Pre¬
incubation of PROK1 with a soluble VEGF receptor however did not abrogate the
PROK1 induced ERK 1/2 response. The VEGF receptors are RTK's, therefore in
order to examine whether the PROK1 receptor was also an RTK the
phosphotyrosine status of the ACE cells was examined after stimulation with
PROK1. ACE cells did not reveal any elevation in tyrosine phosphorylation after
PROK1 stimulation suggesting that the PROK1 receptor is not an RTK in ACE
cells (R Tin et al, 2002). However, incubation of ACE cells with pertussis toxin, an
inhibitor of Gi coupled GPCR's, almost completely abolished the PROK1 mediated
ERK 1/2 phosphorylation. These data therefore suggested, in agreement with the
report of Li et al (2001) that prokineticin receptors were GPCR's.
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Three other reports published in 2002 also proposed prokineticin receptors to be
GPCR's (Lin DC et al, 2002, Masuda et al, 2002, Soga et al, 2002). In the report of
DC Lin et al (2002), the prokineticin receptors were characterised as two G-protein
coupled receptors GPR73a (or prokineticin receptor 1, PROKR1) and GPR73b (or
prokineticin receptor 2, PROKR2). These studies however, demonstrated
prokineticin receptors to be Gq coupled rather than Gi coupled (Lin DC et al,
2002, Masuda et al, 2002, Soga et al, 2002). Measurements of Gq activation
including inositol phosphate mobilisation (Lin DC et al, 2002), and calcium
mobilisation (Masuda et al, 2002) were used to characterise the receptors. PROK1
and PROK2 are suggested to activate both PROKR1 and PROKR2. This was
perhaps most elegantly demonstrated by the ERK phosphorylation data of DC Lin
et al (2002). They demonstrate maximal ERK 1/2 phosphorylation activated by
PROK1 binding to PROKR1, whereas PROK2 activates maximal ERK 1/2
phosphorylation in cells expressing PROKR2. Both ligands, however, were able to
activate some level of ERK 1/2 phosphorylation at both receptors.
PROK1 expression is elevated compared with PROK2 in the endometrium and
demonstrates cyclical variation across the menstrual cycle (LeCouter et al, 2001, Li
M et al, 2001, Battersby et al, 2004a). PROK1 also preferentially activates PROKR1
(Lin DC et al, 2002). This thesis was therefore directed towards further
understanding the role of PROK1-PROKR1 in the human endometrium. An
endometrial epithelial cell line stably expressing PROKR1 was generated, and
downstream signalling pathways activated upon PROK1-PROKR1 interaction
subsequently analysed.
4.2. Materials and methods
4.2.1. Transfection of PROKR1 cDNA
This was fully described in Section 2.3. Briefly, human cDNA encoding
prokineticin receptor 1 (PROKR1) was amplified using RT-PCR. The cDNA
was amplified using Easy-A DNA polymerase (Stratagene) and specific
primers:
Forward 5' GGA TCC AAG CTT GAT GGA GAC CAC CAT GGG G 3'
Reverse 5' CTC GAG GAT ATC TTA TTT TAG TCT GAT GCA GTC CAC CT 3'.
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The PCR product was excised from a 1% agarose gel following electrophoresis,
purified, ligated into sequencing vector pCR4 (Invitrogen) and cloned into
E.Coli TOPIO cells. Cloned plasmid DNA was subjected to automated DNA
sequencing to confirm the cDNA sequence prior to subcloning the Hind III-
EcoRV fragment into pcDNA 3.1(+). This expression construct was
transfected into Ishikawa cells using electroporation and a G418 resistant clone
isolated. These cells are subsequently termed PROKR1 Ishikawa cells.
4.2.2. Polymerase chain reaction
RNA was extracted from WT and PROKR1 Ishikawa cells as described in
Section 2.5. Briefly, media was removed from cells and TRI-reagent added.
RNA was extracted by the phenol chloroform method. RNA was quantified
and prepared at a concentration of lqg in a volume of lOpl in order to make
cDNA as described in Section 2.5. In order to amplify PROKR1 cDNA, PCR
was performed using specific PROKR1 primers provided in section 4.2.1. A
1% TAE agarose gel was prepared and samples run for approximately 1 hour
30 minutes before visualisation using a UV transilluminator.
4.2.3. Taqman quantitative PCR analysis
Expression of RNA within WT and PROKR1 Ishikawa cells was examined by
Taqman quantitative PCR analysis as described in Section 2.5. Briefly, cDNA
was prepared in a random hexamer primed reaction using 200ng RNA per
reaction. Quantitative PCR analysis was performed on the cDNA using
specific primer probe combinations to detect PROKR1 (sequence given in Table
5). The probe was given a FAM fluorescent label with a TAMRA quencher.
Gene expression was normalized by including Vic labelled primer-probe mix to
detect the 18s ribosomal subunit (sequence given in Table 5), as a loading
control for the amount of cDNA added in each sample.
Reaction mixes were loaded in duplicate onto a 96-well MicroAmp fast optical
reaction plate for analysis on an ABI7900 HT Fast Real-Time PCR machine.
Data were analysed and processed using sequence detector version 1.6.3.
Results were expressed as relative to a positive RNA standard included in all
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reactions. The data were analysed using the comparative Ct method for
relative quantification.
4.2.4. Immunocytochemistry
2 xlO5 PROKR1 and WT Ishikawa cells were seeded in 2 well chamber slides,
allowed to attach overnight, subsequently washed in PBS and fixed in ice cold
methanol. A peroxidase block was applied followed by a 5% normal serum
block (swine) prior to application of rabbit anti-PROKRl (1:500) overnight at
4°C. The cells were washed in PBS-tween and PBS, followed by application of
swine anti-rabbit peroxidase labelled antibody (1:200) for 2 hours at room
temperature. TyrCy3 Tyramide amplification agent in substrate was
subsequently applied for 10 minutes. Nuclear counterstain DAPI (1:1000) was
applied prior to mounting in Permafluor aqueous mounting agent. Fluorescent
images were visualised using a laser scanning confocal microscope (LSM 510,
Carl Zeiss, Jena, Germany).
4.2.5. IP assay
PROKR1 Ishikawa cells were seeded out in 12-well plates to a density of
100,000 cells/well and left to settle for 24 hours. The cells were then incubated
in special inositol free DMEM with lpCi/ml [3H] myo-inositol for 24 hours. In
order to determine the concentration of PROK1 which induced the greatest
Inositol phosphate mobilisation the cells were subsequently stimulated with
vehicle, 4pM, 40pM, 400pM, 4nM and 40nM PROK1 for one hour. PROK1
stimulated reactions were terminated by removal of agonist followed by
addition of ice cold lOnM formic acid for at least 45 minutes at 4°C.
Supernatants were then loaded into tubes containing AG-1X8 resin. Samples
were washed a number of times as indicated in section 2.6. 1M ammonium
formate/0.1M formic acid was added to the resin, vortexed and supernatant
removed to scintillation vials. Scintillation fluid was added and 3H counted as
indicated in Section 2.6.
4.2.6. cAMP assay
PROKR1 Ishikawa cells were seeded out in 3cm cell culture dishes to a density
of 200,000 cells/dish and left to settle for 24 hours. Subsequently the cells
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were incubated in serum free medium overnight prior to stimulation. The
phosphodiesterase inhibitor 3-isobutyl-l-methylxanthine (IBMX) was added to
the cells at a final concentration of ImM for 30 minutes at 37°C prior to
treatment with PROK1. 40nM PROK1 was added to the medium for 0, 5, 10,
15 or 20 minutes. Additionally, treatment with Forskolin (lOpM) for 10
minutes was used as a positive control. To terminate the reaction the cell
culture medium was removed and assayed for cAMP as described in Section
2.10. The cells were lysed in hydrochloric acid (HC1) and assayed for protein
concentration using the modified Bradford method as described in Section 2.7.
Concentration of cAMP within samples was normalised for protein
concentration.
4.2.7. PROK1 mediated signalling
4.2.7.1. PROK1 dose response of ERK 1/2 phosphorylation
A dose response study was conducted in order to investigate PROK1
induced ERK 1/2 phosphorylation in PROKR1 Ishikawa cells and to
determine the concentration of PROK1 which elicited maximal ERK 1/2
phosphorylation. PROKR1 Ishikawa cells were seeded at a density of
250,000 cells/well in a 6-well plate. PROKR1 Ishikawa cells were subjected
to serum starvation overnight followed by stimulation with 4pM, 40pM,
400pM, 4nM or 40nM PROK1 for 5 minutes. Reactions were terminated by
removal of agonist and cells were washed in ice cold PBS. The cells were
lysed in NP40 lysis buffer and processed for Western immunoblot analysis,
as indicated in Section 4.2.7.
4.2.7.2. Time course of PROK1 induced ERK 1/2 phosphorylation
A time course study was conducted in order to determine the time point at
which 40nM PROK1 induced maximal ERK 1/2 phosphorylation. PROKR1
Ishikawa cells were seeded at a density of 200,000 cells in 3cm dishes.
PROKR1 Ishikawa cells were subjected to serum starvation overnight
followed by stimulation with 40nM PROK1 for 0, 1, 5, 10 and 20 minutes.
Reactions were terminated by removal of agonist and cells were washed in
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ice cold PBS. The cells were lysed in NP40 lysis buffer and processed for
Western immunoblot analysis, as indicated in Section 4.2.7.
4.2.7.3. Effect of chemical inhibitors of signalling intermediates on PROK1
induced ERK 1/2 phosphorylation
In order to determine the signalling molecules activated by PROK1 in the
signalling cascade to ERK 1/2 phosphorylation chemical inhibitors of
signalling molecules were employed. PROKR1 Ishikawa cells were seeded
at a density of 250,000 cells/well in a 6-well plate. PROKR1 Ishikawa cells
were subjected to serum starvation overnight followed by pre-incubation
with chemical inhibitors or vehicle for one hour prior to stimulation with
40nM PROK1 for 5 minutes. The chemical inhibitors and their working
concentrations are summarised in Table 9. Reactions were terminated by
removal of agonist and cells were washed in ice cold PBS. The cells were
lysed in NP40 lysis buffer and processed for Western immunoblot analysis,
as indicated in Section 4.2.7.
Table 9. Concentrations of inhibitors of signalling molecules
Inhibitor Molecule Inhibited Inhibitor concentration
YM254890 Gq protein lpM
Pertussis Toxin Gi protein 200ng/ml





4.2.7.4.Effect of dominant negative isoforms of signalling molecules on
PROK1 induced ERK 1/2 phosphorylation
In order to further investigate the signalling molecules involved in PROK1
signalling to ERK 1/2, dominant negative isoforms of signalling molecules
were used. These have been previously characterized and described
(Harris, 2002, Levi, 1998). PROKR1 Ishikawa cells were seeded to a
density of 500,000 cells in a 6cm dish. PROKR1 Ishikawa cells were
transiently co-transfected with 2.5pg c-Myc ERK and 7.5pg empty vector
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(pcDNA3) or dominant negative isoforms of cSrc, EGFR, MEK or the small
GTPase Ras in the presence of Superfect transfection reagent for 6 hours.
Transfection mix was removed and cells incubated in complete DMEM
Glutamax media. Transiently transfected PROKR1 Ishikawa cells were
subjected to serum starvation overnight followed by stimulation with
40nM PROK1 for 5 minutes. One sample transfected with pcDNA3 was
incubated with Gq protein inhibitor YM254890 for one hour prior to
stimulation with 40nM PROK1 for 5 minutes. Reactions were terminated
by removal of agonist and cells were washed in ice cold PBS. The cells were
lysed in NP40 lysis buffer and immunoprecipitated with Myc-ERK agarose
conjugate antibody overnight with rotation at 4°C. The
immunoprecipitated samples were collected by centrifugation at 14000
rpm for 15 minutes and washed in ice-cold NP40 lysis buffer 3 times.
Samples were resuspended in Laemmli protein gel loading buffer (Section
2.12) and processed for Western immunoblot analysis, as indicated in
Section 4.2.7.
4.2.7.5. PROK1 induced cSrc and EGFR phosphorylation
A time course study was conducted in order to determine the time point at
which PROK1 induced maximal cSrc and EGFR phosphorylation. PROKR1
Ishikawa cells were seeded at a density of 3 million cells in 10cm dishes.
PROKR1 Ishikawa cells were subjected to serum starvation overnight
followed by stimulation with 40nM PROK1 for 0, 1, 5, 10 and 20 minutes.
Reactions were terminated by removal of agonist and cells were washed in
ice cold PBS. The cells were lysed in NP40 lysis buffer and
immunoprecipitated with anti-phosphotyrosine (PY20) agarose conjugate
to immunoprecipitate the tyrosine phosphorylated cSrc or EGFR. The
immunoprecipitated samples were collected by centrifugation at 14000
rpm for 15 minutes and washed in ice-cold NP40 lysis buffer 3 times.
Samples were resuspended in Laemmli protein gel loading buffer (Section
2.12) and processed for Western immunoblot analysis, as indicated in
Section 4.2.7.
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4.2.8. Western immunoblot analysis
Cells were lysed in NP40 lysis buffer (described in Sections 2.7 and 2.12) and
protein concentration assayed as described in Section 2.7. Proteins were
solubilised in Laemmli protein gel loading buffer (Section 2.12). Samples were
boiled for 5 minutes in order to denature proteins prior to resolution on an
SDS-PAGE gel as described in Sections 2.7.2 and 2.7.3. Proteins were
immunoblotted to a PVDF membrane and non-specific binding blocked with
blocking buffer. Immobilised proteins on the PVDF membrane were probed
with specific primary antibodies for phosphorylated ERK 1/2, total ERK 1/2,
phosphorylated cSrc or phosphorylated EGFR (antibody dilutions in Table 10).
Immunoblotted proteins were visualised by a chemifluorescent or direct
fluorescent detection system as indicated in Section 2.7.
Table 10. Antibody dilutions used for Western immunoblot analysis
Antibody Species raised in Dilution Purchased from
pERK Rabbit 1:1000 Cell Signalling
tERK Mouse 1:1000 Cell signalling
p-EGFR Goat 1:500 Santa Cruz/ Autogen Bioclear
cSrc Rabbit 1:500 Santa Cruz/ Autogen Bioclear
4.2.9. Statistics
Statistical analysis of the data in this study was carried out by ANOVA with
Fishers PLSD (predicted least squares difference) applied, using Statview 5.0
(Abacus Concepts). The data is presented as mean ± SEM of at least 3
experiments.
4.3. Results
4.3.1. Production of PROKR1 Ishikawa cell line
Transfection of PROKR1 cDNA into an endometrial epithelial cell line was
performed in order to provide a model system with which to investigate
PROK1-PROKR1 induced signalling. One clone was isolated and subsequently
screened to assess the level of PROKR1 expression compared with WT
Ishikawa cells.
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Semi-quantitative and real-time quantitative PCR was performed on RNA
isolated from WT and PROKR1 Ishikawa cells. Semi-quantitative PCR
analysis of PROKR1 expression in WT and PROKR1 Ishikawa cells revealed a
single band of the expected molecular weight in PROKR1 Ishikawa cells
(Figure 4.1 A). No band was evident in WT Ishikawa cells. Taqman
quantitative PCR analysis of PROKR1 expression in PROKR1 Ishikawa cells
compared with WT Ishikawa cells confirmed these data. Minimal PROKR1
mRNA expression was detected in WT Ishikawa cells whereas PROKR1 was
found to be expressed in PROKR1 Ishikawa cells (Figure 4.1 B).
1080bp




Figure 4.1. Immunocytochemistry, semi quantitative and real-time Taqman quantitative PCR
expression of PROKR1 in WT and PROKR1 Ishikawa cells. A. Immunocytochemistry
indicates staining for PROKR1 in PROKR1 Ishikawa cells (red) but not in WT Ishikawa cells.
B. PCR gel reveals a band at the expected molecular weight size of 1080bp in PROKR1
Ishikawa cells; no band was evident in WT Ishikawa cells. C. PROKR1 and WT Ishikawa
cells were examined for expression of PROKR1 by Taqman quantitative PCR analysis.
PROKR1 expression was normalised for loading against expression of 18s and relative to a
single endometrial control. Data are presented as mean ± SEM.
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4.3.2. Signalling characterisation of PROKR1 Ishikawa cell line
4.3.2.1. PROK1 mediated inositol phosphate mobilisation
Prokineticin has been suggested to couple to Gq in HEK293 and CHO cells
transfected with prokineticin receptors (Lin DC et al, 2002, Masuda et al,
2002, Soga et al, 2002). In order to investigate if PROKR1 couples to Gq
proteins in PROKR1 Ishikawa cells and demonstrate the presence of
functional prokineticin receptors in PROKR1 Ishikawa cells, inositol
phosphate mobilisation was measured following treatment with PROK1.
WT and PROKR1 Ishikawa cells were stimulated with vehicle, 4pM, 40pM,
400pM, 4nM and 40nM PROK1 for one hour. No significant mobilisation of
inositol phosphate was detected in WT Ishikawa cells at any dose of
PROK1 used (Figure 4.3, grey bars). However, significant elevation of
inositol phosphate mobilisation was detected upon treatment of PROKR1
Ishikawa cells with 40nM PROK1 (2.71 ± 0.25 fold above vehicle treated
control, P<0.05, Figure 4.3, black bars). No significant elevation in inositol
phosphate mobilisation was noted in PROKR1 Ishikawa cells at lower
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Figure 4.2. Induction of Inositol phosphate mobilisation in WT and PROKR1 Ishikawa cells.
WT and PROKR1 Ishikawa cells were stimulated with vehicle, 4pM, 40pM, 400pM, 4nM and
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40nM PROK1 for 1 hours followed by assay for inositol phosphate. The data are presented
as mean ± SEM. (b is significantly different from a P<0.05).
4.3.2.2. PROK1 mediated cAMP production
In order to investigate whether PROKR1 can couple to Gs proteins,
production of cAMP in PROKR1 Ishikawa cells was measured following
treatment with PROK1. PROKR1 Ishikawa cells were treated with 40nM
PROK1 for 0, 5, 10, 15 or 20 minutes or forskolin for 10 minutes. No
significant production of cAMP was detected in response to PROK1
treatment (Figure 4.2). However cAMP production was elevated following
treatment with forskolin for 10 minutes (362.85±52.15 pmol/mg protein).
Forskolin is known to induce cAMP release (Seamon et al, 1981). These
data demonstrate that PROKR1 is not Gs coupled in PROKR1 Ishikawa
cells.
0 5 10 15 20 forskolin
Time (minutes)
Figure 4.3. Induction of cAMP production in response to 40nM PROK1 and forskolin in
PROKR1 Ishikawa cells. PROKR1 Ishikawa cells were stimulated with 40nM PROK1 forO, 1,
5, 10 and 20 minutes. Forskolin treatment was applied for 10 minutes. The media was
assayed for cAMP by ELISA. The data are presented as mean ± SEM (b is significantly
different from a p<0.001).
4.3.2.3.Dose response of PROK1 induced ERK 1/2 phosphorylation
Activation of PROKR1 has been demonstrated to induce ERK 1/2
phosphorylation (Lin R et al, 2002, Lin DC et al, 2002). In order to further
investigate the signalling pathways activated upon PROKR1-PROK1
activation in PROKR1 Ishikawa cells, ERK 1/2 phosphorylation was
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examined. PROKR1 Ishikawa cells were treated with vehicle, 4pM, 40pM,
400pM, 4nM and 40nM PROK1 for 5 minutes and ERK 1/2
phosphorylation examined by Western immunoblot analysis. ERK 1/2
phosphorylation was significantly elevated upon treatment with 40nM
PROK1 at 5 minutes (5.21 ± 0.52 fold above vehicle treated control,
P<0.01, Figure 4.4) compared with all other doses of PROK1. Hence 40nM
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Figure 4.4. Induction of ERK 1/2 phosphorylation in PROKR1 Ishikawa cells. PROKR1
Ishikawa cells were stimulated with vehicle, 4pM, 40pM, 400pM, 4nM and 40nM PROK1 for 5
minutes. Proteins were extracted, quantified and 20pg resolved by SDS-PAGE followed by
Western immunoblot analysis using specific antibodies against phosphorylated ERK 1/2
(pERK). The total amount of ERK in cell lysates was determined by probing the same blot
with antibody recognising total ERK 1/2 (tERK). ERK 1/2 phosphorylation was normalised for
tERK expression. Data are expressed as fold above vehicle treated control. A representative
Western immunoblot is shown with semi-quantitative densitometric analysis of ERK 1/2
phosphorylation. The data are presented as mean ± SEM. (b is significantly different from a
P<0.01).
4.3.2.4.Time course of PROK1 induced ERK 1/2 phosphorylation
Maximal phosphorylation of ERK 1/2 via PROKR1-PROK1 was observed
following treatment with 40nM PROK1. Subsequently the time of maximal
ERK 1/2 phosphorylation in response to 40nM PROK1 was investigated.
PROKR1 Ishikawa cells were treated with 40nM PROK1 for 0, 1, 5, 10 and
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20 minutes and ERK 1/2 phosphorylation determined by Western
immunoblot analysis. ERK 1/2 phosphorylation peaked at 5 minutes (8.03
± 1.59 fold above vehicle treated control, P<0.001, Figure 4.5) with
significant elevation sustained to 10 minutes (7.79 ± 1.54 fold above
vehicle treated control, P<0.001, Figure 4.5). Five minutes stimulation with
40nM PROK1 was used for all subsequent ERK 1/2 phosphorylation
investigations in PROKR1 Ishikawa cells.
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Figure 4.5. Time course of PROK1 induced ERK 1/2 phosphorylation. Induction of ERK 1/2
phosphorylation in PROKR1 Ishikawa cells stimulated with 40nM PROK1 for 0, 1,5, 10 and
20 minutes. Proteins were extracted, quantified and 20/vg resolved by SDS-PAGE followed
by Western immunoblot analysis using specific antibodies against phosphorylated ERK 1/2
(pERK). The total amount of ERK in cell lysates was determined by probing the same blot
with antibody recognising total ERK 1/2 (tERK). ERK 1/2 phosphorylation was normalised for
tERK expression. Data are expressed as fold above vehicle treated control. A representative
Western immunoblot is shown with semi-quantitative densitometric analysis. The data are
presented as mean ± SEM. (b is significantly different from a P<0.001).
4.3.3. Mapping the pathway of PROK1-PROKR1 induced signalling to ERK
1/2
4.3.3.1. PROKR1 signalling is not Gi coupled
It has previously been suggested that PROKR1 couples to either Gq or Gi
(Lin R et al, 2002, Lin DC et al, 2002, Masuda et al, 2002, Soga et al, 2002).
In PROKR1 Ishikawa cells, PROK1 induces inositol phosphate
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mobilisation, suggesting that in this model system PROKR1 couples to Gq.
However, pertussis toxin (PTX) a powerful inhibitor of Gi coupling was
used in order to rule out coupling of PROKR1 to Gi. PROKR1 cells were
pre-incubated with 200ng/ml PTX overnight or for one hour prior to
stimulation with 40nM PROK1 for 5 minutes. PTX did not inhibit PROK1
induced ERK 1/2 phosphorylation with overnight pre-treatment or pre-
treatment for 1 hour. These data demonstrate that PROKR1 does not
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Figure 4.6. ERK 1/2 phosphorylation is not inhibited by PTX. PROKR1 Ishikawa cells were
pre-treated with vehicle or 200ng/ml PTX overnight or for one hour prior to stimulation with
40nM PROK1. Proteins were extracted, quantified and 20yvg resolved by SDS-PAGE
followed by Western immunoblot analysis using specific antibodies against phosphorylated
ERK 1/2 (pERK). The total amount of ERK in cell lysates was determined by probing the
same blot with antibody recognising total ERK 1/2 (tERK). ERK 1/2 phosphorylation was
normalised for tERK expression. Data are expressed as fold above vehicle treated control. A
representative Western immunoblot is shown with semi-quantitative densitometric analysis.
The data are presented as mean ± SEM. (b is significantly different from a P<0.001).
4.3.3.2.PROKR1 is Gq coupled and ERK 1/2 phosphorylation is mediated
via PLC-|3 - Ca2+ - cSrc - EGFR and MEK
Phosphorylation of ERK 1/2 following activation of GPCR's is dependent
on activation of intracellular signalling-phosphorylation cascades (Werry et
al, 2005). Hence, the cascade of signalling molecules activated by PROK1
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signalling to ERK 1/2 in PROKR1 Ishikawa cells was investigated.
PROKR1 is a Gq coupled receptor in PROKR1 Ishikawa cells, as
demonstrated by mobilisation of inositol phosphate. To confirm this,
PROKR1 Ishikawa cells were treated with 40nM PROK1 for 5 minutes in
the presence or absence of a specific inhibitor of Gq protein (YM254890) in
addition to inhibitors of phospholipase C-|3 (U73122), calcium (BAPTA-
AM), cSrc (PP2), EGFR (AG1478) and MEK (PD98059). ERK 1/2
phosphorylation in response to PROK1 (5.86 ± 0.58 fold above vehicle
treated control, Figure 4.7, lane 2, p<0.001) was abolished by co-treatment
with Gq inhibitor (Figure 4.7, lane 3), PLC-(1 inhibitor (Figure 4.7, lane 4),
Ca2+ inhibitor (Figure 4.7, lane 5), cSrc inhibitor (Figure 4.7, lane 6), EGFR
inhibitor (Figure 4.7, lane 7) and MEK inhibitor (Figure 4.7, lane 8). These
data demonstrate that PROK1 induces ERK 1/2 phosphorylation in
PROKR1 Ishikawa cells via a Gq coupled pathway involving activation of


















Figure 4.7. Chemical inhibitors of signalling intermediates inhibit PROK1 induced ERK 1/2
phosphorylation. PROKR1 Ishikawa cells were treated with 40nM PROK1 in the presence or
absence of inhibitors of Gq, PLC, Ca2+, cSrc, EGFR and MEK. Proteins were extracted,
quantified and 20pg resolved by SDS-PAGE followed by Western immunoblot analysis using
specific antibodies against phosphorylated ERK 1/2 (pERK). The total amount of ERK in cell
lysates was determined by probing the same blot with antibody recognising total ERK 1/2
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(tERK). ERK 1/2 phosphorylation was normalised against tERK expression. Data are
expressed as fold above vehicle treated control. PROK1 mediated ERK 1/2 phosphorylation
was significantly inhibited by pre-treatment with inhibitors of Gq protein (YM254890, 1pM,
lane 3), PLC (U73122, 10pM, lane 4), Ca2+ (BAPTA-AM, 50|xM, lane 5), cSrc (PP2, 10pM,
lane 6), EGFR (AG1478, 200nM, lane 7) and MEK (PD98059, 50pM, lane 8). A
representative Western immunoblot is shown with semi-quantitative densitometric analysis. +
denotes presence of agent, - denotes absence of agent. The data are presented as mean +
SEM. (b is significantly different from a P<0.001).
4.3.3.3. PROK1 mediated ERK 1/2 phosphorylation is inhibited by
dominant negative isoforms of signalling pathway intermediates
In order to confirm a role for cSrc, EGFR, MEK and establish a role for the
small monomeric G-protein Ras (against which there are no reliable
chemical inhibitors) cDNA constructs encoding dominant negative mutant
isoforms of the above signalling molecules were utilised. PROKR1
Ishikawa cells were transiently transfected with Myc-tagged ERK and
empty vector cDNA (pcDNA3) or cDNA encoding dominant negative
mutants of cSrc, EGFR, Ras and MEK. Cells were subsequently treated
with 40nM PROK1 for 5 minutes, lysed and immunoprecipitated using
Myc-tagged ERK antibodies followed by Western immunoblot analysis for
ERK 1 phosphorylation. PROK1 induced phosphorylation of Myc-tagged
ERK (5.36 ± 1.37 fold above vehicle treated control Figure 4.8, lane 2,
p<0.001) was abolished by co-expression of the dominant negative
isoforms of cSrc (Figure 4.8, lane 4), EGFR (Figure 4.8, lane 5), Ras (Figure
4.8, lane 6) and MEK (Figure 4.8, lane 7) with Myc-ERK. These data
confirm that ERK 1 phosphorylation is dependent on activation of cSrc and
EGFR as well as the small monomeric G-protein Ras.











Figure 4.8. Inhibition of ERK 1/2 phosphorylation using cDNA constructs encoding
dominant negative mutant isoforms of cSrc, EGFR, Ras and MEK. PROKR1 Ishikawa cells
were co-transfected with Myc-tagged ERK and either empty vector (pcDNA3) or dominant
negative isoforms of cSrc, EGFR, Ras and MEK prior to stimulation with 40nM PROK1 for
5 minutes. 1mg of protein was immunoprecipitated using Myc-tagged ERK agarose
conjugated antibody. Protein was resolved by SDS-PAGE followed by Western immunoblot
analysis using specific antibodies against phosphorylated ERK 1/2 (pERK). The total
amount of ERK in cell lysates was determined by probing the same blot with antibody
recognising total ERK 1/2 (tERK). ERK 1/2 phosphorylation was normalised against tERK
expression. Data are expressed as fold above vehicle treated control. Co-transfection of
PROKR1 Ishikawa cells with c-Myc tagged ERK and dominant negative isoforms of cSrc,
EGFR, Ras or MEK significantly inhibited PROK1 induced ERK phosphorylation. + denotes
presence of agent, - denotes absence of agent. A representative Western immunoblot is
shown with semi-quantitative densitometric analysis. The data are presented as mean ±
SEM. (b is significantly different to a P<0.001).
4.3.3.4.PROK1 induces phosphorylation of cSrc
Studies using chemical inhibitors and cDNA constructs encoding dominant
negative mutants of signalling molecules suggested a role for the non¬
receptor tyrosine kinase cSrc in mediating ERK 1/2 phosphorylation. cSrc
phosphorylation in response to PROK1 stimulation was examined using
specific antisera, which recognises cSrc Tyr418, the stabilised form of the
cSrc kinase domain. PROKR1 Ishikawa cells were stimulated with 40nM
PROK1 for 0, 1, 5, 10 and 20 minutes and immunoprecipitated with anti-
phosphotyrosine (PY20) agarose conjugate to immunoprecipitate the
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tyrosine-phosphorylated cSrc. Immunoprecipitated proteins were
subjected to Western immunoblot analysis using an antibody raised
against phosphorylated cSrc. Maximal phosphorylation of cSrc was
observed at 5 minutes (3.99 ± 0.8 fold above vehicle treated control,
P<0.05/ Figure 4.9), which is within the time frame of maximal ERK 1/2
phosphorylation (i.e. 5-10 minutes). These data demonstrate that PROK1







Figure 4.9. PROK1 induced cSrc phosphorylation in PROKR1 Ishikawa cells. PROKR1
Ishikawa cells were treated with 40nM PROK1 for 0, 1,5, 10 and 20 minutes. 1mg of protein
was immunoprecipitated using anti-phosphotyrosine (PY20) agarose preconjugate. Protein
was resolved by SDS-PAGE followed by Western immunoblot analysis using specific
antibodies against phosphorylated cSrc (p cSrc). The total amount of protein in cell lysates
was determined by quantifying the IgG band (IgG). cSrc phosphorylation was normalised
against IgG. Data are expressed as fold above vehicle treated control. A representative
Western immunoblot is shown with semi-quantitative densitometric analysis. The data are
presented as mean ± SEM. (b is significantly different to a, P<0.05).
4.3.3.5.PROK1 induces phosphorylation of the epidermal growth factor
receptor.
Chemical inhibitors studies and dominant negative studies also suggested
a role for phosphorylation of the EGFR receptor tyrosine kinase in the
signalling cascade activated by PROK1. In order to investigate the
temporal regulation of EGFR phosphorylation, PROKR1 Ishikawa cells
were treated with 40nM PROK1 for 0, 1, 5, 10 and 20 minutes, lysed and
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immunoprecipitated with anti phospho tyrosine (PY20) agarose conjugate
in order to immunoprecipitate tyrosine phosphorylated EGFR.
Immunoprecipitated proteins were subjected to Western immunoblot
analysis using specific antibodies raised against phosphorylated EGFR.
Maximal phosphorylation of EGFR occurred at 5 minutes (2.02 ± 0.27 fold
above vehicle treated control, P<0.01, Figure 4.10). This phosphorylation
was sustained up to 20 minutes following treatment with PROK1.
Maximal phosphorylation of the EGFR occurred within the time frame of
maximal ERK 1/2 phosphorylation. These data demonstrate that PROK1
via PROKR1 induces phosphorylation of EGFR.
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Figure 4.10. PROK1 induced EGFR phosphorylation in PROKR1 Ishikawa cells. PROKR1
Ishikawa cells were treated with 40nM PROK1 for 0, 1,5, 10 and 20 minutes. 1mg protein
was immunoprecipitated with anti phosphotyrosine (PY20) agarose conjugate. Protein was
resolved by SDS-PAGE followed by Western immunoblot analysis using specific antibodies
against phosphorylated EGFR (pEGFR). The total amount of protein in cell lysates was
determined by quantifying the IgG band (IgG). EGFR phosphorylation was normalised
against IgG. Data are expressed as fold above vehicle treated control. A representative
Western immunoblot is shown with semi-quantitative densitometric analysis. The data are
presented as mean ± SEM. (b is significantly different to a, P<0.01).
4.3.3.6.PROK1 induces phosphorylation of cSrc via Gq and Ca2+
Phosphorylation of cSrc and EGFR is maximal at 5 minutes. However cSrc
phosphorylation is transient and has diminished by 10 minutes while EGFR
phosphorylation appears to be sustained until 20 minutes. It is suggested
that intracellular cSrc can induce transactivation of the EGFR (Wetzker,
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2003). In order to determine whether cSrc phosphorylation occur prior to
EGFR and ERK 1/2 phosphorylation chemical inhibitors of Gq protein
(YM254890), Ca2+ (BAPTA-AM), cSrc (PP2), EGFR (AG1478) and MEK
(PD98059) were used. PROK1 induced cSrc phosphorylation (Figure 4.11,
lane 2) was abolished by co-treatment with Gq inhibitor (Figure 4.11, lane
3), calcium inhibitor (Figure 4.11, lane 4) and specific cSrc inhibitor (Figure
4.11, lane 5). PROK1 induced cSrc phosphorylation was not affected by
pre-treatment with inhibitors of EGFR (Figure 4.10, lane 6) or MEK (Figure
4.10, lane 7). These data suggest that in the signalling hierarchy cSrc is
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Figure 4.11. Chemical inhibitors of Gq protein, Ca2+ and cSrc but not EGFR or MEK inhibit
cSrc phosphorylation. PROKR1 Ishikawa cells were pre-treated with inhibitors of Gq protein
(YM254890), Ca2t (BAPTA-AM), cSrc (PP2), EGFR (AG1478) and MEK (PD98059), prior to
stimulation with 40nM PROK1 for 5 minutes. 1mg protein was Immunoprecipitated with anti-
phosphotyrosine (PY20) agarose conjugate antibodies. Protein was resolved by SDS-PAGE
followed by Western immunoblot analysis using specific antibodies against phosphorylated
cSrc (p cSrc). The total amount of protein cell lysates was determined by quantifying the IgG
band (IgG). cSrc phosphorylation was normalised against IgG. Data are expressed as fold
above vehicle treated control. PROK1 mediated cSrc phosphorylation (lane 2) was inhibited
by pre-treatment with inhibitors of Gq (lane 3), Ca2+ (lane 4) and cSrc (lane 5), but not
inhibitors of EGFR (lane 6) or MEK (lane 7). + denotes presence of agent, - denotes absence
of agent. A representative Western immunoblot is shown with semi-quantitative densitometric
analysis. The data are presented as mean ± SEM. (b is significantly different to a p<0.05).
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4.4. Discussion
This chapter describes the establishment of an endometrial epithelial cell line
stably expressing PROKR1 and downstream protein phosphorylation cascade
activation upon PROK1-PROKR1 interaction. One group describes prokineticin
receptors as being Gi coupled (Lin R et al, 2002) while other groups describe them
as being Gq coupled (Lin DC et al, 2002, Masuda et al, 2002, Soga et al, 2002).
This may seem inconsistent, however it may be accounted for by the fact that the
work describing Gi coupling was performed in primary cells while the work
describing Gq coupling was performed in CHO (Chinese hamster ovary) and
HEK293 (human embryonic kidney) cells transfected with prokineticin receptors.
There is a precedent for this difference in signalling, presented by the example of
GnRH receptors. Gq has been described as the predominant G-protein coupled to
the GnRH receptor (Stojilkovic et al, 1995, Poulin et al, 1998, Hseih et al, 1992).
However coupling to Gi has been demonstrated in uterine leiomyosarcomas (Imai
et al, 1996), uterine endometrial carcinomas (Imai et al, 1997) and human prostate
cancers (Limonta et al, 1999). Coupling of the GnRH receptor to Gs has also been
demonstrated in rat pituitary cells (Janovick et al, 1993). These examples
demonstrate that G-protein coupling may be different depending on the tissue
examined, the pathological state of the tissue and, potentially, the species
examined. This study demonstrates that in PROKR1 Ishikawa cells, PROKR1 is
Gq coupled and activates inositol phosphate mobilisation. Whether this represents
the in vivo situation requires clarification with studies in primary endometrium
tissue.
The inositol phosphate mobilisation induced by PROK1 in PROKR1 Ishikawa cells
was approximately 3-fold above vehicle treated controls. To ensure that only Gq
was activated, the cAMP production and pertussis toxin sensitivity of PROK1
induced ERK 1/2 phosphorylation in PROKR1 Ishikawa cells was investigated.
PROKR1 Ishikawa cells did not induce, or inhibit, production of cAMP in response
to 40nM PROK1 at any time. However, forskolin did initiate cAMP production
indicating the cells are responsive and capable of activating Gs to produce cAMP.
Pre-treatment of PROKR1 Ishikawa cells with 200ng/ml pertussis toxin overnight
or for one hour prior to treatment with 40nM PROK1 did not inhibit the PROK1
Chapter 4 PR0K1-PR0KR1 mediated intracellular signalling 138
induced ERK 1/2 phosphorylation. Taken together, these data indicate that
PROKR1 is not Gi or Gs coupled and activation of downstream signalling appears
to occur solely via activation of Gq in PROKR1 Ishikawa cells.
Activation of inositol phosphate mobilisation can be considered as one of the first
steps in activation of intracellular protein phosphorylation cascades (Belcheva &
Coscia, 2002). Protein phosphorylation in PROKR1 Ishikawa cells was
investigated by examining PROK1 induced phosphorylation of ERK 1/2. PROK1
has previously been demonstrated to induce phosphorylation of ERK 1/2 (Lin R et
al, 2002, Lin DC et al, 2002). However, as PROK1 signalling had not been
previously investigated in PROKR1 Ishikawa cells the concentration of PROK1
and time point at which maximal phosphorylation of ERK 1/2 would be induced
was unknown. Treatment of PROKR1 Ishikawa cells with a range of concentration
of PROK1 for 5 minutes indicated that 40nM PROK1 induced maximal
phosphorylation of ERK 1/2. This is in line with previous studies where doses
ranging from 10 - 40nM PROK1 have been used in order to initiate signalling in
response to PROK1 (Lin DC et al, 2002, Lin R et al, 2002). Investigation of the time
frame of maximal ERK 1/2 phosphorylation in response to 40nM revealed ERK
1/2 to be maximally phosphorylated at 5 - 10 minutes in PROKR1 Ishikawa cells.
Again, this corresponds with previous reports investigating PROK1 induced ERK
1/2 phosphorylation where maximal phosphorylation occurred at approximately
10 minutes (Lin R et al, 2002).
The molecules involved in the intracellular protein phosphorylation cascade
activated by PROK1 upstream of ERK 1/2 phosphorylation are currently
unknown. The potential proteins involved in transmitting the phosphorylation
signal to ERK 1/2 were investigated initially by use of chemical inhibitors. Pre-
treatment of PROKR1 Ishikawa cells with chemical inhibitors of Gq protein,
phospholipase C-|3 (PLC-(1), Ca2+, cSrc, EGFR and MEK inhibited the PROK1
induced ERK 1/2 phosphorylation at 5 minutes implicating a role for these
molecules in signalling to ERK 1/2. The involvement of Gq, PLC-(3 and Ca2+ in
signalling to ERK 1/2 could have been anticipated, as PROKR1 is Gq coupled and
activates mobilisation of inositol phosphate, which occurs via activation of PLC-|3
(Lin DC et al, 2002). Previous studies have also demonstrated activation of
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calcium mobilisation upon prokineticin - receptor interaction (Lin DC et al, 2002,
Masuda et al, 2002). Involvement of the non-receptor tyrosine kinase cSrc and
receptor tyrosine kinase EGFR has not previously been implicated in PROK1
induced signalling to ERK 1/2. However, there is an increasing body of evidence
suggesting that activation of non-receptor tyrosine kinases (e.g. cSrc) and
transactivation of receptor tyrosine kinases (e.g. EGFR) is important in
transmitting the signal in GPCR signalling to ERK 1/2 (Werry et al, 2005, Daub et
al, 1997, Shah et al, 2004, Eguchi et al, 2003).
The use of chemical inhibitors suggested the involvement of multiple signalling
intermediates in PROK1 induced ERK 1/2 phosphorylation. In order to confirm
the roles of MEK, cSrc and EGFR, and investigate the role of the small monomeric
GTPase Ras in signalling to ERK 1/2, cDNA encoding dominant negative isoforms
of these signalling molecules were utilised. Dominant negative isoforms of
signalling molecules are mutant molecules and are designed to produce an
inactive form of the parent signalling molecule. This inactive form is dominant in
the cells and is over-expressed compared with the endogenous active molecule.
The mutations can prevent phosphorylation of the protein via an inactive kinase
domain, or in the case of the EGFR produce a mutant receptor that yields
unproductive heterodimers at the cell surface thereby preventing downstream
intracellular signalling (Kashles et al, 1991). Co-transfection of Myc-tagged ERK
with dominant negative isoforms of cSrc, EGFR Ras or MEK significantly inhibited
the PROK1 induced elevation in Myc-tagged ERK phosphorylation. These data
confirm a role for cSrc, EGFR and MEK in signalling to ERK 1/2 and suggest, for
the first time, a role for Ras.
The data generated using chemical inhibitors of signalling molecules and
dominant negative mutants of signalling molecules suggested cSrc and EGFR to
be involved in PROK1 mediated ERK 1/2 phosphorylation. The effect of PROK1
on phosphorylation of cSrc and EGFR was therefore investigated. Stimulation of
PROKR1 Ishikawa cells with PROK1 revealed phosphorylation of both cSrc and
EGFR to be maximal at 5 minutes. These data demonstrate phosphorylation of
cSrc and EGFR by PROK1 and, by their temporal regulation, robustly suggest their
role in signalling to ERK 1/2. Subsequently, the position of cSrc and EGFR in the
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signalling hierarchy mediated by PROK1 was assessed. It is suggested that cSrc
activation may control ectodomain shedding of HB-EGF required for
transactivation of the EGFR (Wetzker et al, 2003). Phosphorylation of cSrc may
therefore occur prior to EGFR phosphorylation. The data presented herein may
support this assertion as cSrc phosphorylation peaks at 5 minutes and rapidly
disappears whereas EGFR phosphorylation is sustained from 5-20 minutes. In
order to determine if cSrc phosphorylation does indeed occur prior to EGFR
phosphorylation, the effect of chemical inhibitors on cSrc phosphorylation was
examined. Co-treatment of PROKR1 Ishikawa cells with PROK1 and inhibitors of
Gq protein, Ca2+ and cSrc inhibited PROK1 induced cSrc phosphorylation.
Ffowever inhibitors of EGR and MEK did not inhibit PROK1 induced cSrc
phosphorylation, suggesting that cSrc is positioned upstream of EGFR and ERK
1/2 in the signalling hierarchy of PROK1 induced signalling, as has been
demonstrated for other GPCR's (Daub et al, 1997, Daub et al, 1998, Luttrell et al,
1996).
This chapter describes the establishment of an endometrial cell line stably
expressing functional PROKR1 and characterises signalling mediated by PROK1
via PROKR1. These data describe for the first time the mechanism of signalling
induced by PROK1 in endometrial epithelial cells. This study demonstrates that
PROKR1 couples to Gq but not Gs or Gi protein in PROKR1 expressing Ishikawa
cells. The data also demonstrates sequential cSrc, EGFR and ERK 1/2
phosphorylation and the specific pathway that mediates ERK 1/2
phosphorylation via PLC-P - Ca2+ - cSrc - EGFR - MEK.
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Chapter 5 - Target genes for PROK1 action
5.1. Introduction
In previous chapters the tissue localisation of the prokineticins and signalling induced by
PROK1-PROKR1 was described. However, there is currently no data available on the
downstream activation of gene expression induced by PROK1 in any cell models, tissues
or pathological conditions and surprisingly little speculation upon the same. In an
attempt to investigate activation of gene expression downstream of PROK1 induced
protein phosphorylation, and to develop some idea of the function PROKR1-PROK1
may play in the endometrium, global gene array analysis was performed. As indicated
in chapter 3, PROK1 expression is temporally regulated across the menstrual cycle and
preferentially binds and activates PROKR1 (Lin DC et al, 2002). This therefore appears
to be the most relevant system to study with reference to physiological function and
prokineticin induced gene activation during the menstrual cycle.
The first step of this study was to perform a genome-wide gene expression scan to
identify target genes for PROK1-PROKR1. Gene expression microarrays are currently the
core technology for such purposes. Gene array analysis has been used in a large number
of studies examining gene expression in the human endometrium across the menstrual
cycle and after treatment with e.g. hCG or mifepristone in the endometrium of humans
and other species such as baboon (Kao et al, 2002, Carson et al, 2002, Riesewijk et al,
2003, Borthwick et al, 2003, Mirkin et al, 2005, Talbi et al, 2006, Sherwin et al, 2007,
Catalano et al, 2003). However, concerns are still raised with regards the reliability and
consistency of microarray data analysis. There are a number of advantages and
disadvantages associated with performing gene array experiments. Clearly, one of the
major advantages is the ability to examine the expression of a large number of genes
within a single RNA sample and has been used in diverse investigations, specifically
within the field of endometrial research to compare expression of genes within the
endometrium taken during different stages of the menstrual cycle or treated with
contraceptives as indicated above. Another advantage of of such microarray technology
lies in the fact that many of the processes are fully automated, reducing the possibility
of technical and operator error. Assuming the starting material is of high quality and the
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microarray chips are suitable (important as the chips have a limited shelf life) then
assays performed at the same time should be highly comparable,
A major disadvantage of microarray studies arises when estimating the number of
samples required giving statistically meaningful results, Application of power
calculations can aid in this decision. Power calculations can be applied to predict the
appropriate sample size required to achieve adequate power i.e. the probability that the
null hypothesis will be rejected. In this study the null hypothesis was that PROK1 would
not regulate expression of genes in PROKR1 Ishikawa cells when compared to vehicle
treated control samples. In samples taken from in vivo studies the power calculations
usually indicate that a large sample number is required to produce statistically
significant data. However, in a homogenous cell line variation should be low, therefore a
smaller sample size may be used. False positive results can also be a disadvantage of
microarray experiments depending on the exclusion criteria set. In this study the criteria
of fold changes of si.5 fold and application of statistical criteria to control for the false
discovery rate in multiple testing according to the Benjamini and Hochberg method
(1995) should protect against the inclusion of any false positive data. However, the gene
array results were not taken as absolute values and a number of genes were chosen for
validation experiments at 8 hours in order to ensure the validity of the gene array data.
Mistakes made at the discovery stage may lead to a waste of resources in validation
experiments performed after the gene array analyses. In order to obtain high confidence
results it was decided to perform a cross-platform study using two different commercial
platforms, the Affymetrix GeneChip® Human Genome U133 plus 2.0 and the AB1700
v.2 Applied Biosystems Human Genome Survey Microarrays. These platforms were
selected as representing diverse approaches to array/probe designs, detection
chemistries as well as gene contents/annotations (Design and Performance of the
GeneChip® Human Genome U133 Plus 2.0 and Human Genome U133A 2.0 Arrays,
Technical note, Affymetrix, 2003; White Paper: The Design and Annotation of the
Human Genome Survey Microarray, ABI, 2004). Genes displaying concordance between
the two different gene array platforms would increase confidence in the gene array
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results and provide a greater degree of reliability when choosing genes to investigate
further.
This study was therefore designed to examine the target genes regulated by PROK1
upon activation of PROKR1 in PROKR1 Ishikawa cells. This was investigated by gene
array analysis on the two different array platforms. This dual platform approach
provides a high degree of confidence in the concordant genes for further studies.
Examination of gene expression regulated by PROK1 in the PROKR1 Ishikawa cells
should enable potential functions of PROK1 in the endometrium to be delineated by
comparisons with studies, which have previously demonstrated functionality of these
genes.
5.2. Materials and methods
5.2.1. Cell Culture and PROK1 treatments
PROKR1 and WT Ishikawa cells were routinely maintained in DMEM F-12 Glutamax
culture medium with 10% FCS and 1% antibiotics (500U/ml penicillin and
500pg/ml streptomycin) at 37°C and 5% CO2. In addition PROKR1 Ishikawa cells
were maintained in media containing 200pg/ml G418 antibiotic.
In order to prepare samples for analysis by gene array, PROKR1 Ishikawa cells were
seeded out to a density of 5 x 105 cells in 5 x 6cm dishes for 40nM PROK1 treated
cells and 5 x 6cm dishes for vehicle treated cells. On the day prior to stimulation,
cells were incubated in serum free medium for at least 16 hours. The following day
40nM PROK1 or vehicle was added to each of 5 dishes of cells for 8 hours. The cells
were then washed in PBS and RNA extracted as indicated below. After RNA
extraction the 5 samples from one experiment, if they passed the inclusion criteria
indicated in Section 5.2.2, were pooled. This was performed to reduce the risk of
single sample variation. This was repeated 3 times in total to yield 3 different
samples (which represented n=15 in total, given the low variability in homogenous
cell lines it was considered that this would represent an adequate sample size to
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provide statistically meaningful results) that were treated with 40nM PROK1 or
vehicle.
5.2.2. RNA extraction and quantification
RNA was extracted from PROKR1 Ishikawa cells treated with 40nM PROK1 or
vehicle for 8 hours using the RNeasy RNA extraction kit supplied by Qiagen. Briefly,
RNeasy lysis buffer (containing P-mercaptoethanol) was added to the cells after
washing with PBS. Cells were harvested by scraping with a rubber policeman (cell
scraper), transferred to RNase free eppendorf tubes and homogenised by passing the
lysate through a 0.22 bore needle a number of times. Cell lysates were then stored at
-80°C before processing for RNA extraction following the manufacturers
recommendations. Briefly the lysates were applied to silica columns, which capture
the RNA, allowing it to be washed and DNase treated before elution of the RNA
from the column with RNase free water. RNA samples were initially quantified using
the Genequant spectrophotometer; this gave an indication of their concentration. The
RNA was then diluted to allow quantification and assessment the quality of the
samples on the 2100 Bioanalyser and RNA nanochip system (Agilent Technologies,
Stockport). Certain criteria were set for the inclusion of RNA samples within the
RNA pool. The criterion for sample inclusion in the gene array was A260/A280>
1.9; this was assessed by the genequant spectrophotometer. The quality was further
assessed with the RNA nanochip system; this gave an RIN (RNA integrity number),
which should be around 2, and a value for 18s/28s, which should also be around 2.
Only if the samples passed these quality control tests were they included in the
sample RNA pool. The 5 plates from each treatment were therefore pooled to create
one representative RNA sample. The RNA was prepared and hybridized on 6
AB1700 (n=3 40nM PROK1 treated and n=3 vehicle treated) and 6 Affymetrix (n=3
40nM PROK1 treated and n=3 vehicle treated) arrays respectively. Hybridisation of
the RNA samples to the gene arrays was performed commercially by Geneservice.
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5.2.3. cRNA preparation and hybridisation to gene chips
5.2.3.1.ABI
The cRNA is produced by reverse transcriptase in vitro transcription (RT-IVT).
Initially the reverse transcriptase enzyme incorporates deoxynucleotide in the
synthesis of single stranded c DNA from sample RNA. The use of T7 poly dT
primer adds the T7 polymerase promoter to the 5' end of the single stranded c
DNA transcript. This is followed by 2nd strand synthesis. RNase H degrades the
RNA in DNA-RNA duplexes to provide priming sites for DNA polymerase to
synthesise the 2nd strand DNA. The c DNA is subsequently purified; this washes
away salts buffers, unincorporated nucleotides, primers and degraded RNA. The
double stranded c DNA is then eluted in a solution suitable for the IVT reaction.
During the IVT labelling the T7 polymerase incorporates ribonucleotides and
digoxigenin (DIG)-UTP to synthesise copy RNA (cRNA) from double stranded c
DNA containing the T7 promoter. This step results in 100- to 1000-fold
amplification of targets. The c RNA is subsequently purified, this washes away
salts, buffers etc, as indicated above. The cRNA is then eluted in a solution
suitable for hybridisation on c RNA to the 1700 microarray.
Prior to chemiluminescent detection the cRNA must be fragmented and
hybridised to the microarray. Divalent cations catalyse the 2'hydroxyl cleavage of
RNA. This c RNA fragmentation reduces the secondary structure and improves
hybridisation kinetics. Prior to hybridisation the microarrays are incubated with
blocking agents to prevent non-specific hybridisation, the DIG labelled cRNA is
then hybridised to probes on the microarray. Washes reduce non-specific
hybridisation of the cRNA to the microarray and prepare the chip for antibody
binding. In preparation for application of antibody, blocking buffer is again
added to the microarray to prevent non-specific antibody binding. Anti-
digoxigenin alkaline phosphatase labelled antibody is added to bind digoxigenin
in the cRNA targets, the RT and IVT controls and the chemiluminescent control
probes on the microarray. Washing steps again remove unbound antibody and
prepare the microarray for the chemiluminescent reaction. An enhancing solution
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is added to the microarray, this acts to increase the quantum yield of the
chemiluminescent reaction, the chemiluminescent substrate is added which reacts
with the alkaline phosphatase label, resulting in dephosphorylation of the
substrate, this reaction emits a light signal. In order to detect this light emitting
reaction, the microarray is loaded onto a heated stage of the applied biosystems
1700 chemiluminescent microarray analyzer, the analysis focuses on the
microarray and obtains the chemiluminescent and fluorescent images of the
microarray.
Clearly, in order to control for technical variation, differences in labelling,
hybridisation, antibody binding and chemiluminescent detection a number of
controls are required, these are absolutely essential in the final analysis of the
microarray. These controls include blank features, control ladders, hybridisation
controls, internal control probe and target, IVT controls, negative controls, RT
controls and spatial normalisation controls. These parameters are all utilised in
the generation of a quality check report which is required in the microarray
analysis.
The signal intensity emitted at the blank features provides information about the
background signal for every region of the microarray and cross talk from other
regions. Non-specific binding of cRNA, antibodies, alkaline phosphatase or other
chemical/mechanical processes may result in background signal. Signals emitted
from the blank features indicate the level of non-specific signal generated from
the assay. The software calculates the amount of background chemiluminescent
signal from blank features and uses the correction to compare all other
chemiluminescent signals on the microarray.
Control ladders are used to perform quality checks of assay spotting and
chemistry, compare reproducibility of spotting across array batches and quality
check the chemiluminescent detection chemistry. They also demonstrate the
sensitivity and dynamic range of chemiluminescent detection chemistry. Fiducial
control ladders produce signals which are independent of labelling and
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hybridisation, they therefore indicate that the chemiluminescent reaction was
successful. Signal intensity variability indicates differences in spotting and
attachment efficiencies across various batches of assays.
The hybridisation controls are used to indicate successful hybridisation and
stringency and can also be used as a spatial normalisation control. Hybridisation
controls consist of 3 DIG labelled oligo control targets and 3 unlabelled probes
which are spotted onto the microarray. The DIG labelled oligo targets are added
to the microarray with the DIG labelled cRNA targets. The hybridisation controls
on the microarray are designed to hybridise with the DIG-labelled oligo targets.
The presence of a signal in these targets indicates that the hybridisation has
occurred successfully and the strength of the signal indicates the stringency of
this hybridisation.
The internal control probe and target are used to normalise the chemiluminescent
signal. The IC target is added to the hybridisation mixture and during the
hybridisation reaction this hybridises to every IC probe which is co-spotted at
every feature in the microarray.
The IVT controls demonstrate the IVT labelling reaction has taken place and the
efficiency of the reaction. Negative controls demonstrate the level of the non¬
specific background signals from all probes on the microarray. Non-specific
binding can result from cross hybridisation, binding of AP enzyme or other
chemical processes that lead to background chemiluminescent signal. The
software calculates the amount of background chemiluminescent signal and
corrects for this when measuring all other chemiluminescent signals on the
microarray. The RT controls indicate, again, if and how well the reaction has
worked.
5.2.3.2.Affymetrix
Preparation and hybridisation was described in main materials and methods
(Section 2.9). Briefly, cDNA synthesis and Bio tin labelling of cRNA were carried
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out using the Ambion Message Amp II cRNA kit. Samples were fragmented,
prepared for hybridisation using the Affymetrix hybridisation control kit and
hybridised to GeneChip® Human Genome U133 plus 2.0 arrays. The GeneChip
arrays were subsequently stained, washed on the fluidics station and scanned.
5.2.4. Data analysis
This analysis was performed by Geneservice. The ABI software uses spatial
normalisation control signal to remove any schematic spatial trends in the feature
ratios across the array. These potential spatial differences across the array might be
caused by non-uniform LED fluorescence illumination, non-uniform hybridisation, or
non-uniform focus of the microarray. The spatial normalisation controls are
distributed throughout the microarray and should produce the same CL/FL signal
ratios.
After the ICP normalisation, the algorithm identifies the spatial trends for CL/FL
signal rations and derives correction factors by interpolating between the spatial
normalisation control CL/FL ratios. The algorithm then removes the spatial trends
from all feature ratios using local correction factors from the nearest normalisation
control. These controls should avoid bias in labelling of samples. Finally, using these
control data a quality check report is generated. As indicated above, this is essential
in the final analysis of the microarray. The performance from the QC report indicates
the sample signal information, the background signal, the median signal to noise
(S/N) values and the number of genes detected above a set threshold. The S/N
threshold in this analysis is set at >3 for inclusion in the dataset. The software
automatically generates flags for poor or missing spots, if the flag measurement is
>100 in this analysis the data were removed from the dataset.
The data, after subjection to these pre-processing steps, was normalised using
variance stabilising normalisation (vsn). This is a statistical model used for
microarray expression data. This model comprises data calibration, quantification of
differential expression and quantification of measurement error. Application of
variance stabilising transformation to achieve a constant signal: noise ration for
Chapter 5 PR0K1 target genes 149
intensity measurements results in a difference statistic which displays approximately
variance independent of the spot intensity, i.e. variance is approximately constant
along the whole intensity range. This transformation also accounts for calibration,
covering different behaviour of dyes or variations between samples and assays. It is
important that intensity measurements must be on a common scale before they can
be compared. The estimation of the calibration parameters is simplified through
application of vsn and the difference statistic is obtained as the difference between
the transformed data of the individual samples, allowing comparison of two
samples and therefore calculation of fold change. (Huber, 2002)
LIMMA is a software package used for the analysis of gene expression microarray
data, especially the use of linear models for analysing experiments and the
assessment of differential expression. The differential expression methods apply to
all assay platforms and treat them in a unified way. LIMMA analysis allows the
fitting of a linear model, smoothing of the standard errors by application of a Bayes
empirical method to a common value. With one channel microarray data, linear
modelling is much the same as ordinary ANOVA or multiple regression except that
a model is fitted for every gene. LIMMA provides functions which summarise the
results of the linear model, perform hypothesis tests and adjust the p-values for
multiple testing. Results provided by LIMMA include (log) fold changes, standard
errors, t-statistics and p-values. The moderated t-value is the basic statistic which is
used for significance analysis, this is computed from each probe. The moderated t-
statistic has the same interpretation as an ordinary t-statistic except that the
standard errors have been moderated across genes, i.e. shrunk towards a common
value. This is performed using a Bayesian model and enables the borrowing of
information from the ensemble of genes to aid with the inference about each
individual gene. Moderated t-statistics result in p-values in the same way as
ordinary t-statistics with the exception that the degrees of freedom are increased; this
reflects the greater reliability associated with the smoothed standard errors. The
common p-value is the associated p-value which results after adjustment for
multiple testing. In this case the p-values were adjusted for multiple testing to
control for the false discovery rate with the Benjamini and Hochberg method (1995).
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The false discovery rate control indicates that if all genes with p-values below
threshold p>0.05 are selected as differentially expressed then the expected
proportion of false discoveries in the selected group is controlled to be less than the
threshold value, in this case 5%.
Cross mapping between AB1700 probes and Affymetrix probesets was courtesy
provided by Applied Biosystems. All unmapped poorly annotated genes were
removed from the analysis. All mapped genes yielding fold changes of more than 1.5
when PROK1 treated samples were compared with vehicle treated samples on both
platforms were selected for further consideration. Genes were further filtered by their
adjusted p-values with significance set at p<0.05.
Gene ontologies (GO) describe how gene products behave in a cellular context i.e.
describe gene products in terms of their associated biological processes, cellular
components and molecular functions. GO's were assigned to PROK1 regulated genes
for biological processes using tools provided by the in the gene ontology database
(www,geneontology .org).
Analysis of the expressed sequence tag tissue library database for PROK1 regulated
genes were conducted using WebGestalt (Web based gene set analysis toolkit) in
order to examine the tissue expression of PROK1 regulated genes.
5.2.5. PCR verification of gene expression
5.2.5.1.RNA extraction
In order to examine the temporal regulation of PROK1 target genes, PROKR1 and
WT Ishikawa cells were treated with 40nM PROK1 or vehicle for 0, 2, 4, 6, 8, 12
and 24 hours. Media was removed and TRI reagent added to the plates for RNA
extraction. TRI reagent cell lysates were transferred to phase-lock tubes and RNA
extracted by the phenol-chloroform method of RNA extraction as described in
Section 2.5. RNA samples were quantified using the genequant or nanodrop
spectrophotometers.
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5.2.5.2.Taqman PCR analysis
Expression of mRNA within cultured cells was examined by Taqman PCR in
order to quantify expression and detect low expression transcripts as described in
Section 2.5. Briefly, cDNA was prepared in a random hexamer primed reaction
using 200ng of RNA per reaction.
Quantitative PCR was conducted on the cDNA using specific primer-probe
mixtures to detect COX-2, LIF, IL6, IL-8 or IL-11 (Sequences given in Table 5).
The Probe was given a FAM fluorescent label. Gene expression was normalised by
including Vic labelled primer-probe mix to detect the 18s ribosomal subunit
(Sequences given in Table 5) as a loading control for the amount of cDNA added
in each sample.
Reaction mixtures were loaded, in duplicate onto a 96-well MicroAmp fast
optical reaction plate (Applied Biosystems) for analysis on an ABI 7900 HT Fast
Real-Time PCR machine (Applied Biosystems). Data were analysed and
processed using Sequence detector version 1.6.3 (Applied Biosystems) according
to the manufacturers instructions. Results were expressed as relative to a positive
RNA standard included in all reactions. The data was analysed using the
comparative Ct method for relative quantification.
5.2.6. Statistics
Other than where indicated, statistical analysis of the data in this study was carried
out by ANOVA with Fishers PFSD (predicted least squares difference) applied,
using Statview 5.0 (Abacus Concepts). The data is presented as mean ± SEM of at
least 3 experiments.
Chapter 5 PR0K1 target genes 152
5.3. Results
5.3.1. Gene expression altered upon treatment of PROKR1 Ishikawa cells with
PROK1
Genes were ranked if they were changed (up-regulated or down-regulated) by greater
than 1.5 fold on both platforms. Multiples, i.e. probes representing the same gene
and unclassified genes were removed and a median value assigned. This revealed
regulation of 277 genes on both arrays of which 226 were up-regulated while 51 were
down-regulated (Table 11). Concordance in changes in gene expression between the
two gene array platforms was examined with application of adjusted p-values of
p<0.05. Application of these further selection criteria reduced the list to 49 genes,
with 46 genes up-regulated and 3 genes down regulated (Table 12).
5.3.2. Classification of PROK1 regulated genes into gene ontologies
In order to determine functional processes which may be regulated by PROK1 in
vivo, the genes induced by PROK1 in the PROKR1 Ishikawa cells were classified into
gene ontology (GO) groups for biological processes. GO's describe how gene
products behave in a cellular context and gene products are assigned GO terms,
which define a biological process, cellular component or molecular function. Analysis
for significantly over-represented Gene Ontology (GO) annotations within the gene
list revealed 3 significant themes; cellular morphogenesis, cell motility/chemotaxis
and blood vessel development/morphogenesis (Table 13). Analysis of the expressed
sequence tag (EST) tissue library database (Zhang B et al, 2005) indicated that genes
regulated by PROK1 are significantly over-expressed in uterine tissue compared to
other tissue libraries, indicating that although the cell line is derived from cancer
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Table 12. Treatment of PROKR1 Ishikawa cells with 40nM PROK1 revealed 49 genes to be regulated with fold
changes (expressed relative to vehicle treated PROKR1 cells) of greater than 1.5 on both gene arrays after
application of selection criteria of adjusted p values of less than or equal to 0.05 on either array. Analysis
revealed 46 genes to be up-regulated by greater than 1.5 fold, while 3 genes were revealed to be down-
regulated (indicated by -) by greater than 1.5 fold.
Gene Symbol Gene Product
mean fold
change
ACSL4 acyl-CoA synthetase long-chain family member 4 isoform 2 1.5
AKAP12 A-kinase anchor protein 12 isoform 2 2.8
AREG amphiregulin preproprotein 5.3
BNC1 basonuclin 1 2.4
CD44 CD44 antigen isoform 4 precursor 1.9
C0R01C coronin 2.3
DAF decay accelerating factor for complement 9.8
DCAMKL1 doublecortin and CaM kinase-like 1 2.6
DKK1 dickkopf homolog 1 8.5
DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 1.9
DSCR1 calcipressin 1 isoform c 5.2
DTR diphtheria toxin receptor/ heparin binding EGF-like growth factor 3.6
DUSP1 dual specificity phosphatase 1 4.4
DUSP14 dual specificity phosphatase 14 1.9
DUSP4 dual specificity phosphatase 4 isoform 2 9.4
DUSP5 dual specificity phosphatase 5 7.2
EGR1 early growth response 1 2.1
EIF2AK3 eukaryotic translation initiation factor 2-alpha kinase 3 1.7
ENAH enabled homolog 1.7
FGD6 RhoGEF and PH domain containing 6 1.8
GEM GTP-binding mitogen-induced T-cell protein 5.3
GREM1 cysteine knot superfamily 1 12.4
HERC4 hect domain and RLD 4 1.9
HMGB2 high-mobility group box 2 -1.6
IER3 immediate early response 3 9.2
IL11 interleukin 11 precursor 19.8
IL6 interleukin 6 17.2
IL8 interleukin 8 precursor 9.7
KRTHA4 type I hair keratin 4 5.8
LAMA3 laminin alpha 3 subunit isoform 2 2.0
LIF leukemia inhibitory factor 2.6
MAIL molecule possessing ankyrin repeats induced by lipopolysaccharide 3.6
NR3C1 nuclear receptor subfamily 3 1.6
NR4A1 nuclear receptor subfamily 4, group A, member 1 isoform 7.0
NR4A2 nuclear receptor subfamily 4, group A, member 2 isoform 4.3
PBEF1 pre-B-cell colony enhancing factor 1 isoform 1.8
PTGS2 prostaglandin-endoperoxide synthase 2 6.3
PTPRR protein tyrosine phosphatase, receptor type, R 2.0
SCHIP1 schwannomin interacting protein 1 2.0
SERPINE1 plasminogen activator inhibitor-1 3.9
SLC20A2 solute carrier family 20, member 2 1.9
STK38L serine/threonine kinase 38 like 1.9
TMEM22 transmembrane protein 22 1.8
TMPRSS2 transmembrane protease, serine 2 -2.1
TNFAIP1 tumor necrosis factor, alpha-induced protein 1 2.3
TRIB1 G-protein-coupled receptor induced protein 2.7
TRIB3 tribbles 3 2.0
TXNIP thioredoxin interacting protein -3.0
ZNF165 zinc finger protein 165 1.6
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Table 13. Treatment of PROKR1 Ishikawa cells with 40nM PROK1 for 8 hours revealed 277
genes to be regulated. Application of gene ontology annotation for biological processes to PROK1
regulated genes revealed 3 significant themes of cellular morphogenesis, cell motility/chemotaxis
and blood vessel development/morphogenesis. GO numbers are numbers assigned to a
biological function within the gene ontology database. Numbers within brackets denote the

















cell structure morphogenesis (16)
cell differentiation (54)
organ morphogenesis (20)
morphogenesis of an epithelium (7)
actin filament bundle formation (4)
actin filament organisation (5)
actin binding (12)
anatomical structure formation (13)
anatomical structure morphogenesis (41)
anatomical structure development (70)
cell motility (18)
locomotory behaviour (11)
regulation of cell motility (6)
chemotaxis (10)













blood vessel morphogenesis (14)
blood vessel development (15)
response to wounding (22)
wound healing (8)
vasculature development (17)
blood vessel development (17)
angiogenesis (15)
regulation of angiogenesis (3)
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5.3.3. Validation of gene expression implicated by gene array
5.3.3.1.Validation of gene expression at 8 hours
As discussed earlier in section 5.1, there are always concerns regarding the
validity of results obtained purely from global gene array analysis of gene
expression. Therefore, in order to verify the data suggested by gene array
analysis, five genes were selected for further investigation to confirm their
regulation by PROK1. COX-2, LIF, IL-6, IL-8 and IL-11 were selected for
further examination by Taqman quantitative PCR analysis. PROKR1 and
WT Ishikawa cells were treated with 40nM PROK1 or vehicle for 8 hours as
this would enable direct comparisons to be drawn with the data obtained
from the gene array analysis. RNA was extracted from the cells following
treatment with vehicle or 40nM PROK1 and subjected to Taqman
quantitative PCR analysis for COX-2, LIF, IL-6, IL-8 and IL-11. Data are
expressed as fold above vehicle treated controls. Taqman quantitative PCR
analysis of these genes confirmed them to be elevated upon treatment with
40nM PROK1 for 8 hours. Fold induction of gene expression by 40nM
PROK1 at 8 hours in PROKR1 Ishikawa cells (Figure 5.1) was as follows:
COX-2 (4.82 ± 1.2 fold), LIF (12.4 ± 3.4 fold), IL-6 (15.55 ± 1.8 fold), IL-8
(152 ± 81.14 fold) and IL-11 (249.6 ± 88.3 fold). However, no significant
elevation of gene expression was observed in WT Ishikawa cells following
treatment with 40nM PROK1 for any of the genes examined (Figure 5.1).
5.3.3.2.Temporal regulation of PROK1 induced gene expression
PROK1 regulated expression of COX-2, LIF, IL-6, IL-8 and IL-11 has been
demonstrated in PROKR1 and WT Ishikawa cells at 8 hours. This validates
gene expression suggested by global gene array analysis. Subsequently the
temporal regulation of PROK1 induced gene expression was examined in
order to determine the time of maximal expression for each gene. PROKR1
and WT Ishikawa cells were treated with vehicle or 40nM PROK1 for 0, 2,
4, 6, 8, 12 and 24 hours. RNA was extracted and subjected to Taqman
quantitative PCR analysis. From these data it is observed that LIF (red
bars) and COX-2 (blue bars) are maximally expressed at 6 hours, IL-6
(yellow bars) and IL-11 (turquoise bars) are maximally expressed at 8
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hours and IL-8 (green bars) is maximally expressed at 8-12 hours in
PROKR1 Ishikawa cells. No elevation of gene expression in response to
PROK1 was observed in WT Ishikawa cells (grey bars) at any time (Figure
5.2).
COX-2 LIF IL-6 IL-8
Cells / Gene
IL-11
Figure 5.1. PROK1 mediated gene expression at 8 hours. WT and PROKR1 Ishikawa cells
were treated with 40nM PROK1 or vehicle for 8 hours. Gene expression was assessed by
Taqman PCR analysis for COX-2, LIF, IL-6, IL-8 and IL-11. Data are expressed as fold above
vehicle treated control. Data are presented as mean ± SEM. (b is significantly different from a
p<0.05).
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Figure 5.2. Temporal regulation of PROK1 induced gene expression. PROKR1 and WT Ishikawa
cells were treated with 40nM PROK1 or vehicle for 0, 2, 4, 6, 8, 12 and 24 hours. Gene
expression was assessed by Taqman quantitative PCR analysis for COX-2. LIF, IL-6, IL-8 and IL-
11. Data are expressed as fold above vehicle treated control. No elevation of gene expression in
response to 40nM PROK1 was observed in WT Ishikawa cells (grey bars) at any time point.
However, there was significant elevation of IL-8 (green bars), IL-6 (yellow bars), IL-11 (turquoise
bars), LIF (red bars) and COX-2 (blue bars). Data are presented as mean ± SEM. (b is
significantly different from b p<0.05)
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5.4. Discussion
In chapter 3 it was demonstrated that PROK1 is elevated during the mid-secretory
phase of the menstrual cycle. Due to elevation during this phase of the menstrual
cycle it was anticipated that PROK1 may be involved in endometrial receptivity
and implantation. A number of proteins which are elevated during this phase of
the menstrual cycle are proposed to play a role in endometrial receptivity, and one
strategy prior to performing a microarray experiment could have been choosing a
number of targets to investigate by real time PCR. However, as there was no
literature concerning gene regulation by PROK1 in the endometrium or any other
tissues, this approach seemed somewhat haphazard and may not have yielded
any data. Additionally, although PROK1 is elevated during the mid-secretory
phase of the menstrual cycle, this elevation was not significantly different to the
elevation observed during the early- or late-secretory phase, therefore focussing
effort on determining potential regulation of genes solely during the mid-secretory
phase of the menstrual cycle may have excluded potentially interesting genes
which are regulated during the early- and late secretory phase of the cycle.
An added complication is that, in examining gene arrays performed on
endometrium collected across the menstrual cycle, there is surprisingly little
consensus in genes regulated. As indicated in Table 1, out of 6 gene array analyses
performed on endometrial tissue comparing receptive with non-receptive
endometrium, only 26 genes were reported as regulated in a concordance of 3
array analyses. This is a surprisingly low number considering the high number of
genes reported to be regulated in the individual gene arrays. Again, these data
represent mainly genes regulated in the receptive endometrium during the mid-
secretory phase of the menstrual cycle; little data exists comparing multiple
phases of the menstrual cycle excepting a recent report by Talbi et al (2006). It
appeared that microarray analysis would give the most meaningful, global
indication of genes regulated by PROK1 in the endometrium as this wouldn't
simply focus on a single phase of the menstrual cycle.
In order to investigate gene activation initiated upon PROK1-PROKR1 interaction
global gene array analysis was performed. Two different platforms, the
Affymetrix GeneChip® Human Genome U133 plus 2.0 and the AB1700 v.2
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Applied Biosystems Human Genome Survey microarrays, were used in this study.
Concordance between the two platforms in significantly changed genes were
extracted from the data. With selection criteria of genes changed by 1.5 fold or
greater on both platforms applied to the data, 277 genes were found to be
differentially regulated. Application of more stringent criteria with a fold change
of 1.5 or more on both platforms and an adjusted p value of <0.05 on either
platform revealed 49 genes to be differentially regulated by PROK1.
Initially, in order to validate the gene array data, five genes were chosen and the
level of expression induced by PROK1 in PROKR1 and WT Ishikawa cells
examined at 8 hours by real-time PCR. These data confirmed the increase in
expression observed in the arrays for COX-2 (4.8 fold), LIF (12.4 fold), IL-6 (15.55
fold), IL-8 (152 fold) and IL-11 (249.6 fold). No increase in gene expression was
detected in WT Ishikawa cells. The large difference in fold change seen with IL-8
and IL-11 between array versus PCR analysis is likely due to the smaller dynamic
range of the gene array at large fold changes compared to high dynamic range of
PCR based analysis. Time course analysis of the effect of PROK1 on expression of
the five chosen genes revealed maximal expression of IL-8 at 8-12 hours, IL-6 at 8
hours, IL-11 at 8 hours, LIF at 6 hours and COX-2 at 6 hours. These data may
indicate that, for a number of genes, 8 hours may not be the maximal time point.
The genes chosen for further investigation were LIF and COX-2. These genes were
chosen as being potentially interesting when considering a potential role for
PROK1 signalling the receptivity and implantation. Although previous reports
disagree on the stage of the menstrual cycle at which maximal COX-2 expression
is observed gene knockout studies have implicated a role for COX-2 in receptivity
and decidualization, this led to the interest in the regulation of COX-2 expression
in the endometrium and decidua by PROK1. LIF expression is elevated during the
mid-secretory phase of the menstrual cycle, and although its role in human
reproduction has not yet been defined, gene knockout studies have demonstrated
an absolutely essential role for this cytokine in implantation in mice. COX-2 and
LIF were therefore chosen as interesting candidate genes to follow up with
reference to a potential role for PROK1 in receptivity and implantation.
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Analysis of gene ontology (GO) annotations for genes regulated by PROK1
revealed three major themes representing biological processes controlled by
PROK1 regulated genes. These 3 areas were cell morphogenesis, cell
motility/chemotaxis and blood vessel development/morphogenesis. These
processes are highly significant with reference to endometrial function specifically
at the time when PROK1 is elevated during the mid-secretory phase of the
menstrual cycle and during early pregnancy. These processes are instrumental in
the endometrium in preparation for and during early pregnancy when
angiogenesis, stromal cell decidualization and cell migration occur.
A large number of genes elevated by PROK1 upon PROKR1 activation have been
implicated in implantation. Some of the best examples, with data provided from
knockout studies, in vitro studies on human tissue and expression analysis in
endometrial tissue across the menstrual cycle include IL-11, LIF, COX-2, HB-EGF
(DTR) and DAF (decay accelerating factor for complement). The genes regulated
by PROK1 also demonstrate some overlap with genes regulated during the
window of implantation demonstrated by gene arrays conducted on endometrium
taken during the mid-secretory phase of the menstrual cycle. These genes include
DAF, Laminin, serine protease inhibitors, Dkk-1, protein tyrosine phosphatase
receptors, LIF, THBS1, metallothioneins, TGF-P superfamily, serine/threonine
kinases, LDL receptor protein and GADD45A (growth arrest and DNA damage
inducible protein, DNA excision repair and cell-cycle regulation) (Kao et al, 2002,
Carson et al, 2002, Riesewijk et al, 2003, Borthwick et al, 2003, Mirkin et al, 2005,
Talbi et al, 2006).
Division of PROK1 regulated genes into GO classifications of cell morphogenesis;
cell motility/chemotaxis and blood vessel development/morphogenesis allows
discussion of the genes within functional groups. A number of genes which were
elevated by PROK1 and which may play functional roles in the endometrium in
preparation for or during implantation, will be discussed further. PROK1 induced
genes may be represented in more than one functional group. Genes will therefore
be discussed within the relevant functional groups with a review of these
functions.
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5.4.1. GO - cell morphogenesis/developmental processes
A large number of genes elevated by PROK1 within the GO classification for
cell morphogenesis/developmental processes are relevant to implantation.
Basonuclin-1 is a cell specific transcription factor; its functions include re-
epithelialisation (Matsuazki et al, 2004) and cell adhesion (Wang J et al, 2006).
Regulation by PROK1 may indicate a role for Basonuclin-1 in blastocyst
adhesion and repair of the luminal epithelium after rupture and invasion by
the trophoblast. As PROK1 is elevated in first trimester decidua, this may also
imply a prolonged role for Basonuclin-1 in repair of areas breached by the
invading trophoblast in the aggressively invasive stage of the first trimester.
Migration of extravillous trophoblast cells mediated by PGE2 is dependent on
proteases called Calpains (Nicola et al, 2005). These Calpains are calcium
dependent proteases involved in cell detachment from the substratum during
migratory responses (Dourdin et al, 2001, Huttenlocher et al, 1997, Glading et
al, 2000). VEGF also mediates angiogenic effects via induction of Calpain 2
(Su Y et al, 2006). Therefore in initiation of an endometrial - trophoblast
dialogue, PROK1 induced Calpain proteases may aid developmental
processes during the early stages of placentation.
Tissues, such as the invading trophoblast, undergoing rapid growth and
regeneration contain hyaluronic acid (Goshen et al, 1996), which mediates its
effect through its major cell surface receptor CD44 (Sherman et al, 1994).
CD44 is suggested to be elevated in the epithelial cells during the window of
implantation (Home et al, 2002, Afify et al, 2006), and may contribute to the
edema observed in the endometrium at this phase of the menstrual cycle
(Okada et al, 2001). CD44 is also suggested to be involved in trophoblast
attachment and implantation (Aplin, 1997, Goshen et al, 1996, Albers et al,
1995). PROK1 via elevation of CD44 may therefore play dual roles in
endometrial edema and blastocyst attachment.
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The a-crystallin B-chain first appears in the early secretory phase of the
menstrual cycle and continues to rise until the late secretory phase (Gruidl et
al, 1997). It localises to the luminal and glandular epithelium and is controlled
by progesterone (Gruidl et al, 1997). a-crystallin B-chain is also elevated in the
baboon endometrium upon treatment with hCG, one of the first embryonic
products, potentially indicating, along with the temporal expression and
localization in the human endometrium a role in implantation (Sherwin et al,
2007). a-crystallin B-chain is suggested to confer resistance against
cytotoxicity induced by TNF-a (suggested to be involved in trophoblast
invasion) and oxidative stress at the time of implantation (Mehlen et al, 1995).
A family of proteins induced by PROK1, and related to a-crystallin B-chain,
are the heat shock proteins. These are stress induced proteins. They are
expressed in the endometrium and HSP27 (heat shock protein 27 or B8)
increases rapidly after ovulation (Tabibzadeh et al, 1996) and are present in
the endometrium until week 10 of pregnancy (Padwick et al, 1994). Like a-
crystallin B-chain, HSP's are thought to confer resistance against cytotoxicity
and oxidative stress (Melen et al, 1995). PROK1 may therefore act as a
protective factor, possibly during the hypoxic phase of placentation via
induction of HSP family members.
DCAMKL-1 (doublecortin and CaM kinase like-1) regulates cell migration and
development (Friocourt et al, 2003). These processes are essential to the
trophoblast during implantation and invasion. However, a role in migration
has thus far been demonstrated solely in neurones (Friocourt et al, 2003).
Expression of DCAMKL-1 is also thought to link calcium signalling and
microtubule dynamics during migration (Lin PT et al, 2000). PROK1 mediated
signalling appears to be calcium dependent (Soga et al, 2002, Masuda et al,
2002). Therefore PROK1 mediated signalling via DCAMKL-1 and calcium
activation may indeed be of relevance to cell migration in the endometrium.
There are currently no reports of DCAMKL-1 expression in the endometrium.
However, if a communication between the developing foetus and the
endometrium is initiated, PROK1 mediated DCAMKL-1 may play a role in
neuronal migration in the fetal brain (Mizuguchi et al, 1999, Qin et al, 2000).
Chapter 5 PR0K1 target genes T73
Dkk-1 (Dickkopf) is a Wnt antagonist and is structurally related to PROK1
(LeCouter et al, 2001). Dkk-1 is elevated during the window of implantation in
a number of gene array analyses examining endometrium taken during this
phase of the menstrual cycle (Kao et al, 2002, Carson et al, 2002, Riesewijk et
al, 2003, Borthwick et al, 2003, Mirkin et al, 2005), is estrogen and progesterone
responsive (Tulac et al, 2006) and peaks in the mid-secretory phase of the
menstrual cycle. As a Wnt antagonist Dkk-1 may limit Wnt actions during the
establishment of endometrial receptivity to implantation and the early stages
of invasion (Tulac et al, 2006). It is proposed that endometrial expression of
Dkk-1 may signal the opening of the implantation window (Zhang et al, 2004),
potentially implicating PROK1 in implantation related functions.
HB-EGF (heparin binding epidermal growth factor) is also known as DTR
(diphtheria toxin receptor) as the transmembrane form of HB-EGF actually
acts as the receptor for diphtheria toxin (Raab et al, 1994, Naglich et al, 1992,
Iwamoto et al, 1994). Expression of HB-EGF in the endometrium has been
heavily implicated in implantation. In the mouse HB-EGF is expressed on the
luminal epithelium 6 hours prior to the attachment reaction between the
epithelium and the blastocyst (Das et al, 1994), while EGFR is expressed on the
trophectoderm (Chobotova et al, 2002b, Dardik et al, 1992). In the LIF null
mouse, which does not display strong blastocyst - endometrial attachment or
implantation, HB-EGF is not expressed at the luminal epithelium at the site of
blastocyst apposition on day 4 or 5 (Song et al, 2000). Cells expressing
transmembrane HB-EGF can adhere to active but not dormant blastocysts in
vitro (Raab et al, 1996). It is therefore suggested that transmembrane HB-EGF
induced at the site of blastocyst apposition may mediate attachment. A role
for HB-EGF has also been suggested in the human endometrium. HB-EGF is
expressed in the human endometrium during the window of implantation
(Leach et al, 1999, Yoo et al, 1997). Its expression coincides with the
appearance of pinopodes, with expression of HB-EGF on the surface of the
pinopodes (Stavreus-Evers et al, 2002). Pinopodes are protrusions, which are
thought to be essential to implantation (Pantos et al, 2004). HB-EGF is also
suggested to improve blastocyst development in vitro (Martin et al, 1998) and
adheres to human blastocysts expressing the EGFR ErbB4 (Chobotova et al,
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2002b) and heparin sulphate proteoglycan (Paria et al, 1999). HB-EGF is also
suggested to have a role in decidualisation as inhibition of HB-EGF inhibits
decidualisation and survival of stromal cells (Chobotova et al, 2002a). TGF-|3,
which is also regulated by PROK1, has been demonstrated to induce
expression of transmembrane HB-EGF (Chobotova et al, 2002a). PROK1 may
therefore regulate HB-EGF expression directly and perpetuate expression
though induction of TGF-|3.
Follistatin is an Activin A binding protein. Activin A promotes decidualisation
(Jones et al, 2002, Tierney and Giudice, 2004), which is inhibited by Follistatin.
Activin A produced by decidualized stromal cells may augment invasion and
placental function; follistatin may serve to limit the Activin A mediated
trophoblast invasion and prevent excessive invasion (Caniggia et al, 1997). The
temporal regulation of Follistatin supports this, as along with Activin A, it is
produced in the decidualized stromal cells of secretory endometrium and early
pregnancy (Jones et al, 2002), potentially suggesting paracrine regulation.
TGF-(3 has similar effects to another member of the TGF superfamily,
Follistatin, described above. TGF-|3 inhibits trophoblast growth (Li RH et al,
1997) invasion and proliferation (Graham and Lala, 1991, Graham, 1997,
Morrish et al, 1991, Graham, 1992 et al, Li & Zhang, 1997, Smith, 2001). TGF-
(33 is over-expressed in pre-eclamptic pregnancies (Caniggia et al, 1999) where
insufficient trophoblast invasion and deficient placentation are markers of this
pathology. Expression of TGF-|33 varies across the menstrual cycle with
elevation and intense glandular epithelial expression in the secretory phase of
the menstrual cycle (Reis et al, 2002, Tang et al, 1994). Activation may release
from the latent form by uPA (Casslen et al, 1998), TGF-(3 as indicated above
may act in a negative feedback mechanism to inhibit excessive invasion.
Elevation of both Follistating and TGF-|33 by PROK1 may implicate a role for
PROK1-PROKR1 signalling in limiting trophoblast invasion.
IL-11 is a member of the IL-6 family and its signalling has been heavily
implicated in early pregnancy. Using knockout mice for the IL-11 receptor a
(IL-llRcx) it was demonstrated that blastocysts could implant. However an
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insufficient decidualisation reaction was initiated in response to the blastocyst.
This was shown to be a maternal defect as 2.5 day embryos transferred from
the IL-llRa null mice to WT mice implanted and survived, while transfer of
2.5 day embryos from WT mothers to IL-llRa null mice again displayed an
insufficient decidualisation reaction (Robb et al, 1998). These data indicate
that endometrial IL-11 signalling is essential for proper decidualisation (Robb
et al, 1998, Bilinski et al, 1998). In order for proper signalling to occur, IL-11
must induce formation of a heterodimeric complex of its own receptor with the
common IL-6 family receptor gpl30. Similarly gpl30 null mice display
intrauterine defects (Ernst et al, 2001). IL-11 and its receptor have been
identified in decidual cells in the secretory phase of the menstrual cycle and
early pregnancy (Chen HF et al, 2002, Cork et al, 2002, Dimitriadis et al, 2002,
2003, Karpovich et al, 2003). The receptors IL-llRa and gpl30 are expressed
on the glandular and luminal epithelium (Cullinan et al, 1996, Cork et al, 2002,
Van Rango et al, 2004) with expression also noted in trophoblast cells
(Dimitriadis et al, 2003). This could imply a signalling dialogue for IL-11
between the endometrium and trophoblast. The observation that IL-11
expression is reduced in anembryonic pregnancies which result in early
abortion (Chen HF et al, 2002), adds weight to the proposed involvement of
IL-11 signalling in implantation and decidualisation.
Expression of Galectins has been detected in the endometrium (Koopman,
2003 et al, Maquoi et al, 1997). Galectins are a group of soluble lectins, which
are thought to mediate trophoblast attachment (Kimber & Spanswick, 2002).
Galectin-1 is proposed to mediate interactions between integrins and ECM
components, which are of vital importance in endometrium-blastocyst
attachment (Gu et al, 1994, Maquoi et al, 1997). PROK1 may therefore play a
role in blastocyst adhesion.
LIF (leukaemia inhibitory factor) has been demonstrated by use of LIF null
mice to be absolutely essential in implantation as they do not display any
signs of implantation and cannot support pregnancy (Stewart et al, 1992). LIF
is also a member of the IL-6 family of cytokines and could possibly substitute
for IL-6 in the IL-6 null animals during implantation (Robertson et al, 2000).
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Expression of endometrial LIF is stimulated by HB-EGF and TGF-a (Arici et
al, 1995). As PROK1 up-regulates expression of these factors as well as LIF
this may provide a mechanism for prolonged LIF expression in the
endometrium. The role of LIF will be discussed more fully in chapter 7.
Expression of IL-8 has been demonstrated in the secretory endometrium (Milne
et al, 1999, Jones et al, 1997, Critchley et al, 1994, Arici et al, 1998). IL-8
enhances adhesion of cells to fibronectin, a component of the extracellular
matrix (Garcia-Velasco et al, 1999, Mulayim et al, 2004). These data suggest a
role for IL-8, and therefore PROK1, in the adhesion of the trophoblast in early
pregnancy.
IL-6, along with its family members, LIF and IL-11, has also been implicated
in implantation. IL-6 null mice can implant and produce live offspring
however, they display a 48% reduction in implantation compared with their
WT counterparts (Robertson et al, 2000), and this may indicate a degree of
redundancy for IL-6 as it may be compensated for by other members of the IL-
6 family. In the human endometrium IL-6 is present in the mid-secretory
endometrium localised to the luminal and glandular epithelium (Tabibzadeh,
1995 et al, Vandermolen & Gu, 1996). IL-6 is suggested to contribute to
trophoblast growth and placental development in humans (Nishino et al,
1990). IL-6 receptors are present in the endometrium and trophoblast during
implantation and placentation (Deb et al, 1999, Nishino et al, 1990, Masuhiro
et al, 1991, Li Y et al, 1992) and via interaction with the trophoblast IL-6
elevates secretion of hCG (Matsuzaki et al, 1995). IL-6 may therefore
contribute to the growth and differentiation of the trophoblast in early
pregnancy.
PTGS2 or COX-2 (cyclooxygenase-2) has been demonstrated by the knockout
mouse model for COX-2 to have an essential role in implantation events and
decidualisation (Cheng & Stewart, 2003, Lim et al, 1997). COX-2 null mice
display a delay in implantation, a defective decidual response and a delay in
parturition. It has been demonstrated in humans that implantation past the
normal window of implantation may leads to defective formation of the feto-
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placental unit and the risk of pregnancy loss increases as a function of
delaying the initiation of pregnancy (Red Horse et al, 2004, Wilcox et al, 1999).
The role of COX-2 will be discussed in more detail in chapter 6.
TGF-a is present in the mouse endometrium throughout pregnancy and in
human endometrium with a peak in the secretory phase of the menstrual cycle
and is localised to the luminal epithelium (Ejskjaer et al, 2005). In human cells
it elevates secretion of hCG from the trophoblast and enhances trophoblast
growth (Edwards, 1995). It also elevates expression of HB-EGF (Chobotova et
al, 2002a) and therefore contributes to decidualisation and stromal cell
survival. PROK1 mediated TGF-a expression may therefore promote
decidualization during early pregnancy.
5.4.2. GO - cellmotility/ chemotaxis
A number of genes elevated by PROK1 are proposed to play important roles in
cell motility and chemotaxis. These are highly important functions during the
invasive phase of implantation and placentation.
CD44 can recruit proteolytically active MMP-7 and HB-EGF to form a cell
surface complex, which may play a role in regulation of tissue remodelling (Yu
WH et al, 2002), which may be important in trophoblast migration and
invasion.
CTGF may have multiple roles in the endometrium. Connective tissue growth
factor (CTGF) has been localised to the glandular and luminal epithelium and
stroma in the secretory phase of the menstrual and decidua of early pregnancy
in human and mouse (Uzumcu et al, 2000, Surveyor et al, 1998). It appears
likely that CTGF is produced as a prelude or in consequence of decidualisation
and is therefore thought to play a role in early pregnancy (Brigstock, 1999).
Roles for CTGF have been suggested in uterine cell growth, migration,
adhesion, and extracellular matrix production (Surveyor et al, 1998).
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Cyr61 is a member of the same family as CTGF, the CCN family (an acronym
for Connective tissue growth factor, Cysteine rich protein (Cyr61), and
Nephroblastoma overexpressed gene). This family mediates diverse roles in
development, cell proliferation and tumourigenesis with its expression rapidly
induced by growth factors cytokines and estrogen (Brigstock, 2003, Kireeva et
al, 1996). Cyr61 is present in baboon endometrium during the menstrual cycle
and localises to the glandular and luminal epithelial cells of eutopic and
ectopic endometrium during the secretory phase of the cycle (Gashaw et al,
2006). In the mouse Cyr61 localises to the luminal epithelium on day 4 at the
time of implantation (Chen Y et al, 2006).
Expression of IL-8 has been localised to the luminal and glandular epithelial
cells and activated macrophages of the secretory endometrium (Milne et al,
1999, Jones et al, 1997, Critchley et al, 1994, Arici et al, 1998). It is suggested
that IL-8 as a chemokine, is involved in recruitment of neutrophils and
leukocytes into the endometrium, large numbers of which are observed in the
secretory phase of the cycle (Arici et al, 1998, Jones et al, 1997). IL-8 elevates
activation of collagenases and matrix metalloproteinases (MMP's, Garcia-
Velasco et al, 1999, Mulayim et al, 2004). These data may suggest a role for
IL-8, and therefore PROK1, in the invasion of the trophoblast in early
pregnancy.
Urokinase plasminogen activator (uPA/ PLAU) is a protease in its own right
and also activates other proteases from their pro-forms e.g. the MMP's.
PROK1 may induce expression of uPA in the endometrium and the
cytotrophoblast also produces uPA (Queenan et al, 1987), therefore uPA is
freely available at the invasion site for invasion of the trophoblast (Nordengren
et al, 2004). As well as aiding invasion uPA may also act to inhibit excessive
invasion. Release of TGF-(1 from its latent form by uPA (Odekon et al, 1994,
Yee et al, 1993) enables active TGF-(3 to inhibit invasion, therefore uPA can
possibly promote invasion and via TGF-|3 initiate a negative feedback
mechanism to inhibit invasion. PROK1 also elevates the receptor for uPA
(PLAUR) therefore enabling its action. Flowever, PROK1 also elevated the
inhibitor for uPA, SERPINE-1. Serine protease inhibitors have also been
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demonstrated by gene array analysis to be elevated the in window of
implantation (Kao, 2002 et al, Carson, 2002 et al, Riesewijk et al, 2003,
Borthwick et al, 2003, Mirkin et al, 2005). The activity of pro- or anti-invasive
mechanisms may therefore depend on the local levels of each or other
regulators present in the endometrial milieu.
5.4.3. GO - blood vessel development/morphogenesis
Another group of PROK1 induced genes that are highlighted in the GO
groupings are those affecting blood vessel development and morphogenesis.
These gene products may contribute to endometrial vessel maturation during
the secretory phase of the cycle or regulation of blood vessels during early
pregnancy.
CD44, as indicated above, is implicated in cell morphogenesis. However, it
also has potential roles in blood vessel development. During the secretory
phase of the menstrual cycle CD44 localises to the perivascular cells and its
expression is most intense adjacent to the spiral arterioles (Afify et al, 2006).
This may suggest a role for CD44, and therefore PROK1, in endothelial cell
support.
CTGF is mainly represented in GO annotations for blood vessel development
and morphogenesis. In the pregnant human endometrium, CTGF localises to
the vascular endothelial cells (Uzumcu et al, 2000). It appears likely that
CTGF is produced as a prelude or in consequence of decidualisation and is
therefore thought to play a role in early pregnancy (Brigstock, 1999), however
this requires further investigation. The related proangiogenic factor Cyr61 is
present in baboon endometrium during the menstrual cycle and localises to the
blood vessels of eutopic and ectopic endometrium during the secretory phase
of the cycle (Gashaw et al, 2006). Cyr61 has been demonstrated to potentiate
the effects of the angiogenic factors FGF-2 and PDGF (Kireeva et al, 1996).
PROK1 may therefore mediate physiological angiogenesis during early
pregnancy.
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DAF has been demonstrated to be elevated during the window of implantation
in a number of gene array analyses examining endometrium taken during this
phase of the menstrual cycle (Kao et al, 2002, Carson et al, 2002, Riesewijk et
al, 2003, Borthwick et al, 2003, Mirkin et al, 2005). DAF localises to the luminal
and glandular epithelium in cycling endometrium (Francis et al, 2006) and is
dramatically elevated during the mid-secretory phase of the cycle (Young et al,
2002, Mirkin et al, 2005 et al, Talbi, 2006), during which time its expression
may be stimulated by EGF family members (Young et al, 2002). However,
expression of DAF is reduced in women exhibiting luteal phase defect, which
is restored after treatment with progesterone (Kaul et al, 1995).
Antiphospholipid syndrome (APS) is associated with placental insufficiency
and a high miscarriage rate; DAF is significantly lower in these patients
(Francis et al, 2006). This is thought to be due to the degree of cellular
protection against complement mediated lysis mediated by DAF. Its reduction
in APS points towards an increased vulnerability to complement mediated cell
damage during trophoblast invasion and placenta formation. DAF therefore
may exert a protective role during implantation and early pregnancy. PROK1
expression may be expected to show a reduction in luteal phase defect and
APS and this warrents further investigation.
FGF2 is an angiogenic factor, which, by its endometrial localisation especially
in and/or around blood vessels is thought to contribute to endometrial
angiogenesis (Moller et al, 2001). This may be of importance in early pregnancy
when PROK1 expression is elevated and the maternal vessels are undergoing
remodelling as FGF-2 is also suggested to be involved in endothelial repair
which is required after breach of the maternal vessels during trophoblast
invasion (Wang DI et al, 1999). PROK1 may therefore play a role in endothelial
repair during trophoblast invasion. FGF-2 is highly expressed in the
mesometrial decidua at a time when extensive angiogenesis takes place in this
tissue (Srivastava et al, 1998). However, other studies have suggested that the
main expression of FGF-2 is located anti-mesometrially (Paria et al, 2001).
Expression of IL-8 has been localised to the peri-vascular cells of the secretory
endometrium (Milne, 1999 et al, Jones, 1997 et al, Critchley, 1994 et al, Arici et
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al, 1998). Localisation to the perivascular cells may imply a role for endothelial
cell support.
As indicated above, COX-2 (cyclooxygenase-2) has been demonstrated by the
knockout mouse model for COX-2 to have an essential role in implantation
and decidualisation (Cheng and Stewart, 2003, Lim et al, 1997). COX-2 null
mice are suggested to display impaired uterine angiogenesis at the
implantation site due to a deficiency in prostaglandins (Matsumoto et al,
2002, Wang & Dey, 2006).
These data indicate PROK1 induces genes, which may contribute to adhesion
during implantation, cell migration and invasion, repair and protection against
toxic stimuli, blood vessel function as well as inhibitors of invasion. The action of
these molecules in vivo may not depend just on induction by PROK1, and there is
extensive opportunity for cross talk between the PROK1 induced genes to elevate
or inhibit expression of others, e.g. PROK1 elevates both uPA and its inhibitor.
Action may depend on other activators or inhibitors present in the endometrial
milieu at the time of implantation. Clearly this work is just the 'tip of the iceberg'
in terms of the in vitro and in vivo investigations required to delineate the action
and role of PROK1 during the window of implantation. However it is encouraging
that a number of genes regulated by PROK1 have previously been demonstrated
to be elevated during the window of implantation, to have a reproductive
phenotype as demonstrated by their knockout mouse model, or to be regulated by
hCG, one of the first embryonic products. These imply PROK1 may indeed play a
role in implantation or early pregnancy. The PROKR1 null mouse did not have a
reported reproductive phenotype (Matsumoto et al, 2006). However, any defect in
the PROKR1 null mouse may be compensated by PROK1 binding to PROKR2, as
the receptors are highly homologous and may initiate similar signalling (Lin DC et
al, 2002) in the endometrium thus avoiding a reproductive phenotype. The
reproductive system does not develop in PROKR2 null animals (Matsumoto et al,
2006) due to an absence of GnRH neurones and a lack of gonadotropic support. In
order to investigate the effect of an absence of both receptors, it would be of
interest to investigate a dual PROKR1 knockout/PROKR2 conditional knockout
mouse model and examine the reproductive phenotype. It would also be of
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interest to investigate the reproductive phenotype of a PROK1 knockout mouse
model, however, at present there are no reports of a PROK1 knockout in the
literature. Alternatively, in the absence of these mouse models it would be of
interest to use receptor inhibitors in vivo in order to investigate potential
reproductive phenotypes and provide further information regarding the role of
PROK1 in reproduction.
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Chapter 6 - Prokineticin regulation of COX-2 expression and prostaglandin
synthesis in PROKR1 Ishikawa cells
6.1. Introduction
In Chapter 3 it was demonstrated that PROK1 was elevated during the secretory
phase of the cycle and further elevated during early pregnancy. It was
subsequently established that PROK1 regulates expression of COX-2. The COX
enzymes, mediate prostanoid biosynthesis and comprise 2 distinct enzymes,
COX-1 and COX-2, which share 60% amino acid identity, and a variant form of
COX-1 known as COX-3, which is produced by alternate splicing of COX-1 and
retention of an intron (Chandrasekharan et al, 2002). The action of the COX-
enzymes is the metabolism of arachidonic acid to produce prostaglandins. A role
for the prostaglandins in female reproductive function has long been recognised. In
1967, Pickles described the prostaglandins in the human endometrium (Pickles,
1967). The prostaglandins, prostaglandin receptors, prostaglandin transporter and
COX-2 expression have since been described in the pregnant and non-pregnant
endometrium and uterine pathologies (Hofmann et al, 1983, Jones et al, 1997,
Tong et al, 2000, Jabbour et al, 2001, Milne et al, 2003, Sales et al, 2004, Battersby
et al, 2004b, Milne et al, 2001, Ferrandina et al, 2002, Smith et al, 1981a,1981b Ota
et al, 2001, Milling-Smith et al, 2007).
COX-2 derived prostaglandins are important in a number of female reproductive
functions. PGF2a, particularly, is important in ovulation for the extrusion of the
ovum from the ovarian follicle (Plunkett et al, 1975). Prostaglandins are also
important in parturition (Friel et al, 2005, Olson, 2003), during which time COX-2
expression is massively elevated above COX-1 expression in term human amnion
(Slater et al, 1994).
There is an increasing amount of evidence pointing towards a role for COX-2 in
implantation and early pregnancy. The COX-2 knockout mouse model provides
compelling evidence for the importance of COX-2 in a number of female
reproductive functions. The COX-2 null mice exhibit a reduced rate of ovulation
and failure of fertilisation when compared with wild type mice. Indeed the eggs
from COX-2 null mice were found to be developmentally abnormal (Lim et al,
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1997). In contrast with the paper of Lim et al (1997), which reported a failure of
wild type blastocyst to implant in the uteri of COX-2 null mice, Cheng & Stewart
(2003) reported that pseudopregnant COX-2 null mice did display recognisable
implantation on days 7 - 10 of pregnancy, which progressed to term. However, it
was observed that the decidual weights were lower, exhibiting a delay in growth of
about 24 hours when compared with wild type mice, and the pups were delivered
about 1 day later in the COX-2 null than the wild type animals. In support of the
requirement for COX-2 derived prostaglandins in decidualization was the
observation that, in contrast to wild type mice, the COX-2 null mouse displays no
decidualisation response to an intraluminal oil infusion on day 4 of
pseudopregnancy (Lim et al, 1997). Indeed, PGE2 has been demonstrated to
induce decidualisation in human stromal cells (Frank, 1994, Dimitriadis, 2005)
and administration of PGI2 partially restores the decidualisation defect in COX-2
null mice (Lim et al, 1997).
In chapter 3 it was demonstrated that PROK1 is elevated in the mid-secretory
phase of the menstrual cycle and further elevated in the pregnant endometrium. In
chapter 5 it was discovered that COX-2 is a target gene for PROK1. Regulation of
COX-2 by PROK1 may provide an important mechanism for prostaglandin
production during early pregnancy. This study was therefore designed to
investigate the role of PROK1 in inducing COX-2 expression and the biosynthesis
of prostaglandins in the PROKR1 Ishikawa cell line model.
6.2. Materials and methods
6.2.1. Immunofluorescent histochemistry and confocal microscopy
Co-localization of PROKR1 with COX-2 was performed by dual
immunofluorescence immunohistochemistry on endometrial tissue or first
trimester decidua. Sections (5pM) were dewaxed in xylene and rehydrated
using decreasing concentrations of ethanol. Antigen retrieval was performed
for 5 minutes in a pressure cooker in boiling 0.1% citrate buffer (pH 6.0).
Endogenous peroxidase activity was quenched with 3% (vol/vol) H2O2 in
methanol at room temperature. Normal horse serum block (5% serum in PBS
with 0.05% BSA) was applied for one hour before overnight incubation at 4°C
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with goat anti-COX-2 antibody at 1:50 or goat IgG for control sections.
Sections were washed in PBS, COX-2 treated sections were incubated with
biotinylated horse anti goat, followed by washing in PBS and incubation with
the fluorochrome Streptavidin 488 diluted 1:200 in PBS. Sections were re-
blocked with 5% normal goat serum block diluted in PBS and incubated with
rabbit anti-human PROKR1 (1:500) overnight at 4°C. Control sections were
incubated with rabbit IgG. Sections were washed in PBS and incubated with
peroxidase goat anti-rabbit, 1:200 in PBS, followed by washing in PBS and
incubation with the fluorochrome Cyanine 3 (red) at 1:50 in substrate provided
with the kit. Sections were washed in PBS and then incubated with the nuclear
counterstain ToPro diluted 1:2000 in PBS. Sections were mounted in
Permafluor and fluorescent images were visualised using a laser-scanning
confocal microscope (LSM 510, Carl Zeiss) with a 40 x 1.4 aperture oil
immersion lens.
6.2.2. Cell culture and treatments
6.2.2.1.Time course analysis of PROK1 mediated COX-2 expression
In order to examine the temporal regulation of COX-2 by PROK1, PROKR1
or WT Ishikawa cells were treated with 40nM PROK1 or vehicle for 0, 2, 4,
6, 8, 12 or 24 hours. Cells were subsequently lysed in NP40 lysis buffer and
processed for Western immunoblot analysis (as described in Section 6.2.4)
or lysed in TRI reagent, followed by RNA extraction and processing for
Taqman quantitative PCR analysis (as described in Section 6.2.3).
6.2.2.2.Mechanism of PROK1 mediated COX-2 RNA and protein
expression
In order to examine the signalling pathway activation leading to PROK1
mediated COX-2 expression, PROKR1 Ishikawa cells were preincubated
with chemical inhibitors of Gq protein (YM254890), PLC-(1 (U73122), Ca2+
(calcium chelators, BAPTA-AM), cSrc (PP2), EGFR kinase (AG1478) or
MEK (PD98059; working concentrations for inhibitors indicated in Table
14). In order to examine PROK1 mediated COX-2 RNA or protein
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expression, PROKR1 Ishikawa cells were subsequently treated with vehicle
or 40nM PROK1 for 6 hours or 8 hours respectively.
In order to determine if PROK1 mediated COX-2 expression was
transcriptionally activated, PROKR1 Ishikawa cells were pre-incubated
with an inhibitor of transcriptional activation (Actinomycin D). PROKR1
Ishikawa cells were subsequently treated with vehicle or 40nM PROK1 for
4, 6 or 8 hours.
Cells were lysed in NP40 lysis buffer and processed for Western
immunoblot analysis (as described in Section 6.2.4), or lysed in TRI
reagent, followed by RNA extraction and processing for Taqman
quantitative PCR analysis (as described in Section 6.2.3).
Table 14. Inhibitor concentrations
Inhibitor Molecule Inhibited Inhibitor concentration
YM254890 Gq protein lpM





Actinomycin D Transcriptional activation 250ng/ml
6.2.3. Polymerase chain reaction
6.2.3.1.RNA extraction
RNA was extracted using TRI-reagent and the phenol-chloroform method
of RNA extraction as described in section 2.5. Briefly, cells were lysed in
TRI-reagent and a homogenous lysate achieved by mixing by pipetting.
Lysed samples were then loaded into heavy gel phase lock tubes with he
addition of bromo-chloro propane. Tubes were shaken vigorously to ensure
adequate mixing of the two solutions. Samples were then processed as
described in section 2.5.
Chapter 6 PR0K1-PR0KR1 mediated COX-2 expression 187
6.2.3.2.Taqman quantitative PCR
Expression of RNA within cultured cells was examined by Taqman
quantitative PCR analysis as described in section 2.5. Briefly, cDNA was
prepared in a random hexamer primed reaction using 200ng RNA per
reaction. Quantitative PCR analysis was performed on the cDNA using
specific primer probe combinations to detect COX-2 (sequence given in
Table 5), these were designed in house and custom synthesised. The probe
was given a FAM fluorescent label with a TAMRA quencher. Gene
expression was normalized by including Vic labelled primer-probe mix to
detect the 18s ribosomal subunit (sequence given in Table 5) as a loading
control for the amount of cDNA added in each sample.
Reaction mixes were loaded in duplicate onto a 96-well MicroAmp fast
optical reaction plate for analysis on an ABI7900 HT Fast Real-Time PCR
machine. Data were analysed and processed using sequence detector
version 1.6.3. Results were expressed as relative to a positive RNA
standard included in all reactions. The data were analysed using the
comparative Ct method for relative quantification.
6.2.4. Western immunoblot analysis
After lysis of PROKR1 Ishikawa cells in NP40 lysis buffer, protein
concentration of lysates was quantified by modified Bradford protein assay
kits as described in section 2.7. In order to examine COX-2 protein expression
40pg of protein was resuspended in Laemmli buffer (Section 2.12) and boiled
for 5 minutes to denature proteins. Proteins were resolved on a 4 - 20% SDS-
PAGE gradient gel and subsequently immunoblotted onto a PVDF membrane.
Non-specific antibody binding was prevented by incubation of the immunoblot
with low fluorescence blocking buffer for one hour (LiCor). Immunoblots were
subsequently exposed to specific antibodies for COX-2 (goat anti COX-2,
1:500) and the loading control (3-actin (goat anti (1-actin, 1:800) overnight at
4°C with gentle motion. The immunoblots were washed and exposed to a
fluorescently labelled antibody directed against goat immunoglobulin. Proteins
were visualised using a LiCor fluorescent scanner and densitometry analysis
performed using LiCor software. Immunoblots were quantified by dividing the
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value obtained for COX-2 by the value obtained for p-actin and expressing
these as fold above vehicle treated control.
6.2.5. Transient transfection of COX-2 promoter reporter luciferase constructs
and dominant negative isoforms of signalling molecules
6.2.5.1.Transient transfection of COX-2 luciferase promoter reporter
constructs
In order to examine the transcriptional regulation of COX-2 by PROK1 the
full length COX-2 luciferase promoter reporter construct was utilized
(described in Section 2.3). PROKR1 Ishikawa cells were seeded at a density
of 100,000 cells/well in a 12-well plate. 1.5 pg of the COX-2 promoter
reporter construct linked to firefly luciferase (described in section 2.3) was
co-transfected with 0.15pg of internal control pRL-TK into each well of
PROKR1 Ishikawa cells for 6 hours in the presence of Superfect
transfection reagent. The transfection mixture was removed and cells
incubated overnight in complete DMEM Glutamax cell culture media.
In order to investigate the temporal regulation of PROK1 mediated COX-2
promoter activation, PROKR1 Ishikawa cells were subjected to serum
starvation overnight followed by stimulation with 40nM PROK1 for 2, 4, 6
or 8 hours.
In order to investigate the signaling pathways involved in PROK1
mediated activation of the COX-2 promoter, the transfected cells were pre-
incubated with inhibitors of signaling molecules for one hour
(concentrations given in table 14) prior to stimulation with 40nM PROK1
for 6 hours.
Reactions were terminated by removal of agonist and the cells were washed
in ice-cold PBS. The cells were lysed in passive lysis buffer and processed
for COX-2 luciferase assay as described in Section 6.2.6.
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6.2.5.2.Co-transfection of COX-2 luciferase promoter reporter constructs
and dominant negative isoforms of signalling molecules
In order to examine the role of signalling molecules in PROK1 mediated
COX-2 promoter activation, PROKR1 Ishikawa cells were co-transfected
with the COX-2 luciferase promoter reporter construct and dominant
negative isoforms of signaling molecules. 1.5 p,g of the COX-2 promoter
reporter construct linked to firefly luciferase (described in section 2.3) was
co-transfected with 1.5 (rg of empty vector (pcDNA3) or DN-cSrc, DN-
EGFR, DN-Ras or DN-MEK with 0.15ng of internal control pRL-TK into
PROKR1 Ishikawa cells for 6 hours in the presence of Superfect
transfection reagent. The transfection mixture was removed and cells
incubated overnight in complete DMEM Glutamax cell culture media.
PROKR1 Ishikawa cells were subjected to serum starvation overnight
followed by stimulation with 40nM PROK1 for 6 hours. Reactions were
terminated by removal of agonist and the cells were washed in ice-cold
PBS. The cells were lysed in passive lysis buffer and processed for COX-2
luciferase assay as described in Section 6.2.6.
6.2.6. COX-2 luciferase assay
The activity of both COX-2 promoter firefly luciferase and renilla within cell
lysates was determined using the dual luciferase assay kit (Promega). Total
luciferase activity was determined by dividing the relative light units generated
by the firefly luciferase by relative light units generated by the renilla luciferase
in the same reaction. Fold increase in luciferase activity was calculated by
dividing the total luciferase activity in cells treated with PROK1 by the total
luciferase activity in cells treated with vehicle or transfected with empty vector.
6.2.7. Prostaglandin ELISA
PGE2 and PGF2a concentration in cell culture media following treatment with
40nM PROK1 was determined by ELISA. This has been described fully in
section 2.10.2. Briefly, PROKR1 Ishikawa cells were stimulated with 40nM
PROK1 alone or in the presence of lOfrM of the specific COX-2 inhibitor NS-
398 for 0, 2, 4, 6, 8, 12 or 24 hours. Arachidonic acid was added to a final
concentration of 3pg/ml 4 hours prior to the time point termination. For assay
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of PGF2„ the media was removed and frozen at -20°C prior to assay. In order
to stabilise PGE2 an equal volume of MOX was added to the culture medium
before storage at -20°C. Prostaglandin concentrations were subsequently
assayed by ELISA as described in section 2.10.
6.2.8. Statistics
Statistical analysis of the data in this study was carried out by ANOVA with
Fishers PLSD (predicted least squares difference) applied, using Statview 5.0
(Abacus Concepts). The data is presented as mean ± SEM of at least 3
experiments.
6.3. Results
6.3.1. Co-expression of PROKR1 and COX-2 in human endometrium and
first trimester decidua
As indicated in chapter 5, global gene array analysis suggests that expression
of COX-2 is under regulatory control of PROK1 via PROKR1. In order to
investigate the potential physiological regulation of COX-2 expression by
PROK1 in vivo, tissue localisation of COX-2 and PROK1 were examined by
fluorescent immunohistochemistry and confocal microscopy. Mid-secretory
phase endometrium and first trimester decidua tissue were examined for the
expression of PROKR1 and COX-2. Expression of COX-2 (red channel) and
PROKR1 (green channel) localized to the glandular epithelial cells and some
stromal cells of mid secretory endometrium and first trimester decidua (yellow
channel, Figure 6.1). The co-localisation of PROKR1 and COX-2 in the same
cellular compartment suggests potential regulation of COX-2 by PROK1-
PROKR1 interaction.




Figure 6.1. Co-localization of PROKR1 and COX-2 in endometrium and first trimester decidua.
Examination of PROKR1 (red channel) and COX-2 (green channel) expression in mid-secretory
endometrium and first trimester decidua by fluorescent immunohistochemistry and confocal
microscopy confirmed co-localisation of PROKR1 and COX-2 (yellow channel) in glandular
epithelial cells and some stromal cells.
6.3.2. Temporal regulation of PROK1 mediated COX-2 expression
6.3.2.1.Temporal regulation of PROK1 induced COX-2 RNA expression in
PROKR1 Ishikawa cells
PROK1-PROKR1 mediated regulation of COX-2 expression has been
demonstrated at 8 hours by global gene array analysis and validation of
expression at 8 hours (Chapter 5). In order to examine the temporal
regulation of PROK1 mediated COX-2 expression, WT and PROKR1
Ishikawa cells were treated with 40nM PROK1 for 0, 2, 4, 6, 8, 12 and 24
hours followed by Taqman quantitative PCR analysis for COX-2 mRNA
expression. PROK1 induced expression of COX-2 in PROKR1 Ishikawa
cells was rapid with elevation in expression evident at 2 hours. PROK1
induced COX-2 expression was maximal at 6 hours (6.9 ±1.2 fold above
vehicle treated control, p<0.01, Figure 6.2), which had declined to basal
levels by 24 hours. No elevation of COX-2 expression was revealed at any
time in WT Ishikawa cells treated with 40nM PROK1. This demonstrates
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that PROK1 induced expression of COX-2 mRNA is rapid with elevation





Figure 6.2. Temporal regulation of PROK1 mediated COX-2 RNA expression. PROKR1 and
WT Ishikawa cells were stimulated with 40nM PROK1 for 0, 2, 4, 6, 8, 12 and 24 hours.
COX-2 expression was assessed by Taqman quantitative PCR analysis. COX-2 expression
was normalized for loading against expression of 18s and relative to a single endometrium
control. Data are expressed as fold above vehicle treated control. WT Ishikawa cells are
represented by grey bars, PROKR1 Ishikawa cells are represented by black bars. COX-2
expression is rapidly elevated by PROK1 in PROKR1 Ishikawa cells and is maximal at 6
hours. No elevation in COX-2 expression is evident in WT Ishikawa cells at any time point
examined. Data are presented as mean ± SEM. (b is significantly different from a p<0.01).
NB. This figure was presented as part of composite figure 5.2 and has been reproduced here
for clarity and interpretation of relevant results within this section.
6.3.2.2.Temporal regulation of COX-2 protein expression in PROKR1
Ishikawa cells
Subsequently, the temporal regulation of PROK1 induced COX-2 protein
expression was investigated. PROKR1 Ishikawa cells were treated with
vehicle or 40nM PROKR1 for 2, 4, 6, 8, 12 and 24 hours and COX-2
expression determined by Western immunoblot analysis. COX-2 protein
expression was rapid with some expression evident at 2 - 4 hours. COX-2
protein expression peaked at 8 hours (9.59 ± 2.1 fold above vehicle treated
control, p<0.01, Figure 6.3) and had declined to basal levels by 24 hours.










































Figure 6.3. Temporal regulation of PROK1 induced COX-2 protein expression. PROKR1
Ishikawa cells were treated with 40nM PROK1 for 2, 4, 6, 8, 12 and 24 hours. Proteins were
extracted and 40^ig subjected to Western immunoblot analysis for COX-2 expression (COX-
2). The total amount of protein in cell lysates was determined by probing the same blot with
antibodies recognising (3-actin (actin). COX-2 expression was normalized for loading against
expression of actin. Data are expressed as fold above vehicle treated control. Grey bars
represent vehicle treated cells, v, black bars represent PROK1 treated cells, p. PROK1
mediated COX-2 protein expression is maximal at 8 hours in response to 40nM PROK1 in
PROKR1 Ishikawa cells. A representative Western immunoblot is shown with semi¬
quantitative densitometric analysis. Data are presented as mean ± SEM. (b is significantly
different from a p<0.01).
6.3.3. Mechanism of PROK1 mediated COX-2 expression
6.3.3.1. PROK1 mediated COX-2 expression is partially transcriptionally
regulated
There is evidence to suggest that COX-2 expression may be only
partially transcriptionally regulated. A report in 2000 revealed that
activation of Gq coupled P2Y nucleotide receptors induced
approximately 137 fold elevation in rat COX-2 expression by one hour.
Chapter 6 PR0K1-PR0KR1 mediated COX-2 expression 194
However, transcriptional induction only accounted for about 3-fold of
this value (Xu et al, 2000). The paper provided strong evidence for
partial transcriptional regulation and partial transcription stabilisation.
This may be the case for COX-2 expression in other systems. In order to
investigate PROK1 induced transcriptional regulation of COX-2
expression, Actinomycin D, a powerful inhibitor of transcriptional
activity, was used. PROKR1 Ishikawa cells were treated with 40nM
PROK1 for 4, 6 and 8 hours in the presence or absence of 250ng/ml
Actinomycin D. PROK1 induced expression of COX-2 was maximal at
6 hours (Figure 6.4). At this time point, treatment with Actinomycin D
reduced PROK1 induced COX-2 expression to about 50% of its
maximal value (Figure 6.4, p<0.05). These data suggest that PROK1
induced expression of COX-2 is partially under transcriptional control













Figure 6.4. Inhibition of PROK1 induced transcriptional activation of COX-2. PROKR1
Ishikawa cells were treated with 40nM PROK1 alone or in the presence of Actinomycin D for
4, 6, and 8 hours. COX-2 expression was assessed by Taqman quantitative PCR analysis.
COX-2 expression was normalized for loading against expression of 18s and relative to a
single endometrial control. Data are expressed as fold above basal levels. Upon treatment of
PROKR1 Ishikawa cells with 40nM PROK1, COX-2 expression is maximal at 6 hours. This is
inhibited to about 50% of the maximal value by Actinomycin D suggesting that PROK1
induced COX-2 expression is partially transcriptionally activated. + denotes presence of
agent, - denotes absence of agent. Data presented as mean ± SEM (b is significantly
different from a p<0.05).
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6.3.3.2. Mechanism of PROK1 mediated transcriptional activation
In order to investigate PROK1 induced transcriptional up-regulation of
COX-2, PROKR1 Ishikawa cells were transfected with the full-length
COX-2 luciferase promoter reporter construct. Initially the effect of
PROK1 on the temporal regulation of COX-2 transcriptional activation
was investigated. PROKR1 Ishikawa cells, transfected with the COX-2
luciferase promoter reporter construct, were treated with 40nM PROK1
for 0, 2, 4, 6 and 8 hours. Luciferase assay revealed PROK1 induced
activity driven by the COX-2 promoter, to be maximal at 6 - 8 hours
(Figure 6.5 A, COX-2 promoter, p<0.05). Therefore all subsequent work
examining PROK1 induced transcriptional activation was performed at
6 hours. There is a risk of non-specific luciferase promoter activity
when the PGL3 vector is used due to the structure of this vector. In
order to rule out non-specific activation, PROKR1 Ishikawa cells were
transfected with the empty PGL3 vector and treated with 40nM PROK1
for 0, 2, 4, 6 and 8 hours. Treatment of empty vector transfected
PROKR1 cells with 40nM PROK1 revealed no increase in luciferase
activity over vehicle treated controls at any time. These data suggest
the results would not be confounded by inaccuracies arising from non¬
specific stimulation (Figure 6.5 A, PGL3 basic).
In order to investigate the signalling pathway regulating PROK1
mediated COX-2 promoter activation, PROKR1 Ishikawa cells were
transfected with the full length COX-2 luciferase promoter reporter
construct and treated with 40nM PROK1 alone or in the presence of
chemical inhibitors of Gq protein, PLC-|3, Ca2+(calcium chelator), cSrc,
EGFR and MEK for 6 hours. 40nM PROK1 induced a 2.05±0.11 fold
increase in COX-2 transcriptional activity (Figure 6.5 B, p<0.01). This
was inhibited following co-treatment with PROK1 and Gq inhibitor
(Figure 6.5 B, lane 3), PLC-|3 inhibitor (Figure 6.5 B, lane 4) Ca2+
inhibitor (Figure 6.5 B, lane 5), cSrc inhibitor (Figure 6.5 B, lane 6) EGFR
inhibitor (Figure 6.5 B, lane 7) and MEK inhibitor (Figure 6.5 B, lane 8).














Figure 6.5. PROK1 mediated transcriptional activation of COX-2. A. PROKR1 Ishikawa
cells were co-transfected with the luciferase vector PGL3 basic or the full length COX-2
promoter firefly luciferase reporter with internal control pRL-TK (renilla). Transfected
PROKR1 Ishikawa cells were stimulated with 40nM PROK1 for 0, 2, 4, 6 and 8 hours.
COX-2 promoter activation was assessed by luciferase assay analysis. B. PROKR1
Ishikawa cells were co-transfected with full-length COX-2 promoter firefly luciferase
reporter and internal control pRL-TK (renilla). Transfected cells were stimulated with
40nM PROK1 alone or in the presence of inhibitors of Gq protein (YM254890), PLC-|3
(U73122), Ca2+ (BAPTA-AM), cSrc (PP2), EGFR (AG1478) or MEK (PD98059) for 6
hours. COX-2 promoter activation was assessed by luciferase assay analysis. COX-2
luciferase activity was normalised against renilla luciferase activity. Data are presented
as fold above vehicle treated control. COX-2 promoter activation is elevated at 4 hours in
PROKR1 Ishikawa cells transfected with the full length COX-2 promoter reporter
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luciferase construct, and peaks at 6 - 8 hours. Co-treatment of PROKR1 Ishikawa cells
transfected with the full length COX-2 promoter reporter luciferase construct with 40nM
PROK1 and chemical inhibitors significantly inhibited maximal PROK1 induced COX-2
promoter activation at 6 hours. + denotes presence of agent, - denotes absence of
agent. Data are presented as mean ± SEM (b is significantly different from a p<0.05).
6.3.3.3. Effect of dominant negative isoforms of signalling molecules on
PROK1 mediated COX-2 transcriptional activation
In order to confirm the role suggested by the use of chemical inhibitors
of signalling molecules on PROK1 mediated transcriptional activation
of COX-2, dominant negative constructs of cSrc, EGFR, MEK and the
small monomeric G-protein Ras were employed. PROKR1 Ishikawa
cells were co-transfected with the full length COX-2 promoter and
empty vector or dominant negative cDNA encoding cSrc, EGFR, Ras
and MEK mutants. Transfected PROKR1 Ishikawa cell were then
stimulated with 40nM PROK1 for 6 hours inducing a 1.78±0.19 fold
increase in COX-2 transcriptional activity (Figure 6.6, lane 2, p<0.01) in
empty vector transfected cells. PROK1 mediated elevation in COX-2
transcriptional activity at 6 hours was reduced to almost basal levels
by co-expression of dominant negative constructs encoding mutants of
cSrc (Figure 6.6, lane 4), EGFR (Figure 6.6, lane 5), Ras (Figure 6.6, lane
6) and MEK (Figure 6.6, lane 7). This further implicates the activation
of cSrc, EGFR, Ras, MEK by PROK1 in the transcriptional activation of
COX-2.


































Figure 6.6. PROK1 mediated transcriptional activation of COX-2 is dependent on
activation of multiple signalling molecules. PROKR1 Ishikawa cells were co-transfected
with full-length COX-2 promoter firefly luciferase reporter along with dominant negative
cDNA constructs encoding mutants of cSrc, EGFR, Ras or MEK and internal control
pRL-TK (renilla). Transfected cells were stimulated with 40nM PROK1 for 6 hours. COX-
2 promoter activation was assessed by luciferase activity analysis. COX-2 luciferase
activity was normalised against renilla luciferase activity. Data are expressed as fold
above vehicle treated control. Expression of dominant negative isoforms of signalling
molecules in PROKR1 Ishikawa cells transfected with the full length COX-2 promoter
reporter luciferase construct significantly inhibited the maximal PROK1 induced COX-2
promoter activation at 6 hours. + denotes presence of agent, - denotes absence of
agent. Data are presented as mean + SEM (b is significantly different from a p<0.01).
6.3.3.4.Mechanism of PROK1 mediated COX-2 RNA expression
Transcriptional activity of COX-2 has been demonstrated as dependent
on activation of multiple signalling molecules. In order to examine how
this affected RNA expression, PROKR1 Ishikawa cells were treated
with 40nM PROK1 alone or in the presence of inhibitors of Gq protein,
PLC-|3, Ca2+ (calcium chelator), cSrc, EGFR and MEK. Treatment of
PROKR1 Ishikawa cells with 40nM PROK1 for 6 hours induced an
11.76±1.93 fold increase in COX-2 RNA expression (Figure 6.7, lane 2,
p<0.01), which was reduced by treatment with inhibitors of PLC-fl
(Figure 6.7, lane 4), Ca2+(Figure 6.7, lane 5), cSrc (Figure 6.7, lane 6),
EGFR (Figure 6.7, lane 7) and MEK (Figure 6.7, lane 8). However,
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treatment with the Gq protein inhibitor reduced COX-2 expression to
basal levels (Figure 6.7, lane 8).
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Figure 6.7. PROK1 mediated COX-2 RNA expression is dependent on activation of
multiple signalling molecules. PROKR1 Ishikawa cells were treated with 40nM PROK1 in
the presence or absence of chemical inhibitors of Gq protein (YM254890), PLC-|3
(U73122), Ca2+ (calcium chelator BAPTA-AM), cSrc (PP2), EGFR (AG1478) or MEK
(PD98059) for 6 hours. COX-2 expression was assessed by Taqman quantitative PCR
analysis. COX-2 expression was normalized for loading against expression of 18s and
relative to an internal endometrial control. Data are expressed as fold above vehicle
treated control. Co-treatment with 40nM PROK1 and chemical inhibitors significantly
inhibited the maximal PROK1 induced COX-2 expression at 6 hours. + denotes
presence of agent, - denotes absence of agent. Data are presented as mean ± SEM. (b
is significantly different from a p<0.01).
6.3.3.5. Mechanism of PROK1 mediated COX-2 protein expression.
In order to examine the impact of signalling molecule activation on
PROK1 induced COX-2 protein expression, PROKR1 Ishikawa cells
were treated with 40nM PROK1 for 8 hours alone or in the presence of
inhibitors of Gq protein, PLC-|3, Ca2+ (calcium chelator), cSrc, EGFR
and MEK. Treatment of PROKR1 Ishikawa cells with 40nM PROK1 for
8 hours induced an 11.65 ± 2.04 fold increase in COX-2 protein
expression (p<0.001, Figure 6.8, lane 2). PROK1 mediated COX-2
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protein expression was significantly reduced by co-treatment of
PROKR1 Ishikawa cells with PROK1 and inhibitors of Gq protein
(Figure 6.8, lane 3), PLC-|3 (Figure 6.8, lane 4), Ca2+ (Figure 6.8, lane 5),
cSrc (Figure 6.8, lane 6), EGFR (Figure 6.8, lane 7) and MEK (Figure 6.8,
lane 8). These data correspond with that obtained from investigation of

































Figure 6.8. PROK1 mediated COX-2 protein expression is dependent on activation of
multiple signalling molecules. PROKR1 Ishikawa cells were treated with 40nM PROK1 in
the presence or absence of chemical inhibitors of Gq protein (YM254890), PLC-(3
(U73122), Ca2+ (calcium chelator BAPTA-AM), cSrc (PP2), EGFR (AG1478) or MEK
(PD98059) for 8 hours. Proteins were extracted and 40fig subjected to Western
immunoblot analysis for COX-2 (COX-2). The total protein content of cell lysates was
determined by probing the same blot with antibodies recognising (3-actin (actin). COX-2
expression was normalized for loading against expression of actin. Data are expressed
as fold above vehicle treated controls. Co-treatment with 40nM PROK1 and chemical
inhibitors significantly inhibited the maximal PROK1 induced COX-2 expression at 8
hours. A representative Western immunoblot is shown with semi-quantitative
densitometric analysis. + denotes presence of agent, - denotes absence of agent. Data
are presented as mean ± SEM. (b is significantly different from a p<0.001).
Chapter 6 PROK1-PROKR1 mediated COX-2 expression 201
6.3.4. De novo synthesis of prostaglandins mediated by PROK1
COX-2 is the rate-limiting enzyme in production of prostaglandins. As PROK1
induces expression of COX-2 protein, it was therefore of interest to determine
whether this resulted in prostaglandin synthesis. PROKR1 Ishikawa cells were
stimulated with 40nM PROK1 for 0, 2, 4, 6, 8, 12 and 24 hours in the presence
of 3pg/ml arachidonic acid in order to facilitate prostaglandin production. At
the designated times, media was removed and assayed for PGE2 and PGF2a
concentrations. PROK1 stimulated production of PGE2 and PGF2,, in a time
dependent manner with production of both prostaglandins initiated at 6 hours
and reaching maximal concentrations by 12 hours (15.28 ± 2.9 and 5.29 ± 0.5
fold above vehicle treated control for PGE2 and PGF2„ respectively, p<0.001,
Figure 6.9 A and B).
6.3.4.1.PROK1 mediated prostaglandin synthesis is dependent on COX-2
expression
In order to investigate the role of PROK1 induced COX-2 expression in
PROK1 mediated prostaglandin production, PROKR1 Ishikawa cells were
treated with 40nM PROK1 in the absence or presence of the specific COX-2
inhibitor NS-398 for 0, 2, 4, 6, 8, 12 and 24 hours with the addition of
3pg/ml arachidonic acid in order to facilitate prostaglandin production.
Co-treatment of PROKR1 Ishikawa cells with PROK1 and NS-398
significantly reduced PROK1 induced prostaglandin production at all time
points examined. This suggests that PROK1 mediated de novo synthesis of
prostaglandins is initiated via the expression of COX-2 (Figure 6.9 A and B
for PGE2 and PGF2a respectively).


































Figure 6.9. PROK1 induced de novo synthesis of prostaglandins in PROKR1 Ishikawa cells.
PROKR1 Ishikawa cells were treated with 40nM PROK1 for 0, 2, 4, 6, 8, 12 and 24 hours in
the presence or absence of specific COX-2 inhibitors with the addition of 3[xg/ml arachidonic
acid. Prostaglandin concentration in cell culture media was measured by ELISA. Data are
expressed as fold above vehicle treated control. PROK1 mediated synthesis of PGE2 (A) and
PGF2a (B) was maximal at 12 hours and was reduced to basal levels by co-treatment with
NS-398 at all time points examined. Data are presented as mean ± SEM. (b is significantly
different from a p<0.001).
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6.4. Discussion
PROK1 is elevated during the secretory phase of the menstrual cycle with
further elevation of both PROK1 and PROKR1 in the human early pregnancy
endometrium. In this study the regulation of COX-2 expression by PROK1,
suggested by gene array analysis of PROKR1 Ishikawa cells treated with 40nM
PROK1 for 8 hours, was further confirmed. Expression of PROKR1 and COX-2
in secretory phase endometrium and pregnant endometrium (first trimester
decidua) localize to the glandular epithelial cells and some cells of the stromal
compartment. This may suggest a potential physiological regulation of COX-2
expression by PROK1 in these cellular compartments in vivo. COX-2
expression induced by PROK1 via PROKR1 is temporally regulated with
elevation in RNA expression noted at 2 hours, and a peak in PROK1 induced
COX-2 RNA expression at 6 hours. No elevation in COX-2 expression was
noted in WT Ishikawa cells at any time point investigated. This implies that,
as PROKR1 expression is low in these cells, PROK1 induced expression of
COX-2 occurs exclusively via activation of PROKR1. Elevation of COX-2
protein expression was also observed from 4 hours, with a peak in protein
expression at 8 hours. This suggests that, from 4 hours, PROK1 induced COX-
2 protein is available to initiate prostaglandin synthesis.
It is of interest to determine the transcriptional activation of COX-2 by PROK1
as COX-2 mRNA expression has been previously demonstrated to be
dependent partially on transcription and partially on stabilisation of the
mRNA (Xu K et al, 2000, Lasa et al, 2000, Mifflin et al, 2004). Use of a
promoter reporter construct containing the full length COX-2 promoter
sequence linked to firefly luciferase revealed maximal transcriptional
activation of COX-2 expression by PROK1 at 6 hours. However, an increase in
COX-2 transcription of around 2 fold was observed, compared with an
increase in COX-2 mRNA expression of approximately 7-fold. Although these
two values are not directly related, the observation suggests that PROK1
mediated control of COX-2 expression is not completely transcriptionally
regulated. Incubation of PROKR1 Ishikawa cells with 40nM PROK1 in the
presence of Actinomycin D, a powerful transcriptional inhibitor, revealed
around a 40 - 50% reduction in COX-2 mRNA expression. These data indicate
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that PROK1 mediated expression of COX-2 is not completely transcriptionally
controlled and stabilisation of COX-2 mRNA may play a role in PROK1
mediated COX-2 expression.
Gene expression is widely recognised to be regulated by up-stream activation
of protein kinase cascades (Su & Karin, 1996). Activation of MAPK signalling
positively regulates the activities of a number of transcriptional factors (Hill &
Treisman, 1995) and post transcriptional control mechanisms (Nair et al,
1994). In addition, activation of protein phosphorylation cascades has been
demonstrated to activate COX-2 expression (Xu et al, 2007, Eckert et al, 2007).
In Chapter 4 it was demonstrated that PROK1 mediated transient
phosphorylation of cSrc, EGFR, ERK 1/2, and activation of ERK 1/2
phosphorylation was dependent on phosphorylation of cSrc and EGFR. In
order to investigate if PROK1 induced expression of COX-2 was dependent on
activation of protein phosphorylation cascades, chemical inhibitors and
dominant negative isoforms of signalling molecules were employed. PROK1
mediated COX-2 promoter activity at 6 hours was inhibited by chemical
inhibitors of Gq, PLC-(3, Ca2+, cSrc, EGFR or MEK, or co-transfection with
dominant negative mutant isoforms of cSrc, EGFR, Ras or MEK. These data
suggested that transcriptional activation of COX-2 by PROK1 is dependent on
activation of protein phosphorylation cascades leading to phosphorylation of
ERK 1/2. However, examination of the effect of chemical inhibitors on PROK1
induced COX-2 mRNA expression at 6 hours revealed that only the Gq
inhibitor inhibited PROK1 induced COX-2 mRNA expression to basal levels.
Inhibitors of PLC-|3, Ca2+, cSrc, EGFR and MEK significantly inhibited COX-2
expression but not to basal levels. These data may imply that activation of the
receptor is necessary but PROK1 may induce other signalling phosphorylation
cascades (e.g. Other MAPK's such as p38 and JNK) in signalling to COX-2.
Investigation of COX-2 protein expression revealed a significant inhibition of
PROK1 induced COX-2 protein expression at 8 hours upon treatment of
PROKR1 Ishikawa cells with 40nM PROK1 in the presence of inhibitors of Gq,
PLC-|3, Ca2+, cSrc, EGFR and MEK. These data indicate that activation of
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protein phosphorylation cascades by PROK1 via PROKR1 are important in
mediating PROK1 induced COX-2 protein expression.
Stimulation of PROKR1 Ishikawa cells with 40nM PROK1 induced de novo
synthesis of PGE2 and PGF2„with maximal synthesis of both prostaglandins at
12 hours. PROK1 induced synthesis of prostaglandins occurred specifically via
COX-2 as incubation of PROK1 treated PROKR1 Ishikawa cells with the
specific COX-2 inhibitor NS-398 inhibited the prostaglandin production to
basal levels at all time points investigated.
Prostaglandins, the bioactive products of COX-2 metabolism of arachidonic
acid, are suggested to be involved in the events of early pregnancy such as
decidualisation, vascular permeability and placentation (Cheng and Stewart,
2003, Matsumoto et al, 2002). The COX-2 null mouse, in contrast to previous
reports (Lim et al, 1997), does support blastocyst implantation. However,
implantation in the null mice was delayed by approximately 24 hours, with a
corresponding reduction in decidual weights and delay in parturition of pups
by approximately 24 hours compared with WT mice (Cheng and Stewart,
2003). Although these studies reported differential outcomes in the absence of
COX-2 epression, this may be due to different genetic backgrounds. It has been
reported that COX-2 null mice on a CD-I background demonstrate elevated
implantation rates compared to mice on a C57BL/6J/129 background due to
up-regulation of COX-1 expression. These data may help explain the
differences between the two studies.
In the uterus of the COX-2 null mouse, administration of stable analogues of
PGI2 have been demonstrated to rescue the decidualisation defect (Lim et al,
1997). However, while PGI2 is the main prostaglandin in the mouse uterus
during early pregnancy, the human endometrium produces little PGI2 (Abel &
Kelly, 1979). PGE2 is suggested to be of more importance in the human and
has been demonstrated to induce decidualisation of human endometrial
stromal cells (Dimitriadis et al, 2005, Frank et al, 1994). The decidualization
response induced by PGE2 is suggested to take place via induction of cAMP
production (Kennedy et al, 1982, Houserman et al, 1989). Therefore the
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elevation of COX-2 and PGE2 production by PROK1 may be important in
regulating decidualisation in early pregnancy in humans. Indeed, the
prostaglandins which induce the decidualisation response appears to vary
considerably among different species (Lim et al, 1999, Pakrasi, 1997, Evans &
Kennedy, 1978, Wang et al, 2004, Kennedy, 1977, Kennedy & Zamecnik 1978).
Initiation of implantation is always associated with an increase in
adhesiveness of the epithelium and an increase in vascular permeability. This
is associated with an increase in COX-2 expression (Chakraborty et al, 1996),
along with expression of PGE synthase, PGE2 and EP receptors at the
implantation site (Shi et al, 2005, Wang et al, 2004, Ni et al, 2002). COX-2 null
mice however display a reduced vascular permeability at the implantation site
compared to WT mice (Matsumoto et al, 2002), potentially associated with a
deficiency in PGE2 influenced uterine angiogenesis (Wang and Dey, 2006).
Again, via induction of COX-2 and PGE2 production in the uterus, PROK1
may regulate this increased permeability and direct physiological blood vessel
development at the implantation site. Indeed, as has been demonstrated in
Chapter 3, PROKR1 is expressed on endothelial cells potentially providing a
site for the direct action of PROK1 on the endothelium.
COX-2 is expressed in the human endometrium with localisation to the
luminal and glandular epithelium in the secretory phase of the menstrual cycle
(Jones et al, 1997, Stavreus-Evers et al, 2005). COX-2 is also specifically
localised to the luminal epithelium and underlying stroma on day 4 of
pregnancy in the mouse, spreading to the primary decidual zone by day 5 of
pregnancy (Song et al, 2000). This expression pattern in the mouse and human
supports a role for COX-2 in implantation and decidualisation. It is also
suggested that COX-2 expression at the mesometrial pole on day 6 of
pregnancy in mice may be important in producing prostaglandins involved in
angiogenesis and placenta formation (Chakraborty et al, 1996). Indeed, COX-2
can induce expression of VEGF (Joo et al, 2003), and this has been further
demonstrated in the mouse at the time of implantation (Matsumoto et al,
2002).
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Another indicator that COX-2 derived prostaglandins are important in
implantation and decidualisation is the observation that the prostaglandin
inhibitor indomethacin inhibits implantation in rodents (Sookvanichsilp et al,
2002, Shafiq et al, 2004). Indeed, initial studies performed using non-steroidal
anti-inflammatory drugs, which were subsequently identified as inhibitors of
prostaglandin synthesis, reported a reduction in edema at the implantation
site (Horan et al, 1971). Many studies have since elaborated on the role of
COX-2 derived prostaglandins in implantation and decidualisation (Biggers et
al, 1981, Kennedy et al, 1990). It has also been reported that prolonged
administration of COX inhibitors reduces fertility in humans (Pall et al, 2001,
Norman & Wu, 2004, Schnitzer et al, 2001).
In the human the risk of early pregnancy loss increases as a function of
delaying implantation outside the normal window of the receptive
endometrium and may result in formation of a defective feto-placental unit
(Red Horse et al, 2004, Wilcox et al, 1999). This may be due to deficient
endometrial expression of certain gene products required for implantation,
decidualisation and early pregnancy events outside the normal window of
receptivity. As COX inhibitors appear to have detrimental effect on human
fertility (Pall et al, 2001) one of these products may be COX-2 and COX-
derived prostaglandins. The parallels with human implantation may be drawn
with the delayed implantation observed in the COX-2 null mouse (Cheng and
Stewart, 2003) with an associated reduction in decidual weights and a delay in
parturition. Expression of COX-2, prostaglandins and appropriate
prostaglandin receptors in the human endometrium may therefore be essential
for correct 'on-time' implantation (Song et al, 2000).
In conclusion, this chapter has highlighted the temporal regulation and
mechanism of activation of COX-2 via PROK1-PROKR1 interaction.
Expression of COX-2 and downstream prostaglandins, with known roles in
implantation and decidualisation, are induced by PROK1 via a PLC-(3 - Ca2+ -
cSrc - EGFR - MEK mediated pathway.
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Chapter 7 — Prokineticin 1 regulation of LIF expression in PROKR1 Ishikawa
cells
7.1. Introduction
In Chapter 5 it was demonstrated that PROK1 elevated expression of leukaemia
inhibitory factor (LIF) in PROKR1 Ishikawa cells. LIF expression in the
endometrium is suggested to be essential for pregnancy (Stewart et al, 1992).
LIF is a pleiotropic cytokine present in many tissues within the human body
(Hilton & Gough, 1991, Schafer-Somi, 2003) and is required for diverse functions
including neuronal differentiation and maintenance, osteoblast formation and
hemopoiesis. LIF is a highly glycosylated protein of 40-50kDa and is a member of
the IL-6 family of cytokines along with oncostatin M (OsM), ciliary neurotrophic
factor (CNTF), cardiotrophin-1 (CT-1) and IL-11 (Callard, 1994). These cytokines
signal through heterodimerisation of their own receptors with the common
receptor gpl30. LIF binds to its own receptor with relatively low affinity; however
heterodimerisation with gpl30 forms a high affinity receptor complex and LIF
signalling is initiated (Heinrich et al, 2002). LIF, also known as interleukin for DA
cells (murine IL-3 sensitive cell line), was originally identified via its induction of
differentiation in the Ml myeloid leukaemia cell line and its inhibition of
differentiation of embryonic cell lines (Hilton et al, 1992, Smith et al, 1988).
Expression of LIF can be detected in the mouse uterus on day 1 of pregnancy. This
expression then disappears, followed by maximal expression in the endometrial
glandular cells following the burst of nidatory estrogen on day 4 of pregnancy.
However, by day 5 LIF expression has again declined (Bhatt et al, 1991).
Examination of pseudopregnant mice revealed the same pattern of expression,
suggesting that endometrial LIF expression is under maternal control rather than
under the influence of the blastocyst (Bhatt et al, 1991). In the LIF null mouse
model it has been demonstrated that endometrial LIF is essential to implantation
(Stewart et al, 1992). In contrast to the mouse, LIF expression in the human
endometrium is not dependent on a burst of estrogen. The mRNA and protein
expression and localization of LIF in the human endometrium across the
menstrual cycle have been extensively examined. It has been reported that mRNA
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expression of LIF is low in the proliferative phase of the menstrual cycle which
then rises to peak in the mid-late secretory phase of the menstrual cycle (Arici et
al, 1995, Vogiagis et al, 1996, Charnock-Jones et al, 1994, Kojima et al, 1994). LIF
protein is detectable only in the mid-late secretory phase of the menstrual cycle
and localises to the luminal and glandular epithelial cells (Charnock-Jones et al,
1994, Vogiagis et al, 1996, Cullinan et al, 1996). The mid secretory phase of the
menstrual cycle is described as the 'window of implantation' (Psychoyos, 1973).
This is the stage of the menstrual cycle when the endometrium becomes receptive,
by a number of morphological and molecular mechanisms, to implantation of a
blastocyst. Production of LIF from endometrial explants also appears to display
elevation in the secretory phase of the menstrual cycle (Laird et al, 1997, Delage et
al, 1995). This production of LIF continues into early pregnancy with LIF
measured in explants of the decidualized endometrium of the first trimester of
pregnancy (Hambartsoumian, 1998b, Ren et al, 1997).
A role for LIF in uterine receptivity has clearly been suggested by the LIF null
mouse model and the expression pattern in the human endometrium. A number
of factors, including IL-1, TGF-p, EGF and hCG have been shown to induce
expression of LIF (Arici et al, 1995, Perrier d'Hauterive et al, 2004, Licht et al,
2001). In chapter 5, LIF was identified as a target gene for PROK1. This study
was therefore designed to investigate the temporal regulation and mechanism of
LIF expression induced by PROK1 in PROKR1 Ishikawa cells.
7.2. Materials and methods
7.2.1. Immunofluorescent histochemistry and confocal microscopy
Co-localization of PROKR1 with LIF was performed by dual
immunofluorescence immunohistochemistry on endometrial tissue or first
trimester decidua. Sections (5pM) were dewaxed in xylene and rehydrated
using decreasing concentrations of ethanol. Antigen retrieval was performed
for 5 minutes in a pressure cooker in boiling 0.1% citrate buffer (Ph 6.0).
Endogenous peroxidase activity was quenched with 3% (vol/vol) H2O2 in
methanol at room temperature. Normal horse serum block (5% serum in Tris-
buffered saline with 0.05% BSA) was applied for one hour before overnight
Chapter 7 PROK1-PROKR1 mediated LIF expression 210
incubation at 4°C with goat anti-LIF antibody at 1:50 or goat IgG for control
sections. Sections were washed in PBS, LIF treated sections were incubated
with biotinylated horse anti goat, followed by washing in PBS and incubation
with the fluorochrome Streptavidin 546 (red) diluted 1:200 in PBS. Sections
were re-blocked with 5% normal goat serum block diluted in PBS and
incubated with rabbit anti-human PROKR1 (1:500) overnight at 4°C. Control
sections were incubated with rabbit IgG. Sections were washed in PBS and
incubated with peroxidase goat anti-rabbit, 1:200 in PBS, followed by washing
in PBS and incubation with the fluorochrome TSA plus Fluorescein (green) at
1:50 in substrate provided with the kit. Sections were washed in PBS and then
incubated with the nuclear counterstain ToPro diluted 1:2000 in PBS. Sections
were mounted in Permafluor and coverslipped, and fluorescent images were
□emodellin using a laser-scanning confocal microscope (LSM 510, Carl Zeiss,
Jena, Germany) with a 40 x 1.4 aperture oil immersion lens.
7.2.2. Cell culture and treatments
7.2.2.1.Time course analysis of PROK1 mediated LIF expression
In order to examine the temporal regulation of LIF by PROK1, PROKR1 or
WT Ishikawa cells were treated with 40nM PROK1 or vehicle for 0, 2, 4, 6,
8, 12 or 24 hours. Cells were subsequently lysed in TRI-reagent, followed
by RNA extraction and processing for Taqman quantitative PCR analysis
(described in Section 7.2.3)
7.2.2.2. Mechanism of PROK1 mediated LIF expression
In order to examine the signalling pathway activation leading to PROK1
mediated LIF expression, PROKR1 Ishikawa cells were preincubated with
chemical inhibitors of Gq protein (YM254890), PLC-(5 (U73122), Ca2+
(calcium chelator, BAPTA-AM), cSrc (PP2), EGFR kinase (AG1478) or
MEK (PD98059; concentrations of inhibitors given in Table 15). PROKR1
Ishikawa cells were subsequently stimulated with vehicle or 40nM PROK1
for 6 hours alone or in the presence of the aforementioned signalling
inhibitors.
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In order to determine if PROK1 mediated LIF expression was
transcriptionally activated, PROKR1 Ishikawa cells were preincubated with
an inhibitor of transcriptional activation (Actinomycin D, 250ng/ml).
PROKR1 Ishikawa cells were treated with 40nM PROK1 for 4, 6 or 8 hours
in the presence or absence of Actinomycin D.
Cells were subsequently lysed in TRI-reagent, followed by RNA extraction
and processing for Taqman quantitative PCR analysis as described in
Section 7.2.3.
Table 15. Inhibitor concentrations
Inhibitor Molecule Inhibited Inhibitor concentration
YM254890 Gq protein lpM





Actinomycin D Transcriptional activation 250ng/ml
7.2.3. Taqman quantitative PCR
7.2.3.1. RNA extraction
RNA was extracted using TRI-reagent and the phenol-chloroform method
of RNA extraction as described in section 2.5. Briefly, cells were lysed in
TRI-reagent and a homogenous lysate achieved by mixing by pipetting.
Lysed samples were then loaded into heavy gel phase lock tubes with the
addition of bromo-chloro propane. Tubes were shaken vigorously to ensure
adequate mixing of the two solutions. Samples were then processed as
described in section 2.5.
7.2.3.2. Taqman quantitative PCR
Expression of RNA within cultured cells was examined by Taqman
quantitative PCR analysis as described in section 2.5. Briefly, cDNA was
prepared in a random hexamers primed reaction using 200ng per reaction.
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Quantitative PCR analysis was performed on the cDNA using specific
primer probe combinations to detect LIF (sequence given in Table 5), these
were designed in house and custom synthesised. The probe was given a
FAM fluorescent label with a TAMRA quencher. Gene expression was
normalized by including primer-probe mix, which was Vic labelled, to
detect the 18s ribosomal subunit (sequence given in Table 5) as a loading
control for the amount of cDNA added in each sample.
Reaction mixes were loaded in duplicate onto a 96-well MicroAmp fast
optical reaction plate for analysis on an ABI7900 HT Fast Real-Time PCR
machine. Data were analysed and processed using sequence detector
version 1.6.3. Results were expressed as relative to a positive RNA
standard included in all reactions. The data were analysed using the
comparative Ct method for relative quantification.
7.2.4. LIF ELISA
The LIF ELISA has been fully described in section 2.10. In order to examine the
temporal regulation of PROK1 mediated LIF protein production, PROKR1
Ishikawa cells were treated with vehicle or 40nM PROK1 for 0, 2, 4, 6, 8, 12
and 24 hours. Medium was removed and frozen until assay. LIF concentration
was calculated by constructing a standard curve using LIF standards of
known concentration. Cell culture samples were expressed as pg/ml as no LIF
secretion was detected in vehicle treated control samples.
7.2.5. Statistics
Statistical analysis of the data in this study was carried out by ANOVA with
Fishers PLSD (predicted least squares difference) applied, using Statview 5.0
(Abacus concepts). The data are presented as mean ± SEM of at least 3
experiments.
Chapter 7 PR0K1-PR0KR1 mediated LIF expression 213
7.3. Results
7.3.1. Co-expression of PROKR1 and LIF in human endometrium and first
trimester decidua
Gene array analysis suggests that expression of endometrial LIF may be under
the regulatory control of PROK1 via PROKR1. In order to investigate the
potential physiological regulation of LIF expression by PROK1 in vivo, tissue
localisation of LIF and PROKR1 were examined by fluorescent
immunohistochemistry and confocal microscopy. Mid-secretory phase
endometrium and first trimester decidua tissue was examined for the
expression of PROKR1 and LIF. Expression of LIF (red channel) and PROKR1
(green channel) were localized to the glandular epithelial cells and some
stromal cells of the mid secretory endometrium and first trimester decidua
(yellow channel, Figure 7.1). LIF expression has been previously demonstrated
in the glandular epithelial cells and sub-luminal stroma on day 4 of pregnancy
(Fouladi - Nashta et al, 2005, Sengupta et al, 2003, Song et al, 2000). These
data suggest that PROK1 - PROKR1 may regulate LIF expression within these




Figure 7.1. Co-localization of PROKR1 and LIF in mid-secretory endometrium and first trimester
decidua tissue. Examination of PROKR1 and LIF expression in mid-secretory endometrium and
first trimester decidua confirmed co-localisation of PROKR1 (green channel) and LIF (red
channel) in glandular epithelial cells of mid-secretory endometrium and first trimester decidua and
decidualized stromal cells of first trimester decidua (yellow channel).
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7.3.2. Temporal regulation of PROK1 induced LIF expression
7.3.2.1.Temporal regulation of PROK1 induced LIF mRNA expression
Regulation of LIF expression by PROK1 via PROKR1 has been
demonstrated by global gene array analysis (section 5.3), and elevation of
LIF expression at 8 hours has been independently verified (section 5.3).
However, in order to investigate the temporal regulation of LIF RNA
expression by PROK1, and therefore elucidate the time of maximal PROK1
induced LIF expression, PROKR1 and WT Ishikawa cells were stimulated
with 40nM PROK1 or vehicle for 0, 2, 4, 6, 8, 12 and 24 hours. RNA was
extracted and LIF RNA expression examined by Taqman quantitative PCR
analysis. PROK1 induced expression of LIF was rapid with an increase in
LIF expression of 7.79 ± 1.32 fold by 2 hours, and maximal expression of
17.8 ± 3.8 fold above vehicle treated control by 6 hours (p<0.001, Figure
7.2) which declined to almost basal levels by 24 hours. Examination of LIF
RNA expression in WT Ishikawa cells treated with 40nM PROK1 for the
same time points did not reveal elevation in LIF RNA expression at any
time. These data indicate that PROK1 mediated LIF expression is rapid,
with maximal LIF expression at 6 hours, which was sustained to 8 hours.
8 12 24
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Figure 7.2. Temporal regulation of PROK1 induced LIF RNA expression in PROKR1 and WT
Ishikawa cells. PROKR1 and WT Ishikawa cells were treated with vehicle or 40nM PROK1
for 0, 2, 4, 6, 8, 12 or 24 hours. LIF expression was assessed by Taqman quantitative PCR
analysis. LIF expression was normalized for loading against expression of 18s and relative to
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a single endometrial control. Data are expressed as fold above vehicle treated control. WT
Ishikawa cells are represented by grey bars, PROKR1 Ishikawa cells are represented by
black bars. LIF expression is rapidly elevated by PROK1 in PROKR1 Ishikawa cells and is
maximal at 6 hours. No elevation in LIF expression is evident in WT Ishikawa cells at any
time point examined. Data are presented as mean ± SEM. (b is significantly different from a
p<0.001). NB. This figure was presented as part of composite figure 5.2 and has been
reproduced here for clarity and interpretation of relevant results within this section.
7.3.2.2. Temporal regulation of PROK1 induced LIF protein production
The temporal regulation of PROK1 mediated LIF secretion was
subsequently investigated. PROKR1 Ishikawa cells were treated with 40nM
PROK1 or vehicle for 0, 2, 4, 6, 8, 12 and 24 hours. At the designated
times, media was removed and LIF protein concentration assessed by
ELISA. No LIF protein expression was induced in vehicle treated samples,
results are therefore expressed as pg/ml rather than fold above vehicle
treated control. LIF protein expression and secretion into culture media
was initiated at 4 hours and increased to peak at 12 hours (27.8 ± 3.9
pg/ml, p<0.05, Figure 7.3).
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Figure 7.3. Temporal regulation of PROK1 induced LIF protein production in PROKR1
Ishikawa cells. PROKR1 Ishikawa cells were treated with 40nM PROK1 for 0, 2, 4, 6, 8, 12
and 24 hours. LIF protein concentration in cell culture media was assessed by ELISA. LIF
production was initiated at 4 hours and production increased to peak at 12 hours followed by
a decline in production to 24 hours. Data presented as mean ± SEM. (b is significantly
different from a p<0.05).
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7.3.3. PROK1 induced LIF expression is transcriptionally regulated
In chapter 6 it was demonstrated that PROK1 mediated COX-2 mRNA
expression was only partially transcriptionally regulated (section 6.3).
However, it has previously been demonstrated that expression of LIF is
transcriptionally regulated (Bamberger et al, 1997a, Bamberger et al, 2004).
Therefore, in order to investigate the transcriptional regulation of PROK1
mediated LIF mRNA expression in this system, Actinomycin D, a powerful
transcriptional inhibitor was utilised. PROKR1 Ishikawa cells were treated
with 40nM PROK1 alone or in the presence of 250ng/ml Actinomycin D for 4,
6, or 8 hours. At 4, 6 and 8 hours, PROK1 mediated LIF mRNA expression
was elevated (Figure 7.4). However, this elevation was reduced to basal levels
upon co-treatment with Actinomycin D (Figure 7.4). This suggests that in
contrast to PROK1 mediated COX-2 expression (Section 6.3), PROK1 induced
LIF expression is completely transcriptionally regulated.
Figure 7.4. PROK1 induced LIF expression is transcriptionally regulated. PROKR1 Ishikawa cells
were treated with 40nM PROK1 in the presence or absence of 250ng/ml Actinomycin D for 4, 6
and 8 hours. LIF expression was assessed by Taqman quantitative PCR analysis. LIF expression
was normalized for loading against expression of 18s and relative to a single endometrial control.
Data are expressed as fold above vehicle treated control. PROK1 induced elevation of LIF RNA
expression was completely abolished upon treatment with Actinomycin D, suggesting that PROK1
mediated expression of LIF is transcriptionally regulated. Data are presented as mean ± SEM. +
denotes presence of agent, - denotes absence of agent, (c is significantly different from a p<0.01,
c is significantly different from b p<0.05).
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7.3.4. Mechanism of PROK1 induced LIF expression in PROKR1 Ishikawa
cells
In chapter 4 it was demonstrated that PROK1 induced phosphorylation of
ERK 1/2 was dependent on activation of multiple signalling molecules
(Section 4.3). It was subsequently demonstrated in Chapter 6 that
downstream activation of COX-2 mRNA and protein expression by PROK1
was dependent on activation of these signalling molecules (Section 6.3). In
order to investigate the importance of signalling cascade activation in PROK1
mediated LIF expression, PROKR1 Ishikawa cells were treated with 40nM
PROK1 in the presence or absence of inhibitors of Gq (YM254890), PLC-(3
(U73122), Ca2+ (BAPTA-AM), cSrc (PP2), EGFR (AG1478) or MEK (PD98059)
for 6 hours. LIF mRNA expression was subsequently examined by Taqman
quantitative PCR. PROK1 induced elevation of LIF expression at 6 hours
(12.44 ± 2.27 fold above vehicle treated control, p<0.001, Figure 7.5, lane 2)
was significantly inhibited upon co-treatment with PROK1 and inhibitors of
Gq protein (Figure 7.5, lane 3), PLC-(1 (Figure 7.5, lane 4), Ca2+ (Figure 7.5,
lane 5), cSrc (Figure 7.5, lane 6), EGFR (Figure 7.5, lane 7) and MEK (Figure
7.5, lane 8). These data suggest that PROK1 induced LIF expression is
mediated via activation of Gq - PLC-(3 - Ca2+ - cSrc - EGFR and MEK as
demonstrated for COX-2 (Section 6.3).
Figure 7.5. Mechanism of PR0K1 induced LIF expression. PR0KR1 Ishikawa cells were
treated with 40nM PROK1 in the presence or absence of inhibitors of Gq protein
(YM254890), PLC-|i (U73122), Ca2+ (BAPTA-AM), cSrc (PP2), EGFR (AG1478) or MEK
(PD98059) for 6 hours. LIF expression was assessed by Taqman quantitative PCR analysis
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and normalized for loading against expression of 18s and relative to a single endometrial
control. Data are expressed as fold above vehicle treated control. Co-treatment of PROKR1
Ishikawa cells with 40nM PROK1 and YM254890, U73122, BAPTA-AM, PP2, AG1478 and
PD98059 abolished PROK1 induced elevation of LIF expression at 6 hours. + denotes
presence of agent, - denotes absence of agent. Data are presented as mean ± SEM. (b is
significantly different from a p<0.001).
7.4. Discussion
In Chapter 3, the temporal regulation of PROK1 expression in the endometrium
across the menstrual cycle and in early pregnancy was described, with elevation of
PROK1 in the secretory phase of the cycle and further elevation in early pregnancy.
PROK1 was suggested, by gene array analysis in chapter 5, to regulate LIF
expression. Co-localization of LIF and PROKR1 mainly to the glandular
epithelium and some stromal cells of mid-secretory endometrium and first
trimester decidua (decidualized endometrium of early pregnancy) may imply an
autocrine/paracrine signalling mechanism for physiological control of LIF
secretion within these cellular compartments in vivo. LIF has previously been
suggested to localise mainly to the glandular epithelial cells in the mid-secretory
endometrium (Charnock-Jones et al, 1994). LIF mRNA expression and secretion
from endometrial explants also peaks in the mid-secretory phase of the menstrual
cycle (Laird et al, 1997, Vogiagis et al, 1996, Arici et al, 1995, Cullinan et al, 1996),
when PROK1 is also elevated.
LIF production has been reported in first trimester decidua explants (Ren et al,
1997) and, as demonstrated in chapter 3 (Section 3.3), PROK1 and PROKR1 are
both elevated in first trimester decidua, indicating potential regulation in early
pregnancy. Appreciation of the contribution of the endometrial glandular
secretions in modulating events at the materno-fetal interface is increasing (Burton
et al, 2007). PROK1 mediated LIF expression may therefore contribute to these
events.
In chapter 5 it was reported that LIF mRNA expression was elevated in PROKR1
Ishikawa cells at 8 hours upon treatment with PROK1. However, whether this
represented the peak in PROK1 induced LIF expression was unknown.
Stimulation of PROKR1 Ishikawa cells with PROK1 induced a rapid elevation in
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LIF mRNA expression with a peak in expression evident at 6 hours, which was
sustained to 8 hours. No elevation of LIF mRNA was noted in WT Ishikawa cells
upon treatment with PROK1 for the same times. Furthermore, a peak in LIF
protein production by PROKR1 Ishikawa cells stimulated with PROK1 was
observed at 12 hours, indicating that PROK1 can stimulate production of
bioactive LIF which could contribute to endometrial function in vivo.
LIF expression induced by IL-1 and TNF is dependent on transcriptional
activation as demonstrated by activation of luciferase promoter reporter
constructs for LIF (Bamberger et al, 1997a, Derigs et al, 1993, Carlson et al, 1996).
In the present study, potential transcriptional activation of LIF by PROK1 was
investigated by use of Actinomycin D. Actinomycin D is a powerful inhibitor of
transcriptional activity. Co-treatment of PROKR1 Ishikawa cells with PROK1 and
Actinomycin D reduced PROK1 induced LIF mRNA expression to basal levels,
suggesting that PROK1 induced LIF expression is completely transcriptionally
regulated. These data can be contrasted with PROK1 induced expression of COX-
2 (Section 6.3), which was only partially transcriptionally activated. These data
may indicate that PROK1 regulates expression of different genes via different
mechanisms.
As indicated above, activation of LIF expression by IL-1 and TNF is mediated by
transcriptional activation (Bamberger et al, 1997a, Derigs et al, 1993, Carlson et al,
1996). However this provides no indication of the signalling cascade that leads to
activation of LIF upon ligand-receptor interaction. Elevation of LIF expression
induced by IL-1 and TNF has been demonstrated as dependent on activation of
Ca2+, PKC and ERK signalling (Carlson et al, 1996, Elias et al, 1994, Fan et al,
2004). LIF activation can also be induced by ionomycin, a potent activator of
calcium signalling (Bamberger et al, 1997a, 1997b). In chapter 6 it was
demonstrated that induction of COX-2 expression by PROK1 was dependent on
induction of Ca2+ and ERK signalling. Hence the role of this pathway in the
regulation of PROK1 mediated LIF expression was investigated. Co-treatment of
PROKR1 Ishikawa cells with PROK1 and inhibitors of Gq, PLC-(5, Ca2+, cSrc,
EGFR and MEK almost completely inhibited PROK1 induced LIF mRNA
expression. This suggests that activation of these intracellular signalling molecules
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represents the primary signalling cascade mediating PROK1 induced LIF
expression.
The LIF null mouse model has provided convincing evidence suggesting a role for
LIF in implantation. LIF null males and females are overtly fertile as mating of LIF
null males with heterozygous females produces viable blastocysts which implant,
develop to term and produce viable adults. Mating of WT or heterozygote males
to LIF null females results in production of viable blastocysts, however, the
pregnancy does not progress beyond production of the blastocysts and their
passage to the uterine lumen as the blastocysts do not implant in the uterine wall
(Stewart et al, 1992). The blastocysts produced by LIF null females appear to be
normal and on days 5-7 of pregnancy they appear to be appropriately located on
the antimesometrial side of the uterine lumen (Chen JR et al, 2000). However, they
develop only loose connections with the luminal epithelium of the uterus and
never develop any stronger connections or display any morphological signs
indicative of implantation. The luminal epithelium remains intact with no
apoptosis evident and no indication of decidualisation. The blastocysts display
the characteristics of delayed implantation and furthermore, the loosely connected
blastocyst can be retrieved, by uterine flushing, from the uterus up to seven days
post coitus with severance of the loose connections it had formed with the uterus
(Chen JR et al, 2000). There is no apparent problem with these blastocysts as,
upon retrieval from the LIF null females and transfer to the uterus of a WT
female, even blastocysts 2-3 days past the time of normal implantation could
implant and develop normally (Stewart et al, 1992). However, blastocyst transfer
from a WT female to a pseudopregnant LIF null female does not result in
implantation in the LIF null female, strongly suggesting a maternal uterine defect
(Stewart et al, 1992).
Expression of proteins known to be present in the mouse uterus at the time of
implantation have also been examined in the LIF null mouse compared with WT
females at the same stage of pregnancy in order to investigate possible interactions
and regulatory mechanisms. Compared with the wild-type mice, the LIF null mice
do not display a deficiency in ovarian steroids, therefore the absence of
implantation cannot be attributed to a defect in the nidatory estrogen surge,
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shown to be essential for implantation in mice (Song et al, 2000). However,
expression of HB-EGF, normally expressed in the luminal epithelium on day 4 and
thought to be involved in adhesion and invasion of the trophectoderm, and COX-
2, normally present in the luminal epithelium and subluminal stroma and
decidual zone on day 4-5 of pregnancy, were aberrantly expressed compared to
the expression observed in WT mice (Song et al, 2000, Fouladi-Nashta et al, 2005).
Epiregulin and Amphiregulin, members of the EGF superfamily and HOXA-10,
were also aberrantly expressed in LIF null mice (Song et al, 2000, Fouladi-Nashta
et al, 2005). It has been suggested that LIF is at the apex of a signalling cascade
controlling expression of these factors. However, data obtained in the present
study from gene array analysis of PROK1 treated PROKR1 Ishikawa cells have
demonstrated that PROK1 regulates expression of LIF, HB-EGF, Amphiregulin,
COX-2 and subsequent downstream prostaglandin production (Chapter 5, Table
12 & Chapter 6). It is therefore tempting to speculate that PROK1 sits at the apex
of a signalling cascade regulating implantation events. However, further research
is required to outline whether the expression of LIF within the endometrium is
solely regulated by PROK1. These data would provide weight to the hypothesis
that PROK1 sits above LIF in the hierarchy of signalling molecules involved in
implantation. However, given the apparent necessity for LIF expression in
implantation, a host of molecules may regulate LIF expression.
The mouse model data may indeed support the role of LIF in implantation.
However, LIF is only highly expressed in the mouse uterus after the surge in
nidatory estrogen on day 4 of pregnancy (Bhatt et al, 1991), whereas in the human
endometrium LIF is expressed from the early to the late secretory phase of the
cycle with a peak in the mid-secretory phase (Charnock-Jones et al, 1994, Vogiagis
et al, 1996, Arici et al, 1995, Cullinan et al, 1996). Human endometrial LIF
expression is therefore not dependent on an estrogen surge as progesterone is the
predominant steroid hormone at the time of implantation.
Does LIF therefore have a proven role in human implantation? There is no
definitive answer to this, as clearly a knockout human cannot be produced to test
the theory. However, there are a number of lines of evidence, which suggest that
LIF is indeed required for human implantation. LIF expression in the human
Chapter 7 PR0K1-PR0KR1 mediated LIF expression 222
endometrium peaks in the mid-secretory phase of the cycle (Charnock-Jones et al,
1994, Vogiagis et al, 1996, Arici et al, 1995, Cullinan et al, 1996), the putative
'window of implantation', suggested as the time when the endometrium is
receptive to implantation by a blastocyst (Psychoyos et al, 1973). It has also been
observed that women who exhibit endometriosis, unexplained infertility or
multiple failures of implantation produce significantly less LIF from endometrial
explants or in uterine flushings or display reduced staining for LIF than women
who are normally fertile (Laird et al, 1997, Delage et al, 1995, Hambartsoumian,
1998b, Dimitriadis et al, 2006). Mutation in human LIF have also been observed in
studies of large cohorts of infertile women (Steck et al, 2004, Giess et al, 1999,
Kralikova et al, 2006, Kralikova et al, 2006). However, these mutations occur
infrequently and appear to be overcome upon application of ovarian stimulation
and IVF (Steck et al, 2004, Kralikova et al, 2007). Additionally, a relationship
between the level of LIF expression and pinopod formation has been suggested
(Aghajanova et al, 2003). These data imply that LIF may have a role in human
implantation. Regulation of PROK1 in unexplained infertility has thus far not been
investigated however it may be anticipated that if LIF is dysregulated then
PROK1 or its receptor may also be aberrantly expressed.
In conclusion, the results from this chapter demonstrate that PROK1 regulates
expression of LIF, via transcriptional activation and activation of a Gq - PLC-|3 -
Ca2+ - cSrc - EGFR - MEK dependent pathway. PROK1 mediated LIF RNA
expression and protein production also appear to occur in a time dependent
manner. LIF has a demonstrated role in murine implantation and has been heavily
implicated in human reproduction. It is therefore plausible to speculate that
PROK1, via induction of LIF expression, may play a significant role in
implantation.
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Chapter 8 — Physiological relevance of PROK1-PROKR1 signalling in early
pregnancy
8.1. Introduction
The data presented thus far is derived from an endometrial epithelial cell line.
Detractors may comment that cell lines represent an artificial system. It may also
be argued that alteration of the cells by e.g. transfecting receptors into the cells line
represents an altered system, which may not prove to be physiologically relevant.
In order to demonstrate potential physiological relevance first trimester decidua
tissue was used to examine signalling phosphorylation events and gene
expression.
First trimester decidua is the endometrial tissue of early pregnancy into which the
early embryo invades. The pregnant endometrium supports the growing embryo
before it invades the maternal endometrial arteries and gains a blood supply
(Burton et al, 2007). The decidua is divided into the decidua basalis, which is in
contact with the embryo, and the decidua parietalis, which is not in contact. By the
method used of collecting first trimester decidua it is unclear whether the tissue is
parietalis or basalis, therefore a mixture would be represented.
In chapter 3 it was demonstrated that PROK1 and PROKR1 are elevated in first
trimester decidua. PROK1-PROKR1 signalling may therefore be expected to play a
role in early pregnancy. In chapter 5, and subsequently in chapters 6 and 7, it was
demonstrated that PROK1-PROKR1 induced expression of COX-2 and LIF. These
genes are implicated in implantation and potentially in the initial endometrium -
blastocyst dialogue. Currently however, there is no experimental evidence
indicating initiation of a dialogue between the blastocyst and endometrial PROK1.
Human chorionic gonadotropin is one of the first products of the developing
blastocyst. Indeed, hCG subunits are transcribed in the 8-cell embryo and the
bioactive hormone is secreted by the blastocyst (Lopata & Hay, 1989) with
detection in maternal serum from approximately 14 days post conception (Keay
et al, 2004). It is increasingly evident that hCG, in addition to its effects on
trophoblast differentiation and maintenance of the corpus luteum, has effects
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directly on the endometrium (Licht et al, 2001). Although hCG detection in
maternal serum is a clinical marker of pregnancy, implantation commences
approximately 5-6 days after conception. Therefore hCG is suggested to have an
effect on endometrial physiology well before its detection in maternal circulation.
In the first weeks of pregnancy, hCG is produced in increasing quantities from the
syncytiotrophoblast (STB), which is in intimate contact initially with the
endometrial luminal epithelium and later with the maternal decidua, as the cells
surrounding the invading cytotrophoblast column (Madanes et al, 1985, Mishell et
al, 1973). Through in vivo work, infusing hCG into the endometrium of humans
and baboons (Licht et al, 2001, Sherwin et al, 2007), and in vitro work, stimulating
primary endometrial cells with hCG (Perrier d'Hauterive et al, 2004, Han et al,
1996, 1999, Zhou et al, 1999), it has been demonstrated that hCG induces
endometrial expression of a number of genes. These include a selection of those
elevated by PROK1 including LIF, COX-2, IL-8, IL-6, and HB-EGF (Licht et al,
2001, Sherwin et al, 2007, Perrier d'Hauterive et al, 2004, Han et al, 1996). hCG is
suggested to have a role in stimulating endometrial secretion and decidualisation,
via induction of COX-2 and downstream prostaglandin production (Han et al,
1996, 1999, Zhou et al, 1999). HCG has also been suggested to have a reciprocal
relationship with endometrial LIF, as LIF elevates trophoblast expression of hCG
(Sawai et al, 1995a), and hCG, as indicated, elevates endometrial LIF. Both are
suggested to induce trophoblast differentiation, as secretion of hCG is a marker of
trophoblast differentiation towards syncytialisation. LIF has also been suggested
to enhance trophoblast differentiation towards an adhesive or anchoring
phenotype rather than an invasive phenotype (Nachtigall et al, 1996), with
extravillous trophoblasts being invasive. However, conflicting data suggest a role
for LIF in trophoblast invasion (Fitzgerald et al, 2005, Poehelmann et al, 2005).
This study was designed with two aims. First, in order to investigate whether the
intracellular signalling cascades and gene expression activated by PROK1-
PROKR1 are physiologically relevant, PROK1 mediated ERK 1/2 phosphorylation
and gene expression (namely LIF and COX-2) were investigated in first trimester
decidua tissue. Secondly, the potential regulation of PROK1 expression and
downstream LIF expression in early pregnancy by hCG was investigated.
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8.2. Materials and Methods
8.2.1. Tissue Collection
Decidua tissue collection was performed with ethical approval from Lothian
Research Ethics Committee under ethics number LREC/05/S1103/32 as
indicated in section 2.2. Gestation of pregnancy was confirmed by ultrasound
scan prior to elective first trimester surgical termination of pregnancy. Written
informed consent was obtained from all subjects prior to tissue collection.
Shortly after collection, tissue was placed in RPMI 1640 (containing 2Mm
(mmol/litre) L-glutamine, 100U penicillin, and lOOpg/ml streptomycin) for
tissue culture.
8.2.2. Cell and Tissue Treatments
8.2.2.1.Time course analysis
In order to examine the temporal regulation of PROK1 mediated ERK 1/2
phosphorylation, first trimester decidua tissue explants were treated with
40nM PROK1 or vehicle for 0, 1, 5, 10, 20, 30, 45 or 60 minutes.
In order to determine the temporal regulation of PROK1 induced COX-2
and LIF gene expression and LIF protein production, first trimester
decidua explants were treated with 40nM PROK1 for 1, 2, 4, 6, 8, 12 or 24
hours.
In order to determine the temporal regulation of hCG induced PROK1 and
LIF gene expression, PROKR1 Ishikawa cells and first trimester decidua
tissue were treated with 1IU hCG for 4, 6, 8, 12, 14, 16, 18 or 24 hours.
Cells or tissue were subsequently lysed in NP40 lysis buffer and processed
for Western immunoblot analysis (described in Section 8.2.3) or lysed in
TRI-reagent, followed by RNA extraction and processing for Taqman
quantitative PCR analysis (described in Section 8.2.4).
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8.2.2.2.Mechanism of PROK1 induced ERK 1/2 phosphorylation, COX-2
and LIF expression
In order to determine the signalling activated by PROK1 in the signalling
cascade to ERK 1/2 phosphorylation, chemical inhibitors of signalling
molecules were employed. First trimester decidua tissue explants were
preincubated with chemical inhibitors of Gq protein (YM254890), PLC-(1
(U73122), Ca2+ (BAPTA-AM), cSrc (PP2), EGFR kinase (AG1478) or MEK
(PD98059; inhibitor concentrations given in Table 16) for one hour prior to
stimulation with vehicle or 40nM PROK1 for 30 minutes.
In order to determine the signalling pathway activation leading to PROK1
mediated COX-2 and LIF expression, first trimester decidua tissue
explants were pre-incubated with the above inhibitors (inhibitor
concentrations given in Table 16) for one hour followed by treatment with
vehicle or 40nM PROK1 for 6 hours.
Tissue was subsequently lysed in NP40 lysis buffer and processed for
Western immunoblot analysis (described in Section 8.2.3) or lysed in TRI-
reagent, followed by RNA extraction and processing for Taqman
quantitative PCR analysis (described in Section 8.2.4).
Table 16. Inhibitor concentrations
Inhibitor Molecule Inhibited Inhibitor concentration
YM254890 Gq protein lpM





Cyclohexamide Protein synthesis 10pg/ml
8.2.2.3. Mechanism of hCG induced LIF expression
In order to determine whether production of an intermediary protein is
required for hCG mediated LIF expression, PROKR1 Ishikawa cells were
pre-incubated with cyclohexamide, an inhibitor of protein synthesis
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(concentration indicated in Table 16) for one hour. PROKR1 Ishikawa cells
were subsequently treated with 1IU hCG for 8, 12, 16, 18, and 24 hours
alone or in the presence of cyclohexamide. Cells were subsequently lysed in
TRI-reagent, followed by RNA extraction and processing for Taqman
quantitative PCR analysis (described in Section 8.2.4).
8.2.3. Western Immunoblot Analysis
In order to examine ERK 1/2 phosphorylation in first trimester decidua,
tissues were finely minced and divided equally for each treatment. Tissue was
homogenised in NP40 lysis buffer (described in sections 2.7 and 2.12) and
protein concentration assayed as described in section 2.7. 50pg of protein was
solubilised in Laemmli protein loading buffer, boiled in order to denature
proteins and resolved on an SDS-PAGE gel as described in sections 2.7.
Proteins were immunoblotted to a PVDF membrane and non-specific binding
blocked with low fluorescence blocking buffer (LiCor). Immunoblotted
proteins were visualised by a fluorescent detection system as indicated in
section 2.7.
8.2.4. Taqman Quantitative PCR
8.2.4.1.RNA extraction
RNA was extracted using TRI-reagent and the phenol-chloroform method
of RNA extraction as described in section 2.5. Briefly, cells or tissue were
lysed in TRI reagent and a homogenous lysate achieved by passing the
lysate up and down the pipette a number of times. Tissue was lysed by
addition of TRI-reagent followed by homogenisation with a tissue lyser
(Qiagen). Tissue samples were snap frozen in 2ml Eppendorf tubes, which
contained a 5mm steel bead. After addition of TRI-reagent the tubes were
loaded onto the tissue lyser and subjected to shaking at 25Hz for 6
minutes, this allowed the tissue to be homogenised by the action of the
steel bead. The homogenised tissue samples were centrifuged at 4°C for 10
minutes at 15000 RPM to clear any cellular debris. Lysed samples were
then loaded into heavy gel phase lock tubes with the addition of bromo-
chloro propane. Tubes were shaken vigorously to ensure adequate mixing
Chapter 8 Signalling and regulation of PROK1 in early pregnancy 228
of the two solutions. Samples were then processed as described in section
2.5.
8.2.4.2.Taqman quantitative PCR
RNA expression within cultured cells and first trimester decidua was
examined by Taqman quantitative PCR analysis as described in section
2.5. Briefly, cDNA was prepared in a random hexamer primed reaction
using 200ng RNA per reaction. Quantitative PCR analysis was performed
on the cDNA using specific primer probe combinations to detect COX-2,
LIF and PROKR1 (sequence given in Table 5). These were designed in
house and were custom synthesised. The probe was given a FAM
fluorescent label with TAMRA quencher. Gene expression was normalized
by including Vic labelled primer-probe mix to detect the 18s ribosomal
subunit (sequence given in Table 5) as a loading control for the amount of
cDNA added in each sample.
Reaction mixes were loaded in duplicate onto a 96-well MicroAmp fast
optical reaction plate for analysis on an ABI7900 HT Fast Real-Time PCR
machine. Data were analysed and processed using sequence detector
version 1.6.3. Results were expressed as relative to a positive RNA
standard included in all reactions. The data were analysed using the
comparative Ct method for relative quantification.
8.2.5. LIFELISA
The LIF ELISA has been fully described in section 2.8.3. Briefly, first trimester
decidua tissue explants were treated with vehicle or 40nM PROK1 for 0, 2, 4,
6, 8, 12 and 24 hours. Medium was removed and frozen until assay. LIF
concentration was calculated by constructing a standard curve using LIF
standards of known concentration. Sample concentrations of LIF were
corrected for the protein content of the sample and expressed as fold above
vehicle treated control.
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8.2.6. In vivo model
This work was performed by JR Sherwin et al, and gene array data yielded
from this study has been previously published (Sherwin, 2007). Experimental
procedures were approved by the Animal Care Committee of the University of
Chicago Illinois (Chicago, IL) and performed by A Fazleabas and JM Hastings
at the University of Chicago, Illinois. Uterine tissue was obtained from six
controls and five hCG-treated adult female baboons (Papio anubis). Ovulation
was detected in cycling female baboons by measuring peripheral serum levels
of estradiol, beginning 7 days after the first day of menses. The day of the
estradiol surge was designated as day -1 with day 0 as the day of the
ovulatory LH surge and day 1 as the day of ovulation. On day 5 post
ovulation (PO), an oviductal cannula was attached to an Alzet osmotic mini-
pump and recombinant hCG was infused at a rate of 1.25 IU/hour for 5 days.
The experiment was terminated on day 10 PO (which corresponds to the day
of expected implantation in baboon). Total RNA was extracted from each
endometrial tissue using TRI reagent as described above. PROK1 mRNA
expression was examined by Taqman quantitative PCR analysis as described
in Section 8.2.4. JR Sherwin and A Sharkey (University of Cambridge) kindly
performed Taqman PCR analysis upon request from J Evans and R Catalano
(University of Edinburgh). The results are reproduced here by kind permission
of JR Sherwin.
8.2.7. Statistics
Statistical analysis of the data in this study was carried out by ANOVA with
Fishers PLSD (predicted least squares difference) applied, using Statview 5.0
(Abacus Concepts). The data is presented as mean ± SEM of at least 3
experiments.
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8.3. Results
8.3.1. Intracellular signalling activated by PROK1 in first trimester decidua
8.3.1.1.Time course of PROK1 mediated ERK 1/2 phosphorylation in first
trimester decidua
To establish whether PROK1 has a physiologically relevant role, first
trimester decidua tissue was utilised to investigate PROK1-PROKR1
signalling. ERK 1/2 phosphorylation was examined in first trimester
decidua tissue treated with 40nM PROK1 for 0, 1, 5, 10, 20, 30, 45 and 60
minutes. Maximal ERK 1/2 phosphorylation occurred at 30 - 45 minutes
(3.83 ± 0.74 and 3.93 ± 1.21 fold above vehicle treated control respectively,
P<0.01, Figure 8.1). These data demonstrate that PROK1-PROKR1
signalling is activated in first trimester decidua tissue and may therefore
play a role in vivo.
0 1 5 10 20 30 45 60
Time (minutes)
Figure 8.1. PROK1 induced ERK 1/2 phosphorylation in first trimester decidua tissue. First
trimester decidua tissue explants were treated with 40nM PROK1 for 0, 1, 5, 10, 20, 30, 45
and 60 minutes. Proteins were extracted and 50/jg resolved by SDS-PAGE followed by
Western immunoblot analysis using specific antibodies against phosphorylated ERK 1/2
(pERK). The total amount of ERK in cell lysates was determined by probing the same blot
with antibody recognising total ERK 1/2 (tERK). ERK 1/2 phosphorylation was normalised
against expression of tERK. A representative Western immunoblot is shown with semi¬
quantitative densitometric analysis. The data are presented as mean ± SEM. (b is
significantly different to a, P<0.01).
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8.3.1.2.Mechanism of PROK1 induced ERK 1/2 phosphorylation in first
trimester decidua
In chapter 4 it was demonstrated that PROK1 induced ERK 1/2
phosphorylation was dependent on activation of an intracellular signalling
cascade (Section 4.3.3). Therefore, in order to determine whether the
signalling phosphorylation cascade activated in PROKR1 Ishikawa cells is
physiologically relevant, the PROK1 induced signalling cascade leading to
ERK 1/2 activation has been investigated in first trimester decidua
explants. Phosphorylation of ERK 1/2 in first trimester decidua is
maximal at approximately 30 minutes. PROK1 induced elevation of ERK
1/2 phosphorylation at 30 minutes (5.4 ± 1.19 fold above vehicle treated
control, p<0.001, Figure 8.2, lane 2) was inhibited by pre-incubation of first
trimester decidua explants with inhibitors of Gq protein (Figure 8.2, lane 3)
PLC-|3 (Figure 8.2, lane 4), Ca2+ (Figure 8.2, lane 5), cSrc (Figure 8.2, lane
6), EGFR (Figure 8.2, lane 7) and MEK (Figure 8.2, lane 8). These data
examining signalling activated by PROK1 in first trimester decidua agree
with the data obtained from the PROKR1 Ishikawa cell line. These data
suggest that in this primary tissue explant model of early pregnancy,
PROKR1 is Gq coupled and activates an intracellular signalling
phosphorylation cascade with ERK 1/2 phosphorylation dependent on
activation of cSrc and EGFR signalling.
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Figure 8.2. Chemical inhibitors of signalling intermediates inhibit PROK1 induced ERK 1/2
phosphorylation. First trimester decidua tissue explants were pre-treated with inhibitors of
Gq protein, PLC-p, Ca2+, cSrc, EGFR and MEK for one hour prior to stimulation with 40nM
PROK1 for 30 minutes. Proteins were extracted and 50jug resolved by SDS-PAGE followed
by Western immunoblot analysis using specific antibodies against phosphorylated ERK 1/2
(pERK). The total amount of ERK in cell lysates was determined by probing the same blot
with antibody recognising total ERK 1/2 (tERK). ERK 1/2 phosphorylation was normalised
against expression of tERK. + denotes presence of agent, - denotes absence of agent. A
representative Western immunoblot is shown with semi-quantitative analysis. The data are
presented as mean ± SEM. (b is significantly different to a, P<0.001).
8.3.2. Gene expression induced by PROK1 in first trimester decidua
8.3.2.1.PROK1 induces expression of COX-2 mRNA in first trimester
decidua
COX-2 expression and prostaglandin production is essential in early
pregnancy for control of physiological processes such as decidualisation,
vascular remodelling and tone and control of permeability at sites
surrounding the blastocyst (Matsumoto et al, 2002, Song et al, 2000, Lim et
al, 1997, Cheng & Stewart, 2003). The temporal regulation of PROK1
induced COX-2 expression in first trimester decidua tissue was therefore
examined. PROK1 induced COX-2 expression was rapid, with elevation in
expression evident from around 2 hours (Figure 8.3). The time point of
maximal expression was at 6 hours (2.7 ± 0.5 fold above vehicle treated
control, p<0.05, Figure 8.3).
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Figure 8.3. Temporal regulation of PROK1 induced COX-2 expression in first trimester
decidua tissue. First trimester decidua tissue explants were treated with 40nM PROK1 for 1,
2, 4, 6, 8 and 24 hours. COX-2 expression was assessed by Taqman quantitative PCR
analysis. COX-2 expression was normalized for loading against expression of 18s and
relative to an internal endometrial control. Data are expressed as fold above vehicle treated
control. PROK1 mediated expression of COX-2 was maximal at 6 hours in first trimester
decidua tissue. Data are presented as mean ± SEM. (b is significantly different from a
p<0.05).
8.3.2.2.PROK1 induces expression of LIF mRNA in first trimester decidua
Endometrial LIF expression is essential for implantation (Stewart et al,
1992). The temporal regulation of LIF by PROK1 was therefore examined.
PROK1 induced LIF RNA expression in first trimester decidua was
maximal at 6 hours (2.99 ± 0.53 fold above vehicle treated control, p<0.05,
Figure 8.4). The PROK1 induced LIF expression then declined almost to
basal levels by 8 hours. These data implicate a role for PROK1 in the
physiological control of LIF RNA expression in early pregnancy.
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Figure 8.4. Temporal regulation of PROK1 induced LIF RNA expression in first trimester
decidua tissue explants. First trimester decidua tissue explants were treated with vehicle or
40nM PROK1 for 0, 2, 4, 6, 8, 12 or 24 hours. LIF expression was assessed by Taqman
quantitative PCR analysis. LIF expression was normalized for loading against expression of
18s and relative to an internal endometrial control. Data are expressed as fold above vehicle
treated control. LIF expression is rapidly elevated by PROK1 in first trimester decidua and is
maximal at 6 hours. Data are presented as mean ± SEM. (b is significantly different from a
p<0.05).
8.3.2.3.PROK1 induces production of LIF protein in first trimester decidua
Time course investigations in PROKR1 Ishikawa cells have indicated that
PROK1 can stimulate the secretion into cell culture medium of LIF protein
(chapter 7). In order to determine if this was the case in first trimester
decidua, tissue explants were stimulated with vehicle or 40nM PROK1 for
0, 2, 4, 6, 8, 12, 18 and 24 hours. At the indicated times, culture medium
was removed and LIF concentration assayed by ELISA. Results are
corrected for protein content and expressed as fold above vehicle treated
control. LIF production was initiated at 4 hours and production increased
to a peak at 12 hours (3.44 ± 1.01 fold above vehicle treated control,
p<0.05, Figure 8.5) which then declined by 24 hours. This indicates that
PROK1 may provide a mechanism of LIF production in vivo during early
pregnancy.
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Figure 8.5. Temporal regulation of PROK1 induced LIF protein production in first trimester
decidua tissue explants. First trimester decidua tissue explants were treated with 40nM
PROK1 for 0, 2, 4, 6, 8, 12, 18 and 24 hours. LIF protein concentration in cell culture medium
was assessed by ELISA analysis. The LIF protein secretion was corrected for protein
concentration of the sample and expressed as fold above vehicle treated control. LIF
production was initiated at 4 hours and production increased to peak at 12 hours followed by
a decline in production to 24 hours. Data presented as mean ± SEM. (b is significantly
different from a p<0.05).
8.3.3. Mechanism of gene expression induced by PROK1 in first trimester
decidua
8.3.3.1.Mechanism of PROK1 induced COX-2 expression in first trimester
decidua
PROK1 induced COX-2 expression in first trimester decidua is maximal at
6 hours. In order to determine the intracellular signalling pathways
activated in PROK1 mediated COX-2 expression, tissue was treated with
40nM PROK1 alone or in the presence of inhibitors of Gq protein, PLC-|3,
Ca2+, cSrc, EGFR and MEK. PROK1 treatment of first trimester decidua for
6 hours induced a 2.39 ± 0.37 fold increase in COX-2 expression (p<0.001,
Figure 8.6, lane 2). PROK1 induced COX-2 expression was reduced to
basal levels by co-treatment with inhibitors of Gq protein (Figure 8.6, lane
3), PLC-|3 (Figure 8.6, lane 4), Ca2+ (Figure 8.6, lane 5), cSrc (Figure 8.6,
lane 6), EGFR (Figure 8.6, lane 7) and MEK (Figure 8.6, lane 8). These data
agree with those observed in the PROKR1 Ishikawa cells and suggest that
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PROK1 mediated COX-2 expression occurs via a Gq - PLC-|f - Ca2+ - cSrc
- EGFR - MEK mediated pathway.
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Figure 8.6. PROK1 mediated expression of COX-2 in first trimester decidua is dependent on
activation of multiple signalling molecules. PROKR1 Ishikawa cells were treated with 40nM
PROK1 in the presence or absence of chemical inhibitors of Gq protein (YM254890), PLC-[3
(U73122), Ca2+ (BAPTA-AM), cSrc (PP2), EGFR (AG1478) or MEK (PD98059) for 6 hours.
COX-2 expression was assessed by Taqman quantitative PCR analysis. COX-2 expression
was normalized for loading against expression of 18s and relative to an internal endometrial
control. Data are expressed as fold above basal levels. Co-treatment with 40nM PROK1 and
chemical inhibitors significantly inhibited the maximal PROK1 induced COX-2 expression at 6
hours. + denotes presence of agent, - denotes absence of agent. Data are presented as
mean ± SEM. (b is significantly different from a p<0.001).
8.3.3.2.Mechanism of PROK1 induced LIF expression in first trimester
decidua
As indicated above, in order to correlate the findings obtained using the
PROKR1 Ishikawa model cell system with PROK1 signalling in vivo first
trimester decidua tissue explants were used to determine the mechanism
of PROK1 induced LIF expression. First trimester decidua tissue explants
were treated with 40nM PROK1 in the presence or absence of inhibitors of
Gq protein, PLC-|3, Ca2+, cSrc, EGFR or MEK for 6 hours, the time point of
maximal PROK1 induced LIF expression in first trimester decidua tissue.
Treatment of first trimester decidua with 40nM PROK1 for 6 hours
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induced a 2.75 ± 0.56 (p<0.001, Figure 8.7, lane 2) fold elevation in LIF
mRNA expression (Figure 8.7, lane 2). PROK1 induced LIF expression was
abolished upon co-treatment with PROK1 and inhibitors of Gq protein
(Figure 8.7, lane 3) PLC-(3 (Figure 8.7, lane 4), Ca2+ (Figure 8.7, lane 5), cSrc
(Figure 8.7, lane 6), EGFR (Figure 8.7, lane 7) and MEK (Figure 8.7, lane 8).
This indicates that the signalling pathways activated upon PROK1
signalling to LIF demonstrated in the PROKR1 Ishikawa cells may be
important in vivo.
Figure 8.7. PROK1 mediated expression of LIF in first trimester decidua is dependent on
activation of multiple signalling molecules. First trimester decidua tissue explants were
treated with 40nM PROK1 in the presence or absence of inhibitors of Gq protein
(YM254890), PLC-|3 (U73122), Ca2+ (BAPTA-AM), cSrc (PP2), EGFR (AG1478) or MEK
(PD98059) for 6 hours. LIF expression was assessed by Taqman quantitative PCR analysis
and normalized for loading against expression of 18s and relative to an internal endometrial
control. Data are expressed as fold above vehicle treated control. Co-treatment of PROKR1
Ishikawa cells with 40nM PROK1 and YM254890, U73122, BAPTA-AM, PP2, AG1478 and
PD98059 abolished PROK1 induced elevation of LIF expression at 6 hours. + denotes
presence of agent, - denotes absence of agent. Data presented as mean ± SEM. (b is
significantly different from a p<0.001).
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8.3.4. hCG mediated regulation of PROK1 and LIF expression
8.3.4.1.hCG mediated regulation of PROK1 in PROKR1 Ishikawa cells, first
trimester decidua and in vivo model
Human chorionic gonadotropin, as one of the earliest embryonic products,
may be a candidate for the regulation of PROK1 expression in early
pregnancy. Initially the potential temporal regulation of PROK1 expression
by hCG was investigated using PROKR1 Ishikawa cells. Treatment of
PROKR1 Ishikawa cells with 1IU hCG for 4, 6, 8, 12, 18 and 24 hours
induced elevation of PROK1 expression, with maximal expression at 6
hours (3.44 ± 0.66 fold above vehicle treated control, p<0.01, Figure 8.8 A).
This then declined to basal levels by 18 hours post stimulation with 1IU
hCG. In order to determine whether this hCG mediated induction of
PROK1 was physiologically relevant two models were used, the first
trimester decidua explants already described and a baboon microdialysis
model.
First trimester decidua is in intimate contact with the hCG producing
syncytiotrophoblast. First trimester decidua would therefore appear to be a
good model system in which to examine the potential in vivo influence of
hCG on endometrial PROK1 expression. First trimester decidua tissue
explants were treated with 1IU hCG for 4, 6, 8, 12, 14, 16, 18 and 24 hours.
Treatment of first trimester decidua explants with hCG induced a peak in
PROK1 expression at 6 hours (1.81 ± 0.2 fold above vehicle treated control,
p<0.05, Figure 8.8 B). This corresponds with the peak in PROK1 expression
induced by hCG in PROKR1 Ishikawa cells.
In the paper of Sherwin et al (2007) it was reported that infusion of hCG
into baboon endometrium at 1.25 IU/hour for 5 days post ovulation
induced elevation in expression of LIF compared to control animals. This
was assessed by gene array analysis and validated by real-time PCR.
Examination of the same samples using specific primers and probes for
baboon PROK1 mRNA revealed a 13.6 fold increase in hCG treated
animals compared with control animals (Figure 8.8 C, P<0.05). This
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demonstrates elevation of PROK1 expression mediated by hCG in vivo in
the endometrium of a non-human primate
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Figure 8.8. Regulation of hCG mediated PROK1 expression. A. PROKR1 Ishikawa cells
were stimulated with 11U hCG for 4, 6, 8, 12, 18 and 24 hours. PROK1 expression was
analysed by Taqman quantitative PCR analysis. PROK1 expression is rapidly elevated by
hCG in PROKR1 Ishikawa cells and is maximal at 6 hours (b is significantly different from a
p<0.01). B. First trimester decidua tissue explants were stimulated with 1IU hCG for 4, 6, 8,
12, 14, 16, 18 and 24 hours. PROK1 expression was assessed by Taqman quantitative PCR
analysis. hCG induced PROK1 expression is maximal at 6 hours (b is significantly different
from a p<0.05). C. hCG mediated PROK1 expression in vivo. Post-ovulatory baboons were
treated with vehicle (control) or 1.25IU hCG per hour for 5 days. PROK1 expression was
assessed by Taqman quantitative PCR analysis. PROK1 expression is elevated by hCG in
baboon endometrium after 5 days of treatment with hCG (b is significantly different from a
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p<0.05). PROK1 expression was normalized for loading against expression of 18s. Data are
expressed as fold above vehicle treated control. Data are presented as mean ± SEM.
8.3.4.2.hCG mediated regulation of LIF in PROKR1 Ishikawa cells and first
trimester decidua
hCG modulates expression of PROK1 as shown in figure 8.8. In chapters 5,
7 and 8, PROK1 was shown to modulate expression of LIF. hCG has also
been demonstrated to regulate expression of LIF (Perrier d'Hauterive et al,
2004, Licht et al, 2001, Sherwin et al, 2007). However, whether hCG
regulates expression of LIF via induction of PROK1 is unknown. Here the
temporal regulation of LIF expression by hCG is examined. Treatment of
PROKR1 Ishikawa cells with 1IU hCG induced an elevation in LIF mRNA
expression which was initiated at 12 hours, peaked at 16 hours (2.16 ± 0.2
fold above vehicle treated control, p<0.05, Figure 8.9 A) and declined to
basal levels by 24 hours. LIF expression is therefore maximal at 16 hours in
PROKR1 Ishikawa cells, 10 hours after the peak in PROK1 expression. This
temporal difference in expression may suggest that hCG regulates LIF
expression via elevation in PROK1 expression.
In order to determine whether this induction of LIF expression by hCG may
occur in vivo, first trimester decidua explants were again employed.
Treatment of first trimester decidua tissue explants with 1IU hCG induced
maximal LIF expression at 14 hours (2.35 ±0.4 fold above vehicle treated
control, p<0.05, Figure 8.9 B), 8 hours after the main peak in PROK1
expression.












Figure 8.9. Temporal regulation of hCG mediated LIF expression. A. PROKR1 Ishikawa cells
were stimulated with 1IU hCG for 4, 6, 8, 12, 16, 18 and 24 hours. LIF expression was
assessed by Taqman quantitative PCR analysis. LIF expression is elevated by hCG in
PROKR1 Ishikawa cells and is maximal at 16 hours (b is significantly different from a
p<0.05). B. First trimester decidua tissue explants were stimulated with 11U hCG for 4, 6, 8,
12, 14, 16, 18 and 24 hours. LIF expression was assessed by Taqman quantitative PCR
analysis. LIF expression is elevated by hCG in first trimester decidua tissue explants and is
maximal at 14 hours (b is significantly different from a p<0.05). LIF expression was
normalized for loading against expression of 18s and relative to an internal endometrial
control. Data are expressed as fold above vehicle treated control. Data are presented as
mean ± SEM.
8.3.4.3.hCG induced LIF expression may be dependent on PROK1
Unfortunately there is no inhibitor of PROK1 commercially available.
Therefore, in order to investigate the requirement for an intermediary
molecule in hCG induced LIF expression, cyclohexamide was used.
Cyclohexamide is a powerful inhibitor of protein synthesis, therefore if a
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protein were synthesised by the action of hCG, cyclohexamide would
inhibit this synthesis and inhibit any downstream effects of this protein.
PROKR1 Ishikawa cells were treated with 1IU hCG alone or in the presence
of pre-treatment with lOpg/ml cyclohexamide. hCG induced elevation in
LIF expression at 12, 16, 18 and 24 hours was reduced to basal levels in
the presence of cyclohexamide. These data indicate that synthesis of an
intermediate protein is necessary in order for hCG to stimulate expression
of LIF.
Figure 8.10. hCG mediated LIF expression is sensitive to inhibition by inhibitors of protein
synthesis. PROKR1 Ishikawa cells were stimulated with 11U hCG for 12, 16 18 and 24 hours
in the presence or absence of 10/vg/ml cyclohexamide. LIF expression was analysed by
Taqman quantitative PCR analysis. LIF expression was normalized for loading against
expression of 18s and relative to an internal endometrial control. Data are expressed as fold
above vehicle treated control. hCG mediated LIF expression in PROKR1 Ishikawa cells and
is significantly inhibited in the presence of cyclohexamide. + denotes presence of agent, -
denotes absence of agent. Data presented as mean ± SEM. (b is significantly different from a
p<0.01).
8.4. Discussion
The data presented in Chapters 4, 5, 6 and 7 have demonstrated that PROK1-
PROKR1 induces phosphorylation of ERK 1/2 and expression of COX-2 and LIF.
However, all these studies were conducted in Ishikawa cells, an endometrial
epithelial cell line, transfected with PROKR1. As this may represent an altered,
non-physiological system, the signalling pathways and gene expression mediated
by PROK1 were investigated in first trimester decidua. First trimester decidua is
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the decidualized endometrium of early pregnancy into which the embryonic
tissues invade and remodel in order to support the developing embryo and
connect with the maternal blood supply.
Treatment of first trimester decidua tissue explants with PROK1 induced
significant ERK 1/2 phosphorylation at 30 - 45 minutes which was subsequently
shown to be dependent on Gq - PLC-P - Ca2+ - cSrc, EGFR and MEK. These data
correspond with that obtained from the PROKR1 Ishikawa cells (Section 4.3)
suggesting the data obtained from these cells may indeed represent physiological
endometrial responses. However, the peak in PROK1 induced ERK 1/2
phosphorylation in first trimester decidua was considerably delayed compared
with the peak in PROKR1 Ishikawa cells (30 minutes in decidua vs. 5 minutes in
cells). This may represent differences in comparing a homogenous cell monolayer
with a tissue explant consisting of a heterogeneous cell population, some of which
will express receptors and some not, possibly with differential levels expressed in
different cell types.
In order to demonstrate that the gene responses elicited by PROK1 are potentially
relevant in vivo, COX-2 and LIF expression were also examined in first trimester
decidua. Again the results in the first trimester decidua correlated with those
obtained from the PROKR1 Ishikawa cell line with a peak in COX-2 and LIF
mRNA expression at 6 hours and a peak in LIF protein production at 12 hours. In
the PROKR1 Ishikawa cell line, the inhibitors of Gq, PLC-|3, Ca2+, cSrc, EGFR and
MEK significantly inhibited PROK1 mediated mRNA expression of COX-2 and
LIF. Studies in the first trimester decidua explants agree with these data with the
expression of COX-2 and LIF inhibited to basal levels by co-treatment with
PROK1 and chemical inhibitors of signalling molecules. These data again suggest
that the data obtained from the cell line is physiologically relevant and activation
of Gq - PLC-|3 - Ca2+ - cSrc - EGFR and MEK are essential in PROK1 mediated
COX-2 and LIF expression during early pregnancy.
It must be considered that, as the first trimester decidua tissue explants are not a
homogenous cell population expressing PROKR1, a proportion of the response
induced by PROK1 may be transmitted via PROKR2. PROKR2 is also expressed
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in the endometrium (Battersby et al, 2004a) and PROK1 can activate PROKR2
(Lin DC et al, 2002). Indeed, the two Prokineticin receptors display 85% amino
acid identity and are effectively identical in their transmembrane domains, and
both ligands can initiate signalling at both receptors (Lin DC et al, 2002, Masuda
et al, 2002, Soga et al, 2002). In order to address the contribution of the two
receptors specific receptor antagonists would be required.
This study was designed to address two issues, the physiological relevance of the
phosphorylation cascades and gene activation mediated by PROK1, and the
potential regulation of PROK1 expression in early pregnancy. The physiological
relevance of the data obtained from the PROKR1 Ishikawa cells has been
demonstrated in first trimester decidua. These data further suggested a role for
PROK1 and prokineticin receptors in early pregnancy. However, the regulatory
mechanisms governing PROK1 expression in early pregnancy are unknown.
PROK1 is elevated in first trimester decidua, as demonstrated in Chapter 3.
Progesterone regulates expression of PROK1 in the endometrium (Battersby et al,
2004a) and the progesterone secreting corpus luteum is maintained in early
pregnancy. It is not clear, however, whether the elevation in PROK1 expression in
first trimester decidua is due simply to maintained progesterone secretion. A
likely candidate for regulation of PROK1 expression during early pregnancy may
be chorionic gonadotropin.
Human chorionic gonadotropin (hCG) is one of the earliest embryonic products,
with bioactive hormone secreted from the blastocyst stage (Lopata & Hay, 1989).
The 'traditional' role of hCG is considered to be its role in maintaining
progesterone production from the corpus luteum in early maternal recognition of
pregnancy. However, direct paracrine effects on the endometrium aiding
implantation are now suggested to precede these endocrine events (Licht et al,
2001, Sherwin et al, 2007). A reciprocal relationship between certain endometrial
cytokines and hCG has been suggested both in vitro and in vivo. In vitro research,
using primary first trimester trophoblast cells, has demonstrated that LIF induces
secretion of hCG (Sawai et al, 1995a, Ren et al, 1997) and functional differentiation
of the trophoblast into syncytiotrophoblast (Sawai et al, 1995b). In vivo research,
in which hCG was infused into the endometrium of baboon or humans, and in
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vitro research, in which primary endometrial cells were treated with hCG, have
shown that hCG induces expression of LIF (Licht et al, 2001, Sherwin et al, 2007,
Perrier d'Hauterive et al, 2004).
As indicated in chapters 5 and 7, PROK1 regulates expression of LIF mRNA and
protein. PROK1 is elevated in first trimester decidua, a tissue in contact with, and
under the influence of the hCG secreting syncytiotrophoblast. It was therefore of
interest to investigate the potential regulation of PROK1 expression by hCG in
order to determine if this regulates PROK1 expression in early pregnancy and
represents a step in hCG induced LIF expression. This may indicate a potential
role of PROK1 in the reciprocal communication between the embryo and
endometrium. As demonstrated in the three different model systems, the PROKR1
Ishikawa cell, first trimester decidua explants and in vivo baboon hCG infusion
model, hCG induces expression of PROK1 mRNA. Using the PROKR1 Ishikawa
cells and first trimester decidua explants, the temporal regulation of hCG induced
PROK1 expression was examined. hCG induced PROK1 expression was maximal
in PROKR1 Ishikawa cells and first trimester decidua at 6 hours. The hCG
infusion into the baboon endometrium was performed for 5 days with infusion of
1.25 IU of hCG per hour. Treatment of baboon endometrium with hCG for 5 days
induced a 13.6 fold elevation in PROK1 mRNA expression. Elevation of LIF has
previously been demonstrated in the baboon model (Sherwin et al, 2007).
Although a peak in hCG induced PROK1 expression was observed after just 6
hours in the PROKR1 Ishikawa cells and first trimester decidua, sustained
elevation of PROK1 may require sustained delivery of hCG, therefore the baboon
hCG infusion model is probably the most physiologically relevant system as, in
vivo, the syncytiotrophoblast would be constantly releasing hCG. However, the in
vitro models do tell us that hCG induced expression of PROK1 is rapid.
LIF expression in response to hCG is observed 14-16 hours after treatment with
hCG in PROKR1 Ishikawa cells and first trimester decidua. It has been
demonstrated in PROKR1 Ishikawa cells and first trimester decidua explants, that
PROK1 mediated LIF expression peaks at 6 hours. Therefore a delay in LIF
expression of 10 hours after the peak in PROK1 expression should provide enough
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time for production and secretion of PROK1 protein in order to stimulate LIF
expression.
It is tempting to speculate, in light of the temporal regulation of PROK1 and LIF
by hCG, that it is necessary for hCG to induce expression of PROK1 prior to
induction of LIF expression. In order to prove this hypothesis an antagonist for
PROKR1 or an siRNA directed against PROK1 is required. During this study,
these tools were not available. An inhibitor of protein synthesis, cyclohexamide,
was therefore used. Cyclohexmide would inhibit protein production induced by
hCG and therefore inhibit downstream signalling mediated by any proteins which
would have been produced. Co-treatment of PROKR1 Ishikawa cells with hCG
and cyclohexamide reduced hCG mediated LIF expression to basal levels,
suggesting protein production, potentially production of PROK1, is required for
hCG induced expression of LIF.
What relevance does this have for the initiation of pregnancy? LIF has been
demonstrated, by the use of the LIF null mouse model, to be essential for
implantation (Stewart et al, 1992). However, LIF is produced by the human
endometrium as a function of secretory transformation (Cullinan et al, 1996, Arici
et al, 1995, Charnock-Jones et al, 1994, Vogiagis et al, 1996) and is available to
facilitate implantation without the aid of hCG. It has therefore been suggested
that, by elevating LIF expression, hCG may prolong the period during which the
endometrium is receptive (Goto et al, 2007, Filicori et al, 2005, de Ziegler et al,
2004), extending the implantation window and optimising the chances of
implantation.
HCG has been demonstrated to modulate other factors associated with early
pregnancy, including IL-6, HB-EGF and COX-2 in the baboon endometrium
(Sherwin et al, 2007). HCG elevates expression of COX-2 and downstream
prostaglandin production in endometrial cells during decidual transformation
(Han et al, 1996, 1999, Zhou et al, 1999), thereby contributing to decidualization.
HB-EGF is thought to mediate attachment of the blastocyst to the endometrium
(Raab et al, 1996, Leach et al, 1999, Yoo et al, 1997, Chobotova et al, 2002a,
2002b), while IL-6 is suggested to be involved in implantation and placental
Chapter 8 Signalling and regulation of PROK1 in early pregnancy 247
growth (Nishino et al, 1990, Robertson et al, 2000). As these are also PROK1
regulated genes, their induction by hCG may be dependent on intermediate
PROK1. As the contribution of the endometrial glandular products in supporting
the developing trophoblast is increasingly understood (Burton et al, 2007), it has
been demonstrated that trophoblast hCG promotes the secretory transformation of
the endometrium (Fazleabas et al, 1999), providing a support system for its own
growth. Although not demonstrated directly here, PROK1 may be one of those
secretory products induced by hCG in the epithelial glandular cells. In Chapter 3 it
was demonstrated that PROK1 localises to the glandular epithelial cells of the
secretory endometrium and first trimester decidua, the cellular compartment to
which the LH/CG receptors have also been localised (Bukovsky et al, 2003).
However, hCG production, and therefore its influence on the endometrium,
decreases by the second trimester of pregnancy (Hay et al, 1988, Gonen et al, 1992,
Wenstrom et al, 1994), suggesting that these roles are specific to the initial
implantation and maintenance of pregnancy. These data implicate PROK1
mediated signalling and gene expression in early pregnancy. A role for COX-2,
LIF, IL-11 and IL-6 in pregnancy and decidualization is suggested by the
reproductive phenotypes of their null mouse models (Lim et al, 1997, Cheng &
Stewart, 2003, Stewart et al, 1992, Robertson et al, 2000, Robb et al, 1998). These
data may implicate a role for PROK1 in implantation and early placental
development.
PROK1 may represent the tip of a signalling and gene expression cascade essential
for regulating pregnancy related functions such as implantation and possibly
decidualization and placentation. However the 'master controllers' regulating
PROK1 expression, and therefore genes downstream of PROK1, appear to be the
hormones progesterone and hCG. PROK1 expression is regulated by progesterone
as previously demonstrated by Battersby et al (2004a). Herein it is demonstrated
that hCG, produced in significant quantities in early pregnancy (Madanes et al,
1985, Mischell et al, 1973), regulates expression of PROK1 in the endometrium.
These data provide an insight into the complexity of the mechanisms controlling
endometrial receptivity, initiation and propagation of pregnancy. Progesterone
may control expression of PROK1 during the secretory phase of the menstrual
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cycle, thereby mediating endometrial receptivity via induction of genes associated
with receptivity by PROK1. In the event of pregnancy, hCG may contribute to the
elevation of endometrial PROK1 and therefore downstream gene activation
maintaining the opening of the window of implantation. As implantation requires
both a receptive endometrium and an appropriately developed blastocyst (Paria
et al, 1993), PROK1, by influencing factors associated with endometrial receptivity
and being under the influence of hCG, may participate in the reciprocal
relationship between the endometrium and the blastocyst contributing to
reproductive success.
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Chapter 9 — Final discussion, conclusions and future work
9.1. Final discussion
9.1.1. Expression and localisation of PROK1 in the non-pregnant and
pregnant endometrium
A role for endometrial PROK1 in implantation has been proposed due to its
temporal regulation across the menstrual cycle. Within the endometrium,
previous studies have localised expression of PROK1 by
immunohistochemistry to the epithelial, stromal and endothelial cells, with
maximal expression during the secretory phase (Battersby et al, 2004a, Ngan
et al, 2006).
Initial studies for this thesis were performed to examine the expression of
PROK1 and its GPCR, PROKR1 across the menstrual cycle, in the pregnant
endometrium and in the pathological endometrium of endometrial cancer.
These studies demonstrated that PROK1 was elevated during the secretory
phase of the menstrual cycle, in agreement with previous studies (Battersby et
al, 2004a, Ngan et al, 2006). It was also found that PROK1 and PROKR1
expression were elevated in the pregnant endometrium compared with the
non-pregnant endometrium, while expression of PROK1 is down-regulated in
endometrial cancer compared with the secretory phase of the menstrual cycle.
Immunohistochemical analysis demonstrated, in agreement with other studies,
expression of PROK1 in the glandular epithelium and stromal compartment
with some expression in the endothelial cells of the microvasculature of the
non-pregnant endometrium. This study also demonstrated localisation of
PROK1 to these compartments in the pregnant endometrium. Similarly,
immunohistochemical localisation of PROKR1 demonstrated expression of
PROKR1 in the glandular epithelium, stroma and endothelial cells of the non¬
pregnant and pregnant endometrium. Examination of PROK1 and PROKR1
localisation in endometrial cancer, however, demonstrated minimal expression
of either protein in well, moderately or poorly differentiated carcinoma
samples.
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Expression of PROKR1 is localised to the endothelial cells of the endometrium,
potentially suggesting a direct effect of PROK1 on endothelial cells. Expression
of PROK1 and PROKR1 is demonstrated in macrophages with expression of
PROK1 also localised to the uterine natural killer (uNK) cells. These cells
cluster around the invading trophoblast and the maternal blood vessels
(Trundley & Moffett, 2004). It is proposed that signals released by uNK cells
aid in the remodelling of the maternal blood vessels (Guimond et al, 1997).
Therefore, PROK1 may contribute to the endometrial endothelial remodelling
during pregnancy. This has been demonstrated for other factors, such as
VEGF, released by the uNK cells (Hanna et al, 2006). However, if PROK1 does
contribute to endometrial endothelial remodelling it appears to occur only
during physiological processes, not pathological, as PROK1 expression in
downregulated in endometrial cancer compared with secretory phase
endometrium. Prokineticins are proposed to regulate macrophage activation
(Martucci et al, 2005). Macrophages are thought to play a role in the tolerance
of the invading trophoblast (Rai & Regan, 2002). Therefore, through potentially
regulating the activation status of the macrophages, and thereby the cytokines
that they secrete (Gordon et al, 1995), PROK1 may contribute to maternal
tolerance of the invading foetus.
Immunohistochemical analysis also demonstrated expression of PROK1 and
PROKR1 in the early placental tissues. In agreement with previous studies,
expression of PROK1 localised to the syncytio- and cytotrophoblast layers of
the early invading placenta (Hoffmann et al, 2006). Expression of PROKR1
also localised to these trophoblast layers, again indicating potential for
autocrine or paracrine signalling during early pregnancy and a possible role for
PROK1-PROKR1 in maternal-fetal dialogue. Expression of PROK1 by the
trophoblast may initiate a communication with the endometrium and guide
the trophoblast or maternal blood vessels in order to develop the fetal blood
supply. This type of trophic system has been suggested for other factors such
as VEGF (Carmeliet, 2005).
These initial data indicated a potential autocrine or paracrine signalling
mechanism for PROK1 in vivo, during the secretory phase of the cycle and
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during early pregnancy. PROK1 has previously been implicated in the
chemotaxis of endothelial cells (LeCouter et al, 2001), and may therefore play
a role in blood vessel maturation and repair during the secretory phase of the
cycle or during early pregnancy, when the blood vessels are actively invaded by
the fetal trophoblast.
9.1.2. PROK1 mediated intracellular signalling
In order to investigate further the role of PROK1-PROKR1 in the endometrium,
an endometrial epithelial cell line (Ishikawa) stably expressing PROKR1 was
produced. Elevated expression of PROKR1 in these cells compared with
PROKR1 expression in wild type cells was confirmed by PCR analysis.
Previous studies have shown that upon activation of prokineticin receptors,
inositol phosphate and calcium are mobilised leading to ERK 1/2
phosphorylation (Lin DC et al, 2002, Lin R et al, 2002, Soga et al, 2002,
Masuda et al, 2002). Therefore inositol phosphate mobilisation and ERK 1/2
phosphorylation were initially examined in order to demonstrate functionality
of this receptor within the transfected cells. PROK1 significantly elevated
inositol phosphate mobilisation and ERK 1/2 phosphorylation upon treatment
with 40nM PROK1 suggesting the receptors were functional.
PROKR1 is a GPCR (Li M et al, 2001, Lin DC et al, 2002, Lin R et al, 2002,
Soga et al, 2002, Masuda et al, 2002). In this study, PROK1-PROKR1
interaction induced inositol phosphate mobilisation and ERK 1/2
phosphorylation, but not cAMP production, suggesting Gq coupling. The ERK
1/2 phosphorylation induced by PROK1 was not inhibited by pertussis toxin,
suggesting that PROKR1 is not Gi coupled in these cells. Activation of GPCR's
induces down-stream activation of phosphorylation cascades (Werry et al,
2005). Investigation of the pathway regulating PROK1 mediated ERK 1/2
phosphorylation revealed that activation of Gq protein, PLC-p, Ca2+, cSrc,
EGFR and MEK was required in PROKR1 Ishikawa cells and first trimester
decidua. It was subsequently demonstrated that PROK1 induced
phosphorylation of cSrc and EGFR, with phosphorylation of cSrc apparently
preceding EGFR phosphorylation. These data suggest that the signalling
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pathways activated by PROK1 in PROKR1 Ishikawa cells are physiologically
relevant and may represent the in vivo situation during early pregnancy.
9.1.3. PROK1 mediated gene expression
There have been no previous reports demonstrating gene expression induced
upon PROK1-PROKR1 interaction in the endometrium or any other tissue.
Therefore in an attempt to determine PROK1 target genes in the endometrium,
global gene array analysis was performed on two platforms, using RNA
extracted from PROKR1 Ishikawa cells treated with vehicle or 40nM PROK1
for 8 hours.
277 genes were found to be changed by 1.5 fold or more on both platforms, of
which 225 were found to be up-regulated with 52 down-regulated. 49 genes
were found to be significantly altered by ps0.05. A large number of genes
regulated by PROK1 have potential roles in endometrial receptivity and
implantation, as demonstrated by the reproductive phenotype of mice with
null mutations for these genes or investigation of their expression in human or
animal endometrium.
Five genes were selected from the list of 49 significantly changed genes for
validation. These were COX-2, LIF, IL-6, IL-8 and IL-11. In the validation
experiments at 8 hours, these genes were elevated in PROKR1 Ishikawa cells.
Examination of the temporal regulation of COX-2, LIF, IL-6, IL-8 and IL-11
demonstrated maximal elevation of all genes between 6-12 hours in PROKR1
Ishikawa cells. Importantly, no elevation in gene expression was observed in
WT Ishikawa cells in which, as demonstrated in Chapter 4, PROKR1
expression is minimal. These data suggested that genes regulated by PROK1
on the gene array occur via activation of PROKR1.
Follow up studies focused on the examination of PROK1 mediated expression
of COX-2 and LIF. Expression of both COX-2 and LIF co-localised with
PROKR1 mainly to the glandular epithelium of mid-secretory and pregnant
endometrium, potentially suggesting regulation within this compartment. The
temporal expression of COX-2 and LIF induced by PROK1 revealed both
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factors to be expressed maximally at 6 hours in PROKR1 Ishikawa cells and in
first trimester decidua explants, suggesting the cell line data to be
representative of the in vivo response. Further investigation of the regulation of
LIF and COX-2 by PROK1 revealed LIF to be transcriptionally regulated, while
COX-2 appeared to be only partially transcriptionally regulated. These data
may imply that PROK1 mediated COX-2 expression may derive in part from
RNA stabilisation mechanisms, as has been reported in other systems (Xu et al,
2000, Lasa et al, 2000, Mifflin et al, 2004).
Investigation of the signalling pathways that lead to PROK1 mediated COX-2
and LIF expression in PROKR1 Ishikawa cells revealed that, similar to PROK1
induced ERK, gene expression was dependent on activation of Gq - PLC-|3 -
Ca2+ - cSrc - EGFR - MEK, as summarised in Figure 9.1. Examination of the
signalling pathway leading to PROK1 mediated LIF and COX-2 RNA
expression in first trimester decidua revealed inhibition of PROK1 induced LIF
and COX-2 to almost basal levels upon treatment with inhibitors of the above
signalling molecules, suggesting these data to be of importance in vivo.
Activation of LIF expression has been demonstrated as dependent on
activation of calcium and ERK 1/2 signalling (Bamberger et al, 2004, 1997b,
Carlson et al, 1996, Elias et al, 1994, Fan et al, 2004). Therefore, the pathway
leading to LIF activation presented herein appears to correspond with that
observed previously. Similarly, COX-2 expression has previously been
demonstrated as dependent on activation of PLC (Luo et al, 2003) and RTK's
(Xu et al, 2007, Liu et al, 2007), therefore, the data presented herein again agree
with previous studies.
PROK1 induced COX-2 protein expression in PROKR1 Ishikawa cells was
temporally regulated, with a peak in expression at 8 hours. This was followed
by a peak in prostaglandin production in PROKR1 Ishikawa cells at 12 hours,
which was dependent on activation of COX-2. These data suggest that
PROK1, via induction of COX-2 expression can induce production of
prostaglandins in vivo. Prostaglandins are suggested to have multiple roles in
female reproduction. PROK1 mediated LIF protein production peaks in both
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PROKR1 Ishikawa cells and first trimester decidua at 12 hours, demonstrating
that PROK1 can induce production of bioactive LIF for functions in vivo.
hCG
Figure 9.1. Schematic representation of PROK1 mediated signalling and gene activation. PROK1 via
PROKR1 activates its Gq coupled receptor and activates intracellular signalling molecules inducing
phosphorylation of cSrc, EGFR and ERK 1/2. Downstream of ERK 1/2 phosphorylation, PROK1
mediates expression of a number of genes, including LIF and COX-2. PROK1 subsequently induces
production of LIF protein and prostaglandins. In the event of pregnancy, PROK1 expression is
positively regulatd by embryonic hCG.
Elevation of PROK1 during the secretory phase of the cycle is regulated by
progesterone (Battersby et al, 2004a, Ngan et al, 2006). Progesterone secretion
by the corpus luteum is maintained in early pregnancy by luteotrophic hCG.
PROK1 is significantly elevated in early pregnancy decidua compared with
non-pregnant endometrium. It is suggested herein that this is in response to
embryonic hCG, rather than solely a continued response to progesterone
(Figure 9.1). It is now appreciated that hCG has a direct effect on the
endometrium (Licht et al, 2001, Perrier d'Hauterive et al, 2004, Sherwin et al,
2007), and has been demonstrated to regulate expression of endometrial LIF
(Licht et al, 2001, Sherwin et al, 2007). The data presented in this thesis
demonstrate that PROK1 is regulated by hCG in PROKR1 Ishikawa cells, first
trimester decidua and an in vivo baboon model. Furthermore, hCG induced
LIF expression appears to be dependent on expression of PROK1, illustrated
HB-EGF no-EGF
LIF Prostaglandins
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by the temporal delay between PROK1 expression and LIF expression, and the
inhibition of hCG induced LIF expression by an inhibitor of protein synthesis.
9.1.4. Relevance to implantation and early pregnancy
9.1.4.1.Human endometrial gene expression
The regulation of PROK1 during the secretory phase of the menstrual cycle
and regulation by progesterone points towards a potential role for PROK1
in endometrial receptivity. PROK1 is specifically elevated during the mid-
secretory phase of the menstrual cycle, a period known as the window of
implantation (Battersby et al, 2004a, Ngan et al, 2006). The results of this
thesis have made further advances and demonstrate that PROK1 regulates
genes suggested to play roles in endometrial receptivity and are expressed
in the human endometrium during this time. These genes include CD44,
DAF, Dkk-1, HB-EGF, GADD45A, IL-11, IL-6, LIF, Metallothioneins,
COX-2, and the TGF(3 superfamily. DAF, Dkk-1, GADD45A, the
metallothioneins and TGF|3 superfamily members have been shown, by
gene array analysis, to be elevated in the receptive endometrium (Kao et al,
2002, Carson et al, 2002, Riesewjik et al, 2003, Borthwick et al, 2003, Mirkin
et al, 2005, Talbi et al, 2006). Other proteins, such as HB-EGF, CD44, IL-6
and also LIF and IL-11 have been implicated in endometrial receptivity
due to their expression across the menstrual cycle in humans, with an
elevation in the secretory phase of the cycle (Leach et al, 1999, Yoo et al,
1997, Stavreus-Evers et al, 2002, Home et al, 2002, Afify et al, 2006,
Tabibzadeh et al, 1995, Vandermolen and Gu, 1996, Dimitriadis et al,
2002, 2003, Arici et al, 1995, Cullinan et al, 1996, Charnock-Jones et al,
1994, Vogiagis et al, 1996).
9.1.4.2. Gene knockout studies
A number of PROK1 regulated genes have proposed roles in reproductive
function due to the phenotypes of mice null for these genes. LIF null mice
do not implant or display a decidualization reaction (Stewart et al, 1992,
Chen JR et al, 2000) due to a maternal defect in LIF production. COX-2
null mice display a defect in decidualization and a delay in parturition due
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to an absence in endometrial prostaglandin production (Cheng & Stewart,
2003, Lim et al, 1997, Matsumoto et al, 2002). IL-11 Rcc null display
defective decidualization and death of embryos in utero (Robb et al, 1998,
Bilinski, 1998), while IL-6 null mice are reported to exhibit a 48% reduction
in implantation (Robertson et al, 2000). Interestingly, a number of
implantation related genes, including HB-EGF, Amphiregulin, COX-2 and
HOXA-10 are aberrantly expressed in the LIF null mouse (Song et al, 2000,
Nashta-Fouladi et al, 2005), potentially suggesting LIF to be at the top of a
signalling cascade mediating implantation.
9.1.4.3.Endometrial pathologies
Examination of gene expression in endometrial pathologies associated with
implantation defects or inadequate endometrial receptivity have provided
further information pertaining to genes required for successful pregnancy.
DAF, or CD55, is elevated in the receptive endometrium, as demonstrated
by gene array analysis (Kao et al, 2002, Carson et al, 2002, Riesewijk et al,
2003, Borthwick et al, 2003, Mirkin et al, 2005). DAF is down-regulated in
women with antiphospholipid syndrome, a condition associated with a
high miscarriage rate (Francis et al, 2006).
Aberrant expression of PROK1 regulated genes in pathological disorders,
such as a reduction in DAF expression in women who suffer from
antiphospholipid syndrome (Francis et al, 2006), may indicate a
requirement for examination of PROK1 expression in this disorder. LIF
production is suggested to be reduced in women who suffer from
unexplained infertility (Laird, 1997 et al, Hambartsoumian, 1998b). IL-6
expression is also suggested to be reduced in women who suffer from
recurrent miscarriage (Jasper et al, 2007). Dkk-1 is proposed to be down-
regulated in endometriosis (Kao et al, 2003) As LIF, IL-6 and Dkk-1 are
PROK1 regulated genes, examination of PROK1 expression in women with
unexplained infertility, recurrent miscarriage or endometriosis may reveal a
reduction in the level of PROK1.
Chapter 9 Final discussion 257
9.1.4.4.Trophoblast function
Examination of the genes regulated by PROK1 reveals elevation of a group
of genes which are proposed to be pro-invasive and a group of genes,
which are proposed to be anti-invasive. The overall outcome of these genes
would presumably depend on the surrounding endometrial milieu
governing activation or inactivation of these gene products.
PROK1 elevates expression of adrenomedullin. Adrenomedullin has been
suggested to enhance invasion of the trophoblast, specifically maternal
expression of adrenomedullin is suggested to play a role in implantation
and placentation (Zhang X et al, 2005, Li M et al, 2006). The elevation of
COX-2 expression by PROK1 has been demonstrated herein to induce
down-stream production of prostaglandins. PGE2 is proposed to enhance
trophoblast invasion through activation of calpain 2, another PROK1
regulated gene (Nicola et al, 2005). Calpains are protease enzymes, which
aid cell migration (Dourdin et al, 2001, Huttenlocher et al, 1997, Glading et
al, 2000). PROK1 also regulates expression of other proteases including
MMP-10 and uPA. PROK1 also elevates expression of the receptor for
uPA, which is essential for its activity. However, PROK1 elevates PAI-1,
the inhibitor of uPA, thereby potentially providing a control mechanism.
In contrast to the pro-invasive genes regulated by PROK1, a number of
anti-invasive genes are also elevated. Activin A is suggested to stimulate
trophoblast migration (Caniggia et al, 1997), however, PROK1 elevates
expression of its inhibitor, Follistatin. This may imply PROK1 has an
inhibitory effect on trophoblast invasion. PROK1 also elevates expression
of TGF-(33, which inhibits trophoblast outgrowth and invasion (Caniggia &
Winter, 2002, Caniggia et al, 2000). It is also elevated in syndromes of
deficient placental invasion such as pre-eclampsia (Caniggia et al, 1999),
potentially suggesting PROK1 to be involved in the pathogenesis of pre¬
eclampsia. A recent study has suggested that no differences exist in the
expression of PROK1 between pre-eclamptic and normal placentas (Chung
et al, 2004). This study was conducted on placentas collected at term.
However, as the pathogenesis of pre-eclampsia starts in the first trimester
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of pregnancy, potential effects of PROK1 in the initiation of this disease
may be masked in advanced gestation.
9.1.4.5.Embryonic signals
Regulation of PROK1 by hCG, and the expression of PROK1 and PROKR1
in first trimester decidua implies a continued role for PROK1 during early
pregnancy, after the initial implantation reaction. hCG has been
demonstrated to elevate expression of a number of PROK1 regulated
genes, including COX-2, LIF and IL-6 (Perrier d'Hauterive et al, 2004,
Sherwin, 2007 et al, Licht et al, 2001, Han et al, 1996, Zhou et al, 1999).
This thesis suggests that hCG may regulate expression of these genes via
induction of PROK1. LIF and IL-6 have a reciprocal effect on the
trophoblast, stimulating hCG production, and it may be assumed
syncytialisation, as hCG production takes place as a function of
syncytialisation (Matsuzaki et al, 1995, Sawai et al, 1995a, 1995b, Yang et
al, 2003).
Whether PROK1 enters into a similar reciprocal relationship with hCG is
not yet known. However, as demonstrated in Chapter 3, the trophoblast
does express PROKR1. It is suggested that early placental expression of
PROKR1 peaks in weeks 8 - 10 of pregnancy (Hoffmann et al, 2006). This
may therefore provide a mechanism whereby endometrial PROK1 may
communicate with the invading trophoblast.
9.1.5. Potential therapeutic uses for prokineticins or prokineticin inhibitors
It has been demonstrated that simple light microscopy examination of the
endometrial histology provides little information regarding the receptivity of
the endometrium (Saleh et al, 1995). Therefore molecular markers would aid
the definition. No single marker of uterine receptivity has thus far been
identified. A number of candidates, such as LIF, IL-11, HB-EGF, av|33 integrin
and IL-6 have been suggested as markers of uterine receptivity. However, it is
likely that no one factor will define the period of receptivity in all women.
Examination of a number of markers used in concert should help to better
identify the receptive endometrium. In this study, PROK1 is proposed as a
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potential marker of uterine receptivity. PROK1 is elevated in the endometrium
during the secretory phase of the cycle, which encompasses the window of
implantation, and is further elevated during pregnancy. PROK1 also regulates
a number of implantation related genes, suggesting it may act as a 'master
controller' in the endometrium during the receptive phase. Expression is also
regulated by hCG, a hormone produced by the blastocyst and
syncytiotrophoblast during early pregnancy and routinely given during IVF
cycles (Hoult et al, 1981, Jones et al, 1982). hCG induced PROK1 may therefore
contribute to endometrial receptivity during stimulated cycles.
As PROK1 appears to regulate expression of endometrial receptivity and
implantation related genes it is plausible that delivery of PROK1 during
stimulated cycle for IVF may aid receptivity. However, the route of delivery
would have to be investigated, as the systemic effects of PROK1 are not yet
known. PROK1 has been demonstrated to induce gastrointestinal (GI)
contractions or relaxation, depending on which section of the GI tract was
examined (Li M et al, 2001, Hoogerwerf, 2006). This may be a complication if
systemic delivery of PROK1 were used. If it were possible to administer
PROK1 vaginally, a more localised effect of PROK1 may be observed.
Currently, the physiological concentration of PROK1 is unknown. Furthermore,
no ELISA is available at present to measure the concentration of PROK1 in
fluids such as endometrial lavage fluid. Therefore, the concentration of PROK1
that may be used in such treatments is currently unknown. This is an
important consideration as PROK1 may induce uterine contractions. PROK1
may induce contractions directly by acting on the uterine smooth muscle,
which express PROKR1 (Battersby et al, 2004a), as observed in the
gastrointestinal tract (Li M et al, 2001). PROK1 may also induce contractions
indirectly by elevating genes such as COX-2 and downstream production of
prostaglandins. Prostaglandins have been demonstrated to stimulate uterine
contractions (Friel et al, 2005) and synthetic prostaglandins are used to induce
early first trimester abortions (Bjorge et al, 2001, Bygdeman et al, 2000,
Bygdeman et al, 1994). Therefore, the incorrect concentration of PROK1 may be
detrimental to the successful establishment and maintenance of pregnancy.
Chapter 9 Final discussion 260
If PROK1 mediates endometrial receptivity to an implanting embryo, then
inhibitors of PROK1 action, such as receptor antagonists, may cause the
endometrium to become refractory to implantation. This may provide a novel
contraceptive with fewer side effects than traditional hormonal contraceptives.
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9.2. Conclusions
In conclusion, this thesis has demonstrated the temporal expression across the
menstrual cycle of PROK1 and PROKR1. Expression and localisation of both
factors has also been examined in the pregnant and pathological endometrium.
PROK1 displays elevation during the secretory phase of the cycle, with both
PROK1 and PROKR1 elevated in the pregnant endometrium. However, no
abberation in expression of these factors is observed in endometrial
adenocarcinoma. Signalling via PROK1 induces activation and phosphorylation of
multiple signalling molecules including cSrc, EGFR and ERK 1/2. Furthermore
activation of PROKR1 mediates expression of a number of genes, two of which,
COX-2 and LIF, were investigated further. Expression of both COX-2 and LIF is
induced by PROK1 in a temporal manner with expression dependent on activation
of Gq - PLC-|3 - Ca2+ - cSrc - EGFR and MEK. PROK1 expression is induced by
hCG, and hCG mediated LIF expression may be dependent on induction of
PROK1. These data outline a possible function for PROK1-PROKR1 interaction in
contributing to endometrial receptivity and implantation through induction of
factors proposed to be necessary for the initiation of pregnancy. PROK1-PROKR1
in the first trimester of pregnancy, may contribute to the continued growth and
development of the placenta.
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9.3. Future research direction
The data presented herein have characterised the signalling and gene activation
induced by PROK1 via PROKR1. The genes regulated by PROK1 include a
number of genes proposed to play a role in implantation. Thus, it is proposed that
PROK1-PROKR1 plays a role in endometrial receptivity and implantation.
The role of PROK1-PROKR1 in endometrial receptivity and implantation has,
therefore, to be defined. Does PROK1 signalling via PROKR1 act as a master
controller of implantation downstream of hormonal regulation? A PROKR1
knockout mouse has been produced by Matsumoto et al (2006), however, the
reproductive phenotype for this mouse is not yet known. In the absence of a
reproductive phenotype it may be proposed that PROK1 signalling through
PROKR2 may compensate for the absence of PROKR1. The PROKR2 knockout
mouse does not have a functional reproductive system due to the non-
development of GnRH neurones and therefore gonadotropin support for the
reproductive tract. Use of a knockout mouse model for PROK1 or specific
inhibitors of PROK1-PROKR1 induced signalling may help answer the question of
whether PROK1 plays a role in implantation. In order to decipher the role of the
two prokineticin receptors in implantation, a PROKR1 null/PROKR2 conditional
endometrial knockout mouse model or PROKR1 null/PROKR2 null with
exogenous gonadotropin support may be used. These models should help
delineate the presence or absence of compensatory signalling (ie. PROK1 signalling
via PROKR1 and/or PROKR2) and determine the role of prokineticin signalling in
implantation.
Knockout rodent models provide useful tools with which to study the
physiological role of genes in vivo. However, caution should be applied when
extrapolating data from mouse models into human implantation. A number of
genes, such as LIF, expressed during the secretory phase of the cycle in the human
endometrium are only expressed after the nidatory estrogen surge on day 4 of
pregnancy in mice (Bhatt et al, 1991). This dependence on estrogen represents a
difference between humans and rodents, as humans are not dependent on this
surge of estrogen for implantation. Decidualisation in the mouse endometrium
demonstrates differential regulation compared with the human endometrium.
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Decidualization in the mouse is mainly dependent on PGI2, with signalling
occurring via PPAR6 (Lim et al, 1999, Lim et al, 1997, Barak et al, 2002). However,
decidualization in the human is suggested to occur via PGE2 induction of Camp
(Dimitriadis et al, 2005, Frank et al, 1994), and the human endometrium produces
little PGI2 (Abel & Kelly, 1979). Although both humans and mice exhibit
haemochorial placentation, differences exist in the depth of trophoblast invasion
between the two species, with human trophoblasts being highly invasive. Mouse
models provide a useful in vivo system in which implantation and associated
decidualization and placentation can be studied in more detail with experimental
manipulation. Other model systems in which implantation, decidualization and
placentation may be studied, with closer parallels to the human, include non-
human primates such as the baboon. Data presented in this thesis demonstrate
that treatment of baboon endometrium with hCG induces expression of PROK1,
potentially indicating a role for endometrial PROK1 in pregnancy. Hence,
application of antagonists directed against PROKR1, or inhibitors of PROK1-
PROKR1 mediated signalling, may be useful in understanding the role of PROK1
in primate implantation and pregnancy.
It is suggested herein that hCG mediated LIF expression is dependent on
expression of PROK1. However, this has only been investigated using a general
inhibitor of protein synthesis. These studies should therefore be extended using an
inhibitor of PROK1 or an siRNA against PROK1 in order to further determine its
role in regulating hCG mediated LIF expression.
Factors induced by PROK1, including HB-EGF, LIF, COX-2, CD44 and galectins
are proposed to play roles in mediating blastocyst attachment to the luminal
epithelium. It may be proposed therefore, that PROK1 may play a role in
blastocyst attachment via induction of these proteins at the endometrial -
blastocyst interface. Indeed, preliminary studies, using adhesion assays and
choriocarcinoma cells, have suggested a role for PROK1 induced products in
mediating adhesion of trophoblast cells to extracellular matricies. Hence the
mechanism by which prokineticin regulates cellular adhesion warrants further
research.
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The potential role of PROK1 and PROKR1 in infertility should be examined. As
discussed in Section 9.1.4.3, expression of PROK1 regulated genes, including
DAF, LIF and IL-6, are down regulated in endometrial pathologies associated
with infertility. DAF expression is down-regulated in antiphospholipid syndrome,
a condition associated with a high miscarriage rate (Francis et al, 2006). LIF and
IL-6 are down-regulated in women with unexplained infertility and recurrent
miscarriage (Laird et al, 1997, Hambartsoumian, 1998b, Jasper et al, 2007).
Endometrial PROK1 and PROKR1 expression should therefore be examined in
these conditions in order to determine the expression pattern in infertile women or
those suffering from recurrent miscarriage. If PROK1 expression or signalling is
dysfunctional in unexplained infertility or spontaneous abortion, treatment
regimes may be developed in order to deal with these targets. Such treatment may
improve the probability of successful pregnancy.
Assuming PROK1 does play a role in implantation and early pregnancy events,
the next question to be answered is what physiological processes it regulates at
this time. PROK1 induces expression of LIF. LIF has been demonstrated, via
induction of hCG to contribute to the formation of the placental syncytium (Yang
et al, 2003, Sawai et al, 1995b). As hCG induces expression of PROK1 this may
indicate a positive feedback loop for the induction of syncytialisation. PROK1 also
induces expression of COX-2. hCG mediates COX-2 expression during the
differentiation of human endometrial stromal cells into decidua (Han et al, 1996).
Thus PROK1 may play a role in syncytialisation of the trophoblast and
decidualization of the endometrium via induction of these genes. This may
suggest a role for PROK1 in limiting trophoblast invasion, as syncytiotrophoblasts
are not invasive and decidua produces inhibitors to the proteases produced by the
trophoblast (Alexander et al, 1996, Afonso et al, 1997). Indeed, in the absence of
appropriate decidua formation the trophoblast proliferation is unrestrained (Robb
et al, 1998).
PROK1 elevates expression of a number of pro-invasive and anti-invasive genes. It
would therefore be of interest to investigate which of these groups would display
dominance and whether the net effect would be invasion or inhibition of invasion.
However, any studies in vitro examine only one factor in isolation, whereas in vivo,
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the surrounding milieu would enhance or inhibit factors. The net effect in vivo may
therefore be different to that observed in vitro. Preliminary studies have been
performed by Alfaidy et al (89th Endocrine Society meeting, 2007). This group
reports that PROK1 inhibits the migration and invasion of extravillous
trophoblasts while increasing the proliferation of the cytotrophoblasts, suggesting
that PROK1 may regulate placental development in the first trimester. If PROK1
does indeed have an anti-invasive effect it may be postulated that this protein has
a role in conditions associated with the under-invasion of the trophoblast such as
the pathogenesis of pre-eclampsia and intrauterine growth restriction. A study
examining the PROK1 in term placenta from pre-eclamptic pregnancies found no
differences in expression of PROK1 between these and normal pregnancies (Chung
et al, 2004). However, as the pathogenesis of these conditions may arise from
defective invasion during the first trimester, differences in PROK1 expression in
early pregnancy may be more indicative of the initiation of the disease as
discussed in Section 9.1.4.4. The onset of pre-eclampsia is not detected until week
20 of pregnancy, during the second trimester. Therefore, pre-eclamptic first
trimester trophoblast samples are unavailable as the pregnancy is terminated
before week 12 of gestation, and diagnosis of pre-eclampsia is not made until
week 20. The potential role of PROK1 in pre-eclampsia may therefore be
investigated using animal models of induced pre-eclmapsia (Karumanchi et al,
2006). The administration of PROK1 during various stages of pregnancy in the
mouse may also shed some light on the effect of PROK1 on placental development
during pregnancy.
PROK1 is expressed in term placenta (LeCouter et al, 2001, Hoffmann et al, 2006,
Chung et al, 2004, Li M et al, 2001). In light of the reported effects of PROK1 in
inducing contractions in smooth muscle it would be interesting to investigate the
expression of PROK1 and PROKR1 in term chorionic membranes. As this study
has demonstrated, PROK1 can induce expression of COX-2 and production of
downstream prostaglandins. Prostaglandins have a proven role in parturition,
during which time COX-2 expression is elevated (Friel et al, 2005, Slater et al,
1994). Other factors induced by PROK1, including IL-8 are suggested to play a
role in parturition (Maul et al, 2002). This may suggest a role for PROK1 signalling
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throughout human pregnancy, during the initiation of pregnancy at the time of
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